Skip to main content
SpringerLink
Log in

Complement and Complement Reactions

  • Chapter
The Complement System

  • 142 Accesses

Abstract

Introduction. The nine components1 that comprise the classical pathway constitute a family of proteins whose functions can be divided into three phases: recognition, activation, and attack. Most early work in the field focused on defining the functional activities of the various components, leading to our present concept of their reaction sequence. More recently, as modern biochemical techniques have been used to study these proteins, the physicochemical basis for their activities has begun to be elucidated.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Austen KF, Becker EL, Borsos T, Lachmann PJ, Lepow IH, Mayer MM, Müller-Eberhard HJ, Nelson RA, Rapp HJ, Rosen FS, Trnka Z (1968) Nomenclature of complement. Bull WHO 39:935–938

    Google Scholar 

  2. Reid KBM, Porter RR (1981) The proteolytic activation system of complement. Ann Rev Biochem 50:433–464

    PubMed  CAS  Google Scholar 

  3. Ziccardi RJ (1983) The first component of human complement (C1): activation and control. Springer Semin Immunopathol 6:213–230

    PubMed  CAS  Google Scholar 

  4. Cooper NR (1983) Activation and regulation of the first complement component. Fed Proc 42:134–138

    PubMed  CAS  Google Scholar 

  5. Ziccardi RJ (1981) Activation of the early components of the classical complement pathway under physiologic conditions J Immunol 126:1769–1773

    PubMed  CAS  Google Scholar 

  6. Ziccardi RJ (1983) Nature of the metal ion requirement for assembly and function of the first component of complement. J Biol Chem 258:6187–6192

    PubMed  CAS  Google Scholar 

  7. Ziccardi RJ (1984) The role of immune complexes in the activation of the first component of human complement. J Immunol 132:283–288

    PubMed  CAS  Google Scholar 

  8. Bartholomew RM, Esser AF (1977) The first complement component: evidence for an equilibrium between C1s free in serum and C1s bound in the Cl complex. J Immunol 119:1916–1922

    PubMed  CAS  Google Scholar 

  9. Reid KBM, Porter RR (1976) Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochem J 155:19–23

    PubMed  CAS  Google Scholar 

  10. Porter RR, Reid KBM (1978) The biochemistry of complement. Nature 275:699–704

    PubMed  CAS  Google Scholar 

  11. Mizouchi T, Yonemasu K, Yamashita K, Kobata A (1978) The asparagine linked sugar chains of subcomponent C1q of the first component of human complement. J Biol Chem 253:7404–7409

    Google Scholar 

  12. Reid KBM (1976) Isolation, by partial pepsin digestion, of the three collagen-like regions present in subcomponent C1q of the first component of human complement. Biochem J 155:5–17

    PubMed  CAS  Google Scholar 

  13. Sim RB, Porter RR, Reid KBM (1977) The structure and enzymic activities of the C1r and C1s subcomponents of C1, the first component of human serum complement. Biochem J 163:219–227

    PubMed  CAS  Google Scholar 

  14. Sim RB (1981) The human complement system serine proteases C1r and C1s and their proenzymes. Methods Enzymol 80:26–42

    PubMed  CAS  Google Scholar 

  15. Tschopp J (1982) Kinetics of activation of the first component of complement (C1) by IgG oligomers. Mol Immunol 19:651

    PubMed  CAS  Google Scholar 

  16. Kasahara T, Takahashi K (1982) Formation of a conformationally changed C1r, a subcomponent of the first component of human complement, as an intermediate of its autoactivation reaction. FEBS Lett 141:128–135

    PubMed  CAS  Google Scholar 

  17. Bauer J, Valet G (1981) Conformational changes of the subunits C1q, C1r, and C1s of human complement component Cl demonstrated by 125I labelling. Biochem Biophys Acta 670:129

    PubMed  CAS  Google Scholar 

  18. Villiers CL, Chesne S, Lacroix MB, Arlaud GJ, Colomb MG (1982) Structural features of the first component of human complement, C1, as revealed by surface iodination. Biochem J 203:185–193

    PubMed  CAS  Google Scholar 

  19. Ziccardi RJ (1980) Specific Cl dissociation immunoassays as an indicator for classical pathway activation and Cl inactivator function. In: Nakamura RM, Dito WR, Tucker III ES (eds) Immunoassays: clinical laboratory techniques for the 1980’s. Liss, New York, pp 433–442

    Google Scholar 

  20. Ziccardi RJ, Cooper NR (1979) Active disassembly of the first complement component, C1 by Cl inactivator. J Immunol 123:788–792

    PubMed  CAS  Google Scholar 

  21. Kerr MA (1981) The second component of human complement. Methods Enzymol 80:54–64

    CAS  Google Scholar 

  22. Nagasawa S, Stroud RM (1977) Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b. Proc Natl Acad Sci USA 74:2998–3001

    PubMed  CAS  Google Scholar 

  23. Kerr MA (1979) Limited proteolysis of complement components C2 and factor B: structural analogy and limited sequence homology. Biochem J 183:615–622

    PubMed  CAS  Google Scholar 

  24. Medicus RG, Götze O, Müller-Eberhard HJ (1976) The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways. Scand J Immunol 5:1049–1055

    PubMed  CAS  Google Scholar 

  25. Jersild C, Rubinstein P, Day NK (1976) The HLA system and inherited deficiencies of the complement system. Transplant Rev 32:43–71

    PubMed  CAS  Google Scholar 

  26. Meo T, Atkinson JP, Bernoco M, Bernoco O, Ceppelini R (1977) Structural heterogeneity of C2 complement protein and its genetic variants in man: a new polymorphism of the HLA region. Proc Natl Acad Sci USA 74:1672

    PubMed  CAS  Google Scholar 

  27. Tack BF, Prahl JW (1976) Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry 15:4513–4521

    PubMed  CAS  Google Scholar 

  28. Tack BF, Morris SC, Prahl JW (1979) Third compoment of human complement: structural analysis of the polypeptide chains of C3 and C3b. Biochemistry 18:1497–1503

    PubMed  CAS  Google Scholar 

  29. Tack BF, Janatova J, Thomas ML, Harrison RA, Hammer CH (1981) The third, fourth, and fifth components of human complement: isolation and biochemical properties. Methods Enzymol 80:64–101

    CAS  Google Scholar 

  30. Schreiber RD, Müller-Eberhard HJ (1974) Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med 140:1324–1334

    PubMed  CAS  Google Scholar 

  31. Gigli I, von Zabern I, Porter RR (1977) The isolation and structure of C4, the fourth component of human complement. Biochem J 165:439–446

    PubMed  CAS  Google Scholar 

  32. Bolotin C, Morris S, Tack B, Prahl J (1977) Purification and structural analysis of the fourth component of human complement. Biochemistry 16:2008–2015

    PubMed  CAS  Google Scholar 

  33. Law SK, Levine RP (1977) Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci USA 74:2701–2705

    PubMed  CAS  Google Scholar 

  34. Goers JWF, Porter RR (1978) The assembly of early components of complement on anti-body-antigen aggregates and on antibody-coated erythrocytes. Biochem J 175:675–684

    PubMed  CAS  Google Scholar 

  35. Law SK, Lichtenberg NA, Levine RP (1979) Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. J Immunol 123:1388–1394

    PubMed  CAS  Google Scholar 

  36. Law SK, Fearon DT, Levine RP (1979) Action of the C3b-inactivator on cell-bound C3b. J Immunol 122:759–765

    PubMed  CAS  Google Scholar 

  37. Law SK, Lichtenberg NA, Levine RP (1980) Covalent binding and hemolytic activity of complement proteins. Proc Natl Acad Sci USA 77:7194–7198

    PubMed  CAS  Google Scholar 

  38. Campbell RD, Dodds AW, Porter RR (1980) The binding of human complement component C4 to antibody-antigen aggregates. Biochem J 189:67–80

    PubMed  CAS  Google Scholar 

  39. Law SK, Lichtenberg NA, Holcombe FH, Levine RP (1980) Interaction between the labile binding sites of the fourth (C4) and fifth (C5) complement proteins and erythrocyte cell membranes. J Immunol 125:634–639

    PubMed  CAS  Google Scholar 

  40. Janatova J, Lorenz PE, Schechter AN, Prahl JW, Tack BF (1980) Third component of human complement: appearance of a sulfhydryl group following chemical or enzymatic inactivation. Biochemistry 19:4471–4478

    PubMed  CAS  Google Scholar 

  41. Janatova J, Tack BF, Prahl JW (1980) Third component of human complement: structural requirements for its function. Biochemistry 19:4479–4485

    PubMed  CAS  Google Scholar 

  42. Pangburn MK, Müller-Eberhard HJ (1980) Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 152:1102–1114

    PubMed  CAS  Google Scholar 

  43. Lundwall A, Malmheden I, Heilman U, Sjöquist (1981) Interaction between the labile binding site of human C4 and methylamine. Scand J Immunol 13:199–203

    PubMed  CAS  Google Scholar 

  44. Gorski JP, Silversmith R, Fiebeger S, Moilanen T (1982) Covalent modification of fourth component of human complement with primary amines. J Biol Chem 257:10948–10954

    PubMed  CAS  Google Scholar 

  45. Tack BF, Harrison RA, Janatova J, Thomas ML, Prahl JW (1980) Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci USA 77:5764–5768

    PubMed  CAS  Google Scholar 

  46. Thomas ML, Janatova J, Gray WR, Tack BF (1982) Third component of human complement: localization of the internal thiolester bond. Proc Natl Acad Sci USA 79:1054–1058

    PubMed  CAS  Google Scholar 

  47. Janatova J, Tack BF (1981) Fourth component of human complement: studies of an amine-sensitive site comprised of a thiol component. Biochemistry 20:2394–2402

    PubMed  CAS  Google Scholar 

  48. Harrison RA, Thomas ML, Tack BF (1981) Sequence determination of the thiolester site of the fourth component of human complement. Proc Natl Acad Sci USA 78:7388–7392

    PubMed  CAS  Google Scholar 

  49. Hostetter MK, Thomas ML, Rosen FS, Tack BF (1982) Binding of C3b proceeds by a transesterification reaction at the thiolester site. Nature 298:72–75

    PubMed  CAS  Google Scholar 

  50. Mann J, O’Brien R, Hostetter MK, Alper CA, Rosen FS, Babior BM (1981) The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway. J Immunol 126:2370–2372

    PubMed  CAS  Google Scholar 

  51. Capel PJA, Groeneboer O, Grosveld G, Pondman KW (1978) The binding of activated C3 to polysaccharides and immunoglobulins. J Immunol 121:2566–2572

    PubMed  CAS  Google Scholar 

  52. Sim RB, Twose TM, Paterson DS, Sim E (1981) The covalent-binding reaction of complement component C3. Biochem J 193:115–127

    PubMed  CAS  Google Scholar 

  53. Law SKA, Minich TM, Levine RP (1981) Binding reaction between the third human complement protein and small molecules. Biochemistry 20:7457–7463

    PubMed  CAS  Google Scholar 

  54. Law SKA (1983) Non-enzymatic activation of the covalent binding reaction of the complement protein C3, Biochem J 211:381–389

    PubMed  CAS  Google Scholar 

  55. Isenman DE, Kells DIC, Cooper NR, Müller-Eberhard HJ, Pangburn MK (1981) Nucleo-philic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry 20:4458–4467

    PubMed  CAS  Google Scholar 

  56. Isenman DE, Cooper NR (1981) The structure and function of the third component of human complement-I. The nature and extent of conformational changes accompanying C3 activation. Mol Immunol 18:331–339

    PubMed  CAS  Google Scholar 

  57. Isenman DE, Kells DI (1982) Conformational and functional changes in the fourth component of human complement produced by nucleophilic modification and by proteolysis with C1s. Biochemistry 21:1109–1117

    PubMed  CAS  Google Scholar 

  58. Isenman DE (1983) Conformational changes accompanying proteolytic cleavage of human complement protein C3b by the regulatory enzyme factor I and its cofactor H. J Biol Chem 258:4238–4244

    PubMed  CAS  Google Scholar 

  59. von Zabern I, Nolte R, Vogt W (1981) Treatment of human complement components C4 and C3 with amines or chaotropic ions. Scand J Immunol 13:413–431

    Google Scholar 

  60. von Zabern I, Bloom EL, Chu V, Gigli I (1982) The fourth component of human complement treated with amines or chaotropes or frozen-thawed (C4b-like C4): interaction with C4 binding protein and cleavage by C3b/C4b inactivator. J Immunol 128:1433–1438

    Google Scholar 

  61. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1981) Formation of the initial C3 convertase of the alternative complement pathway. J Exp Med 154:856–867

    PubMed  CAS  Google Scholar 

  62. Berger M, Gaither TA, Hammer CH, Frank MM (1981) Lack of binding of human C3, in its native state, to C3b receptors. J Immunol 127:1329–1334

    PubMed  CAS  Google Scholar 

  63. Dixit R, Schneider R, Law SK, Kulczycki A Jr, Atkinson JP (1981) Ligand binding specificity of a rabbit alveolar macrophage receptor for C3b. J Biol Chem 257:1595–1597

    Google Scholar 

  64. Gorski JP, Howard JB (1980) Effect of methylamine on the structure and function of the fourth component of human complement, C4. J Biol Chem 255:10025–10028

    PubMed  CAS  Google Scholar 

  65. Parkes C, DiScipio RG, Kerr MA, Prohaska R (1981) The separation of functionally distinct forms of the third component of human complement (C3). Biochem J 193:963–970

    PubMed  CAS  Google Scholar 

  66. Müller-Eberhard HJ, Nilsson U, Aronsson T (1960) Isolation and characterization of two β 1-glycoproteins of human serum. J Exp Med 111:201–215

    PubMed  Google Scholar 

  67. Müller-Eberhard HJ, Nilsson U (1960) Relation of a β 1-glycoprotein of human serum to the complement system. J Exp Med 111:217–234

    PubMed  Google Scholar 

  68. West CD, Davis NC, Forristal J, Herbst J, Spitzer R (1966) Antigenic determinants of human β 1C - and β 1G-globulins. J Immunol 96:650–658

    PubMed  CAS  Google Scholar 

  69. Spitzer RE, Stitzel AE, Pauling VL, Davis NC, West CD (1971) The antigenic and molecular alterations of C3 in the fluid phase during an immune reaction in normal human serum. J Exp Med 134:656–680

    PubMed  CAS  Google Scholar 

  70. Molenaar JL, ten Velde A, Pondman KW (1973) Anti-C3a, anti-C3b (anti-B) and their reaction with the anaphylatoxic fragment C3a. J Immunol 110:702–708

    PubMed  CAS  Google Scholar 

  71. Molenaar JL, Müller MAC, Engelfriet CP, Pondman KW (1974) Changes in antigenic properties of human C3 upon activation and conversion by trypsin. J Immunol 112:1444–1451

    PubMed  CAS  Google Scholar 

  72. Asghar SS, Cormane RH (1976) Interaction of the B-determinant of the third component of complement with amidino compounds. Immunochemistry 13:975–978

    PubMed  CAS  Google Scholar 

  73. Lachmann PJ, Oldroyd RG, Milstein C, Wright BW (1980) Three rat monoclonal antibodies to human C3. Immunology 41:503–515

    PubMed  CAS  Google Scholar 

  74. Lachmann PJ, Pangburn MK, Oldroyd RG (1982) Breakdown of C3 after complement activation. J Exp Med 156:205–216

    PubMed  CAS  Google Scholar 

  75. Tack BF, Morris SC, Prahl JW (1979) Fifth component of human complement: purification from plasma and polypeptide chain structure. Biochemistry 18:1490–1497

    PubMed  CAS  Google Scholar 

  76. Fernandez HN, Hugli TE (1976) Partial characterization of human C5a anaphylatoxin. J Immunol 117:1688–1694

    PubMed  CAS  Google Scholar 

  77. Fernandez HN, Hugli TE (1977) Chemical evidence for common genetic ancestry of complement components C3 and C5. J Biol Chem 252:1826–1828

    PubMed  CAS  Google Scholar 

  78. Gerard C, Hugli TE (1981) Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des- Arg-C5a. Proc Natl Acad Sci USA 78:1833–1837

    PubMed  CAS  Google Scholar 

  79. Wetsel RA, Kolb WP (1982) Complement-independent activation of the fifth component (C5) of human complement: limited trypsin digestion resulting in the expression of biologic activity. J Immunol 128:2209–2216

    PubMed  CAS  Google Scholar 

  80. Wetsel RA, Kolb WP (1983) Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments. J Exp Med 157:2029–2048

    PubMed  CAS  Google Scholar 

  81. Kolb WP, Kolb LM, Savary JR (1982) Biochemical Characterization of the sixth component of complement. Biochemistry 21:294–301

    PubMed  CAS  Google Scholar 

  82. Discipio RG, Gagnon J (1982) Characterization of human complement components C6 and C7. Mol Immunol 19:1425–1431

    PubMed  CAS  Google Scholar 

  83. Podack ER, Kolb WP, Müller-Eberhard HJ (1976) Purification of the sixth and seventh component of human complement without loss of hemolytic activity. J Immunol 116:263–269

    PubMed  CAS  Google Scholar 

  84. Podack ER, Kolb WP, Esser AF, Müller-Eberhard HJ (1979) Structural similarities between C6 and C7 of human complement. J Immunol 123:1071–1077

    PubMed  CAS  Google Scholar 

  85. Kolb WP, Müller-Eberhard HJ (1976) The membrane attack complex of complement: the three polypeptide chain structure of the eighth component (C8). J Exp Med 143:1131–1139

    CAS  Google Scholar 

  86. Steckel EW, York RG, Monahan JB, Sodetz JM (1980) The eighth component of human complement. Purification and physicochemical characterization of its unusual subunit structure. J Biol Chem 255:11997–12005

    PubMed  CAS  Google Scholar 

  87. Monahan JB, Sodetz JM (1980) Binding of the eighth component of human complement of the soluble cytolytic complex is mediated by its β subunit. J Biol Chem 255:10579–10582

    PubMed  CAS  Google Scholar 

  88. Monahan JB, Sodetz JM (1981) Role of the β subunit in interaction of the eighth component of human complement with the membrane-bound cytolytic complex. J Biol Chem 256:3258–3262

    PubMed  CAS  Google Scholar 

  89. Zeff RA, Osika RA, Osika-Morley CJ, Faaberg KS, Lint TF (1983) Reconstitution of C8 activity in C8 deficient sera: A Ca++ requirement for C8B chain binding. Immunobiology 164:271

    Google Scholar 

  90. Schultz DR, Zarco RM (1970) Inhibition of the eighth component of complement (C8) by EDTA. J Immunol 104:279–288

    PubMed  CAS  Google Scholar 

  91. Biesecker G, Müller-Eberhard HJ (1980) The ninth component of human complement purification and physicochemical characterization. J Immunol 124:1291–1296

    PubMed  CAS  Google Scholar 

  92. Biesecker G, Gerard C, Hugh TE (1982) An amphiphilic structure of the ninth component of human complement: evidence from analysis of fragments produced by α-thrombin. J Biol Chem 257:2584–2590

    PubMed  CAS  Google Scholar 

  93. Ishida B, Wisnieski BJ, Lavine CH, Esser AF (1982) Photolabelling of a hydrophobic domain of the ninth component of human complement. J Biol Chem 257:10551–10553

    PubMed  CAS  Google Scholar 

  94. Kolb WP, Müller-Eberhard HJ (1974) Mode of action of human C9: Adsorption of multiple C9 molecules to cell bound C8. J Immunol 113:479–488

    PubMed  CAS  Google Scholar 

  95. Ware CF, Kolb WP (1981) Assembly of the functional membrane attack complex of human complement: formation of disulfide linked C9 dimers. Proc Natl Acad Sci USA 78:6426–6430

    PubMed  CAS  Google Scholar 

  96. Podack ER, Tschopp J (1982) Polymerization of the ninth component of complement: Formation of poly (C9) with a tubular ultrastructure resembling the membrane attack complex of complement. Proc Natl Acad Sci USA 79:574–578

    PubMed  CAS  Google Scholar 

  97. Yamamoto KI, Migita S (1983) Mechanisms for the spontaneous formation of covalently linked polymers of the terminal membranolytic complement component (C9). J Biol Chem 258:7887–7889

    PubMed  CAS  Google Scholar 

  98. Falk RJ, Dalmasso AP, Kim Y, Tsai CH, Scheinman JÏ, Gewurz H, Michael AF (1983) Neoantigen of the polymerized ninth component of complement: characterization of a monoclonal antibody and histochemical localization in renal disease. J Clin Invest 72:560–573

    PubMed  CAS  Google Scholar 

  99. Douglas GN (1983) Complement system. Calbiochem-Behring, La Jolla, Ca pp 1–28

    Google Scholar 

  100. Nelson RA, Brebner E (1974) Isoelectric focusing of components of the complement system and certain related proteins in human serum. Immunol Commun 3:109–132

    PubMed  CAS  Google Scholar 

  101. Austen KF, Becker EL, Borsos T, Lachmann PJ, Lepow IH, Mayer MM, Müller-Eberhard HJ, Nelson RA, Rapp HJ, Rosen FS, Trnka Z (1968) Nomenclature of complement. Bull WHO 39:935–938

    Google Scholar 

  102. Ferrata A (1907) Die Unwirksamkeit der komplexen Hämolysine in salzfreien Lösungen und ihre Ursache. Berlin Klin Wochenschr 44:366–369

    Google Scholar 

  103. Nelson RA, Jensen J, Gigli I, Tamura N (1966) Methods for the separation, purification, and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry 3:111–135

    PubMed  CAS  Google Scholar 

  104. Vroon DH, Schultz DR, Zarco RM (1970) The separation of nine components and two inactivators of components of complement in human serum. Immunochemistry 7:43–61

    PubMed  CAS  Google Scholar 

  105. Sargent AU, Johnson SB, Richardson AK (1976) The isolation and functional purification of the first seven components of canine hemolytic complement. Immunochemistry 13:823–829

    PubMed  CAS  Google Scholar 

  106. Barta O, Nelson RA Jr, Kuo CY (1976) Separation of six bovine complement components and one inactivator. Immunol Commun 5:75–86

    PubMed  CAS  Google Scholar 

  107. Hammer CH, Wirtz GH, Renfer L, Gresham HD, Tack BF (1981) Large scale isolation of functionally active components of the human complement system. J Biol Chem 256:3995–4006

    PubMed  CAS  Google Scholar 

  108. Tack BF, Janatova J, Thomas ML, Harrison RA, Hammer CH (1981) The third, fourth, and fifth components of human complement: Isolation and biochemical properties. In: Lorand L (ed) Methods in enzymology. Academic, New York, pp 64–101 (Proteolytic enzymes, part C, vol 80)

    Google Scholar 

  109. Tamura N, Shimada A (1971) The ninth component of guinea-pig complement. Isolation and identification as an α2-globulin. Immunology 20:415–425

    PubMed  CAS  Google Scholar 

  110. Hammer CH, Nicholson A, Mayer MM (1975) On the mechanism of cytolysis by complement: evidence on insertion of C5b and Cl subunits of the C5b, 6, 7 complex into phospholipid bilayers of erythrocyte membranes. Proc Natl Acad Sci USA 72:5076–5080

    PubMed  CAS  Google Scholar 

  111. Hammer CH, Abramovitz AS, Mayer MM (1976) A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b, 6 and terminal components. J Immunol 117:830–834

    PubMed  CAS  Google Scholar 

  112. Hammer CH, Shin ML, Abramovitz AS, Mayer MM (1977) On the mechanism of cell membrane damage by complement: evidence on insertion of polypeptide chains from C8 and C9 into the lipid bilayer of erythrocytes. J Immunol 119:1–8

    PubMed  CAS  Google Scholar 

  113. Borsos T, Rapp HJ (1967) Immune hemolysis: a simplified method for the preparation of EAC’4 with guinea pig or with human complement. J Immunol 99:263–268

    PubMed  CAS  Google Scholar 

  114. Borsos T, Rapp HJ, Cook CT (1961) Studies on the second component of complement. III. Separation of the second component from guinea pig serum by chromatography on cellulose derivatives. J Immunol 87:330–336

    CAS  Google Scholar 

  115. Gaither TA, Alling DW, Frank MM (1974) A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement. J Immunol 113:574–583

    PubMed  CAS  Google Scholar 

  116. Steinbuch M, Audran R (1969) The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys 134:279–284

    PubMed  CAS  Google Scholar 

  117. March SC, Parikh I, Cuatrecasas P (1974) A simplified method for cyanogen bromide activation of agarose for affinity chromatography. Anal Biochem 60:149–152

    PubMed  CAS  Google Scholar 

  118. Deutsch DG, Mertz ET (1970) Plasminogen purification from human plasma by affinity chromatography. Science 170:1095–1097

    PubMed  CAS  Google Scholar 

  119. Tack BF, Prahl JW (1976) Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry 15:4513–4521

    PubMed  CAS  Google Scholar 

  120. Bolotin C, Morris S, Tack B, Prahl J (1977) Purification and structural analysis of the fourth component of human complement. Biochemistry 16:2008–2015

    PubMed  CAS  Google Scholar 

  121. Nilsson UR, Tomar RH, Taylor FB Jr (1972) Additional studies on human C5: development of a modified purification method and characterization of the purified product by polyacrylamide gel electrophoresis. Immunochemistry 9:709–723

    PubMed  CAS  Google Scholar 

  122. Nilsson UR, Müller-Eberhard HJ (1965) Isolation of β 1F-globulin from human serum and its characterization as the fifth component of complement. J Exp Med 122:277–298

    PubMed  CAS  Google Scholar 

  123. Harrison RA, Lachmann PJ (1979) An improved purification procedure for the third component of complement and β 1H globulin from human serum. Mol Immunol 16:767–776

    PubMed  CAS  Google Scholar 

  124. Shimada K, Mayumi M, Seline T, Nishioka K (1972) An improved method for separation of the fourth component of complement and C4 inactivating substance Jpn J Exp Med 42:423–434

    PubMed  CAS  Google Scholar 

  125. Berger M, Gaither TA, Hammer CH, Frank MM (1981) Lack of binding of human C3, in its native state, to C3b receptors. J Immunol 127:1329–1334

    PubMed  CAS  Google Scholar 

  126. Biesecker G, Müller-Eberhard HJ (1980) The ninth component of human complement: purification and physicochemical characterization. J Immunol 124:1291–1296

    PubMed  CAS  Google Scholar 

  127. Reboul A, Thielens N, Villiers MB, Colomb MG (1979) Purification of human complement subcomponent C4. FEBS Lett 103:156–161

    PubMed  CAS  Google Scholar 

  128. Mayer MM, Miller JA, Shin HS (1970) A specific method for purification of the second component of guinea pig complement and a chemical evaluation of the one-hit theory. J Immunol 105:327–341

    PubMed  CAS  Google Scholar 

  129. Thielens NM, Villiers MB, Reboul A, Villiers CL, Colomb MG (1982) Human complement subcomponent C2: purification and proteolytic cleavage in fluid phase by #. FEBS Lett 141:19–24

    PubMed  CAS  Google Scholar 

  130. Kerr MA, Porter RR (1978) The purification and properties of the second component of human complement. Biochem J 171:99–107

    PubMed  CAS  Google Scholar 

  131. Whaley K, Ruddy S (1976) Modulation of the alternative complement pathway by β1H globulin. J Exp Med 144:1147–1163

    PubMed  CAS  Google Scholar 

  132. Rauterberg EW, Hänsch G, Rother U (1979) Isolation of late complement components by affinity chromatography. II. Purification of the human complement component C6. Immunobiology 156:142–152

    PubMed  CAS  Google Scholar 

  133. Kolb WP, Kolb LM, Savary JR (1982) Biochemical characterization of the sixth component (C6) of human complement. Biochemistry 21:294–301

    PubMed  CAS  Google Scholar 

  134. Podack ER, Kolb WP, Müller-Eberhard HJ (1976) Purification of the sixth and seventh component of human complement without loss of hemolytic activity. J Immunol 116:263–269

    PubMed  CAS  Google Scholar 

  135. Discipio RG, Gagnon J (1982) Characterization of human complement components C6 and C7. Mol Immunol 19:1425–1431

    PubMed  CAS  Google Scholar 

  136. Tamura N, Nelson RA Jr (1968) The purification and reactivity of the first component of complement from guinea pig, human and canine sera. J Immunol 101:1333–1345

    PubMed  CAS  Google Scholar 

  137. Gigli I, Porter RR, Sim RB (1976) The unactivated form of the first component of human complement, C1. Biochem J 157:541–548

    PubMed  CAS  Google Scholar 

  138. Sim RB (1981) The first component of human complement-C1. Methods Enzymol 80:6–16

    PubMed  CAS  Google Scholar 

  139. Medicus RG, Chapuis RM (1980) The first component of complement. I. Purification and properties of native C1. J Immunol 125:390–395

    PubMed  CAS  Google Scholar 

  140. Assimeh SN, Bing DH, Painter RH (1974) A simple method for the isolation of the subcomponents of the first component of complement by affinity chromatography. J Immunol 113:225–234

    PubMed  CAS  Google Scholar 

  141. Bing DH, Andrews JM, Morris KM, Cole E, Irish V (1980) Purification of subcomponents C1q, C1r, and C1s of the first component of complement from Cohn Fraction 1 by affinity chromatography. Prep Biochem 10:269–296

    PubMed  CAS  Google Scholar 

  142. Arlaud GJ, Sim RB, Duplaa M, Colomb MG (1979) Differential elution of C1q, C1r, and C1s from human Cl bound to immune aggregates. Use in the rapid purification of Cl subcomponents. Mol Immunol 16:445–450

    PubMed  CAS  Google Scholar 

  143. von Zeipel G, Hanson HS, von Stedingk LV (1977) Purification from euglobulin of the first component of complement and its subcomponents by heparin-Sepharose chromatography. Acta Pathol Microbiol Scand 85:123–130

    Google Scholar 

  144. Chapuis RM, Isliker H, Assimeh SN (1977) Studies on the precursor form of the first component of complement. I. Isolation of the proenzyme forms of C1r and C1s. Immunochemistry 14:313–317

    PubMed  CAS  Google Scholar 

  145. Reid KBM (1981) Preparation of human C1q, a subcomponent of the first component of the classical pathway of complement. Methods Enzymol 80:16–25

    CAS  Google Scholar 

  146. Tenner AJ, Lesavre PH, Cooper NR (1981) Purification and radiolabelling of human C1q. J Immunol 127:648–653

    PubMed  CAS  Google Scholar 

  147. Kolb WP, Kolb LM, Podack ER (1979) C1q: Isolation from human serum in high yield by affinity chromatography and development of a highly sensitive hemolytic assay. J Immunol 122:2103–2111

    PubMed  CAS  Google Scholar 

  148. McKay EJ (1981) A simple two-step procedure for the purification of plasma C1q from different animal species. Immunol Let 3:303–308

    CAS  Google Scholar 

  149. Haines AL, Lepow IH (1964) Studies on human C’1-esterase. II. Function of purified C’1-esterase in the human complement system. J Immunol 92:468–478

    PubMed  CAS  Google Scholar 

  150. de Bracco ME, Stroud RM (1971) C1r, subunit of the first complement component: purification, properties, and assay based on its linking role. J Clin Invest 50:838–848

    PubMed  Google Scholar 

  151. Okamura K, Muramatu M, Fujii S (1973) Purification of C1s, a subunit of the first component of complement from human plasma. Biochim Biophys Acta 295:252–257

    PubMed  CAS  Google Scholar 

  152. Sakai K, Stroud RM (1973) Purification, molecular properties, and activation of Cl proesterase, C1s. J Immunol 110:1010–1019

    CAS  Google Scholar 

  153. Valet G, Cooper NR (1974) Isolation and characterization of the proenzyme form of the C1s subunit of the first complement component. J Immunol 112:339–350

    PubMed  CAS  Google Scholar 

  154. Valet G, Cooper NR (1974) Isolation and characterization of the proenzyme form of the first complement component. J Immunol 112:1667–1673

    PubMed  CAS  Google Scholar 

  155. Sim RB (1981) The human complement system serine proteases C1r and C1s and their proenzymes. Methods Enzymol 80:26–42

    PubMed  CAS  Google Scholar 

  156. Kerr MA, Gagnon J (1982) The purification and properties of the second component of guinea-pig complement. Biochem J 205:59–67

    PubMed  CAS  Google Scholar 

  157. Polley MJ, Müller-Eberhard HJ (1968) The second component of human complement: its isolation, fragmentation by C’1 esterase, and incorporation into C’3 convertase. J Exp Med 128:533–551

    PubMed  CAS  Google Scholar 

  158. Nagasawa S, Stroud RM (1977) Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b and C4b. Proc Natl Acad Sci USA 74:2998–3001

    PubMed  CAS  Google Scholar 

  159. Kerr MA (1979) Limited proteolysis of complement components C2 and factor B. Biochem J 183:615–622

    PubMed  CAS  Google Scholar 

  160. Ngan B-Y, Minta JO (1981) Proteolysis of C2 and factor B: analyses of cleavage products by one- and two-dimensional peptide mapping. Mol Immunol 18:1035–1047

    PubMed  CAS  Google Scholar 

  161. Pâques EP (1980) Isolation and partial characterization of the third component of the complement from porcine serum (C3) and of a crystallizable degradation product of the component of the complement system from human serum (C4). Hoppe Seylers Z Physiol Chem 361:445–456

    PubMed  Google Scholar 

  162. Jacobse-Geels HEL, Daha MR, Horzinek MC (1980) Isolation and characterization of feline C3 and evidence for the immune complex pathogenesis of feline infectious peritonitis. J Immunol 125:1606–1610

    PubMed  CAS  Google Scholar 

  163. Daha MR, Stuffers-Heiman M, Kijlstra A, Van Es LA (1979) Isolation and characterization of the third component of rat complement. Immunology 36:63–70

    PubMed  CAS  Google Scholar 

  164. Davrinche C, Rivat C, Rivat-Peran L (1980) An improved three-step method for the purification of the third component of human complement. J Immunol Methods 35:353–359

    PubMed  CAS  Google Scholar 

  165. Kunkel SL, Kreutzer DL, Goralnick S, Ward PA (1980) Purification of the third and fifth components of human complement: application of hydrophobic chromatography. J Immunol Methods 35:337–351

    PubMed  CAS  Google Scholar 

  166. Thomas ML, Tack BF (1983) Identification and alignment of a thiol ester site in the third component of guinea pig complement. Biochemistry 22:942–947

    PubMed  CAS  Google Scholar 

  167. Gigli I, von Zabern I, Porter RR (1977) The isolation and structure of C4, the fourth component of human complement. Biochem J 165:439–446

    PubMed  CAS  Google Scholar 

  168. Lundwall A, Malmheden I, Stalenheim G, Sjoquist J (1981) Isolation of component C4 of human complement and its polypeptide chains. Eur J Biochem 117:141–146

    PubMed  CAS  Google Scholar 

  169. Chan PCY, Cebra JJ (1968) Isolation and purification of the fourth component of guinea- pig complement. Immunochemistry 5:17–22

    PubMed  CAS  Google Scholar 

  170. Burge J, Nicholson-Weller A, Austen KF (1981) Isolation of the fourth component of guinea pig complement and its single polypeptide chain precursor from plasma. Mol Immunol 18:47–54

    PubMed  CAS  Google Scholar 

  171. Booth NA, Campbell D, Fothergill JE (1979) The purification and characterization of bovine C4, the fourth component of complement. Biochem J 177:959–965

    PubMed  CAS  Google Scholar 

  172. Daha MR, van Es LA (1979) Isolation of the fourth component (C4) of rat complement. J Immunology 123:2261–2264

    CAS  Google Scholar 

  173. Tack BF, Morris SC, Prahl JW (1979) Fifth component of human complement: purification from plasma and polypeptide chain structure. Biochemistry 18:1490–1497

    PubMed  CAS  Google Scholar 

  174. Wetsel RA, Jones MA, Kolb WP (1980) Immunoadsorbent affinity purification of the fifth component (C5) of human complement and development of a highly sensitive hemolytic assay. J Immunol Methods 35:319–335

    PubMed  CAS  Google Scholar 

  175. Dessauer A, Rother U (1983) The fifth component of complement (C5): purification without activation. Immunobiology 164:370–379

    PubMed  CAS  Google Scholar 

  176. Linscott WD, Nishioka K (1963) Components of guinea pig complement. II. Separation of serum fractions essential for immune hemolysis. J Exp Med 118:795–815

    PubMed  CAS  Google Scholar 

  177. Cook CC, Shin HS, Mayer MM, Laudenslayer KA (1971) The fifth component of the guinea pig complement system. J Immunol 106:467–472

    PubMed  CAS  Google Scholar 

  178. Kinoshita T, Hong K, Kondo K, Inoue K (1981) Fifth component of guinea pig complement: purification and characterization. J Immunol 126:2414–2418

    PubMed  CAS  Google Scholar 

  179. Nilsson U (1967) Separation and partial purification of the sixth, seventh and eighth components of human haemolytic complement. Acta Pathol Microbiol Immunol Scand 70:469–480

    CAS  Google Scholar 

  180. Arroyave CM, Müller-Eberhard HJ (1971) Isolation of the sixth component of complement from human serum. Immunochemistry 8:995–1006

    PubMed  CAS  Google Scholar 

  181. Podack ER, Kolb WP, Esser AF, Müller-Eberhard HJ (1979) Structural similarities between C6 and C7 of human complement. J Immunol 123:1071–1077

    PubMed  CAS  Google Scholar 

  182. Arroyave CM, Müller-Eberhardt HJ (1973) Isolation of the C system from human serum. J Immunol (Abstract) 111:302–303

    Google Scholar 

  183. Manni JA, Müller-Eberhard HJ (1969) The eighth component of human complement (C8): isolation, characterization, and hemolytic efficiency. J Exp Med 130:1145–1160

    PubMed  CAS  Google Scholar 

  184. Kolb WP, Müller-Eberhard HJ (1976) The membrane attack mechanism of complement: the three polypeptide chain structure of the eighth component (C8). J Exp Med 143:1131–1139

    CAS  Google Scholar 

  185. Steckel EW, York RG, Monahan JB, Sodetz JM (1980) The eighth component of human complement. Purification and physicochemical characterization of its unusual subunit structure. J Biol Chem 255:11997–12005

    PubMed  CAS  Google Scholar 

  186. Kinoshita T, Hong K, Kondo K, Inoue K (1982) Eighth component of guinea pig complement: purification and characterization. Mol Immunol 19:589–597

    PubMed  CAS  Google Scholar 

  187. Hadding U, Müller-Eberhard HJ (1969) The ninth component of human complement: Isolation, description and mode of action. Immunology 16:719–735

    PubMed  CAS  Google Scholar 

  188. Rauterberg EW, Schieck C, Hänsch G (1979) Isolation of late complement components by affinity chromatography: I. Purification of the human complement component C9 and production of a C9-defective human serum. Z Immun Forsch 155:365–377

    CAS  Google Scholar 

  189. Ackerman SK, Friend PS, Hoidal JR, Douglas SD (1978) Production of C2 by human alveolar macrophages. Immunology 35:369–372

    PubMed  CAS  Google Scholar 

  190. Al-Adnani MS, McGee JOD (1976) C1q production and secretion by fibroblasts. Nature 263:145–146

    PubMed  CAS  Google Scholar 

  191. Almeda S, Rosenberg RD, Bing DH (1983) The binding properties of human complement component C1q. J Biol Chem 258:784–791

    Google Scholar 

  192. Alper CA (1981) Complement and the MHC. In: Dorf ME (ed) The role of the major histocompatibility complex in immunobiology. Garland, New York, pp 173–220

    Google Scholar 

  193. Alper CA, Johnson AM, Birtch AG, Moore RD (1969) Human C’3: evidence for the liver as the primary site of synthesis. Science 163:286–288

    PubMed  CAS  Google Scholar 

  194. Alper CA, Marcus D, Raum D, Petersen BH, Spira TJ (1983) Genetic polymorphism in C8 beta-chains. J Clin Invest 72:1526–1531

    PubMed  CAS  Google Scholar 

  195. Alper CA, Raum D, Awdeh Z, Petersen BH, Taylor PD, Starzl TE (1980) Studies of hepatic synthesis in vivo of plasma proteins including orosomucoid, transferrin, alpa-1-antitrypsin, C8 and factor B. Clin Immunol Immunopathol 16:84–89

    PubMed  CAS  Google Scholar 

  196. Alpert SE, Auerbach HS, Cole FS, Colten HR (1983) Macrophage maturation: differences in complement secretion by marrow, monocyte, and tissue macrophages detected with an improved hemolytic plaque assay. J Immunol 130:102–107

    PubMed  CAS  Google Scholar 

  197. Atkinson JP, McGinnis K, Brown L, Peterein J, Shreffler D (1980) A murine C4 molecule with reduced hemolytic efficiency. J Exp Med 151:492–497

    PubMed  CAS  Google Scholar 

  198. Atkinson JP, Shin H, Frank MM (1974) Metabolic behavior of C3 in normal, C4-deficient (C4D) and cortisone treated guinea pigs. J Immunol 113:1085–1090

    PubMed  CAS  Google Scholar 

  199. Auerbach HS, Baker RD, Matthews WJ, Colten HR (1984) Molecular mechanism for feedback regulation of C4 biosynthesis in guinea pig peritoneal macrophages. J Exp Med 159:1750–1761

    PubMed  CAS  Google Scholar 

  200. Auerbach HS, Lalande ME, Latt S, Colten HR (1983) Isolation of guinea pig macrophages bearing surface C4 by fluorescence activated cell sorting: correlation between surface C4 antigen and C4 protein secretion. J Immunol 131:2420–2426

    PubMed  CAS  Google Scholar 

  201. Barber TA, Burkholder PM (1978) Enumeration and ultrastructure of C4 producing free alveolar cells from guinea pig lung. J Immunol 120:716–725

    PubMed  CAS  Google Scholar 

  202. Baltz ML, Gomer K, Davies AJS, Evans DJ, Klaus GGB, Pepys MB (1980) Differences in the acute phase responses of serum amyloid P-complement (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains. Clin Exp Immunol 39:355–360

    PubMed  CAS  Google Scholar 

  203. Bates CJ, Levene CI, Oldroyd RG, Lachmann PJ (1978) Complement component C1q is insensitive to acute vitamin C deficiency in guinea pigs. Biochemin Biophys Acta 540:423–430

    CAS  Google Scholar 

  204. Beatty DW, Davis AE, Cole FS, Einstein LP, Colten HR (1981) Biosynthesis of complement by human monocytes. Clin Immunol Immunopathol 18:334–343

    PubMed  CAS  Google Scholar 

  205. Bentley CD, Bitter-Suermann D, Hadding U, Brade V (1976) In vitro synthesis of factor B of the alternative pathway of complement by mouse peritoneal macrophages. Eur J Immunol 6:393–398

    PubMed  CAS  Google Scholar 

  206. Bentley C, Fries W, Brade V (1978) Synthesis of factors D, B and P of the alternative pathway of complement activation, as well as of C3, by guinea pig peritoneal macrophages in vitro. Immunology 35:971–980

    PubMed  CAS  Google Scholar 

  207. Bing DH, Spurlock SE, Bern MM (1975) Synthesis of the first component of complement by primary cultures of human tumors of the colon and urogenital tract and comparable normal tissue. Clin Immunol Immunopathol 4:341–351

    PubMed  CAS  Google Scholar 

  208. Bitter-Suermann D, Hoffman T, Burger R, Hadding U (1981) Linkage of total deficiency of the second component (C2) of the complement system and of genetic polymorphism to the major histocompatibility complex of the guinea pig. J Immunol 127:608–612

    PubMed  CAS  Google Scholar 

  209. Bitter-Suermann D, Kronke M, Brade V, Hadding U (1977) Inherited polymorphism of guinea pig factor B and C4: evidence for genetic linkage between the C4 and Bf loci. J Immunol 118:1822–1826

    PubMed  CAS  Google Scholar 

  210. Bordin S, Kolb WP, Page RC (1983) C1q receptors on cultured human gingival fibroblasts: analysis of binding properties. J Immunol 130:1871–1875

    PubMed  CAS  Google Scholar 

  211. Borsos T, Loos M, Chapuis RM, Medicus R, Isliker H (1980) A novel way of relating the structure of C1q to the hemolytic activity of the first component of complement. Mol Immunol 17:1415–1421

    PubMed  CAS  Google Scholar 

  212. Brade V, Damerau B, Kreuzpaintner G (1981) Studies on the influence of C3 fragments on the secretory function and viability of guinea pig peritoneal macrophages. In: Forster O, Landy M (eds), Heterogeneity of mononuclear phagocytes. Academic, New York, pp 270–277

    Google Scholar 

  213. Brade V, Hall RE, Colten HR (1977) Biosynthesis of pro-C3, a precursor of the third component of complement. J Exp Med 146:759–765

    PubMed  CAS  Google Scholar 

  214. Brade V, Kreuzpaintner G (1982) Functional C4 active complement components secreted by guinea pig peritoneal macrophages. Immunobiology 161:315–321

    PubMed  CAS  Google Scholar 

  215. Burton DR, Boyd J, Brampton AD, Easterbrook-Smith SB, Emanuel EJ, Novotny J, Rademacher TW, van Schravendijk MR, Sternberg MJE, Dwek RA (1980) The C1q receptor site on immunoglobulin G. Nature 288:338–344

    PubMed  CAS  Google Scholar 

  216. Carroll MC, Campbell DR, Bentley DR, Porter RR (1984) A molecular map of the human major histocompatibility complex class III region linking complement genes C4, C2 and factor B. Nature 307:237–241

    PubMed  CAS  Google Scholar 

  217. Carroll MC, Capra JD (1979) Studies on murine Ss-protein: demonstration that S locus encodes the structural gene for fourth component of complement. Proc Natl Acad Sci USA 76:4641–4645

    PubMed  CAS  Google Scholar 

  218. Carroll MC, Porter RR (1983) Cloning of a human complement component C4 gene. Proc Natl Acad Sci USA 80:264–267

    PubMed  CAS  Google Scholar 

  219. Chan AC, Mitchell KR, Munns TW, Karp DR, Atkinson JP (1983) Identification and partial characterization of the secreted form of the fourth component of human complement: evidence that it is different from the major plasma form. Proc Natl Acad Sci USA 80:268–272

    PubMed  CAS  Google Scholar 

  220. Chaplin DD, Woods DW, Whitehead AS, Goldberger G, Colten HR, Seidman JG (1983) Molecular map of the murine S region. Proc Natl Acad Sci USA 80:6947–6951

    PubMed  CAS  Google Scholar 

  221. Chapuis RM, Hauptmann G, Grosshans E, Isliker H (1982) Structural and functional studies in C1q deficiency. J Immunol 129:1509–1512

    PubMed  CAS  Google Scholar 

  222. Christie DL, Gagnon J (1983) Amino acid sequence of the Bb fragment from complement factor B. Biochem J 209:61–70

    PubMed  CAS  Google Scholar 

  223. Cole FS, Auerbach HS, Goldberger G, Colten HR (1983) Mechanisms regulating complement production during monocyte-macrophage maturation. Immunobiol 164:224

    Google Scholar 

  224. Cole FS, Matthews WJ, Marino JT, Gash DJ, Colten HR (1980) Control of complement synthesis and secretion in bronchoalveolar and peritoneal macrophages. J Immunol 125:1120–1124

    PubMed  CAS  Google Scholar 

  225. Cole FS, Matthews WJ, Rossing TH, Gash DJ, Lichtenberg NA, Pennington JE (1983) Complement biosynthesis by human bronchoalveolar macrophages. Clin Immunol Immunopathol 27:153–159

    PubMed  CAS  Google Scholar 

  226. Cole FS, Schneeberger EE, Lichtenberg NA, Colten HR (1982) Complement biosynthesis in human breast milk macrophages and blood monocytes. Immunol 46:429–441

    CAS  Google Scholar 

  227. Colten HR (1972) In Vitro synthesis of a regulator of mammalian gene expression. Proc Natl Acad Sci USA 69:2233–2236

    PubMed  CAS  Google Scholar 

  228. Colten HR (1972) Ontogeny of the human complement system: in vitro biosynthesis of individual complement components by fetal tissues. J Clin Invest 51:725–730

    PubMed  CAS  Google Scholar 

  229. Colten HR (1976) Biosynthesis of complement. Adv Immunol 22:67–118

    PubMed  CAS  Google Scholar 

  230. Colten HR (1982) Biosynthesis of the MHC-linked complement proteins (C2, C4, and factor B) by mononuclear phagocytes. Mol Immunol 19:1279–1285

    PubMed  CAS  Google Scholar 

  231. Colten HR (1983) Molecular genetics of the major histocompatibility linked complement genes. Springer Semin Immunopathol 6:149–158

    PubMed  CAS  Google Scholar 

  232. Colten HR, Alper CA, Rosen FS (1981) Genetics and biosynthesis of complement proteins. N Engl J Med 304:653–656

    PubMed  CAS  Google Scholar 

  233. Colten HR, Borsos T, Rapp HJ (1966) In vitro synthesis of the first component of complement by guinea pig small intestine. Proc Natl Acad Sci USA 56:1158–1163

    PubMed  CAS  Google Scholar 

  234. Colten HR, Einstein LP (1976) Complement metabolism: cellular and humoral regulation. Trans Rev 32:3–11

    CAS  Google Scholar 

  235. Colten HR, Frank MM (1972) Biosynthesis of the second and fourth components of complement in vitro by tissues isolated from guinea pigs with genetically determined C4 deficiency. Immunol 22:991–999

    CAS  Google Scholar 

  236. Colten HR, Goldberger G, Kay RM, Woods DE (1983) Biosynthesis, processing and secretion of biologically active complement proteins by Xenopus oocytes injected with human mRNA. Immunobiology 164:225–226

    Google Scholar 

  237. Colten HR, Gordon JM, Borsos T, Rapp HJ (1968) Synthesis of the first component of human complement in vitro. J Exp Med 128:595–604

    PubMed  CAS  Google Scholar 

  238. Colten HR, Gordon JM, Rapp HJ, Borsos T (1968) Synthesis of the first component of guinea pig complement by columnar epithelial cells of the small intestine. J Immunol 100:788–792

    PubMed  CAS  Google Scholar 

  239. Colten HR, Ooi YM, Edelson PJ (1979) Synthesis and secretion of complement proteins by macrophages. Ann NY Acad Sci 332:482–490

    PubMed  CAS  Google Scholar 

  240. Colten HR, Parkman R (1972) Biosynthesis of C4 (fourth component of complement) by hybrids of C4-deficient guinea pig cells and HeLa cells. Science 176:1029–1031

    PubMed  CAS  Google Scholar 

  241. Cooper NR (1983) Activation and regulation of the first complement component. Fed Proc 42:134–137

    PubMed  CAS  Google Scholar 

  242. DaSilva FP, Hoecker GE, Day NK, Vienne D, Rubinstein P (1978) Murine complement component 3: genetic variation and linkage to H-2. Proc Natl Acad Sci USA 75:963–965

    CAS  Google Scholar 

  243. Day NK, Gewurz H, Pickering RJ, Good RA (1970) Ontogenetic development of C1q synthesis in the piglet. J Immunol 104:1316–1319

    PubMed  CAS  Google Scholar 

  244. DeCeulaer C, Papazoglou S, Whaley K (1980) Increased biosynthesis of complement components by cultured monocytes, synovial fluid macrophages and synovial membrane cells from patients with rheumatoid arthritis. Immunology 41:37–43

    CAS  Google Scholar 

  245. Domdey H, Wiebauer K, Kazmaier M, Muller V, Odink K, Fey G (1982) Characterization of the mRNA and cloned cDNA specifying the third component of mouse complement. Proc Natl Acad Sci USA 79:7619–7623

    PubMed  CAS  Google Scholar 

  246. Einstein LP, Alper CA, Bloch KJ, Herrin JT, Rosen FS, David JR, Colten HR (1975) Biosynthetic defect in monocytes from human beings with genetic deficiency of the second component of complement. N Engl J Med 292:1169–1171

    PubMed  CAS  Google Scholar 

  247. Einstein LP, Hansen PJ, Ballow M, Davis AE, Davis JS, Alper CA, Rosen FS, Colten HR (1977) Biosynthesis of the third component of complement (C3) in vitro by monocytes from both normal and homozygous C3-deficient humans. J Clin Invest 60:963–969

    PubMed  CAS  Google Scholar 

  248. Einstein LP, Schneeberger EE, Colten HR (1976) Synthesis of the second component of complement by long-term primary cultures of human monocytes. J Exp Med 143:114–126

    PubMed  CAS  Google Scholar 

  249. Ellman L, Green I, Frank MM (1970) Genetically controlled total deficiency of the fourth component of complement in the guinea pig. Science 170:74–75

    PubMed  CAS  Google Scholar 

  250. Ezekowitz RAB, Sim RB, Hill M, Gordon S (1984) Local opsonisation by secreted macrophage complement components. Role of receptors for complement in uptake of zymosan. J Exp Med 159:244–260

    PubMed  CAS  Google Scholar 

  251. Ferreira A, Michaelson J, Nussenzweig V (1980) A polymorphism of the gamma-chain of mouse C4 controlled by the S region of the major histocompatibility complex. J Immunol 125:1178–1182

    PubMed  CAS  Google Scholar 

  252. Fey G, Colten HR (1981) Biosynthesis of complement components. Fed Proc 40:2099–2104

    PubMed  CAS  Google Scholar 

  253. Fey G, Domdey H, Wiebauer K, Whitehead AS, Odink K (1983) Structure and expression of the C3 gene. Springer Semin Immunopathol 6:119–147

    PubMed  CAS  Google Scholar 

  254. Fey G, Odink K, Chapuis RM (1980) Synthesis of the mouse complement component C4 (Ss-protein) by peritoneal macrophages: kinetics of secretion and glycosylation of the subunits. Eur J Immunol 10:75–82

    PubMed  CAS  Google Scholar 

  255. Ferreira A, Nussenzweig V, Gigli I (1978) Structural and functional differences between the H-2 controlled Ss and Slp proteins. J Exp Med 148:1186–1197

    PubMed  CAS  Google Scholar 

  256. Fleming KA, McGee JOD (1982) The relationship between collagen and C1q biosynthesis in cultured human fibroblasts. Biochem J 206:287–293

    PubMed  CAS  Google Scholar 

  257. Fleming KA, Reid KBM, McGee JOD (1983) An assay for C1q biosynthesis in cultured human fibroblasts. J Immunol Methods 56:43–54

    PubMed  CAS  Google Scholar 

  258. Fu SM, Kunkel HG, Brusman HP, Allen FH, Fotino M (1974) Evidence for linkage between HL-A histocompatibility genes and those involved in the synthesis of the second component of complement. J Exp Med 140:1108–1111

    PubMed  CAS  Google Scholar 

  259. Gagnon J, Christie DL (1983) Amino acid sequence of the Bb fragment from human complement factor B. Biochem J 209:51–60

    PubMed  CAS  Google Scholar 

  260. Geiger H, Day NKB, Good RA (1972) Ontogenetic development and synthesis of hemolytic C8 by piglet tissues. J Immunol 108:1092–1097

    PubMed  CAS  Google Scholar 

  261. Germain RN, Norcross MA (1983) Functional expression of a transfected murine class II MHC gene. Nature 306:190–194

    PubMed  CAS  Google Scholar 

  262. Gigli I (1978) A single chain precursor of human C4 in serum. Nature 272:836–837

    PubMed  CAS  Google Scholar 

  263. Gitlin D, Biasucci A (1969) Development of γG, γA, γM, β1C/β1A, C1 esterase inhibitor, ceruloplasmin, transferrin, hemopexin, haptoglobin, fibrinogen, plasminogen, alpha-1-antitrypsin, orosomucoid, beta-lipoprotein, alpha-2macroglobulin, and prealbumin in the human conceptus. J Clin Invest 48:1433–1442

    PubMed  CAS  Google Scholar 

  264. Goldberger G, Abraham GN, Williams J, Colten HR (1980) Primary structure of pro-C4, the precursor of the fourth component of guinea pig complement. J Biol Chem 255:7071–7074

    PubMed  CAS  Google Scholar 

  265. Goldberger G, Arnaout MA, Aden D, Kay R, Rits M; Colten HR (1984) Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines. J Biol Chem 259:6492–6497

    PubMed  CAS  Google Scholar 

  266. Goldberger G, Brenner MJ, Colten HR (1979) Kinetics of synthesis and secretion of a precursor of the fourth component of complement. Fed Proc 38:1011

    Google Scholar 

  267. Goldberger G, Cole FS, Einstein LP, Auerbach HS, Bitter-Suermann D, Colten HR (1982) Biosynthesis of a structurally abnormal C2 complement protein by macrophages from C2 deficient guinea pigs. J Immunol 129:2061–2065

    PubMed  CAS  Google Scholar 

  268. Goldberger G, Colten HR (1980) Precursor complement protein (pro-C4) is converted in vitro to native C4 by plasmin. Nature 286:514–516

    PubMed  CAS  Google Scholar 

  269. Goldberger G, Thomas ML, Tack BF, Williams J, Colten HR, Abraham GN (1981) NH2-terminal structure and cleavage of guinea pig pro-C3, the precursor of the third complement component. J Biol Chem 256:12617–12619

    PubMed  CAS  Google Scholar 

  270. Goldman MB, Cohen L, O’Rourke KS, Goldman JN (1982) Functional and developmental differences between genetically controlled phenotypes of the sixth component of complement in rabbits. J Immunol 129:180–183

    PubMed  CAS  Google Scholar 

  271. Goldman MB, Cohen L, Stronski K, Bangalone S, Goldman JN (1982) Genetic control of C6 polymorphism and C6 deficiency in rabbits. J Immunol 128:43–48

    PubMed  CAS  Google Scholar 

  272. Goldman MB, O’Rourke KS, Goldman JN (1982) Antibody-induced suppression and post-supression stimulation of complement in vitro. I. Effects of anti-C4 on cultured guinea pigs peritoneal cells. Cell Immunol 70:118–131

    PubMed  CAS  Google Scholar 

  273. Gorski JP, Hugli TE, Muller-Eberhard HJ (1979) C4a: the third anaphylatoxin of the human complement system. Proc Natl Acad Sci USA 76:5299–5302

    PubMed  CAS  Google Scholar 

  274. Hadding U, Bentley C, Bitter-Suermann D, Brade V (1976) Factor B of the properdin system is synthesized by mouse peritoneal macrophages in vitro. Fed Proc 35:654

    Google Scholar 

  275. Halbluachs L, Lachmann PJ (1976) Factor B of the alternative complement pathway on human lymphocytes. Scand J Immunol 5:697–702

    Google Scholar 

  276. Hall RE, Colten HR (1977) Cell-free synthesis of the fourth component of guinea pig complement (C4): identification of a precursor of serum C4 (pro-C4). Proc Natl Acad Sci USA 74:1707–1710

    PubMed  CAS  Google Scholar 

  277. Hall RE, Colten HR (1977) Molecular size and subunit structure of the fourth component of guinea pig complement. J Immunol 118:1903–1905

    PubMed  CAS  Google Scholar 

  278. Hall RE, Colten HR (1978) Genetic defect in biosynthesis of the precursor form of the fourth component of complement. Science 199:69–70

    PubMed  CAS  Google Scholar 

  279. Hannema AJ, Kluin-Nelemans HC, Hack CE, Mallee C, van Helden HPT, Eerenber-Belmer AJM (1982) A functional deficiency of C1q in 3 family members. Mol Immunol 19:1373

    Google Scholar 

  280. Hartveit F, Borve W, Thunold S (1973) Serum complement levels and response to turpentine inflammation in mice. Acta Pathol Microbiol Immunol Scand [A] [Suppl] 236:54–59

    CAS  Google Scholar 

  281. Hugli TE (1981) The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a and C5a. CRC Crit Rev Immunol 1:321–366

    CAS  Google Scholar 

  282. Johnson AM, Alper CA, Rosen FS, Craig JM (1971) Immunofluorescent hepatic localization of complement proteins: evidence for a biosynthetic defect in hereditary angioneurotic edema (HANE). J Clin Invest 50:50a

    Google Scholar 

  283. Karp DR (1983) Post-translational modification of the fourth component of complement. Effect of tunicamycin and amino acid analogs on the formation of the internal thiol ester and disulfide bonds. J Biol Chem 258:14490–14495

    PubMed  CAS  Google Scholar 

  284. Karp DR (1983) Post-translational modification of the fourth component of complement. Sulfation of the alpha chain. J Biol Chem 258:12745–12748

    PubMed  CAS  Google Scholar 

  285. Karp DR, Capra JD, Atkinson JP, Shreffler DC (1982) Structural and functional characterization of an incompletely processed form of murine C4 and Slp. Immunol 128:2336–2341

    CAS  Google Scholar 

  286. Karp DR, Parker KL, Shreffler DC, Slaughter C, Capra JD (1982) Amino acid sequence homologies and glycosylation differences between the fourth component of murine complement and sex-limited protein. Proc Natl Acad Sci USA 79:6347–6349

    PubMed  CAS  Google Scholar 

  287. Karp DR, Shreffler DC, Atkinson JP (1982) Characterization of the Mr difference between secreted murine fourth component of complement and the major plasma form: evidence for carboxyl-terminal cleavage of the alpha chain. Proc Natl Acad Sci USA 79:6666–6670

    PubMed  CAS  Google Scholar 

  288. Kerr MA, Gagnon J (1982) The purification and properties of the second component of guinea pig complement. Biochem J 205:59–67

    PubMed  CAS  Google Scholar 

  289. Knobel JR, Villiger W, Isliker H (1972) Chemical analysis and electron microscopy studies of human C1q prepared by different methods. Eur J Immunol 5:78–81

    Google Scholar 

  290. Knowles BB, Howe CC, Aden DP (1980) Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209:497–499

    PubMed  CAS  Google Scholar 

  291. Kohler PF (1973) Maturation of the human complement system. I.Onset time and sites of fetal C1q, C4, C3, and C5 synthesis. J Clin Invest 52:671–677

    PubMed  CAS  Google Scholar 

  292. Kolski GB, Strunk RC (1981) Soybean oil emulsion induces a selective and reversible inhibition of C2 production by human mononuclear phagocytes. J Immunol 126:2267–2271

    PubMed  CAS  Google Scholar 

  293. Kreuzpaintner G, Brade V (1983) Effect of cycloheximide and of anti-C3 Fab’ on the intrinsic synthesis and secretion of lysosomal enzyme and of complement components by guinea pig peritoneal macrophages. Immunology 49:337–342

    PubMed  CAS  Google Scholar 

  294. Lai AF, van Furth R (1975) In vitro synthesis of some complement components (C1q, C3, and C4) by lymphoid tissues and circulating leukocytes in man. Immunology 28:359–368

    Google Scholar 

  295. Lally ET, McArthur WP, Baehni PC (1982) Biosynthesis of complement components in chronically inflamed gingiva. J Periodontol Res 17:257–262

    CAS  Google Scholar 

  296. Lappin D, Whaley K (1980) Effect of histamine on monocyte complement production. I. Inhibition of C2 production mediated by its action on H2 receptors. Clin Exp Immunol 41:497–504

    PubMed  CAS  Google Scholar 

  297. Leddy JP, Frank MM, Gaither T, Baum J, Klemperer MR (1974) Hereditary deficiency of the sixth component of complement in man. I. Immunochemical, biologic and family studies. J Clin Invest 53:544–553

    PubMed  CAS  Google Scholar 

  298. Lepow IH, Naff GB, Todd EW, Pensky J, Hinz CH (1963) Chromatographic resolution of the first component of human complement into three activities. J Exp Med 117:983–1008

    PubMed  CAS  Google Scholar 

  299. Levy NL, Snyderman R, Ladda RL, Lieberman R (1973) Cytogenetic engineering in vivo: restoration of biologic complement activity to C5-deficient mice by intravenous inoculation of hybrid cells. Proc Natl Acad Sci USA 70:3125–3129

    PubMed  CAS  Google Scholar 

  300. Littleton CD, Kessler D, Burkjolder PM (1970) Cellular basis for synthesis of the fourth component of guinea pig complement as determined by a hemolytic plaque assay. Immunology 18:691–702

    Google Scholar 

  301. Littman BH, Ruddy S (1977) Production of the second component of complement by human monocytes: stimulation by antigen activated lymphocytes or lymphokines. J Exp Med 145:1344–1352

    PubMed  CAS  Google Scholar 

  302. Littman BH, Hall RE, Muchmore AV (1983) Lymphokine and phorbol (PMA) regulation of complement (C2) synthesis using U937. Cell Immunol 76:189–195

    PubMed  CAS  Google Scholar 

  303. Loos M (1983) Biosynthesis of the collagen-like C1q molecule and its receptor functions for Fc and polyanionic molecules on macrophages. Curr Top Microbiol Immunol 102:2–56

    Google Scholar 

  304. Lundwall AB, Wetsel RA, Kristensen T, Whitehead AS, Woods D, Ogden RL, Colten HR, Tack BF (1985) Isolation and sequence analysis of a cDNA clone encoding the fifth component of human complement. J Biol Chem 260:2108–2112

    PubMed  CAS  Google Scholar 

  305. McClelland DBL, van Furth R (1976) In vitro synthesis of beta-1-C/beta-1-A globulin (the C3 component of complement) by tissues and leucocytes of mice. Immunology 31:855–861

    PubMed  CAS  Google Scholar 

  306. McPhaden AR, Lappin D, Whaley K (1982) Biosynthesis of complement components. J Clin Lab Immunol 8:1–8

    PubMed  CAS  Google Scholar 

  307. McPhaden AR, Whaley K (1982) Modulation of C2 biosynthesis by antigen-antibody complexes. J Clin Lab Immunol 7:15–19

    PubMed  CAS  Google Scholar 

  308. Matthews WJ, Goldberger F, Marino JT, Einstein LP, Gash DJ, Colten HR (1982) Complement proteins C2, C4, and factor B: effect of glycosylation on their secretion and catabolism. Biochem J 204:839–846

    PubMed  CAS  Google Scholar 

  309. Matthews WJ, Marino JT, Goldberger G, Gash DJ, Colten HR (1979) Feedback inhibition of the biosynthesis of the fourth component of complement (C4). Fed Proc 38:1011

    Google Scholar 

  310. Minta JO, Ngan BY, Pang ASD (1979) Purification and characterization of a single chain precursor C3-protein (pro-C3) from normal human plasma. J Immunol 123:2415–2420

    PubMed  CAS  Google Scholar 

  311. Mondino BJ, Sundar-Raj CV, Brady KJ (1982) Production of first component of complement by corneal fibroblasts in tissue culture. Arch Ophthalmol 100:478–480

    PubMed  CAS  Google Scholar 

  312. Morris KM, Aden DP, Knowles BB, Colten HR (1982) Complement biosynthesis by the human hepatoma-derived cell line, Hep G2. J Clin Invest 70:906–913

    PubMed  CAS  Google Scholar 

  313. Morris KM, Colten HR, Bing DH (1978) The first component complement. A quantitative comparison of its biosynthesis in culture by human epithelial and mesenchymal cells. J Exp Med 148:1007–1019

    PubMed  CAS  Google Scholar 

  314. Morris KM, Goldberger G, Colten HR, Aden DP, Knowles BB (1982) Biosynthesis and processing of a human precursor complement protein, pro-C3, in a hepatoma-derived cell line. Science 215:399–400

    PubMed  CAS  Google Scholar 

  315. Müller W, Hanauske-Abel H, Loos M (1978) Synthesis of the first component of complement by human and guinea pig peritoneal macrophages: evidence for an independent production of the C1 subunits. J Immunol 121:1578–1584

    PubMed  Google Scholar 

  316. Müller W, Hanauske-Abel H, Loos M (1978) Reversible inhibition of C1q release from guinea pig macrophages by 2,2′-dipyridyl. FEBS Lett 90:218–222

    PubMed  Google Scholar 

  317. Nagasawa S, Stroud RM (1977) Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b, Proc Natl Acad Sci USA 74:2998–3001

    PubMed  CAS  Google Scholar 

  318. Newell SL, Shreffler DC, Atkinson JP (1982) Biosynthesis of C4 by mouse peritoneal macrophages. I. Characterization of an in vitro culture system and comparison of C4 synthesis of “low” vs “high” C4 strains. J Immunol 129:653–659

    PubMed  CAS  Google Scholar 

  319. Newell SL, Atkinson JP (1983) Biosynthesis of C4 by mouse peritoneal macrophages. II. Comparison of C4 synthesis by resident and elicited cell populations. J Immunol 130:834–838

    PubMed  CAS  Google Scholar 

  320. Nilsson UR, Mandle RJ, McConnell-Mapes JA (1975) Human C3 and C5: subunit structure and modification by trypsin and C42-C423. J Immunol 114:815–822

    PubMed  CAS  Google Scholar 

  321. Ogata RT, Shreffler DC, Sepich DS, Lilly SP (1983) cDNA clone spanning the alpha- gamma subunit junction in the precursor of the murine fourth complement component (C4). Proc Natl Acad Sci USA 80:5061–5065

    PubMed  CAS  Google Scholar 

  322. Ooi YM (1982) Histamine suppressed in vitro synthesis of precursor (pro-C5) of the fifth complement component (C5) by mouse peritoneal macrophages. J Immunol 129:200–205

    PubMed  CAS  Google Scholar 

  323. Ooi YM, Colten HR (1979) Biosynthesis and post-synthetic modification of a precursor (pro-C5) of the fifth component of mouse complement (C5). J Immunol 123:2494–2498

    PubMed  CAS  Google Scholar 

  324. Ooi YM, Colten HR (1979) Genetic defect in secretion of complement C5 in mice. Nature 282:207–208

    PubMed  CAS  Google Scholar 

  325. Ooi YM, Harris DE, Edelson PJ, Colten HR (1980) Post-translational control of complement (C5) production by resident and stimulated mouse macrophages. J Immunol 124:2077–2081

    PubMed  CAS  Google Scholar 

  326. Ooi YM, Ooi BS (1982) Biosynthesis of membrane factor B by mouse peritoneal macrophages. Nature 298:389–391

    PubMed  CAS  Google Scholar 

  327. Pangburn MK (1983) Activation of complement via the alternative pathway. Fed Proc 42:139–143

    PubMed  CAS  Google Scholar 

  328. Parker KL, Capra JD, Shreffler DC (1980) Partial amino acid sequences of the murine fourth component of complement (C4): demonstration of homology with human C4 and identification of amino terminal subunit in pro-C4. Proc Natl Acad Sci USA 77:4275–4278

    PubMed  CAS  Google Scholar 

  329. Parker KL, Carroll MC, Shreffler DC, Capra JD (1981) Identification of H-2-controlled structural variants of the murine Slp protein and demonstration of cis-regulation of its expression. J Immunol 126:995–997

    PubMed  CAS  Google Scholar 

  330. Parker KL, Roos MH, Shreffler DC (1979) Structural characterization of the murine fourth component of complement and sex-limited proteins and their precursors: evidence for two loci in the S-region of the H-2 complex. Proc Natl Acad Sci USA 76:5853–5857

    PubMed  CAS  Google Scholar 

  331. Passmore HC, Shreffler DC (1970) A sex-linked serum protein variant in the mouse: inheritance and association with the H-2 region. Biochem Genet 4:351–365

    PubMed  CAS  Google Scholar 

  332. Patel F, Minta JO (1979) Biosynthesis of a single chain pro-C5 by normal mouse liver mRNA: analysis of the molecular basis of C5 deficiency in AKR/J mice. J Immunol 123:2408–2414

    PubMed  CAS  Google Scholar 

  333. Pennington JE, Matthews WJ, Marino JT, Colten HR (1979) Cyclophosphamide and cortisone acetate inhibit complement biosynthesis by guinea pig bronchoalveolar macrophages. J Immunol 123:1318–1321

    PubMed  CAS  Google Scholar 

  334. Perlmutter DH, Cole FS, Goldberger G, Colten HR (1984) Distinct primary translation products from human liver mRNA give rise to secreted and cell-associated forms of complement protein C2. J Biol Chem 259:10380–10385

    PubMed  CAS  Google Scholar 

  335. Phillips MR, Rother UA, Rother KO, Thorbecke GJ (1969) Studies on the serum proteins of chimeras. III. Detection of donor type C5 in allogenic and congenic post-irradiation chimeras. Immunology 17:315–321

    PubMed  CAS  Google Scholar 

  336. Porter RR, Reid KBM (1978) The biochemistry of complement. Nature 275:699–704

    PubMed  CAS  Google Scholar 

  337. Porter RR, Reid KBM (1979) Activation of the complement system by antibody-antigen complexes: The classical pathway. Adv Protein Chem 33:1–71

    PubMed  CAS  Google Scholar 

  338. Quastei M, Harrison R, Cicardi M, Alper CA, Rosen FS (1983) Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 71:1041–1046

    Google Scholar 

  339. Raum D, Donaldson VH, Rosen FS, Alper CA (1980) Genetics of complement. Curr Top Hematol 3:111–174

    PubMed  CAS  Google Scholar 

  340. Raum D, Glass D, Carpenter CB, Schur PH, Alper CA (1979) Mapping of the structural gene of the second component of complement with respect to the human major histocompatibility complex. Am J Hum Genet 31:35–41

    PubMed  CAS  Google Scholar 

  341. Reid KBM (1976) Complete amino acid sequences of the three collagen-like regions present in subcomponent of the first component of human complement. Biochem J 179:367–371

    Google Scholar 

  342. Reid KBM (1983) Proteins involved in the activation and control of the two pathways of human complement. Biochem Soc Trans 11:1–12

    PubMed  CAS  Google Scholar 

  343. Reid KBM, Edmondson J (1984) Location of the binding site in subcomponent C1q for plasma fibronectin. Acta Path Microbiol Immunol. Sect C Suppl 284, 92:11–17

    Google Scholar 

  344. Reid KBM, Gagnon J, Frampton J (1982) Completion of the amino acid sequences of the A and B chains of subcomponent C1q of the first component of human complement. Biochem J 203:559–569

    PubMed  CAS  Google Scholar 

  345. Reid KBM, Proter RR (1976) Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochem J 155:19–23

    PubMed  CAS  Google Scholar 

  346. Reid KBM, Porter RR (1981) The proteolytic activation system of complement. Annu Rev Biochem 50:433–464

    PubMed  CAS  Google Scholar 

  347. Reid KBM, Solomon E (1977) Biosynthesis of the first component of complement by human fibroblasts. Biochem J 167:647–660

    PubMed  CAS  Google Scholar 

  348. Reid KBM, Thompson RA (1983) Characterization of a non-functional form of C1q found in patients with a genetically linked deficiency of C1q activity. Mol Immunol 20:1117–1125

    PubMed  CAS  Google Scholar 

  349. Roos MH, Atkinson JP, Shreffler DC (1978) Molecular characterization of the Ss and Slp (C4) proteins of the mouse H-2 complex: subunit composition, chain size polymorphism and an intracellular (pro-Ss) precursor. J Immunol 121:1106–1115

    PubMed  CAS  Google Scholar 

  350. Roos MH, Demant P (1982) Murine complement factor B (BF): sexual dimorphism and H-2-linked polymorphism. Immunogenetics 15:23–30

    PubMed  CAS  Google Scholar 

  351. Roos MH, Kornfeld S, Shreffler DC (1980) Characterization of the oligosaccharide units of the fourth component of complement (Ss protein) synthesized by murine macrophages. J Immunol 124:2860–2863

    PubMed  CAS  Google Scholar 

  352. Roos MH, Mollenhauer E, Demant P, Rittner C (1982) A molecular basis for the two locus (C4A and C4B) of the fourth component of human complement (C4). Nature 298:854–856

    PubMed  CAS  Google Scholar 

  353. Rosa PA, Shreffler DC (1983) Cultured hepatocytes from mouse strains expressing high and low levels of the fourth component of complement differ in rate of synthesis of the protein. Proc Natl Acad Sci USA 80:2332–2336

    PubMed  CAS  Google Scholar 

  354. Rosenfeld SI, Ruddy S, Austen KF (1969) Structural polymorphism of the fourth component of human complement. J Clin Invest 48:2283–2292

    PubMed  CAS  Google Scholar 

  355. Rother K, Rother U, Muller-Eberhard HJ, Nilsson UR (1966) Deficiency of the sixth component of complement in rabbits with an inherited complement defect. J Exp Med 124:773–785

    PubMed  CAS  Google Scholar 

  356. Rother U, Thorbecke GJ, Stecher-Levin VJ, Hurlimann J, Robert K (1968) Formation of C6 by rabbit liver tissue in vitro. Immunology 14:649–655

    PubMed  CAS  Google Scholar 

  357. Ruddy S, Colten HR (1974) Rheumatoid arthritis: biosynthesis of complement proteins by synovial tissues. N Engl J Med 290:1284–1288

    PubMed  CAS  Google Scholar 

  358. Sackstein R, Colten HR (1984) Molecular regulation of MHC class III (CH and factor B) gene expression in mouse peritoneal macrophages. J Immunol 133:1618–1626

    PubMed  CAS  Google Scholar 

  359. Schorlemmer HU (1981) The role of complement in the function of the monocyte-macro-phage system. Hematol Blood Transfus 27:59–71

    Google Scholar 

  360. Schreiber RD, Müller-Eberhard HJ (1974) Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med 140:1324–1335

    PubMed  CAS  Google Scholar 

  361. Senger DR, Hynes RO (1978) C3 component of complement secreted by established cell lines. Cell 15:375–384

    PubMed  CAS  Google Scholar 

  362. Shreffler DC, Owen RD (1963) A serologically detected variant in mouse serum: inheritance and association with the histocompatibility-2 locus. Genetics 48:9–25

    PubMed  CAS  Google Scholar 

  363. Sim RB, Porter RR, Reid KBM, Gigli I (1977) The structure and enzymic activities of the C1r and C1s subcomponents of C1, the first component of human serum complement. Biochem J 163: 219–227

    PubMed  CAS  Google Scholar 

  364. Skok J, Solomon E, Reid KBM, Thompson RA (1981) Distinct genes for fibroblast and serum C1q. Nature 292:549–551

    PubMed  CAS  Google Scholar 

  365. Stecher VJ, Thorbecke GJ (1967) Sites of synthesis of serum proteins. I. Serum proteins produced by macrophages in vitro. J Immunol 99:643–652

    PubMed  CAS  Google Scholar 

  366. Stecher VJ, Thorbeeke GJ (1967) Sites of synthesis of serum proteins. III. Production of beta-1-C, beta-1-E and transferrin by primate and rodent cell lines. J Immunol 99:660–662

    PubMed  CAS  Google Scholar 

  367. Strunk RC, Whitehead AS, Cole FS (1985) Pretranslational regulation of the synthesis of the third Component of complement in human mononuclear phagocytes by the lipid A portion of lipopolysaccharide. J Clin Invest 76:985–990

    PubMed  CAS  Google Scholar 

  368. Strunk RC, Kunke KS, Giclas PC (1983) Human peripheral blood monocyte-derived macrophages produce haemolytically active C3 in vitro. Immunology 49:169–174

    PubMed  CAS  Google Scholar 

  369. Strunk RC, Tashjian AH, Colten HR (1975) Complement biosynthesis in vitro by rat hepatoma cell strains. J Immunol 114:331–335

    PubMed  CAS  Google Scholar 

  370. Sundsmo JS (1982) The leukocyte complement system. Fed Proc 41:3094–3098

    PubMed  CAS  Google Scholar 

  371. Sundsmo JS, Gotze O (1981) Human monocyte spreading induced by factor Bb of the alternative pathway of complement activation. J Exp Med 154:763–777

    PubMed  CAS  Google Scholar 

  372. Sundsmo JS, Selberg JK, Chin AC, Gotze O (1979) A possible role for complement in lymphocyte activation. In: Kaplan JG (ed) The molecular basis of immune cell function. Elsevier-North Holland, Amsterdam, pp 466–478

    Google Scholar 

  373. Tedesco F, Densen P, Villa MA, Petersen BH, Sirchia G (1983) Two types of dysfunctional eighth component of complement (C8) molecules in C8 deficiency in man. Reconstitution of normal C8 from the mixture of two abnormal C8 molecules. J Clin Invest 71:183–191

    PubMed  CAS  Google Scholar 

  374. Tedesco F, Bardare M, Giovannetti AM, Sirchia G (1980) A familial dysfunction of the eighth component of complement (C8). Clin Immunol Immunopathol 16:180–191

    PubMed  CAS  Google Scholar 

  375. Tenner AJ, Cooper NR (1980) Analysis of receptor-mediated C1q binding to human peripheral blood mononuclear cells. J Immunol 125:1658–1664

    PubMed  CAS  Google Scholar 

  376. Tenner AJ, Cooper NR (1981) Identification of types of cells in human peripheral blood that bind C1q. J Immunol 126:1174–1179

    PubMed  CAS  Google Scholar 

  377. Tenner AJ, Cooper NR (1982) Stimulation of a human polymorphonuclear leukocyte oxidative response by the C1q subunit of the first complement component. J Immunol 128:2547–2552

    PubMed  CAS  Google Scholar 

  378. Thomas ML, Janatova J, Gray WR, Tack BF (1982) Third component of human complement: localization of the internal thiolester bond. Proc Natl Acad Sci USA 79:1054–1058

    PubMed  CAS  Google Scholar 

  379. Thomspon RA, Haeney M, Reid KBM, Davies JG, White RHR, Cameron AH (1980) A genetic defect of the C1q complement subcomponent associated with (immune complex) nephritis. N Engl J Med 303:22–24

    Google Scholar 

  380. Thorbecke GJ, Hochwald GM, van Furth R, Müller-Eberhard HJ, Jacobson EB (1965) Problems in determining the sites of synthesis of complement components. In: Wolstenholme GEW, Knight J (eds) CIBA symposium: Complement. Churchill, London, pp 99–119

    Google Scholar 

  381. Tschopp J, Esser AF, Spira TJ, Müller-Eberhard HJ (1981) Occurrence of an incomplete C8 molecule in homozygous C8 deficiency in man J Exp Med 154:1599–1607

    PubMed  CAS  Google Scholar 

  382. Whaley K (1980) Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J Exp Med 151:501–516

    PubMed  CAS  Google Scholar 

  383. Whaley K, Lappin D, Hamilton AO (1983) Serum-treated antigen-antibody complexes inhibit the production of C2 and factor B by mononuclear phagocytes. Immunology 48:255–263

    PubMed  CAS  Google Scholar 

  384. Whaley K, Lappin D, Barkas T (1981) C2 synthesis by human monocytes is modulated by a nicotinic cholinergic receptor. Nature 293:580–583

    PubMed  CAS  Google Scholar 

  385. Whitehead AS, Goldberger G, Woods DW, Markham AF, Colten HR (1983) Use of a cDNA clone for the fourth component of human complement (C4) for analysis of a genetic deficiency of C4 in guinea pig. Proc Natl Acad Sci USA 80:5387–5391

    PubMed  CAS  Google Scholar 

  386. Whitehead AS, Sim RB, Bodmer WF (1981) A monoclonal antibody against human complement component C3: the production of C3 by human cells in vitro. Eur J Immunol 11:140–146

    PubMed  CAS  Google Scholar 

  387. Whitehead AS, Solomon E, Chambers S, Bodmer WF, Povey S, Fey G (1982) Assignment of the structural gene for the third component of human complement to chromosome 19. Proc Natl Acad Sci USA 79:5021–5025

    PubMed  CAS  Google Scholar 

  388. Wiebauer K, Domdey H, Diggelman H, Fey G (1982) Isolation and analysis of genomic DNA clones encoding the third component of mouse complement. Proc Natl Acad Sci USA 79:7077–7081

    PubMed  CAS  Google Scholar 

  389. Winkelstein JA, Cork LC, Griffin DE, Griffin JW, Adams RJ, Price DL (1981) Genetically determined deficiency of the third component of complement in the dog. Science 212:1169–1170

    PubMed  CAS  Google Scholar 

  390. Winkelstein JA, Johnson JP, Swift AJ, Ferry F, Yolken R, Cork LC (1982) Genetically determined deficiency of the third component of complement in the dog: in vitro studies on the complement system and complement-mediated serum activities. J Immunol 129:2598–2602

    PubMed  CAS  Google Scholar 

  391. Woo P, Lachmann PJ (1981) The detection and characterization of a membrane protein with factor B-like activity on human lymphoid cells. Immunology 44:629–639

    PubMed  CAS  Google Scholar 

  392. Woods DW, Markham AP, Ricker AT, Goldberger G, Colten HR (1982) Isolation of cDNA clones for the human complement protein factor B, a class III major histocompatibility complex gene product. Proc Natl Acad Sci USA 79:5661–5665

    PubMed  CAS  Google Scholar 

  393. Wyatt HV, Colten HR, Borsos T (1972) Production of the second (C2) and fourth (C4) components of guinea pig complement by single peritoneal exudate cells. Evidence that one cell may produce both components. J Immunol 108:1609–1614

    PubMed  CAS  Google Scholar 

  394. Ziccardi RJ, Cooper NR (1976) Physicochemical and functional characterization of the C1r subunit of the first complement component. J Immunol 116:496–503

    PubMed  CAS  Google Scholar 

  395. Ziccardi RJ, Cooper NR (1976) Activation of C1r by proteolytic cleavage. J Immunol 116:504–509

    PubMed  CAS  Google Scholar 

  396. Zimmer B, Hartung HP, Scharfenberger G, Bitter-Suermann D, Hadding U (1982) Quantitative studies of the secretion of complement component C3 by resident, elicited, and activated macrophages. Comparison with C2, C4 and lysosomal enzyme release. Eur J Immunol 12:426–430

    PubMed  CAS  Google Scholar 

  397. Alper CA, Johnson AM, Birtch AG, Moore FD (1969) Human C’3: evidence for the liver as the primary site of synthesis. Science 163:286

    PubMed  CAS  Google Scholar 

  398. Alper CA, Raum D, Awdeh Z, Petersen BH, Taylor PD, Starzl TE (1980) Studies of hepatic synthesis in vivo of plasma protein including orosomucoid, transferrin, alpha-1-antitrypsin, C8 and factor B. Clin Immunol Immunopathol 16:84

    PubMed  CAS  Google Scholar 

  399. Auerbach HS, Baker RD, Matthews WJ, Colten HR (1984) Molecular mechanism for feedback regulation of C4 biosynthesis in guinea pig peritoneal macrophages. J Exp Med 159:1750

    PubMed  CAS  Google Scholar 

  400. Barnum SR, Volanakis JE (1985) In vitro biosynthesis of complement protein D by U 937 cells. J Immunol 134:1799

    PubMed  CAS  Google Scholar 

  401. Barnum SR, Volanakis JE (1985) Biosynthesis of complement protein D by Hep G2 cells: a comparison of D produced by Hep G2 cells, U 937 cells and blood monocytes. Eur J Immunol 15:1148

    PubMed  CAS  Google Scholar 

  402. Beatty DW, Davis AE, Cole FS, Einstein LP, Colten HR (1981) Biosynthesis of complement by human monocytes. Clin Immunol Immunopathol 18:334

    PubMed  CAS  Google Scholar 

  403. Bentley CD, Bitter-Suermann D, Hadding U, Brade V (1976) In vitro synthesis of factor B of the alternative pathway of complement by mouse peritoneal macrophages. Eur J Immunol 6:393

    PubMed  CAS  Google Scholar 

  404. Bentley CD, Hadding U, Bitter-Suermann D, Brade V (1977) Effect of in vivo stimulation of mice on the secretion of factor B of the alternative pathway by peritoneal macrophages. Eur J Immunol 7:188

    PubMed  CAS  Google Scholar 

  405. Bentley CD, Fries W, Brade V (1978) Synthesis of factors D, B, and P of the alternative pathway of complement activation as well as C3 by guinea pig peritoneal macrophages in vitro. Immunology 35:971

    PubMed  CAS  Google Scholar 

  406. Bentley CD, Zimmer B, Hadding U (1981) The macrophage as a source of complement components. In: Pick E (ed) Lymphokines, vol 4. Academic, New York, p 197

    Google Scholar 

  407. Brade V, Bentley CD (1980) Synthesis and release of complement components by macrophages. In: van Furth R (ed) Mononuclear phagocytes. Functional aspects. Nijhoff, The Hague, p 1385

    Google Scholar 

  408. Brade V, Kreuzpaintner G (1982) Functional active complement components secreted by guinea pig peritoneal macrophages. Immunobiology 161:315

    PubMed  CAS  Google Scholar 

  409. Caroll MC, Campbell RD, Bentley DR, Porter RR (1984) A molecular map of the human histocompatibility complex class III region Unking complement genes C4, C2 and factor B. Nature 307:237

    Google Scholar 

  410. Cole FS, Schneeberger EE, Lichtenberg NA, Colten HR (1982) Complement biosynthesis in human breast milk macrophages and blood monocytes. Immunology 46:429

    PubMed  CAS  Google Scholar 

  411. Cole FS, Matthews WJ, Rossing TH, Gash DJ, Lichtenberg NA, Pennington JE (1983) Complement biosynthesis by human bronchoalveolar macrophages. Clin Immunol Immunopathol 27:153

    PubMed  CAS  Google Scholar 

  412. Cole FS, Auerbach HS, Goldberger G, Colten HR (1985) Tissue-specific pretranslational regulation of complement production in human mononuclear phagocytes. J Immunol 134:Z610

    Google Scholar 

  413. Cole FS, Strunk RC, Perlmutter DH, Colten HR (1985) Gamma interferon (IFN-γ) increases expression of class III complement genes C2 and factor B in human monocytes and in murine fibroblasts transfected with human C2 and factor B genes. Complement 2:18 (Abstract)

    Google Scholar 

  414. Colten H (1976) Biosynthesis of complement. Adv Immunol 22:67

    PubMed  CAS  Google Scholar 

  415. Colten HR (1982) Biosynthesis of the MHC-linked complement proteins (C2, C4, and factor B) by mononuclear phagocytes. Mol Immunol 19:1279

    PubMed  CAS  Google Scholar 

  416. Colten HR (1983) Molecular genetics of the major histocompatibility linked complement genes. Springer Semin Immunopathol 6:149

    PubMed  CAS  Google Scholar 

  417. Colten HR (1983) The complement genes. Immunol Today 4:151

    CAS  Google Scholar 

  418. De Ceulaer C, Papazoglon S, Whaley K (1980) Increased biosynthesis of complement components by cultured monocytes, synovial fluid macrophages and synovial membrane cells from patients with rheumatoid arthritis. Immunology 41:37

    PubMed  Google Scholar 

  419. Götze O, Bianco C, Cohn ZA (1979) The induction of macrophage spreading by factor B of the properdin system. J Exp Med 149:372

    PubMed  Google Scholar 

  420. Halbwachs L, Lachmann PJ (1976) Factor B of the alternative complement pathway on human lymphocytes. Scand J Immunol 5:697

    PubMed  CAS  Google Scholar 

  421. Hartung HP, Hadding U (1983) Synthesis of complement by macrophages and modulation of their functions through complement activation. Springer Semin Immunopathol 6:283

    PubMed  CAS  Google Scholar 

  422. Kawamoto Y, Keda M, Ichikawa H, Miyama A (1979) Complement protein and macrophages. I. Quantitative estimation of factor B produced by mouse peritoneal macrophages. Microbiol. Immunol. 23:987

    PubMed  CAS  Google Scholar 

  423. Kreuzpaintner G, Brade V (1983) Effect of cycloheximide and of anti-C3 Fab’ on the intrinsic synthesis and secretion of lysosomal enzyme and of complement components by guinea pig peritoneal macrophages. Immunology 49:337

    PubMed  CAS  Google Scholar 

  424. Lappin D, Moseley HL, Whaley K (1980) Effect of histamine on monocyte complement production. II. Modulation of protein secretion, degradation and synthesis. Clin Exp Immunol 42:515

    PubMed  CAS  Google Scholar 

  425. Lappin DF, Whaley K (1982) Prostaglandins and prostaglandin synthetase inhibitors regulate the synthesis of complement components by human monocytes. Clin Exp Immunol 49:623

    PubMed  CAS  Google Scholar 

  426. Lappin D. Whaley K (1982) Cyclic AMP modulation of complement protein production. Int J Immunopharmacol 4:415

    PubMed  CAS  Google Scholar 

  427. Matthews WJ, Goldberger G, Marino JT, Einstein LP, Gash DJ, Colten HR (1982) Complement proteins C2, C4, and factor B: effect of glycosylation on their secretion and catabolism. Biochem J 204:839

    PubMed  CAS  Google Scholar 

  428. Miyama A, Kawamoto Y, Ichikawa H, Okamoto K, Hara S, Inoue T (1980) Complement proteins and macrophages. II. The secretion of factor B by lipopolysaccharide-stimulated màcrophages. Microbiol Immunol 24:1223

    PubMed  CAS  Google Scholar 

  429. Miyama A, Kawamoto Y, Ichikawa H, Mariyana T, Okamato K, Tahakashi T (1981) Complement proteins and macrophages. III. The production of factor B by particle ingesting macrophages. Microbiol Immunol 25:195

    PubMed  CAS  Google Scholar 

  430. Morris KM, Aden DP, Knowles BB, Colten HR (1982) Complement biosynthesis by the human hepatoma-derived cell line HepG2. J Clin Invest 70:906

    PubMed  CAS  Google Scholar 

  431. Newell SL, Atkinson JP (1983) Biosynthesis of C4 by mouse peritoneal macrophages. II. Comparison of C4 synthesis by resident and elicited cell populations. J Immunol 130:834

    PubMed  CAS  Google Scholar 

  432. Ooi YM, Ooi BS (1982) Biosynthesis of membrane factor B by mouse peritoneal macrophages. Nature 298:389

    PubMed  CAS  Google Scholar 

  433. Osthar K, Dybkjaer E (1974) Complement components on the surface of normal lymphocytes. Scand J Haematol 13:24

    Google Scholar 

  434. Perlmutter DH, Colten HR, Grossberger D, Strominger J, Seidman JG, Chaplin DD (1985) Expression of complement proteins C2 and factor B in transfected L cells. J Clin Invest 76:1449

    PubMed  CAS  Google Scholar 

  435. Perlmutter DH, Goldberger G, Dinarello CA, Mizel SB, Colten HR (1985) Regulation of factor B, not C2, by interleukin 1 (IL-1) in murine fibroblasts transfected with the corresponding human genes. Complement 2:62 (Abstract)

    Google Scholar 

  436. Ramadori G, Sipe JD, Dinarello CA, Mizel SB, Colten HR (1985) Pretranslational modulation of a acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL1. J Exp Med 162:930

    PubMed  CAS  Google Scholar 

  437. Robertson J, Caldwell JR, Castle JR, Waldman RH (1976) Evidence for the presence of components of the alternative (properdin) pathway of complement activation in respiratory secretions. J Immunol 117:900

    PubMed  CAS  Google Scholar 

  438. Ruddy S, Colten HR (1974) Rheumatoid arthritis. Biosynthesis of complement proteins by synovial tissues. N Engl J Med 290:1284

    PubMed  CAS  Google Scholar 

  439. Sackstein R, Colten HR (1984) Molecular regulation of MHC class III (C4 and factor B) gene expression in mouse peritoneal macrophages. J Immunol 133:1618

    PubMed  CAS  Google Scholar 

  440. Sundsmo JS (1982) The leucocyte complement system. Fed Proc 41:3094

    PubMed  CAS  Google Scholar 

  441. Sundsmo JS, Chin JR, Papin RA, Fair DS, Werb Z (1985) Factor B, the complement alternative pathway serine proteinase, is a major constitutive protein synthesized and secreted by resident and elicited mouse macrophages. J Exp Med 161:306

    PubMed  CAS  Google Scholar 

  442. Whaley K (1980) Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J Exp Med 151:501

    PubMed  CAS  Google Scholar 

  443. Whaley K, Lappin D, Hamilton AO (1983) Serum-treated antigen-antibody complexes inhibit the production of C2 and factor B by mononuclear phagocytes. Immunology 48:255

    PubMed  CAS  Google Scholar 

  444. Woo P, Lachmann PJ (1981) The detection and characterization of a membrane protein with factor B-like activity on human lymphoid cells. Immunology 44:629

    PubMed  CAS  Google Scholar 

  445. Agnello V, Gell J, Tye MJ (1983) Partial genetic deficiency of the C4 component of complement in discoid lupus erythematosus and urticaria/angioedema. J Am Acad Dermatol 9:894–897

    PubMed  CAS  Google Scholar 

  446. Albert ED, Rittner C, Grosse-Wilde H, Netzel B, Scholz S (1975) Recombination frequency and linkage disequilibrium between HL-A and Bf. In: Kissmeyer-Nielsen F (ed) Histocompatibility testing 1975. Munksgaard, Copenhagen, pp 941–944

    Google Scholar 

  447. Allen FH (1974) Linkage of HL-A and GBG. Vox Sang 27:382–384

    PubMed  Google Scholar 

  448. Alper CA (1976) Inherited structural polymorphism in human C2: evidence for genetic linkage between C2 and Bf. J Exp Med 144:1111–1115

    PubMed  CAS  Google Scholar 

  449. Alper CA, Propp RP (1968) Genetic polymorphism of the third component of human complement (C3). J Clin Invest 47:2181–2191

    PubMed  CAS  Google Scholar 

  450. Alper CA, Johnson AM (1969) Immunofixation electrophoresis: a technique for the study of protein polymorphism. Vox Sang 17:445–452

    PubMed  CAS  Google Scholar 

  451. Alper CA, Robin NI, Refetoff S (1971) Genetic polymorphism in rhesus C3 and Gc globulin. J Immunol 107:96–98

    PubMed  CAS  Google Scholar 

  452. Alper CA, Rosen FS (1971) Studies of a hypomorphic variant of human C3. J Clin Invest 50:324–326

    PubMed  CAS  Google Scholar 

  453. Alper CA, Azen EA, Geserick G, Goedde HW, Rittner C, Teisberg P, Wieme R (1972) Statement on the polymorphism of the third component of complement in man (C3). Vox Sang 25:18–20

    Google Scholar 

  454. Alper CA, Boenisch T, Watson L (1972) Genetic polymorphism in human glycine-rich beta-glycoprotein. J Exp Med 135:68–80

    PubMed  CAS  Google Scholar 

  455. Alper CA, Hobart MJ, Lachman PJ (1975) Polymorphism of the sixth component of complement. In: Arbuthnott JP, Beeley JA (eds) Isoelectric focusing. Butterworth, London

    Google Scholar 

  456. Alper CA, Awdeh ZL, Raum D, Yunis EJ (1982) Extended major histocompatibility complex haplotypes in man: role of alleles analogous to murine t mutants. Clin Immun Immunopathol 24:276–285

    CAS  Google Scholar 

  457. Alper CA, Marcus D, Raum D, Petersen BH (1983) Genetic polymorphism in C8 betachain. Evidence for two unlinked genetic loci for the eighth component of human complement (C8). J Clin Invest 72:1526–1531

    PubMed  CAS  Google Scholar 

  458. Alper CA, Raum D, Karp S, Awdeh ZL, Yunis EJ (1983) Serum complement supergenes of the major histocompatibility complex in man (complotypes). Vox Sang 45:62–67

    PubMed  CAS  Google Scholar 

  459. Arvilommi H (1974) Capacity of complement C3 phenotypes to bind on the mononuclear cells in man. Nature 251:740–741

    PubMed  CAS  Google Scholar 

  460. Awdeh ZL, Raum D, Alper CA (1979) Genetic polymorphism of human complement C4 and detection of heterozygotes. Nature 282:205–207

    PubMed  CAS  Google Scholar 

  461. Awdeh ZL, Alper CA (1980) Inherited polymorphism of human C4 as revealed by de-sialyzation. Immunobiology 158:35–41

    PubMed  CAS  Google Scholar 

  462. Awdeh ZL, Alper CA (1980) Inherited structural polymorphism of the fourth component of human complement. Proc Natl Acad Sci USA 77:3576–3580

    PubMed  CAS  Google Scholar 

  463. Awdeh ZL, Raum D, Yunis EJ, Alper CA (1983) Extended HLA/complement allele haplotypes: evidence for T/t-like complex in man. Proc Natl Acad Sci USA 80:259–264

    PubMed  CAS  Google Scholar 

  464. Awdeh ZL, Raum D, Yunis EJ, Alper CA (1984) An extended major histocompatibility haplotype with duplicated C4A. Immunobiology 164:317 (Abstract)

    Google Scholar 

  465. Azen EA, Smithies O (1968) Genetic polymorphism of C3 (beta-1c-globulin) in human serum. Science 162:905–907

    PubMed  CAS  Google Scholar 

  466. Barbosa J, Weitkamp L, Guttormsen S, Johnson J, Szalapski E Jr (1979) Bf in early-onset insulin-dependent diabetes. Lancet 2:1239–1240

    PubMed  CAS  Google Scholar 

  467. Baur MP, Danilovs JA (1980) Reference tables of two and three-locus haplotype frequencies for HLA-A, B, C, DR, BF, and GLO. In: Terasaki PI (ed) Histocompatibility testing 1980. UCLA Tissue Typing Laboratory Los Angeles, California, pp 1294–1310

    Google Scholar 

  468. Baur MP, Bertrams J, Louton TK, Mauff G, Rittner C, Schaede C (1984) Human C4 haplotype frequencies and their linkage disequilibria in the German population, (unpublished)

    Google Scholar 

  469. Belt KT, Carroll MC, Porter RR (1984) The structural basis of the multiple forms of human complement component C4. Cell 36:907–914

    PubMed  CAS  Google Scholar 

  470. Belt KT, Yu YC, Carroll MC, Porter RR (1985) Polymorphism of human complement component C4. Immunogenetics 21:173–180

    PubMed  CAS  Google Scholar 

  471. Bentley DR, Porter RR (1984) Isolation of cDNA clones for human complement component C2. Proc Natl Acad Sci USA 80:1212–1215

    Google Scholar 

  472. Bentley DR, Campbell RD (1985) Primary structure of C2 and relationship to other components of the complement system. Complement 2:9 (Abstract)

    Google Scholar 

  473. Bentley DR, Campbell RD, Cross SJ (1985) DNA polymorphism of the C2 locus. Immunogenetics 22:377–390

    PubMed  CAS  Google Scholar 

  474. Bertrams J, Opferkuch W, Grosse-Wilde H, Luboldt W, Schuppien W, Kuwert E (1976) C2 hypocomplementemia in multiple sclerosis. Lancet 2:1358–1359

    PubMed  CAS  Google Scholar 

  475. Bertrams J, Opferkuch W, Grosse-Wilde H, Schuppien W, Luboldt W, Kuwert E (1978) HLA-Dw2 associated C2-hypocomplementemic in multiple sclerosis. In: Opferkuch W, Rother K, Schultz DR (eds) Clinical aspects of the complement system. Thieme, Stuttgart, pp 212–216

    Google Scholar 

  476. Bertrams J, Baur MP, Grüneklee D, Hintzen U (1980) Association of Bf F1 and haplotype HLA-B18, Bf F1 with insulin-dependent diabetes mellitus. Immunobiology 158:129–133

    PubMed  CAS  Google Scholar 

  477. Bertrams J, Dewald G, Spitznas M, Rittner C (1980) HLA-A, B, C, DR, Bf, and C2 alleles in insulin-dependent diabetes mellitus with proliferative retinopathy. Immunobiology 158:113–118

    PubMed  CAS  Google Scholar 

  478. Bertrams J, Hintzen U, Schlicht V, Schoeps S (1982) C4: another marker for type 1 diabetes. Lancet 1:42

    Google Scholar 

  479. Bertrams J, Hintzen U, Schlicht V, Schoeps S, Gries FA, Louton TK, Baur MP (1984) Gene and haplotype frequencies of the fourth component of complement in type 1 diabetics and normal. Immunobiology 166:335–344

    PubMed  CAS  Google Scholar 

  480. Bertrams J, Mauff G (1985) Another family with a silent allele of properdin factor B polymorphism (BF*QO). Hum Genet 70:321–323

    PubMed  CAS  Google Scholar 

  481. Bitter-Suermann D, Krönke M, Brade V, Hadding U (1977) Inherited polymorphism of guinea pig factor B and C4: evidence for genetic linkage between the C4 and Bf loci. J Immunol 118:1822–1826

    PubMed  CAS  Google Scholar 

  482. Bodmer WF (1979) Gene clusters and the HLA-system. In: Porter R, O’Connor M (eds) Human genetics: possibilities and realities. Ciba Foundation Symposium 66 (new series). Excerpt Medica, Elsevier, Amsterdam, pp 205–229

    Google Scholar 

  483. Böttger EC, Hoffmann T, Hadding U, Bitter-Suermann D (1985) Influence of genetically inherited complement deficiencies on humoral immune response in guinea pigs. J Immunol 135:4100–4107

    PubMed  Google Scholar 

  484. Brandt-Casadevall C, Dimo-Simonin N, Gugler HR (1983) A rare phenotype C3*FFO.8 encountered in three successive generations of one family. Z Rechtsmed 91:135–138

    PubMed  CAS  Google Scholar 

  485. Brönnestam R (1973) Studies of the C3 polymorphism. Relationship between C3 phenotypes and rheumatoid arthritis. Hum Hered 23:206–213

    PubMed  Google Scholar 

  486. Brönnestam R, Cedergren B (1973) Studies of the C3 polymorphism. Relationship between C3 phenotypes and antibody titres. Hum Hered 23:214–219

    PubMed  Google Scholar 

  487. Bruun-Petersen G, Lamm LU, Juncker Sorensen I, Buskjaer L, Mortensen JP (1981) Family studies of complement C4 and HLA in man. Hum Genet 58:260–267

    PubMed  CAS  Google Scholar 

  488. Bruun-Petersen G, Lamm LU, Jacobsen BK, Kristensen T (1982) Genetics of complement C4. Two homoduplication haplotypes C4SC4S and C4FC4F in a family. Hum Genet 61:36–38

    PubMed  CAS  Google Scholar 

  489. Budowle B, Rosemann JM, Go RCP, Louv W, Barger BO, Acton RT (1983) Phenotypes of the fourth complement component (C4) in Black Americans from the Southeastern United States. J Immunogenet 10:199–204

    PubMed  CAS  Google Scholar 

  490. Bulusu LK, Clark EA (1982) Genetic polymorphism of C3 in Papio and Macaca species. Biochem Genet 20:859–864

    PubMed  CAS  Google Scholar 

  491. Campbell RD, Porter RR (1983) Molecular cloning and characterization of the gene coding for human complement protein factor B. Proc. Natl Acad Sci USA 80:4464–4468

    PubMed  CAS  Google Scholar 

  492. Campbell RD, Morley BJ, Sargent CA, Janjua NJ (1985) Molecular basis for allelic variation at the factor B locus. Complement 2:14 (Abstract)

    Google Scholar 

  493. Carroll MC, Capra JD (1978) Studies on the murine Ss protein: demonstration that the Ss protein is functionally the fourth component of complement. Proc Natl Acad Sci USA 75:2424–2427

    PubMed  CAS  Google Scholar 

  494. Carroll MC, Capra JD (1979) Studies on murine Ss protein: demonstration that S region encodes structural gene for fourth component of complement. Proc Natl Acad Sci USA 76:4641–4644

    PubMed  CAS  Google Scholar 

  495. Carroll MC, Passmore HC, Capra JD (1980) Structural studies on the murine fourth component of complement (C4). IV. Demonstration that C4 and Slp are encoded by separate loci. J Immunol 124:1745–1749

    PubMed  CAS  Google Scholar 

  496. Carroll MC, Porter RR (1983) Cloning of a human complement component C4 gene. Proc Natl Acad Sci USA 80:264–267

    PubMed  CAS  Google Scholar 

  497. Carroll MC, Campbell RD, Bentley DR, Porter RR (1984) A molecular map of the human major histocompatibility complex class III region linking complement genes C4, C2 and factor B. Nature 307:237–241

    PubMed  CAS  Google Scholar 

  498. Carroll MC, Belt KT, Palsdottir A, Yu Y (1985) Molecular genetics of the fourth component of human complement and steroid 21-hydroxylase. Immunol Rev 87:40–60

    Google Scholar 

  499. Carroll MC, Campbell RD, Porter RR (1985) Mapping of steroid 21-hydroxylase genes adjacent to the complement component C4 genes in HLA, the major histocompatibility complex in man. Proc Natl Acad Sci USA 82:521–525

    PubMed  CAS  Google Scholar 

  500. Carroll MC, Palsdottir A, Belt KT, Porter RR (1985) Deletion of complement C4 and steroid 21-hydroxylase genes in the HLA class III region. EMBO J 4:2547–2552

    PubMed  CAS  Google Scholar 

  501. Carroll MC, Schneider PM, Rumsby G (1987) Molecular genetics of human steroid 21- hydroxylase genes. In: Gallo RC, Della Porta G, Albertini A (eds) Monoclonals and DNA probes in diagnostic and preventive medicine. Raven, New York, pp 63–72

    Google Scholar 

  502. Chan AC, Atkinson JP (1985) Oligosaccharide structure of human C4. J Immunol 134:1790–1798

    PubMed  CAS  Google Scholar 

  503. Chaplin DD, Woods DE, Whitehead AS, Goldberger G, Colten HR, Seidman JG (1983) Molecular map of the murine S region. Proc Natl Acad Sci USA 80:6947–6951

    PubMed  CAS  Google Scholar 

  504. Chung LP, Bentley DR, Reid KBM (1985) Molecular cloning anc characterization of the cDNA coding for C4b-binding protein, a regulatory protein of the classical pathway of the human complement system. J Biochem 230:133–141

    CAS  Google Scholar 

  505. Cole FS, Whitehead AS, Auerbach HS, Lint T, Zeitz HJ, Kilbridge P, Colten HR (1985) The molecular basis for genetic deficiency of the second component of human complement. N Engl J Med 313:11–16

    PubMed  CAS  Google Scholar 

  506. Colten HR (1984) Expression of the MHC class III genes. Philos Trans R Soc Lond [Biol] 306:355–366

    CAS  Google Scholar 

  507. Colten HR, Borsos T, Rapp HJ (1970) Isoelectric focusing of human and guinea pig C2: polymorphism of guinea pig C2. Immunology 18:467–472

    PubMed  CAS  Google Scholar 

  508. Colten HR, Alper CA (1972) Hemolytic efficiencies of genetic variants of human C3. J Immunol 108:1184–1187

    PubMed  CAS  Google Scholar 

  509. Cross SJ, Edwards JH, Bentley DR, Campbell RD (1985) DNA polymorphism of the C2 and factor B genes. Immunogenetics 21:39–48

    PubMed  CAS  Google Scholar 

  510. Curman B, Östberg L, Sandberg L, Malmheden-Eriksson I, Stalenheim G, Rask L, Peterson PA (1975) H-2 linked Ss protein is C4 component of complement. Nature 25:243–244

    Google Scholar 

  511. Curry RA, Dierich MP, Pellegrino MA, Hoch JA (1976) Evidence for linkage between HLA antigens and receptors for complement components C3b and C3d in human-mouse hybrids. Immunogenetics 3:465–471

    CAS  Google Scholar 

  512. David V, Fauchet R, Phengsavath H, Guenet L, LeGall JY (1983) Properdin factor B (Bf) polymorphism: subtyping of SS phenotypes. Hum Genet 64:189–190

    PubMed  CAS  Google Scholar 

  513. Dawkins RL, Christiansen FT, Kay PH, Garlepp M, McCluskey J, Hollingsworth PN, Zilko PJ (1983) Disease associations with complotypes, supratypes and haplotypes. Immunol Rev 70:1--22

    Google Scholar 

  514. Day NK, L’Esperance P, Good RA, Michael FA, Hansen JA, Dupont B, Jersild C (1975) Hereditary C2 deficiency: genetic studies and associations with the HLA system. J Exp Med 141:1464–1469

    PubMed  CAS  Google Scholar 

  515. De Bruijn MHL, Fey GH (1985) Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci USA 82:708–712

    PubMed  Google Scholar 

  516. Demant P, Capkova J, Hinzova E, Voracova B (1973) The role of the histocompatibility- 2-linked Ss-Slp region in the control of mouse complement. Proc Natl Acad Sci USA 70:863–864

    PubMed  CAS  Google Scholar 

  517. De Mouzon A, Ohayon E, Ducos J, Hauptmann G (1979) Bf and C4 markers for insulin- dependent diabetes in Basques. Lancet 2:1364

    PubMed  Google Scholar 

  518. Dewald G, Rittner C (1979) Polymorphism of the second component of human complement (C2): observation of the rare phenotype C2 2 ( = C2 B) and data on the localization of the C2 locus in the HLA region. Vox Sang 37:47–54

    PubMed  CAS  Google Scholar 

  519. DiScipio RG, Gagnon J (1982) Characterization of human complement components C6 and C7. Mol Immunol 19:1425–1431

    PubMed  CAS  Google Scholar 

  520. Dissing J, Lund J, Soerensen H (1972) C3 polymorphism in a group of old arteriosclerotic patients. Hum Hered 22:466–472

    PubMed  CAS  Google Scholar 

  521. Dodds AW, Law SK, Porter RR (1985) The origin of the very variable haemolytic activities of the common human complement component C4 allotypes including C4-A6. EMBO J 4:2239–2244

    PubMed  CAS  Google Scholar 

  522. Dornan J, Allan P, Noel EP, Sampson L, Farid NR (1981) Alleles of the second component of complement (C2) in insulin-dependent diabetes mellitus. Hum Hered 31:211–213

    PubMed  CAS  Google Scholar 

  523. Dupont B, Oberfîeld SE, Smithwick EM, Lee TD, Levine LS (1977) Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet 2:1309

    PubMed  CAS  Google Scholar 

  524. Dupont B, Pollack MS, Levine LS, O’Neill GJ, Hawkins BR, New MI (1980) Congenital adrenal hyperplasia. In: Terasaki PI (ed) Histocompatibility testing 1980. UCLA Tissue Typing Laboratory, Los Angeles, CA, pp 693–706

    Google Scholar 

  525. Dyer PA, Klouda PT, Harris R, Malliek NT (1980) Properdin factor B alleles in patients with idiopathic membranous nephropathy. Tissue Antigens 15:505–507

    PubMed  CAS  Google Scholar 

  526. Dyer PA, Davidson JA (1983) Allotypes of properdin factor B (BF) and lymphocytoxic antibody production. Immunobiology 164:234–235 (Abstract)

    Google Scholar 

  527. Dykes DD, Crawford MH, Polesky HF (1981) Genetic variants of properdin factor B (Bf) in Papio hamadryas baboons. Folia Primatol (Basel) 36:226–231

    PubMed  CAS  Google Scholar 

  528. Dykman TR, Cole JL, Iida K, Atkinson JP (1983) Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci USA 80:1698–1702

    PubMed  CAS  Google Scholar 

  529. Dykman TR, Cole JL, Iida K, Atkinson JP (1983) Structural heterogeneity of the C3b/C4b receptor (CR1) on human peripheral blood cells. J Exp Med 157:2160–2165

    PubMed  CAS  Google Scholar 

  530. Dybnan TR, Hatch JA, Atkinson JP (1984) Polymorphism of the human C3b/C4b receptor: identification of a third allele and analysis of receptor phenotypes in families and patients with systemic lupus erythematosus. J Exp Med 159:691–703

    Google Scholar 

  531. Farhud DD, Walter H (1973) Polymorphism of C3 in German, Bulgarian, Iranian and Angolan population. Human Genet 17:161–164

    CAS  Google Scholar 

  532. Fearon DT (1983) The human C3b receptor. Springer Semin Immunopathol 6:159–172

    PubMed  CAS  Google Scholar 

  533. Ferreira A, Nussenzweig V (1975) Genetic linkage between serum levels of the 4th component of complement and the H-2 complex. J Exp Med 141:513–517

    PubMed  CAS  Google Scholar 

  534. Ferreira A, Takahashi M, Nussenzweig V (1977) Purification and characterization of mouse serum protein with specific binding affinity for C4 (Ss protein). J Exp Med 146:1001–1018

    PubMed  CAS  Google Scholar 

  535. Ferreira A, Nussenzweig V, Gigli I (1978) Structural and functional differences between the H-2 controlled Ss and Slp proteins. J Exp Med 148:1186–1197

    PubMed  CAS  Google Scholar 

  536. Ferreira A, David CS, Nussenzweig V (1980) The murine H-2.7 specificity is an antigenic determinant of C4d, a fragment of the fourth component of the complement system. J Exp Med 151:1424–1435

    PubMed  CAS  Google Scholar 

  537. Ferreira A, Michaelson J, Nussenzweig V (1980) H-2-controlled polymorphism of the gamma-chain of Slp (Sex-limited protein). Immunogenetics 11:491–497

    PubMed  CAS  Google Scholar 

  538. Ferreira A, Michaelson J, Nussenzweig V (1980) A polymorphism of the gamma-chain of mouse C4 controlled by the S region of the major histocompatibility complex. J Immunol 125:1178–1182

    PubMed  CAS  Google Scholar 

  539. Ferreira A, Eichinger D (1981) A simplified two-dimensional electrophoretic technique. J Immunol Methods 43:291–299

    PubMed  CAS  Google Scholar 

  540. Fey GH (1983) Structure and expression of the C3 gene. Springer Semin Immunopathol 6:119–147

    PubMed  CAS  Google Scholar 

  541. Fielder AHL, Walport MJ, Batchelor JR, Rynes RI, Black CM, Dodi IA, Hugher GRV (1983) Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J 286:425–428

    CAS  Google Scholar 

  542. Fleischnick E, Awdeh ZL, Raum D, Granados J, Alosco SM, Crigler JF, Gerald PS, Giles CM, Yunis EJ, Alper CA (1983) Extended MHC haplotypes in 21-hydroxylase deficiency congenital adrenal hyperplasia: shared genotypes in unrelated patients. Lancet 1:153–156

    Google Scholar 

  543. Ford EB (1940) Polymorphism and taxonomy. In: Huxley J (ed) The new systematics. Clarendon, Oxford, pp 493–513

    Google Scholar 

  544. Friend R, Handwerger BS, Kim Y, Michael AF, Yunis EJ (1975) C2 deficiency in man. Genetic relationship to a mixed lymphocyte reaction determinant. Immunogenetics 2:569–576

    Google Scholar 

  545. Fu SM, Kunkel HG, Brusman HP, Allen FH, Fotino M (1974) Evidence for linkage between HL-A histocompatibility genes and those involved in the synthesis of the second component of complement. J Exp Med 140:1108–1111

    PubMed  CAS  Google Scholar 

  546. Gelfand MC, Sachs DH, Lieberman R, Paul WE (1974) Ontogeny of B lymphocytes III. H-2 linkage of a gene controlling the rate of appearance of complement receptor lymphocytes. J Exp Med 139:1142–1148

    PubMed  CAS  Google Scholar 

  547. Geseriek G, Rose M (1973) The discovery of a genetic polymorphism in a conversion product of C3 by starch gelelectrophoneis: the Pt system. Methodological, genetic and forensic aspects. Vox Sang 25:11 (Abstract)

    Google Scholar 

  548. Geserick G, Waltz H, Patzelt D, Rose M (1980) Polymorphism of C3 in rabbits. Immunobiology 158:25–29

    PubMed  CAS  Google Scholar 

  549. Geserick G, Patzelt D, Schröder H (1983) Zum Nachweis von Subtypen des Bf-Systems: Verteilung in einer Stichprobe der Berliner Bevölkerung (DDR). Biomed Biochem Acta 42:581–585

    CAS  Google Scholar 

  550. Geserick G, Patzelt D, Schröder H, Nagai T (1983) Isoelectrofocusing in the study the Bf system: existence of two common serotypes of the BfF allele. Vox Sang 44:178–182

    PubMed  CAS  Google Scholar 

  551. Gibson DJ, Glass D, Carpenter CB, Schur P (1976) Hereditary C2 deficiency: diagnosis and HLA gene complex associations. J Immunol 116:1065–1070

    PubMed  CAS  Google Scholar 

  552. Giles CM (1980) Antigens in plasma. A seminar on antigens on blood cells and body fluids. 33rd annual meeting of Am Assoc Blood Banks, Washington, DC, 1980, pp 33–49

    Google Scholar 

  553. Giles CM (1984) A new genetic variant for Chido. Vox Sang 46:149–156

    PubMed  CAS  Google Scholar 

  554. Giles CM (1984) Partial inhibition of anti-Rg and anti-Ch reagents. I. Assessment for Rg/ Ch typing by inhibition. Vox Sang 48:160–166

    Google Scholar 

  555. Giles CM (1984) Partial inhibition of anti-Rg and anti-Ch reagents. II. Demonstration of separable antibodies for different determinants. Vox Sang 48:167–173

    Google Scholar 

  556. Giles CM, Batchelor JR, Dodi IA, Fielder AHL, Rittner C, Mauff G, Bender K, Levene C, Schreuder I, Wells L (1984) HLA and C4 haplotypes associated with partial inhibition of anti-Rg and anti-Ch. Immunogenetics 21:305–317

    Google Scholar 

  557. Glass D, Raum D, Gibson D, Stillman JS, Schur PH (1976) Inherited deficiency of the second component of complement. J Clin Invest 58:853–861

    PubMed  CAS  Google Scholar 

  558. Glass D, Raum D, Balavitch D, Kagan E, Rabson A, Schur PH, Alper CA (1978) Inherited deficiency of the sixth component of complement: a silent or null gene. J Immunol 120:538–541

    PubMed  CAS  Google Scholar 

  559. Götze O, Müller-Eberhard HJ (1971) Isolation of the precursor and the active form of the C3 activator from human serum. J Immunol 107:313 (Abstract)

    Google Scholar 

  560. Goldman MB, Cohen C, Stronski K, Bangalore S, Goldman JN (1982) Genetic control of C6 polymorphism and C6 deficiency in rabbits. J Immunol 128:43–48

    PubMed  CAS  Google Scholar 

  561. Granados J, Karp S, Giles CM, Raum D, Awdeh ZI, Balner H, Yunis EJ, Alper CA (1982) There are two loci for C4 in the chimpanzee. IV. International Workshop for the Genetics of Complement Boston, MA, June, 1982 (Abstract)

    Google Scholar 

  562. Greiner J, Weber FJ, Mauff G, Baur MP (1980) Genetic polymorphisms of properdin factor B (Bf), the second component (C2), and the fourth component (C4) of complement in leprosy patients and healthy controls from Thailand. Immunobiology 158:134–138

    PubMed  CAS  Google Scholar 

  563. Grosse-Wilde H, Doxiadis G, Krumbacher K, Dekkers-Bijma A, Kolb HJ (1983) Polymorphism of the fourth complement component the dog and linkage to the DLA system. Immunogenetics 18:537–540

    PubMed  CAS  Google Scholar 

  564. Gross-Bellard M, Oudet P, Chambon P (1973) Isolation of high molecular weight DNA from mammalian cells. Eur J Biochem 36:32–38

    PubMed  CAS  Google Scholar 

  565. Hall JE Jr, Alper CA (1977) Genetic polyporphism of the sixth component of complement in the Rhesus monkey. J Immunol 119:253–255

    PubMed  CAS  Google Scholar 

  566. Hardy DB, Barnicot NA, Alper CA (1975) Protein polymorphism in the Hanuman langur (Presbytus). Folia Primatol (Basel) 23:173–187

    Google Scholar 

  567. Hatch JA, Atkinson JP, Suarez BK, Dykman TR (1984) Non-linkage of the C3b/C4b receptor with HLA. J Immunol 132:2168–2169

    PubMed  CAS  Google Scholar 

  568. Haupt H, Heide K (1965) Isolierung und Eigenschaften eines beta-2-Glykoproteins aus Humanserum. Clin Chim Acta 12:419–424

    PubMed  CAS  Google Scholar 

  569. Hauptmann G (1974) Lupus erythemateux aigus et deficits hereditaires en complement. Ann Dermatol Syphil 101:479–496

    Google Scholar 

  570. Hauptmann G (1980) C4 deficiency in early-onset insulin-dependent diabetes: a hypothesis. Lancet 1:1034

    PubMed  CAS  Google Scholar 

  571. Hauptmann G, Sasportes M, Tongio MM, Mayer S, Dausset J (1976) The localization of the Bf locus within the MHS region on chromosome No. 6. Tissue Antigens 7:52–54

    PubMed  CAS  Google Scholar 

  572. Hauptmann G, Tongio MM, Grosse-Wilde H, Mayer S (1977) Linkage between C2 deficiency and the HLA-A10, B18, Dw2/BfS haplotype in a French family. Immunogenetics 4:557–565

    Google Scholar 

  573. Hauptmann G, Tongio MM, Klein J, Mayer S, Cinqualbre J, Jeanblanc B, Kieny R (1980) Change in serum properdin factor B following human orthoptic liver transplantation. Immunobiology 158:76–81

    PubMed  CAS  Google Scholar 

  574. Hauptmann G, Goetz J, Uring-Lambert B, Grosshans E (1986) C4 deficiency. In: Rother K (ed) Hereditary and acquired complement deficiencies. Prog Allergy 39, pp 232–249

    Google Scholar 

  575. Heilman U, Eggertsen G, Lundwall A, Engström A, Sjöquist J (1984) Primary sequence differences between Chido and Rodgers variants of tryptic C4d of the human complement system. FEBS Lett 170:254–258

    Google Scholar 

  576. Hing SN, Giles CM, Fielder AHL, Batchelor JR (1986) HLA haplotypes with C4B5: evidence for further allelic heterogeneity. Immunogenetics 23:151–155

    PubMed  CAS  Google Scholar 

  577. Hobart MJ, Lachmann PJ, Alper CA (1975) Polymorphism of human C6. In: Peeters H (ed) Protides of the biological fluids. Pergamon, Oxford, pp 575–580

    Google Scholar 

  578. Hobart MJ, Lachmann PJ (1976) Allotypes of complement components in man. Transplant Rev 32:26–42

    PubMed  CAS  Google Scholar 

  579. Hobart MJ, Cook PJL, Lachmann PJ (1977) Linkage studies with C6. J Immunogenet 4:423–428

    PubMed  CAS  Google Scholar 

  580. Hobart MJ, Joysey V, Lachmann PJ (1978) Inherited structural variation and linkage relationships of C7. J Immunogenet 5:157–163

    PubMed  CAS  Google Scholar 

  581. Hobart MJ, Vazguedes MA, Lachmann PJ (1981) Polymorphism of human C5. Ann Hum Genet 45:1–4

    PubMed  CAS  Google Scholar 

  582. Holers VM, Cole JL, Lublin DM, Seya T, Atkinson JP (1985) Human C3b- and C4b-regu- latory proteins: a new gene family. Immunol Today 6:188–192

    CAS  Google Scholar 

  583. Huang CM, Klein J (1979) Murine antigen H-2.7: its genetics, tissue expression, and strain distribution. Immunogenetics 9:233–243

    Google Scholar 

  584. Iida K, Mornaghi R, Nussenzweig V (1982) Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med 155:1427–1438

    PubMed  CAS  Google Scholar 

  585. Isenman DE, Young JR (1984) The molecular basis for the difference in immune hemolysis activity of the Chido and Rodgers isotypes of human complement C4. J Immunol 132:3019–3027

    PubMed  CAS  Google Scholar 

  586. Isenman DE, Young JR (1986) Covalent binding properties of the C4A and C4B isotypes of the fourth component of human complement on several C1-bearing cell surfaces. J Immunol 136:2542–2550

    PubMed  CAS  Google Scholar 

  587. Kaidoh T, Natsuume-Sakai S, Takahashi M (1981) Murine C4-binding protein: a rapid purification method by affinity chromatography. J Immunol 126:463–467

    PubMed  CAS  Google Scholar 

  588. Kaidoh T, Natsuume-Sakai S, Takahashi M (1981) Murine binding protein of the fourth component of complement: structural polymorphism and its linkage to the major histocompatibility complex. Proc Natl Acad Sci USA 78:3794–3798

    PubMed  CAS  Google Scholar 

  589. Karp DR, Atkinson JP, Shreffler DC (1982) Genetic variation in glycosylation of the fourth component of murine complement: association with hemolytic activity. J Biol Chem 257:7330–7335

    PubMed  CAS  Google Scholar 

  590. Kay PH, Dawkins RL (1984) Genetic polymorphism of complement C4 in dog. Tissue Antigens 23:151–155

    PubMed  CAS  Google Scholar 

  591. Kay PH, Dawkins RL, Penhale JW (1985) The molecular structure of different polymorphic forms of canine C3 and C4. Immunogenetics 21:313–319

    PubMed  CAS  Google Scholar 

  592. Kirk RL, Serjeantson SW, Theophilos J, Zimmet P, Whitehouse S, Court JM (1979) Age relationship between insulin-dependent diabetes mellitus and rare alleles of properdin factor B. Lancet 2:537

    PubMed  CAS  Google Scholar 

  593. Klickstein LB, Wong WW, Smith JA, Morton C, Fearon DT, Weis JH (1985) Identification of long homologous repeats in human CR1. Complement 2:44 (Abstract)

    Google Scholar 

  594. Kolb WP, Müller-Eberhard HJ (1976) The membrane attack mechanism of complement: the three polypeptide chain structure of the eighth component (C8). J Exp Med 143:1131–1139

    CAS  Google Scholar 

  595. Kristensen T, Wetsel RA, Tack BF (1986) Structural analysis of human complement protein H: 1. Homology with C4b binding protein beta-2-glycoprotein I, and the Ba fragment of BF. J Immunol 136:3407–3411

    PubMed  CAS  Google Scholar 

  596. Krönke M, Hadding U, Geczy AF, Weck AL, Bitter-Suermann D (1977) Linkage of guinea pig Bf and C4 to GPLA. J Immunol 119:2016–2018

    PubMed  Google Scholar 

  597. Kunstmann G, Mauff G (1980) Genetic polymorphism of rabbit C6. Immunobiology 158:30–33

    PubMed  CAS  Google Scholar 

  598. Kunstmann G, Mauff G, Pulverer G (1980) C6 polymorphism and rare alleles in Western Germany. Immunobiology 158:55–59

    PubMed  CAS  Google Scholar 

  599. Kurtz F, Juif JG, Hauptmann GR, Goetz J (1983) Insulin-dependent diabetes in children and fourth component of complement (C4). In: Chiumello G, Sperling M (eds) Recent progress in pediatric endocrinology. Raven, New York

    Google Scholar 

  600. Lachmann PJ, Hobart MJ, Aston WP (1974) Complement technology. In: Weir DM (ed) Handbook of experimental immunology. Blackwell, Oxford, pp 5.1–5.17

    Google Scholar 

  601. Lachmann PJ, Grennan D, Martin K, Demant P (1975) Identification of Ss protein as murine C4. Nature 258:242–243

    PubMed  CAS  Google Scholar 

  602. Lachmann PJ, Hobart MJ, Woo P (1978) Combined genetic deficiency of C6 and C1 in man. Clin Exp Immunol 33:193–203

    PubMed  CAS  Google Scholar 

  603. Lachmann PJ, Hobart MJ (1979) The genetics of the complement system. In: Porter R, O’Connor M (eds) Human genetics: possibilities and realities. Ciba Foundation Symposium 66 (new series). Excerta Medica, Elsevier, Amsterdam, pp 231–250

    Google Scholar 

  604. Law SKA, Dodds AW, Porter RR (1984) A comparison of the properties of two classes, C4A and C4B of the human complement component C4. EMBO J 3:1819–1823

    PubMed  CAS  Google Scholar 

  605. Lesavre PH, Müller-Eberhard HJ (1978) Mechanism of action of factor D of the alternative complement pathway. J Ep Med 148:1498–1509

    CAS  Google Scholar 

  606. Levi-Strauss M, Tosi M, Steinmetz M, Klein J, Meo T (1985) Multiple duplications of complement C4 gene correlate with H-2 controlled testosterone-independent expression of its sex-limited isoform, C4-Slp. Proc Natl Acad Sci USA 82:1746

    PubMed  CAS  Google Scholar 

  607. Lundwall AB, Wetsel RA, Kristensen T, Whitehead AS, Woods DE, Ogden RC, Colten HR, Tack BF (1985) Isolation and sequence analysis of a cDNA clone encoding the fifth component of complement. J Biol Chem (in press)

    Google Scholar 

  608. Lundwall A, Hellmann U, Eggertsen G, Sjöquist J (1982) Isolation of tryptic fragments of human C4 expressing Chido and Rodgers antigens. Mol Immunol 19:1655–1665

    PubMed  CAS  Google Scholar 

  609. Lundwall A, Wetsel RA, Domdey H, Tack BF, Fey GH (1984) Structure of murine complement component C3. Nucleotide sequence of cloned complementary and genomic DNA coding for the beta-chain. J Biol Chem 259:13851

    PubMed  CAS  Google Scholar 

  610. Mäkalä AL, Eerola E, Lehtonen OP, Ruuska P, Lantto R (1983) Erythrocyte C3b receptors in juvenile rheumatoid arthritis. N Engl J Med 309:673

    Google Scholar 

  611. Maniatis T, Fritsch E, Sambrook J (1982) Molecular cloning. A laboratory manual. Cold Spring Harbor, New York

    Google Scholar 

  612. Martin A, Lachmann PJ, Halbwachs L, Hobart MJ (1976) Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry 13:317–324

    PubMed  CAS  Google Scholar 

  613. Martin W, Ziegler C (1981) Bf-Immunfixation auf Cellogel-Folien. Blut 42:23–26

    PubMed  CAS  Google Scholar 

  614. Mauff G (1977) Untersuchungen zum Komplementsystem des Menschen. Genetik und Biochemie der dritten und vierten Komponente des Komplementsystems sowie des Properdinfaktor B. Dissertation, University of Köln

    Google Scholar 

  615. Mauff G (1985) The complement system: genetics and function. In: Kocielak J, Wiktor-Jedrezejczak W, Kotelba-Witkowska B, Traczyk Z (eds) Trends in hematology. Institute of Hematology, Warszaw

    Google Scholar 

  616. Mauff G, Freis H, Potrafki BG, Hummel K, Pulverer G (1974) Zur Problematik der Bestimmung seltener Varianten des C3-Polymorphismus. Untersuchungen an zwei Sippen mit den Merkmalen F0.65 und F0.5. Hum Genet 22:211–220

    Google Scholar 

  617. Mauff G, Potrafki BG, Freis H, Pulverer G (1974) Vergleichende Untersuchungen zum Polymorphismus des Posttransferrins (Pt) und der dritten Komponente des Humankomplementes. Hum Genet 21:75–80

    CAS  Google Scholar 

  618. Mauff G, Hummel K, Pulverer G (1975) Properdin Factor B (glycine-rich beta-glycoprotein or C3 proactivator)-polymorphism: genetic and biochemical aspects, first application to paternity cases. Z Immun Forsch 150:327–338

    CAS  Google Scholar 

  619. Mauff G, Gauchel FD, Hitzeroth HW (1976) Polymorphism of properdin factor B in South African, Negroid, Indian and Colored populations. Hum Genet 33:319–322

    PubMed  CAS  Google Scholar 

  620. Mauff G, Bender K, Fischer B (1978) Genetic polymorphism of the fourth component of human complement. Vox Sang 34:296–301

    PubMed  CAS  Google Scholar 

  621. Mauff G, Hauptmann G, Hitzeroth HW, Gauch F, Scherz R (1978) The nomenclature of properdin factor B allotypes. Immunobiology 154:115–120

    PubMed  CAS  Google Scholar 

  622. Mauff G, Adam R, Wachauf B, Hitzeroth HW, Miller C (1980) Serum concentration and functional efficiency of factor B alleles. Immunobiology 158:86–90

    PubMed  CAS  Google Scholar 

  623. Mauff G, Alper CA, Hobart M, Kühnl P, Kunstmann G, Meo T, Olving JH, Rittner C (1980) Statement on the nomenclature of human C6 polymorphism. Immunobiology 158:139–144

    PubMed  CAS  Google Scholar 

  624. Mauff G, Federmann G, Hauptmann G (1980) A hemolytically inactive gene product of properdin factor B. Immunobiology 158:96–100

    PubMed  CAS  Google Scholar 

  625. Mauff G, Alper CA, Awdeh ZL, Batchelor JR, Bertrams J, Bruun-Petersen G, Dawkins RL, Demant P, Edwards JH, Grosse-Wilde H, Hauptmann G, Klouda P, Lamm L, Mollenhauer E, Nerl C, Olaisen B, O’Neill G, Rittner C, Roos MH, Skanes V, Teisberg P, Wells L (1983) Statement on the nomenclature of human C4 allotypes. Immunobiology 164:184–191

    PubMed  CAS  Google Scholar 

  626. Mauff G, Steuer M, Weck M, Bender K (1983) The C4 beta-chain: evidence for a genetically determined polymorphism. Hum Genet 64:186–188

    PubMed  CAS  Google Scholar 

  627. Mauff G, Bender K, Giles CM, Goldmann S, Opferkuch W, Wachauf B (1984) Human C4 polymorphism: pedigree analysis of qualitative, quantitative, and functional parameters create a basis for phenotype interpretations. Hum Genet 65:362–372

    PubMed  CAS  Google Scholar 

  628. McCluskey J, Kay PH, Stuckey M, Christiansen FT, Dawkins RL, Wilson G (1983) MHC supratype predicting heterozygous 21-hydroxylase deficiency. Lancet 1:764–765

    PubMed  CAS  Google Scholar 

  629. McCluskey J, McCann VJ, Kay PH, Zilko PJ, Christiansen FT, O’Neill GJ, Dawkins RL (1983) HLA and complement allotypes in Type 1 (insulin-dependent) diabetes. Diabetologia 24:162–165

    PubMed  CAS  Google Scholar 

  630. McLean RH, Bryan RK, Winkelstein J (1983) Hypomorphic variant of C3 slow (C3 S), hypocomplementemia, and hematuria. Immunobiology 164:275 (Abstract)

    Google Scholar 

  631. McMahan MR (1981) Studies of the genetic polymorphism of the third component of complement (C3) in non-human primates. Am J Primatol 1:320 (Abstract)

    Google Scholar 

  632. Meier EMM (1984) Biochemische und Assoziations-Studien zum Polymorphismus der vierten Komponente des Humankomplements. Thesis, University of Bonn

    Google Scholar 

  633. Meo T, Krasteff T, Shreffler DC (1975) Immunochemical characterization of murine H2- controlled Ss (serum substance) protein through identification of its human homologue as the fourth component of complement. Proc Natl Acad Sci USA 72:4536–4539

    PubMed  CAS  Google Scholar 

  634. Meo T, Atkinson J, Bernoco M, Bernoco D, Ceppellini R (1976) Mapping of the HLA locus controlling C2 structural variants and linkage disequilibrium between alleles C*2 and Bw15. Eur J Immunol 6:916–919

    Google Scholar 

  635. Meo T, Atkinson JP, Bernoco M, Bernoco D, Ceppellini R (1977) Structural heterogeneity of C2 complement protein and its genetic variants in man: a new polymorphism of the HLA region. Proc Natl Acad Sci USA 74:1672–1675

    PubMed  CAS  Google Scholar 

  636. Mevag B, Olaisen B, Teisberg P (1981) Electrophoretic polymorphism of human C4 is due to charge differences in the alpha-chain, presumably in the C4d fragment. Scand J Immunol 14:303–307

    PubMed  CAS  Google Scholar 

  637. Mevag B, Olaisen B, Teisberg P, Smith J (1983) Two C4 loci in macaca monkeys. Immunobiology 164:276–277 (Abstract)

    Google Scholar 

  638. Mevag B, Rogde S, Olaisen B, Gedde-Dahl T, Teisberg P, Tedesco F (1983) Genetic polymorphism of complement component C8. Proceedings, 10th Congress of forensic haemogenetics, München, 11–15 Oct 1983, pp 361–365

    Google Scholar 

  639. Miyakawa X, Xamada A, Kosaka K, Tsuda F, Kosugi E, Mayumi M (1981) Defective im- muneadherence (C3b) receptor on erythrocytes from patients with systemic erythematosus. Lancet 2:493–497

    PubMed  CAS  Google Scholar 

  640. Möller G (ed) (1983) HLA and disease susceptibility. Immunol Rev 70

    Google Scholar 

  641. Mole JE, Anderson JK, Davison EA, Woods DE (1984) Complete primary structure for the zymogen of human complement factor B. J Biol Chem 260:2108

    Google Scholar 

  642. Mollenhauer E, Schmidt RE, Heinrichs M, Rittner C (1984) Scleroderma: possible significance of silent alleles at the C4B locus. Arthritis Rheum 27:711–712

    PubMed  CAS  Google Scholar 

  643. Monahan JB, Sodetz JM (1980) Binding of the eighth component of human complement to the soluble cytolytic complex is mediated by its beta subunit. J Biol Chem 255:10579–10582

    PubMed  CAS  Google Scholar 

  644. Monahan JB, Sodetz JM (1981) Role of the beta subunit in interaction of the eighth component of human complement with the membranebound cytolytic complex. J Biol Chem 256:3258–3262

    PubMed  CAS  Google Scholar 

  645. Morley BJ, Campbell RD (1984) Internal homologies of the Ba fragment from human complement component factor B, a class III MHC antigen. EMBO J 3:153–157

    PubMed  CAS  Google Scholar 

  646. Mortensen JP, Buskjaer L, Lamm LU (1980) Studies on the C2-deflciency in man. Immunology 39:541–549

    PubMed  CAS  Google Scholar 

  647. Mortensen JP, Lamm LU (1981) Quantitative differences between complement factor-B phenotypes. Immunology 24:505–511

    Google Scholar 

  648. Nakamura S, Ooue O, Abe K (1984) Genetic polymorphism of the seventh component of complement in Japanese population. Hum Genet 66:279–281

    PubMed  CAS  Google Scholar 

  649. Nakamura S, Ooue O, Akiyama K, Abe K (1984) Genetic polymorphism of the complement C6 and the haplotype analysis between C6 and C7 in a Japanese population. Hum Genet 68:138–141

    PubMed  CAS  Google Scholar 

  650. Nakamura S, Abe K (1985) Genetic polymorphism of human factor I (C3b inactivator). Hum Genet 71:45–48

    PubMed  CAS  Google Scholar 

  651. Nakamura S, Ooue O, Abe K (1986) A new BF F subtype by polyacrylamide gel isoelectric focusing. Hum Genet (in press)

    Google Scholar 

  652. Nakamura S, Ooue O, Abe K (1986) Genetic polymorphism of human complement component C81 in the Japanese population. Hum Genet (in press)

    Google Scholar 

  653. Nakamura T, Sekizawa A, Fujii T, Katairi CH (1986) Cosegregation of the polymorphic C4 with the MHC in the frog, Xenopus laevis. Immunogenetics 23:181–186

    PubMed  CAS  Google Scholar 

  654. Natsuume-Sakai S, Hayakawa JI, Takahashi M (1978) Genetic polymorphism of murine C3 controlled by a single co-dominant locus on chromosome 17. J Immunol 121:491–498

    PubMed  CAS  Google Scholar 

  655. Natsuume-Sakai S, Moriwaki K, Amano S, Hayakaawa JI, Kaidoh T, Takahashi M (1979) Allotypes of C3 in laboratory and wild mouse distinguished by alloantisera. J Immunol 123:216–221

    PubMed  CAS  Google Scholar 

  656. Natsuume-Sakai S, Kaidoh T, Nonaka M, Takahashi M (1980) Structural polymorphism of murine C4 and its linkage to H-2. J Immunol 124:2714–2720

    PubMed  CAS  Google Scholar 

  657. Natsuume-Sakai S, Moriwaki K, Migita S, Sudo K, Suzuki K, Lu DY, Wang C, Takahashi M (1983) Structural polymorphism of murine factor B controlled by a locus closely linked to the H-2 complex and demonstration of multiple alleles. Immunogenetics 18:117–124

    PubMed  CAS  Google Scholar 

  658. Nelson DS (1963) Immune adherence. Immunology 3:131–180

    Google Scholar 

  659. Nerl CW, Mayeux R, O’Neill GJ (1982) Complement C4 allotypes in Alzheimer’s disease. Lancet 2:1343

    PubMed  CAS  Google Scholar 

  660. Nerl C, Grosse-Wilde H, Valet G (1977) Association of low C2 and C4 serum levels with the HLA-Dw2 allele in healthy individuals. J Exp Med 148:704–708

    Google Scholar 

  661. New MI (ed) (1985) Congenital adrenal hyperplasia. Ann NY Acad Sci 458

    Google Scholar 

  662. Newell SL, Shreffler DC, Atkinson JP (1982) Biosynthesis of C4 by mouse peritoneal macrophages. J Immunol 129:653–659

    PubMed  CAS  Google Scholar 

  663. Newman SL, Vogler LB, Feigin RD, Johnston R (1978) Recurrent septicemia associated with congenital deficiency of C2 and partial defciency of factor B and the alternative complement pathway. N Engl J Med 299:290–292

    PubMed  CAS  Google Scholar 

  664. Nishimukai H, Kitamura H, Sano Y, Tamaki Y (1985) C3 variants in Japanese. Hum Hered 35:69–72

    PubMed  CAS  Google Scholar 

  665. Noel EP, Sampson L, Pepper BM, Farid NR (1980) Polymorphism of the second component of complement (C2) in Graves disease. Hum Hered 30:245–247

    PubMed  CAS  Google Scholar 

  666. Nonaka M, Natsuume-Sakai S, Kaidoh I, Nonoka M, Takahashi M (1980) Characterization of allotypic determinants of murine complement C3. J Immunol 125:2025–2030

    PubMed  CAS  Google Scholar 

  667. Nonaka M, Takahashi M, Natsuume-Sakai S, Nonaka M, Tanaka S, Shimizu A, Honjo T (1984) Isolation of cDNA clones specifying the fourth component of mouse complement and its isotype, sex-limited protein. Proc Natl Acad Sci USA 81:6822–6826

    PubMed  CAS  Google Scholar 

  668. Nonaka M, Nakayama K, Yeul YD, Takahashi M (1986) Complete nucleotide and derived amino acid sequences of sex-limited protein (Slp), nonfunctional isotype of the fourth component of mouse complement (C4). J Immunol 136:2989–2993

    PubMed  CAS  Google Scholar 

  669. Nordhagen R, Olaisen B, Teisberg P, Gedde-Dahl T Jr (1980) Association between the electrophoretically determined C4 M haplotype products and partial inhibition of anti-Ch(a). J Immunogenet 7:301–306

    PubMed  CAS  Google Scholar 

  670. Nordhagen R, Olaisen B, Teisberg P, Gedde-Dahl T Jr, Thorsby E (1981) C4 haplotype products and partial inhibition of anti-Rodgers sera. J Immunogenet 8:4895–4912

    Google Scholar 

  671. Ochs HD, Rosenfeld SI, Thomas ED, Giblett ER, Alper CA, Dupont B, Schaller JG, Gilliland BC, Hansen JA, Wedgwood RJ (1977) Linkage between the gene (or genes) controlling synthesis of the fourth component of complement and the major histocompatibility complex. N Engl J Med 296:470–475

    PubMed  CAS  Google Scholar 

  672. Ogata RT (1985) Structure and expression of murine fourth component of complement (C4) and sex-limited protein (Slp). Immunol Rev 87:101–122

    PubMed  CAS  Google Scholar 

  673. Ogata RT, Shreffler DC, Sepich DS, Lilly SP (1983) cDNA clone spanning the alpha- gamma subunit junction in the precursor of the murine fourth complement component (C4). Proc Natl Acad Sci USA 80:5061–5065

    PubMed  CAS  Google Scholar 

  674. Ogata RT, Sepich DS (1985) Murine sex-limited protein: complete cDNA sequence and comparison with murine fourth component of complement. J Immunol 135:4239–4244

    PubMed  CAS  Google Scholar 

  675. Ohno S (1970) Evolution by gene duplication. Springer, Berlin Heidelberg New York

    Google Scholar 

  676. Olaisen B, Teisberg P, Jonassen R (1980) The C4 system: quantitative studies of different genotypes. Immunobiology 158:82–85

    PubMed  CAS  Google Scholar 

  677. Olaisen B, Teisberg P, Konassen R, Gedde-Dahl T Jr, Moen T, Thorsby E (1981) Complement loci of the HLA complex. Studies on families with intra-HLA crossovers and haplotype associations. Hum Immunol 2:247–254

    PubMed  CAS  Google Scholar 

  678. Olving JH, Olaisen B, Teisberg P, Gedde-Dahl T Jr, Thorsby E (1977) Non-linkage between C6 and chromosome 6 markers. Hum Genet 37:125–129

    PubMed  CAS  Google Scholar 

  679. Olving JH, Teisberg P, Olaisen B (1980) Polymorphism of the sixth component of complement (C6) in Norwegian Lapps. Hum Hered 30:211–214

    PubMed  CAS  Google Scholar 

  680. Opferkuch W, Rother K, Schultz DR (eds) (1978) Clinical aspects of the complement system. Thieme, Stuttgart

    Google Scholar 

  681. O’Neill GJ, Yang SY, Dupont B (1978) Two HLA-linked loci controlling the fourth component of human complement. Proc Natl Acad Sci USA 75:5165–5169

    PubMed  Google Scholar 

  682. O’Neill GJ, Yang SY, Tegoli J, Berger R, Dupont B (1978) Chido and Rodgers blood groups are distinct antigenic components of human complement C4. Nature 272:668–670

    Google Scholar 

  683. O’Neill GJ, Miniter P, Pollack MS, Dupont B (1980) Different HLA antigen association for the functionally active and inactive product of the complement C4F1 allele. Hum Immunol 1:23–30

    PubMed  Google Scholar 

  684. O’Neill GJ, Dupont B, Pollack MS, Levine LS, New MI (1982) Complement C4 allotypes in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: further evidence for different allelic variants at the 21-hydroxylase locus. Clin Immunol Immunopathol 23:312–322

    PubMed  Google Scholar 

  685. O’Neill GJ, Nerl CW, Kay PH, Christiansen FT, McCluskey J, Dawkins RL (1982) Complement C4 is a marker for adult rheumatoid arthritis. Lancet 2:214

    PubMed  Google Scholar 

  686. O’Neill GJ, Nerl C, Pollack MS (1983) Analysis of active and inactive complement C4 complotypes associated with subtypes of HLA-B17 in different racial groups. Am J Hum Genet 35:309–317

    PubMed  Google Scholar 

  687. O’Neill GJ, Mueller-Eckhaardt G, Prel L, Schendel DJ (1984) C4 allotyping distinguishes HLA-B14.1 and B14.2 subtypes. Immunogenetics 19:335–341

    PubMed  Google Scholar 

  688. Palsdottir A, Cross SJ, Edwards JH, Carroll MC (1983) Correlation between a restriction fragment length polymorphism and C4A6 protein. Nature 306:615–616

    PubMed  CAS  Google Scholar 

  689. Papiha SS, Bernal JE, Roberts DF, Habeebullah CM, Mishra SC (1979) C3 polymorphism in some Indian populations. Hum Hered 29:193–196

    PubMed  CAS  Google Scholar 

  690. Parker KL, Atkinson JP, Roos MH, Shreffler DC (1980) Genetic and structural characterization of H-2 controlled allelic forms of murine C4. Immunogenetics 11:55–63

    PubMed  CAS  Google Scholar 

  691. Parker KL, Capra JD, Shreffler DC (1980) Partial amino acid sequences of the murine fourth component of complement (C4): demonstration of homology with human C4 and identification of the amino-terminal subunit in Pro-C4. Proc Natl Acad Sci USA 77:4275–4278

    PubMed  CAS  Google Scholar 

  692. Parker KL, Carroll MC, Shreffler DC, Capra JD (1981) Identification of H-2 controlled structural variants of the murine Slp protein and demonstration of cis-regulation of its expression. J Immunol 126:995–997

    PubMed  CAS  Google Scholar 

  693. Passmore HC, Shreffler DC (1970) A sex limited serum protein variant in the mouse. Inheritance and association with the H-2 region. Biochem Genet 4:351–365

    PubMed  CAS  Google Scholar 

  694. Penalva da Silva F, Hoecker GF, Day NK, Vienne K, Rubinstein P (1978) Murine complement component 3: genetic variation and linkage to H-2. Proc Natl Acad Sci USA 75:963–965

    Google Scholar 

  695. Pericak-Vance MA, Elston RC, Spira TJ, Band J (1982) Segregation and linkage analysis of immunochemical C8 levels in a family with C8 beta-chain deficiency. Am J Hum Genet 34:190A

    Google Scholar 

  696. Perlmutter DH, Colten HR, Grossberger D, Strominger J, Seidman JG, Chaplin DD (1985) Expression of complement proteins C2 and factor B in transfected L-cells. J Clin Invest 76:1449–1454

    PubMed  CAS  Google Scholar 

  697. Petersen BH, Graham JA, Brooks GF (1976) Human deficiency of the eighth component complement. The requirement of C8 for serum Neisseria gonorrhoeae bactericidal activity. J Clin Invest 57:283–290

    PubMed  CAS  Google Scholar 

  698. Porter RR (1983) Complement polymorphism, the major histocompatibility complex and associated diseases: a speculation. Mol Biol Med 1:161–168

    PubMed  CAS  Google Scholar 

  699. Porter RR, Reid KBM (1979) Activation of the complement system by antibody-antigen complexes: the classical pathway. Adv Protein Chem 33:1–64

    PubMed  CAS  Google Scholar 

  700. Prentice HL, Schneider PM, Strominger JL (1986) C4B gene polymorphism detected in a human cosmid clone. Immunogenetics 23:274–276

    PubMed  CAS  Google Scholar 

  701. Raanford PR, Kirk RL, Zimmet P (1982) Distribution of complement factors BF, C2 and C6 in the Western Pacific. Acta Anthropogenet 6:23–32

    Google Scholar 

  702. Rao AG, Howard OMZ, Ng SC, Snyder JV, Whitehead AS, Colten HR, Sodetz JM (1986) Characterization of a cDNA clone encoding the alpha-subunit of the eighth component of human complement. Proceedings 6th International Congress of Immunology, Toronto, Canada, 6–11 July 1986, p 197 (Abstract)

    Google Scholar 

  703. Rapp HJ, Borsos T (1970) Molecular basis of complement action. Appleton-Century-Crofts, New York

    Google Scholar 

  704. Raum D, Glass D, Agnello V, Schur P, Alper CA (1978) Congenital deficiency of C2 and factor B. N Engl J Med 299:1313

    PubMed  CAS  Google Scholar 

  705. Raum D, Alper CA, Stein R, Gabbay KH (1979) Genetic marker for insulin-dependent diabetes mellitus. Lancet 2:1208–1210

    Google Scholar 

  706. Raum D, Spencer MA, Balavitch D, Tidoman S, Merritt AD, Taggart RT, Petersen BH, Day NK, Alper CA (1979) Genetic control of the eighth component of complement. J Clin Invest 64:858–865

    PubMed  CAS  Google Scholar 

  707. Raum D, Balner H, Petersen BH, Alper C (1980) Genetic polymorphism of serum complement components in the chimpanzee. Immunogenetics 10:455–468

    Google Scholar 

  708. Raum D, Donaldson VH, Rosen FS, Alper CA (1980) Genetics of complement. Curr Top Hematol 3:111–174

    PubMed  CAS  Google Scholar 

  709. Raum D, Awdeh ZL, Alper CA (1981) BF types and the mode of inheritance of insulin- dependent diabetes mellitus (IDDM). Immunogenetics 12:59–74

    PubMed  CAS  Google Scholar 

  710. Raum D, Awdeh Z, Anderson J, Strong L, Granados J, Teran L, Giblett E, Yunis EJ, Alper CA (1984) Human C4 haplotypes with duplicated C4A or C4B. Am J Hum Genet 36:72–79

    PubMed  CAS  Google Scholar 

  711. Reid KBM (1985) Application of molecular cloning to studies on the complement system. Immunology 55:185–196

    PubMed  CAS  Google Scholar 

  712. Reveille JD, Arnett FC, Wilson RW, Bias WB, McLean RH (1985) Null alleles of the fourth component of human complement and HLA haplotypes in familial systemic lupus erythematosus. Immunogenetics 21:299–311

    PubMed  CAS  Google Scholar 

  713. Rigby PWJ, Dieckmann M, Rhodes C, Berg P (1977) Labelling deoxynucleic acid to high specific activity in vitro by nick translation with DNA polymerase I. J Mol Biol 113:237–251

    PubMed  CAS  Google Scholar 

  714. Righetti PG (1983) Isoelectric focusing: theory, methodology and applications. In: Work TS, Burdon RH (eds) Laboratory techniques in biochemistry and molecular biology. Elsevier Biomedical, Amsterdam

    Google Scholar 

  715. Rittner C (ed) (1972) First international symposium and workshop on the polymorphism of the third component of the human complement system. Vox Sang 25:9–27

    Google Scholar 

  716. Rittner C (1983) Chromosomes and complement in scleroderma. Proceedings of the Scleroderma Symposium London, 12–13 May 1983, Smith, Kline and French Laboratories, London, pp 23–28

    Google Scholar 

  717. Rittner C, Rittner B (1973) Qualitative and quantitative comparison of C3 variant sera during the Bonn Workshop. Vox Sang 25:21–27

    PubMed  CAS  Google Scholar 

  718. Rittner C, Rittner B (1974) Report 1973/1974 of the reference laboratory of the third component (C3) of the human complement system. Vox Sang 27:464–472

    PubMed  CAS  Google Scholar 

  719. Rittner C, Grosse-Wilde H, Rittner B, Netzel B, Scholz S, Lorenz H, Albert ED (1975) Linkage group HL-A-MLC-BF (Properdin factor B). Hum Genet 27:173–183

    CAS  Google Scholar 

  720. Rittner C, Hauptmann G, Grosse-Wilde H, Grosshans E, Tongio MM, Mayer S (1975) Linkage between HL-A (major histocompatibility complex) and genes controlling the synthesis of the fourth component of complement. In: Kissmeyer-Nielsen F (ed) Histocompatibility testing 1975. Munksgard, Copenhagen, pp 945–954

    Google Scholar 

  721. Rittner C (1976) Genetic loci of components of the classical and alternate pathway of complement activation: a new dimension of the immunogenetic linkage group (HLA) on chromosome 6 in man. Hum Genet 35:1–20

    PubMed  CAS  Google Scholar 

  722. Rittner C, Grosse-Wilde H, Albert ED (1976) Localization of the Bf locus within the HLA region. Report on a informative family and critical evaluation of available data of Bf mapping. Hum Genet 35:79–82

    PubMed  CAS  Google Scholar 

  723. Rittner C, Opferkuch W, Wellek B, Grosse-Wilde H, Wernet P (1976) Lack of linkage between gene(s) controlling the synthesis of the seventh component of complement and the HLA region on chromosome No. 6 in man. Hum Genet 34:137–142

    PubMed  CAS  Google Scholar 

  724. Rittner C, Dewald G, Berghoff E, Mollenhauer E (1979) C6-Polymorphismus der sechsten Komplementkomponente. Ein neues, aussagekräftiges System in der Abstammungsbegutachtung. Z Rechtsmed 83:17–25

    PubMed  CAS  Google Scholar 

  725. Rittner C, Zaschke S, Berghoff E, Mollenhauer E, Opferkuch W, Baur MP (1980) Comparative studies of human C4 phenotypes their population genetics and association with HLA-B antigens. Immunobiology 158:119–128

    PubMed  CAS  Google Scholar 

  726. Rittner C, Bertrams J (1981) On the significance of C2, C4, and Factor B polymorphisms in disease. Hum Genet 56:235–247

    PubMed  CAS  Google Scholar 

  727. Rittner C, DeMarchi M, Mollenhauer E, Carbonara A (1984) Coeliac disease and C4A* QO: an association secondary to HLA-DR3. Tissue Antigens 23:130–134

    PubMed  CAS  Google Scholar 

  728. Rittner C, Giles CM, Roos MH, Demant P, Mollenhauer E (1984) Genetics of human C4 polymorphism: detection and segregation of rare and duplicated haplotypes. Immunogenetics 19:321–333

    PubMed  CAS  Google Scholar 

  729. Rittner C, Hargesheimer W, Mollenhauer E (1984) Population and formal genetics of the human C81 (alpha-gamma) polymorphism. Hum Genet 67:166–169

    PubMed  CAS  Google Scholar 

  730. Rittner C, Kühnl P, Black CM, Pereira S, Welsh KI (1984) Scleroderma: possible association with the C4 system — a progress report. In: Albert ED, Baur MP, Mayr W (eds) Histocompatibility testing 1984. Springer, Berlin Heidelberg New York

    Google Scholar 

  731. Rittner C, Meier EMM, Stradmann B, Giles CM, Köchling R, Mollenhauer E, Kreth HW (1984) Partial C4 deficiency in subacute sclerosing panencephalitis. Immunogenetics 20:407–415

    PubMed  CAS  Google Scholar 

  732. Rittner C, Tippett P, Giles CM, Mollenhauer E, Berger R, Nordhagen R, Buskjaer L, Bruun-Petersen G, Lamm L, Roos MH (1984) An international reference typing for Ch and Rg determinants on rare human C4 allotypes. Vox Sang 46:224–234

    PubMed  CAS  Google Scholar 

  733. Rittner C, Hargesheimer W, Stradmann B, Bertrams J, Baur MP, Petersen BH (1986) Human C81 (alpha-gamma) polymorphism: detection in the alpha-gamma subunit on SDS-PAGE, formal genetics and linkage relationship. Am J Hum Genet 38:482–486

    PubMed  CAS  Google Scholar 

  734. Robinson MA, Carroll MC, Johnson AH, Hartzman RJ, Belt KT, Kindt TJ (1985) Localization of C4 genes within the HLA complex by molecular genotyping. Immunogenetics 21:143–152

    PubMed  CAS  Google Scholar 

  735. Rodriguez de Cordoba S, Dykman TR, Fellner FG, Ercilla G, Aqua M, Atkinson JP, Rubinstein P (1984) Evidence for linkage between the loci coding for the binding protein for the fourth component of human complement (C4BP) and for the C3b/C4b receptor. Proc Natl Acad Sci USA 81:7890–7892

    Google Scholar 

  736. Rodriguez de Cordoba S, Ferreira A, Nussenzweig V, Rubinstein P (1983) Genetic polymorphism of human C4-binding protein. J Immunol 131:1565

    PubMed  Google Scholar 

  737. Rodriguez de Cordoba S, Rubinstein P (1984) Genetic polymorphism of human factor H (beta-1H). J Immunol 132:1906–1908

    Google Scholar 

  738. Rodriguez de Cordoba S, Rubinstein P, Ferreira A (1984) High resolution isoelectric focusing of immunoprecipitated proteins under denaturing conditions. A simple analytical method applied to the study of complement component polymorphisms. J Immunol Methods 60:165–172

    Google Scholar 

  739. Rodriguez de Cordoba S, Lublin DM, Rubinstein P, Atkinson JP (1985) Human genes for three complement components that regulate the activation of C3 are tightly linked. J Exp Med 161:1189–1195

    Google Scholar 

  740. Rogde S, Mevag B, Olaisen B, Gedde-Dahl T, Teisberg P (1984) Structural gene(s) for complement factor C8 (C8) on chromosome 1. Cytogenet Cell Genet 34:571 (Abstract)

    Google Scholar 

  741. Rogde S, Mevag B, Teisberg P, Gedde-Dahl T Jr, Tedesco F, Olaisen B (1985) Genetic polymorphism of complement component C8. Hum Genet 70:211–216

    PubMed  CAS  Google Scholar 

  742. Roos MH, Atkinson JP, Shreffler DC (1978) Molecular characterization of the Ss and Slp (C4) proteins of the mouse H-2 complex: subunit composition, chain size polymorphism, and an intracellular (Pro-Ss) precursor. J Immunol 121:1106–1115

    PubMed  CAS  Google Scholar 

  743. Roos MH, Demant P (1982) Murine complement factor B (BF): sexual dimorphism and H-2-linked polymorphism. Immunogenetics 15:23–30

    PubMed  CAS  Google Scholar 

  744. Roos MH, Mollenhauer E, Demant P, Rittner C (1982) A molecular basis for the two locus model of human complement component C4. Nature 298:854–856

    PubMed  CAS  Google Scholar 

  745. Roos MH, Demant P (1983) New polymorphisms of murine C4 are detected by high resolution electrophoresis. Immunobiology 164:289 (Abstract)

    Google Scholar 

  746. Roos MH, Giles CM, Demant P, Mollenhauer E, Rittner C (1984) Rodgers (Rg) and Chido (Ch) determinants on human C4: characterization of two C4 B5 subtypes one of which contains both Rg and Ch determinants. J Immunol 133:2634–2640

    PubMed  CAS  Google Scholar 

  747. Rose M, Geserick G (1969) Ein neuer Serumpolymorphismus: Pt. Erste Hinweise für eine genetische Steuerung. Acta Biol Med Germ 23:351–356

    PubMed  CAS  Google Scholar 

  748. Rosenfeld SI, Weitkamp LR, Ward F (1977) Hereditary C5 deficiency in man: genetic linkage studies. J Immunol 119:604–608

    PubMed  CAS  Google Scholar 

  749. Rosenfeld SI, Weitkamp LR, Countryman JR (1978) Nonlinkage for a locus of human complement C5 deficiency to the complement C6 structural locus. Immunogenetics 7:95–97

    PubMed  CAS  Google Scholar 

  750. Rosenfeld S, Ruddy S, Austen KF (1969) Structural polymorphism of the fourth component of human complement. J Clin Invest 48:2283–2292

    PubMed  CAS  Google Scholar 

  751. Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, Taylor RP, Myones BL, Lachmann PJ (1985) Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol 135:2005–2014

    PubMed  CAS  Google Scholar 

  752. Rother K, Rother U, Müller-Eberhard HJ, Nilsson UR (1966) Deficiency of the sixth component of complement in rabbits with an inherited complement defect. J Exp Med 12:773–777

    Google Scholar 

  753. Rother K, Rother U (eds) (1986) Complement deficiencies in animals and man. Prog Allergy 39. Karger, Basel

    Google Scholar 

  754. Rother U, Rother K (1961) Über einen angeborenen Komplementdefekt bei Kaninchen. Z Immun Forsch 121:224–228

    CAS  Google Scholar 

  755. Rubinstein P, Rosenfleld-Steele P, Day NK (1977) Murine factor B: electrophoretic polymorphism. Immunogenetics 5:363–366

    Google Scholar 

  756. Rubinstein P, Vienne K, Hoecker GF (1979) The location of the C3 and GLO (glyoxalase 1) loci of the IXth linkage group in mice. J Immunol 122:2584–2589

    PubMed  CAS  Google Scholar 

  757. Sackstein R, Colten HR, Woods DE (1983) Phylogenetic conservation of a class III major histocompatibility complex antigen, factor B: isolation and nucleotide sequencing of mouse factor B cDNA clones. J Biol Chem 258:14693–14697

    PubMed  CAS  Google Scholar 

  758. Sackstein R, Roos MH, Demant P, Colten HR (1984) Subdivision of the S region of the mouse major histocompatibility complex by identification of genomic polymorphisms of the class III genes. Immunogenetics 20:321

    PubMed  CAS  Google Scholar 

  759. Scharfstein J, Ferreira A, Nussenzweig V (1978) Human C4 binding protein. I. Isolation and characterization. J Exp Med 148:207–211

    PubMed  CAS  Google Scholar 

  760. Schifferli JA, Steiger G, Paccaud JP, Sjödholm AG, Hauptmann G (1986) Difference in the biological properties of the two forms of the fourth component of human complement (C4). Immunology 63:473–477

    CAS  Google Scholar 

  761. Schiotz PO, Hioby N, Norling N, Sörensen H (1978) C3 polymorphism in a Danish cystic fibrosis population and its possible association with antibody response. Hum Hered 28:293–300

    PubMed  CAS  Google Scholar 

  762. Schneider PM, Rittner C, Carroll MC, Colten HR (1985) Genomic structure of the C4 and 21-OH loci in a family with a C4A (Ch+) gene product. Complement 2:71 (Abstract)

    Google Scholar 

  763. Schneider PM, Carroll MC, Alper CA, Rittner C, Whitehead AS, Yunis EJ, Colten HR (1986) Polymorphism of the human complement C4 and steroid 21-hydroxylase genes: restriction fragment length polymorphisms revealing structural deletions, homoduplications and size variants. J Clin Invest 78:650–657

    PubMed  CAS  Google Scholar 

  764. Schröder R, Zander H, Andreas A, Mauff G (1983) Multiple sclerosis: immunogenetic analysis of sibpair doublecase families. II. Studies on the association of multiple sclerosis with C2, C4, BF, C3, C6, and Gm polymorphisms. Immunobiology 164:160–170

    PubMed  Google Scholar 

  765. Sepich DS, Noonan DJ, Ogata RT (1985) Complete cDNA sequence of the fourth component of murine complement. Proc Natl Acad Sci USA 82:5895–5899

    PubMed  CAS  Google Scholar 

  766. Shows TB, Alper CA, Bootsma D, Dorf M, Doublas T, Huisman T, Kits S, Klinger HP, Kozak C, Lalley PA, Lindsley D, McAlpine PJ, McDougall JK, Meera Khan P, Meisler M, Morton NE, Opitz JM, Partridge CW, Payne R, Roderick TH, Rubinstein P, Ruddle FH, Shaw M et al. (1979) International system for human gene nomenclature — ISGN (1979). Cell Genet 25:96–116

    CAS  Google Scholar 

  767. Shreffler DC (1976) The S region of the mouse major histocompatibility complex H-2: genetic variation and functional role in complement system. Transplant Rev 32:40–167

    Google Scholar 

  768. Shreffler DC, Owen RD (1963) A serologically detected variant in mouse serum: inheritance and association with the histocompatibility-2 locus. Genetics 48:9–25

    PubMed  CAS  Google Scholar 

  769. Shreffler DC, Atkinson JP, Karp DR, Killion CC, Ogata RT, Rosa PA (1984) The C4 and Slp genes of the complement region of the murine H-2 major histocompatibility complex. Philos Trans R Soc Lond [Biol] 306:112–126

    Google Scholar 

  770. Southern EM (1975) Detection of specific sequences among DNA fragments separated by electrophoresis. J Mol Biol 98:503–517

    PubMed  CAS  Google Scholar 

  771. Spinella DG, Passmore HC (1983) A newly defined murine alloantigen controlled by the S region of the H-2 complex: molecular association with the fourth component of complement. J Immunol 130:824–828

    PubMed  CAS  Google Scholar 

  772. Steckel EW, York RG, Monahan JB, Sodetz J (1980) The eighth component of human complement: purification and physiochemical characterization of its unusual subunit structure. J Biol Chem 255:11997–12005

    PubMed  CAS  Google Scholar 

  773. Suciu-Foca N, O’Neill GJ, Rubinstein P (1980) Evidence for the existence of a possible Bf “null” allele. In: Terasaki PI (ed) Histocompatibility testing 1980. UCLA Tissue Typing Laboratory Los Angeles, California, pp 935–936

    Google Scholar 

  774. Suzuki K, O’Neill GJ, Matsumoto H (1986) A product of the C4B locus lacking hemolytic activity. Hum Genet 73:101–103

    PubMed  CAS  Google Scholar 

  775. Takahashi S, Takahashi M, Kaideh T, Natsuume-Sakai S, Takahashi T (1984) Genetic mapping of mouse C4-BP locus to the H-2D-Qa interval. J Immunol 132:6–8

    PubMed  CAS  Google Scholar 

  776. Tappeiner G (1982) Disease states in genetic complement deficiencies. Int J Dermatol 21:175–188

    PubMed  CAS  Google Scholar 

  777. Tedesco F (1986) C8 deficiency: clinical, biochemical and genetic aspects. Prog Allergy 39 pp 295–306

    PubMed  CAS  Google Scholar 

  778. Tedesco F, Densen P, Villa MA, Petersen BH (1983) Two types of dysfunctional eighth component of complement (C8) molecules in C8 deficiency in man. J Clin Invest 71:183–191

    PubMed  CAS  Google Scholar 

  779. Teisberg P (1970) High voltage agarose gel electrophoresis in the study of C3 polymorphism. Vox Sang 19:47–56

    PubMed  CAS  Google Scholar 

  780. Teisberg P (1971) The distribution of C3 types in Norway. Hum Hered 21:154–161

    PubMed  CAS  Google Scholar 

  781. Teisberg P, Olaisen B, Gedde-Dahl T Jr, Thorsby E (1975) On the localization of the Gb locus within the MHS region of chromosome No. 6. Tissue Antigens 5:257–261

    CAS  Google Scholar 

  782. Teisberg P, AkessonI, Olaisen B, Gedde-Dahl T Jr, Thorsby E (1976) Genetic polymorphism of C4 in man and localization of a structural C4 locus to the HLA gene complex of chromosome 6. Nature 264:253–254

    PubMed  CAS  Google Scholar 

  783. Teisberg P, Olaisen B, Gedde-Dahl T Jr, Thorsby E, Nordhagen R (1980) Further investigations on the genetics of the C4 protein polymorphism. Immunobiology 158:45–49

    PubMed  CAS  Google Scholar 

  784. Teisberg P, Olaisen B, Nordhagen R, Thorsby E, Gedde-Dahl T Jr (1980) A haemolytically non-active C4 gene product. Immunobiology 158:91–95

    PubMed  CAS  Google Scholar 

  785. Teng YS, Tan SG (1982) Subtyping of properdin factor B (Bf) by isoelectrofocusing. Hum Hered 32:362–366

    PubMed  CAS  Google Scholar 

  786. Tilley CA, Romans DG, Crookston MC (1978) Localization of Chido and Rodgers determinants to the C4d fragment of human C4. Nature 276:713–715

    PubMed  CAS  Google Scholar 

  787. Tokunaga K, Araki C, Juji T, Omoto K (1981) Genetic polymorphism of the complement C2 in Japanese. Hum Genet 58:213–216

    PubMed  CAS  Google Scholar 

  788. Tokunaga K, Araki C, Juji T, Omoto K (1982) Polymorphism of properdin factor B in Japanese. Description of a rare variant and data of association with HLA and C2. Hum Genet 60:42–45

    PubMed  CAS  Google Scholar 

  789. Tokunaga K, Yukiyama Y, Omoto K (1983) Polymorphism of the complement component C6 in Japanese. J Immunogenet 10:419–424

    PubMed  CAS  Google Scholar 

  790. Tokunaga K, Omoto K, Akiyama N, Ando H, Juji T (1984) A new variant (C2*BJ) of the C2 polymorphism. Transplant Proc (in press)

    Google Scholar 

  791. Tokunaga K, Omoto K, Fujii Y, Juji T (1984) Joint report: haplotype study on HLA-link-age genetic markers. Transplant Proc (in press)

    Google Scholar 

  792. Tokunaga K, Omoto K, Sakurai M, Saji H, Maruya E, Juji T (1984) A possible BF “silent” allele (BF*QO). Transplant Proc (in press)

    Google Scholar 

  793. Tokunaga K, Omoto K, Yukiyama Y, Sakurai M, Saji H, Maruya E (1984) Further study on a BF silent allele. Hum Genet 67:449–451

    PubMed  CAS  Google Scholar 

  794. Tokunaga K, Omoto K, Akaza T, Akiyama N, Amemiya H, Naito S, Sasazuki T, Satoh H, Juji T (1986) Haplotype study on C4 polymorphism in Japanese. Associations with MHC alleles, complotypes, and HLA-complement haplotypes. Hum Genet (in press)

    Google Scholar 

  795. Tosi M, Levi-Strauss M, Georgatsou E, Amor M, Meo T (1985) Duplications of complement and non-complement genes of the H-2S region: evolutionary aspects of the C4 isotypes and molecular analysis of their expression variants. Immunol Rev 87:151–184

    PubMed  CAS  Google Scholar 

  796. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76:4350–4354

    PubMed  CAS  Google Scholar 

  797. Uring-Lambert B, Giles CM, Goetz J, Tongio MM, Mayer S, Hauptmann G (1984) C4 haplotypes with duplicated C4A or C4B: frequency and associations with BF, C2, and HLA-A, B, C, DR alleles with special reference to the duplication B1, 2. In: Albert E, Baur MP, Mayr W (eds) Histocompatibility testing 1984. Springer, Berlin Heidelberg New York Tokyo, pp 604–608

    Google Scholar 

  798. Wahl GM, Stern M, Stark GR (1979) Efficient transfer of large DNA fragments from agarose gels to diazobenzoloxymethyl-paper and rapid hybridization using dextran sulfate. Proc Natl Acad Sci USA 76:3683–3687

    PubMed  CAS  Google Scholar 

  799. Wank R, Schendel DJ, O’Neill GJ, Riethmüller G, Held E, Feucht HE (1984) Rare variant of complement C4 is seen in high frequency in patients with primary glomerulonephritis. Lancet 1:872–873

    PubMed  CAS  Google Scholar 

  800. Weidinger S, Schwarzfischer F, Cleve H (1979) Properdin factor B polymorphism. An indication for the existence of a Bf allele. Z Rechtsmed 83:259–264

    PubMed  CAS  Google Scholar 

  801. Weidinger S, Schwarzfischer F, Burgemeister R, Cleve H (1984) Two new Bf S subtypes revealed by isoelectric focusing and immunoflxation. Hum Genet 68:90–92

    PubMed  CAS  Google Scholar 

  802. Wetsel RA, D’Eustachio P, Strunk RC, Ogata RT, Tack BF (1985) Fifth complement component: complete cDNA sequence, chromosomal assignment, and deficiency studies. Complement 2:86 (Abstract)

    Google Scholar 

  803. White PC, New MI, Dupont B (1984) HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci USA 81:7505–7509

    PubMed  CAS  Google Scholar 

  804. White PC, Grossberger D, Onufer BJ, Chaplin DD, New MI, Dupont B, Strominger JL (1985) Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proc Natl Acad Sci USA 82:1089–1093

    PubMed  CAS  Google Scholar 

  805. White PC, New MI, Dupont B (1985) Adrenal 21-hydroxylase cytochrome P-450 genes within the MHC class III region. Immunol Rev 87:123–150

    PubMed  CAS  Google Scholar 

  806. Whitehead AS, Solomon E, Chambers SP, Povey S, Bodmer WF (1982) Assignment of the gene for the third component of human complement (C3) to chromosome 19 using human-mouse somatic cell hybrids. Cytogenet Cell Genet 13:183–184

    Google Scholar 

  807. Whitehead AS, Solomon E, Chambers S, Bodmer WF, Povey S, Fey G (1982) Assignment of the structural gene for the third component of human complement to chromosome 19. Proc Natl Acad Sci USA 79:5021–5025

    PubMed  CAS  Google Scholar 

  808. Whitehead AS, Goldberger G, Woods DE, Markham AF, Colten HR (1983) Use of a cDNA clone for the fourth component of human complement (C4) for analysis of genetic deficiency of C4 in guinea pig. Proc Natl Acad Sci USA 80:5387–5391

    PubMed  CAS  Google Scholar 

  809. Whitehead AS, Woods DE, Fleischnick E, Chin JE, Yunis EJ, Katz AJ, Gerald PS, Alper CA, Colten HR (1984) DNA polymorphism of the C4 genes. A new marker for analysis of the major histocompatibility complex. N Engl J Med 310:88–91

    PubMed  CAS  Google Scholar 

  810. Whitehead AS, Colten HR, Chang CC, Demars R (1985) Localization of the human MHC- linked complement genes between HLA-B and HLA-DR by using HLA mutant cell lines. J Immunol 134:641–643

    PubMed  CAS  Google Scholar 

  811. Whitehead AS, Sackstein R (1985) Molecular biology of the human and mouse MHC class III genes: phylogenetic conservation, genetics and regulation of expression. Immunol Rev 87:185–208

    PubMed  CAS  Google Scholar 

  812. Whitehead AS, Schneider PM, Awdeh ZL, Fleischnick E, Blumenthal M, Costello W, Gerald PS, Yunis EJ, Alper CA (1986) The distribution of C4 DNA variants in relation to MHC alleles and extented haplotypes. Hum Immunol (in press)

    Google Scholar 

  813. Whitehouse DB, Putt W (1983) Immunological detection of the sixth complement component (C6) following flat bed polyacrylamide gel isoelectric focusing and electrophoretic transfer to nitrocellulose filters. Ann Hum Genet 47:1–8

    PubMed  CAS  Google Scholar 

  814. Wieme RJ, Demeulenaere L (1967) Genetically determined electrophoretic variant of the human complement component C3. Nature 214:1042–1043

    PubMed  CAS  Google Scholar 

  815. Wilson JG, Wong WW, Schnur PH, Fearon DT (1982) Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med 307:981–986

    PubMed  CAS  Google Scholar 

  816. Wilson J, Murphy EE, Wong WW, Klickstein LB, Weis JH, Fearon DT (1985) Restriction fragment length polymorphism of the CR1 gene correlating with low number of CR1 on erythrocytes. Complement 2:87 (Abstract)

    Google Scholar 

  817. Wong WW, Wilson JG, Fearon DT (1983) Genetic regulation of a structural polymorphism of human C3b receptor. J Clin Invest 72:685–692

    PubMed  CAS  Google Scholar 

  818. Wong WW, Klickstein LB, Smith JA, Weis JH, Fearon DT (1985) Identification of a partial cDNA clone for the human receptor for complement fragments C3b/C4b. Proc Natl Acad Sci USA 82:7711–7715

    PubMed  CAS  Google Scholar 

  819. Woods DE, Markham AF, Ricker AT, Goldberger G, Colten HR (1982) Isolation of cDNA clones for the human complement protein factor B, a class III major histocompatibility complex gene product. Proc Natl Acad Sci USA 79:5661–5665

    PubMed  CAS  Google Scholar 

  820. Woods DE, Edge MD, Colten HR (1984) Isolation of a cDNA clone for the human complement protein C2 and its use in the identification of a restriction fragment length polymorphism. J Clin Invest 74:634–638

    PubMed  CAS  Google Scholar 

  821. Yu CY, Belt KT, Giles CM, Porter RR (1985) Chido antigenic determinants. Complement 2:89 (Abstract)

    Google Scholar 

  822. Zhao TM (1983) Genetic polymorphism of C3 and Bf in the Chinese population. Hum Hered 33:36–38

    Google Scholar 

  823. Ziegler JB, Alper CA, Balner H (1975) Properdin factor B and histocompatibility loci linked in the rhesus monkey. Nature 254:609–611

    PubMed  CAS  Google Scholar 

  824. Ziegler JB, Watson L, Alper CA (1975) Genetic polymorphism of properdin factor B in the rhesus: evidence for single subunit structure in primates. J Immunol 114:1649–1653

    PubMed  CAS  Google Scholar 

  825. Loos M (1982) The classical complement pathway: mechanism of activation of the first component by antigen-antibody complex. Prog Allergy 30:135–192

    PubMed  CAS  Google Scholar 

  826. Ishizaka T, Ishizaka K, Borsos R, Rapp H (1966) C1 fixation of C1 by G and M but not by A antibody. J Immunol 97:716–726

    PubMed  CAS  Google Scholar 

  827. Müller-Eberhard HJ, Kunkel HG (1961) Isolation of a thermolabile serum protein which precipitates γ-globulin aggregates and participates in immune hemolysis. Proc Soc Exp Biol Med 106:291–295

    PubMed  Google Scholar 

  828. Augener W, Grey HM, Cooper NR, Müller-Eberhard HJ (1971) The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry 8:1011–1020

    PubMed  CAS  Google Scholar 

  829. Bubb MO, Conradie JD (1976) The importance of quaternary structure in the expression of the #-binding site of IgM. Immunology 31:893–902

    PubMed  CAS  Google Scholar 

  830. Hurst MM, Volanakis JE, Hester RB, Stroud RM, Bennett JC (1974) The structural basis for binding of complement by immunoglobulin M. J Exp Med 140:1117–1121

    PubMed  CAS  Google Scholar 

  831. Hurst MM, Volanakis JE, Stroud RM, Bennett JC (1975) CT fixation and classical complement pathway activation by a fragment of the CH4 domain of IgM. J Exp Med 142:1322–1326

    PubMed  CAS  Google Scholar 

  832. Plaut AG, Cohen S, Tomasi TB (1972) Immunoglobulin M: fixation of human complement by the Fc fragment. Science 176:55–56

    PubMed  CAS  Google Scholar 

  833. Sledge CR, Bing DH (1973) Binding properties of the human complement protein C1q. J Biol Chem 248:2818–2823

    PubMed  CAS  Google Scholar 

  834. McKenzie MR, Creevy N, Heh M (1971) The interaction of human IgM and C1q. J Immunol 106:65–68

    Google Scholar 

  835. Hyslop NE, Dourmashkin RR, Green NM, Porter RR (1970) The fixation of complement and the activated first component (#) of complementary by complexes formed between antibody and divalent hapten. J Exp Med 131:783–802

    PubMed  CAS  Google Scholar 

  836. Borsos T, Rapp HJ (1965) Complement fixation on cell surfaces by 19S and 7S antibodies. Science 150:505–506

    PubMed  CAS  Google Scholar 

  837. Borsos T, Rapp HJ (1965) Hemolysis titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysis suffices to sensitize an erythrocyte. J Immunol 95:559–566

    PubMed  CAS  Google Scholar 

  838. Mayer MM (1961) Development of the one-hit theory of immune hemolysis. In: Heidelberger M, Plescia OJ (eds) Immunochemical approaches to problems in microbiology. Rutgers University Press, New Brunswick NJ, pp 268–279

    Google Scholar 

  839. Isliker H, Jocot-Guillermod H, Waldesbühl M, von Feilenberg R, Cerrotini JC (1967) Complement fixation by different IgG proportions and fragments. In: Miescher, Grabar (eds) Immunopathology V. pp 197–206

    Google Scholar 

  840. Kehoe JM, Fougereau M (1969) Immunoglobulin peptide with complement fixing activity. Nature 224:1212–1213

    PubMed  CAS  Google Scholar 

  841. Arlaud GJ, Meyer CM, Colomb MG (1976) Use of an IgG fragment prepared with particulate plasmin to study the C1 binding and activation. FEBS Lett 66:132–136

    PubMed  CAS  Google Scholar 

  842. Lee JP, Painter RH (1980) Complement binding properties of two peptides from the C2 region of human IgG 1. Mol Immunol 17:1155–1162

    PubMed  CAS  Google Scholar 

  843. Allan R, Isliker H (1974) Studies on the complement-binding site of rabbit immunoglobulin G. II. The reaction of rabbit IgG and its fragments with C1q. Immunochemistry 11:243–248

    PubMed  CAS  Google Scholar 

  844. Colten HR, Borsos T, Rapp HJ (1967) Efficiency of the first component of complement (C’1) in the hemolytic reaction. Science 158:1590–1529

    PubMed  CAS  Google Scholar 

  845. Golan MD, Hitschold T, Loos M (1981) The reconstitution of human C1, the first complement component. Binding of C1r and C1s to C1q influences the C1q conformation. FEBS Lett 128:281–285

    PubMed  CAS  Google Scholar 

  846. Circolo A, Borsos T (1982) Lysis of hapten-labeled cells by anti-hapten IgG and complement: effect of cell surface hapten density. J Immunol 128:1118–1121

    PubMed  CAS  Google Scholar 

  847. Müller-Eberhard HG (1969) Complement. Ann Rev Biochem 38:389–414

    PubMed  Google Scholar 

  848. Heinz HP, Burger R, Golan MD, Loos M (1984) Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q. J Immunol 132:804–808 #

    PubMed  CAS  Google Scholar 

  849. Schultz DR, Arnold PI, Wu MC, Lo TM, Volanakis JR, Loos M (1979) Isolation and partial characterization of a polysaccharide in ant venom (Pseudomyrmex sp.) that activates the classical complement pathway. Mol Immunol 16:253–264

    PubMed  CAS  Google Scholar 

  850. Schultz DR, Loos M, Bub F, Arnold PI (1980) Differentiation of hemolytically active fluid-phase and cell-bound human C1q by an ant venom-derived polysaccharide. J Immunol 124:1251–1257

    PubMed  CAS  Google Scholar 

  851. Golan MD, Burger R, Loos M (1982) Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J Immunol 129:445–447

    PubMed  CAS  Google Scholar 

  852. Loos M, Borsos T, Rapp HJ (1972) Activation of the first component of complement. Evidence for an internal activation step. J Immunol 108:683–688

    PubMed  CAS  Google Scholar 

  853. Loos M, Borsos T, Rapp HJ (1973) The first component of complement in serum: evidence for a hitherto unrecognized factor in C1 necessary for internal activation. J Immunol 110:205–212

    PubMed  CAS  Google Scholar 

  854. Dodds AW, Sim RB, Porter RP, Kerr MA (1978) Activation of the first component of human complement (C1) by antibody-antigen aggregates. Biochem J 175:383–390

    PubMed  CAS  Google Scholar 

  855. Porter RR, Reid KBM (1979) Activation of the complement system by antibody-antigen complexes: the classical pathway. Adv Protein Chem 33:1–71

    PubMed  CAS  Google Scholar 

  856. Ziccardi RJ (1983) The first component of human complement (C1): activation and control. Springer Semin Immunopathol 6:213–230

    PubMed  CAS  Google Scholar 

  857. Loos M (1982) Antibody independent activation of C1, the first component of complement. Ann Immunol (Paris) 133C:165–179

    CAS  Google Scholar 

  858. Arroyave CM, Müller-Eberhard HJ (1973) Interactions between human C5, C6, and C7 and their functional significance in complement-dependent cytolysis. J Immunol 111:536–545

    PubMed  CAS  Google Scholar 

  859. Bokisch VA, Dierich MP, Müller-Eberhard HJ (1975) Third component of complement (C3): structural properties in relation to functions. Proc Natl Acad Sci USA 72:1989–1993

    PubMed  CAS  Google Scholar 

  860. Borsos T, Rapp HJ, Colten HR (1970) Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. I. Functional differences among C4 sites on cell surfaces. J Immunol 105:1439–1446

    PubMed  CAS  Google Scholar 

  861. Brown EJ, Ramsey J, Hammer CH, Frank MM (1983) Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes. J Immunol 131:403–408

    PubMed  CAS  Google Scholar 

  862. Burger R, Deubel U, Hadding U, Bitter-Suermann D (1982) Identification of functionally relevant determinants on the complement component C3 with monoclonal antibodies. J Immunol 129:2042–2050

    PubMed  CAS  Google Scholar 

  863. Chakravarti DN, Müller-Eberhard HJ (1985) Purification of human C6 to homogeneity: lack of evidence of serine protease nature. Complement 2:16

    Google Scholar 

  864. Conrad DH, Carlo JR, Ruddy S (1978) Interaction of β1H globulin with cell-bound C3b: quantitative analysis of binding and influence of alternative pathway components on binding. J Exp Med 147:1792–1805

    PubMed  CAS  Google Scholar 

  865. Cooper NR (1975) Enzymatic activity of the second component of complement. Biochemistry 14:4245–4250

    PubMed  CAS  Google Scholar 

  866. Cooper NR, Müller-Eberhard HJ (1968) A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry 5:155–169

    PubMed  CAS  Google Scholar 

  867. Cooper NR, Müller-Eberhard HJ (1970) The reaction mechanism of human C5 in immune hemolysis. J Exp Med 132:775–793

    PubMed  CAS  Google Scholar 

  868. Daha MR, Hazefoet HM, van Es LA, Cats A (1980) Stabilization of the classical pathway C3 convertase #, by a factor #, isolated from serum of patients with systemic lupus erythematosus. Immunology 40:417–424

    PubMed  CAS  Google Scholar 

  869. Dessauer A, Rother U, Rother K (1984) Freeze-thaw activation of the complement attack phase: I Separation of two steps in the formation of the active # complex. Acta Microbiol Immunol Scand [C] Suppl 284, 92:75–81

    Google Scholar 

  870. DiScipio RG (1981 a) The binding of human complement proteins C5, factor B, β1H and properdin to complement fragment C3b on zymosan. Biochem J 199:485–496

    PubMed  CAS  Google Scholar 

  871. DiScipio RG (1981 b) The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase. Biochem J 199:497–504

    PubMed  CAS  Google Scholar 

  872. DiScipio RG, Smith CA, Müller-Eberhard HJ, Hugli TE (1983) The activation of human complement component C5 by a fluid phase C5 convertase. J Biol Chem 258:10629–10636

    PubMed  CAS  Google Scholar 

  873. Fearon DT, Austen KF (1975) Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med 142:856–863

    PubMed  CAS  Google Scholar 

  874. Fernandez HN, Hugli TE (1978) Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. J Biol Chem 253:6955–6964

    PubMed  CAS  Google Scholar 

  875. Fishelson Z, Müller-Eberhard HJ (1982) C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium. J Immunol 129:2603–2607

    PubMed  CAS  Google Scholar 

  876. Fishelson Z, Pangburn MK, Müller-Eberhard HJ (1983) C3 convertase of the alternative pathway. Demonstration of an active, stable C3b, Bb(Ni) complex. J Biol Chem 258:7411–7415

    PubMed  CAS  Google Scholar 

  877. Gigli I, Austen KF (1969) Fluid phase destruction of C2hu by C1hu. I. Its enhancement and inhibition by homologous and heterologous C4. J Exp Med 129:679–696

    PubMed  CAS  Google Scholar 

  878. Gigli I, Sorvillo J, Mecarelli-Halbwachs L, Leibowitch J (1981) Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway C3 convertase. J Exp Med 154:1–12

    PubMed  CAS  Google Scholar 

  879. Goldlust MB, Shin HS, Hammer CH, Mayer MM (1974) Studies of complement complex C5b,6 eluted from EAC-6: reaction of C5b,6 with EAC4b,3b and evidence on the role of C2a and C3b in the activation of C5. J Immunol 113:998–1007

    PubMed  CAS  Google Scholar 

  880. Hammer CH, Hänsch G, Gresham HD, Shin ML (1983) Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a biomolecular lytic complex, C5b,6a. J Immunol 131:892–898

    PubMed  CAS  Google Scholar 

  881. Harrison RA, Thomas ML, Tack BF (1981) Sequence determination of the thiol ester site of the fourth component of human complement. Proc Natl Acad Sci USA 78:7388–7392

    PubMed  CAS  Google Scholar 

  882. Isenman D, Kells DIC (1982) Conformational and functional changes in the fourth component of human complement produced by nucleophilic modification and by proteolyis with Cls. Biochemistry 21:1109–1117

    PubMed  CAS  Google Scholar 

  883. Isenman DE, Young JR (1984) The molecular basis for the difference in immune hemolysis activity of the Chido and Rodgers isotypes of human complement component C4. J Immunol 132:3019–3027

    PubMed  CAS  Google Scholar 

  884. Isenman DE, Podack ER, Cooper NR (1980) The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase. J Immunol 124:326–331

    PubMed  CAS  Google Scholar 

  885. Isenman DE, Kells DIC, Cooper NR, Müller-Eberhard HJ; Pangburn MK (1981) Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry 20:4458–4467

    PubMed  CAS  Google Scholar 

  886. Janatova J, Tack BF (1981) Fourth component of human complement: studies of an amine- sensitive site comprised of a thiol component. Biochemistry 20:2394–2402

    PubMed  CAS  Google Scholar 

  887. Janatova J, Lorenz PE, Schechter AN, Prahl JW, Tack BF (1980) Third component of human complement: appearance of a sulfhydryl group following chemical or enzymic inactivation. Biochemistry 19:4471–4478

    PubMed  CAS  Google Scholar 

  888. Kerr MA (1980) The human complement system: assembly of the classical pathway C3 convertase. Biochem J 189:173–181

    PubMed  CAS  Google Scholar 

  889. Kitamura H, Matsumoto M, Nagaki K (1984) C3-independent immune haemolysis: haemolysis of EAC14oxy2 cells by C5-C9 without participation of C3. Immunology 53:575–582

    PubMed  CAS  Google Scholar 

  890. Kolb WP, Kolb LM, Savary JR (1982) Biochemical characterization of the sixth component (C6) of human complement. Biochemistry 21:294–301

    PubMed  CAS  Google Scholar 

  891. Lachmann PJ, Thompson RA (1970) Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as # and the participation of C8 and C9. J Exp Med 131:643–657

    PubMed  CAS  Google Scholar 

  892. Law SKA, Dodds AW, Porter RR (1984) A comparison of the properties of two classes, C4A and C4B, of the human complement component C4. EMBO J 3:1819–1823

    PubMed  CAS  Google Scholar 

  893. Law SK, Lichtenberg NA, Holcombe FH, Levine RP (1980 a) Interaction between the labile binding sites of the fourth (C4) and fifth (C5) human complement proteins and erythrocyte cell membranes. J Immunol 125:634–639

    PubMed  CAS  Google Scholar 

  894. Law SK, Lichtenberg NA, Levine RP (1980 b) Covalent binding and hemolytic activity of complement proteins. Proc Natl Acad Sci USA 77:7194–7198

    PubMed  CAS  Google Scholar 

  895. Lay WH, Nussenzweig V (1968) Receptors for complement on leukocytes. J Exp Med 128:991–1007

    PubMed  CAS  Google Scholar 

  896. Mardiney MR, Müller-Eberhard HJ (1968) Ultrastructural localization of the third and fourth components of complement on complement-cell complexes. Am J Pathol 53:253–260

    PubMed  Google Scholar 

  897. Müller-Eberhard HJ, Polley MA, Calcott MA (1967) Formation and functional significance of a molecular complex derived from the second and fourth components of human complement. J Exp Med 125:359–380

    PubMed  Google Scholar 

  898. Nagasawa S, Stroud RM (1977) Cleavage of C2 by # into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b. Proc Natl Acad Sci USA 74:2998–3001

    PubMed  CAS  Google Scholar 

  899. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF (1982) Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 129:184–189

    PubMed  CAS  Google Scholar 

  900. Nilsson UR, Mandle RJ, McConnell-Mapes JA (1975) Human C3 and C5: subunit structure and modifications by trypsin and #. J Immunol 114:815–822

    PubMed  CAS  Google Scholar 

  901. Okada H, Tanaka H, Okada N (1983) Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes. Eur J Immunol 13:340–344

    PubMed  CAS  Google Scholar 

  902. Pangbum MK, Müller-Eberhardt HJ (1978) Complement C3 convertase: cell surface restriction of β1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci USA 75:2416–2420

    Google Scholar 

  903. Pangbum MK, Müller-Eberhard HJ (1980) Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 152:1102–1114

    Google Scholar 

  904. Polley MJ, Müller-Eberhard HJ (1967) Enhancement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med 126:1013–1025

    PubMed  CAS  Google Scholar 

  905. Rother U, Hänsch G, Rauterberg FW, Jungfer H, Rother K (1978) Deviated lysis: lysis of unsensitized cells by complement. V. Generation of the activity by low pH or low ionic strength. Z Immunitätsforsch 155:118–129

    CAS  Google Scholar 

  906. Schmitt M, Mussel HH, Dierich MP (1981) Qualitative and quantitative assessment of C3- receptor reactivities on lymphoid and phagocytic cells. J Immunol 126:2042–2047

    PubMed  CAS  Google Scholar 

  907. Shin HS, Pickering RJ, Mayer MM (1971) The fifth component of the guinea pig complement system. III. Dissociation and transfer of C5b, and the probable site of C5b fixation. J Immunol 106:480–493

    PubMed  CAS  Google Scholar 

  908. Sim E, Law SKA (1985) Hydrazine binds covalently to complement component C4. Different reactivity of C4A and C4B gene products. FEBS Lett 184:323–327

    PubMed  CAS  Google Scholar 

  909. Sim RB, Twose TM, Paterson DS, Sim E (1981) The covalent-binding reaction of complement component C3. Biochem J 193:115–127

    PubMed  CAS  Google Scholar 

  910. Sitomer G, Stroud RM, Mayer MM (1966) Reversible adsorption of C’2 by EAC’4: role of Mg2 +, enumeration of competent SAC’4, two-step nature of C’2 fixation and estimation of its efficiency. Immunochemistry 3:57–69

    PubMed  CAS  Google Scholar 

  911. Strunk R, Colten HR (1974) The first component of human complement (C1): kinetics of reaction with its natural substrates. J Immunol 112:905–910

    PubMed  CAS  Google Scholar 

  912. Tack BF, Morris SC, Prahl JW (1979) Third component of human complement: structural analysis of the polypeptide chains of C3 and C3b. Biochemistry 18:1497–150

    PubMed  CAS  Google Scholar 

  913. Tack BF, Harrison RA, Janatova J, Thomas ML, Prahl JW (1980) Evidence for the presence of an internal thioester-bond in the third component of complement. Proc Natl Acad Sci USA 77:5764–5768

    PubMed  CAS  Google Scholar 

  914. Tamerius JD, Pangburn MK, Müller-Eberhard HJ (1982) Selective inhibition of functional sites of cell-bound C3b hybridoma-derived antibodies. J Immunol 128:512–514

    PubMed  CAS  Google Scholar 

  915. Vogt W (1979) Substrate modulation as a control mechanism of plasma multienzyme systems. In: Holzer H, Tschesche H (eds) Biological functions of proteinases. Springer, Berlin Heidelberg New York, pp 233–237

    Google Scholar 

  916. Vogt W, Dames W, Schmidt G, Dieminger L (1977) Complement activation by the properdin system: formation of a stoichiometric, C3 cleaving complex of properdin factor B with C3b. Immunochemistry 14:201–205

    PubMed  CAS  Google Scholar 

  917. Vogt W, Schmidt G, von Buttlar B, Dieminger L (1978) A new function of the activated third component of complement: binding to C5, an essential step to C5 activation. Immunology 34:29–40

    PubMed  CAS  Google Scholar 

  918. Vogt W, Hinsch B, Schmidt G, von Zabern I (1980) Cleavage of C5 by # in the fluid phase; support by high concentrations of C3. 4th International Congress of Immunology, Paris, 1980:15.1.24.

    Google Scholar 

  919. Vogt W, Hinsch B, Schmidt G, von Zabern I (1982) Function of the activated fourth component of complement (C4b) in activation of C2. FEBS Lett 144:195–198

    PubMed  CAS  Google Scholar 

  920. Vogt W, Lühmann B, Hesse D (1984) “Inactivated” third component of complement (C3b-like C3; C3i) acquires C5 binding capacity and supports C5 activation upon covalent fixation to a solid surface. Complement 1:87–96

    PubMed  CAS  Google Scholar 

  921. von Zabern I, Bloom EL, Chu V, Gigli I (1982 a) The fourth component of human complement treated with amines or chaotropes or frozen-thawed (C4b-like C4): interaction with C4 binding protein and cleavage by C3b/C4b inactivator. J Immunol 128:1433–1438

    Google Scholar 

  922. von Zabern I, Gigli I (1982 b) Conformational changes in complement C4 induced by activation, treatment with amines, chaotropes, or freezing-thawing, detectable by radioiodination using lactoperoxidase. J Immunol 128:1439–1442

    Google Scholar 

  923. von Zabern I, Hinsch B, Przyklenk H, Schmidt G, Vogt W (1980) Comparison of Naja n naja and Naja h haje cobra venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage. Immunobiology 157:499–514

    Google Scholar 

  924. von Zabern I, Nolte R, Vogt W (1981) Treatment of human complement components C4 and C3 with amines or chaotropic ions. Scand J Immunol 13:413–431

    Google Scholar 

  925. Götze O, Müller-Eberhard HJ (1976) The alternative pathway of complement activation. Adv Immunol 24:1–35

    PubMed  Google Scholar 

  926. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AL (1954) The properdin system and immunity: I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120:279–285

    PubMed  CAS  Google Scholar 

  927. Nelson RA (1958) An alternative mechanism for the properdin system. J Exp Med 108:515–535

    PubMed  CAS  Google Scholar 

  928. Pensky J, Hinz CF, Todd EW, Wedgwood RJ, Boyer JT, Lepow IH (1968) Properties of highly purified human properdin. J Immunol 100:142–258

    CAS  Google Scholar 

  929. Gewurz H, Shin HS, Mergenhagen SE (1968) Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components. J Exp Med 128:1049–1057

    PubMed  CAS  Google Scholar 

  930. Schur PH, Becker EL (1963) Pepsin digestion of rabbit and sheep antibodies. The effect on complement fixation. J Exp Med 118:891–904

    PubMed  CAS  Google Scholar 

  931. Sandberg AL, Osier AG, Shin HS, Oliveira B (1970) The biological activities of guinea pig antibodies: II. Modes of complement interaction with gamma1 and gamma2 immunoglobulins. J Immunol 104:329–334

    PubMed  CAS  Google Scholar 

  932. Frank MM, May J, Gaither T, Ellman L (1971) In vitro studies of complement function in sera of C4-deficient guinea pigs. J Exp Med 134:176–187

    PubMed  CAS  Google Scholar 

  933. Götze O, Müller-Eberhard HJ (1971) The C3-activator system: an alternate pathway of complement activation. J Exp Med 134:90s-108s

    PubMed  Google Scholar 

  934. Boenisch T, Alper CA (1970) Isolation and properties of a glycine-rich β-glycoprotein of human serum. Biochim Biophys Acta 221:529–535

    PubMed  CAS  Google Scholar 

  935. Haupt H, Heide K (1965) Isolierung und Eigenschaften eines β2-Glykoproteins aus Humanserum. Clin Chim Acta 12:419–424

    PubMed  CAS  Google Scholar 

  936. Müller-Eberhard HJ, Götze O (1972) C3 proactivator convertase and its mode of action. J Exp Med 135:1003–1008

    PubMed  Google Scholar 

  937. Ballow M (1977) Phylogenetics and ontogenetics of the complement systems. In: Day NK, Good RA (eds) Comprehensive immunology 2. Biological amplification systems in immunology. Plenum, New York, pp 183–204

    Google Scholar 

  938. Vogel C-W, Müller-Eberhard HJ (1982) The cobra venom factor-dependent C3 convertase of human complement. J Biol Chem 257:8292–829

    PubMed  CAS  Google Scholar 

  939. Sjöholm AG, Braconier J-H, Söderström C (1982) Properdin deficiency in a family with fulminant meningococcal infections. Clin Exp Immunol 50:291–297

    PubMed  Google Scholar 

  940. Sissons JGP, Schreiber RD, Perrin LH, Cooper NR, Müller-Eberhard HJ, Oldstone MBA (1979) Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody. J Exp Med 150:445–454

    Google Scholar 

  941. Schreiber RD, Götze O, Müller-Eberhard HJ (1976) Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. J Exp Med 144:1062–1075

    PubMed  CAS  Google Scholar 

  942. Davis AE III, Ziegler JB, Gelfand EW, Rosen FS, Alper CA (1977) Heterogeneity of nephritic factor and its identification as an immunoglobulin. Proc Natl Acad Sci USA 74:3980–3983

    PubMed  CAS  Google Scholar 

  943. Daha MR, Austen KF, Fearon DT (1978) Heterogeneity, polypeptide chain composition and antigenic reactivity of C3 nephritic factor. J Immunol 120:1389–1394

    PubMed  CAS  Google Scholar 

  944. Lachmann PJ, Hughes-Jones NC (1984) Initiation of complement activation. Springer Semin Immunopathol 7:143–162

    PubMed  CAS  Google Scholar 

  945. Lachmann PJ, Halbwachs L (1975) The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol 21:109–114

    PubMed  CAS  Google Scholar 

  946. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1981) Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med 154:856–867

    PubMed  CAS  Google Scholar 

  947. Tack BF, Harrison RA, Janatova J, Thomas ML, Prahl JW (1980) Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci USA 77:5764–5768

    PubMed  CAS  Google Scholar 

  948. Müller-Eberhard HJ, Dalmasso AP, Calcott MA (1966) The reaction mechanism of β1C-globulin (C’3) in immune hemolysis. J Exp Med 123:33–54

    Google Scholar 

  949. Law SK, Levine RP (1977) Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci USA 74:2701–2705

    PubMed  CAS  Google Scholar 

  950. Law SK, Lichtenberg NA, Levine RP (1979) Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. J Immunol 123:1388–1394

    PubMed  CAS  Google Scholar 

  951. Pangburn MK, Müller-Eberhard HJ (1980) Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 152:1102–1114

    PubMed  CAS  Google Scholar 

  952. Janatova J, Lorenz PE, Schechter HN, Prahl JW, Tack BF (1980) Third component of complement: appearance of a sulfhydryl group following chemical or enzymatic activation. Biochemistry 19:4471–4478

    PubMed  CAS  Google Scholar 

  953. Von Zabern I, Nolte R, Vogt W (1981) Treatment of human complement components C4 and C3 with amines or chaotropic ions. Scand J Immunol 13:413–431

    Google Scholar 

  954. Fishelson Z, Pangburn MK, Müller-Eberhard HJ (1984) Characterization of the initial C3 convertase of the alternative pathway of human complement. J Immunol 132:1430–1434

    PubMed  CAS  Google Scholar 

  955. Pryzdial ELG, Isenman DE (1986) A reexamination of the role of magnesium in the human alternative pathway of complement. Mol Immunol 23:87–96

    PubMed  CAS  Google Scholar 

  956. Fishelson Z, Pangburn MK, Müller-Eberhard HJ (1983) C3 convertase of the alternative complement pathway: demonstration of an active, stable C3b, Bb(Ni) complex. J Biol Chem 258:7411–7415

    PubMed  CAS  Google Scholar 

  957. Lesavre PH, Hugli TE, Esser AF, Müller-Eberhard HJ (1979) The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol 123:529–534

    PubMed  CAS  Google Scholar 

  958. Johnson MS, Gagnon J, Reid KBM (1980) Factor D of the alternative pathway of human complement. Purification, alignment and N-terminal amino acid sequences of the major cyanogen bromide fragments, and localization of the serine residue at the active site. Biochem J 187:863–874

    PubMed  CAS  Google Scholar 

  959. Medicus RG, Götze O, Müller-Eberhard HJ (1976) Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med 144:1076–1093

    PubMed  CAS  Google Scholar 

  960. Pangburn MK, Müller-Eberhard HJ (1986) The C3 convertase of the alternative pathway of human complement. Enyzmic properties of the bimolecular proteinase. Biochem J 235:723–730

    PubMed  CAS  Google Scholar 

  961. Law SK, Lichtenberg NA, Levine RP (1980) Covalent binding and hemolytic activity of complement proteins. Proc Natl Acad Sci USA 77:7194–7198

    PubMed  CAS  Google Scholar 

  962. Sim RB, Twose TM, Paterson DS, Sim E (1981) The covalent-binding reaction of complement component C3. Biochem J 193:115–127

    PubMed  CAS  Google Scholar 

  963. Capel PJA, Groeneboer O, Grosveld G, Pondman KW (1978) The binding of activated C3 to polysaccharides and immunoglobulins. J Immunol 121:2566–2572

    PubMed  CAS  Google Scholar 

  964. Law SA, Minich TM, Levine RP (1981) Binding reaction between the third human complement protein and small molecules. Biochemistry 20:7457–7463

    PubMed  CAS  Google Scholar 

  965. Mann J, O’Brien R, Hostetter MK, Alper CA, Rosen FS, Babior BM (1981) The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway. J Immunol 126:2370–2372

    PubMed  CAS  Google Scholar 

  966. Daha MR, Fearon DT, Austen KF (1976) C3 requirements for formation of alternative pathway C5 convertase. J Immunol 117:630–634

    PubMed  CAS  Google Scholar 

  967. Medicus RG, Schreiber RD, Götze O, Müller-Eberhard HJ (1976) A molecular concept of the properdin pathway. Proc Natl Acad Sci USA 73:612–616

    PubMed  CAS  Google Scholar 

  968. Vogt W, Schmidt G, von Buttlar B, Dieminger L (1978) A new function of the activated third component of complement: binding to C5, an essential step for C5 activation. Immunology 34:29

    PubMed  CAS  Google Scholar 

  969. Isenman DE, Podack ER, Cooper NR (1980) The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase. J Immunol 124:326–331

    PubMed  CAS  Google Scholar 

  970. Discipio RG (1981) The binding of human complement proteins C5, factor B, β1H and properdin to complement fragment C3b on zymosan. Biochem J 199:485–496

    PubMed  CAS  Google Scholar 

  971. Weiler JM, Daha MR, Austen KF, Fearon DT (1976) Control of the amplification convertase of complement by the plasma protein β1H. Proc Natl Acad Sci USA 73:3268–3272

    PubMed  CAS  Google Scholar 

  972. Whaley K, Ruddy S (1976) Modulation of the alternative complement pathway by β1H globulin. J Exp Med 144:1147–1163

    PubMed  CAS  Google Scholar 

  973. Pangburn MK, Müller-Eberhard HJ (1978) Complement C3 convertase: cell surface restriction of β1H control and generation of restriction on neuroaminidase-treated cells. Proc Natl Acad Sci USA 75:2416–2420

    PubMed  CAS  Google Scholar 

  974. Lachmann PJ, Müller-Eberhard HJ (1968) The demonstration in human serum of “conglu- tinogen-activating factor” and its effect on the third component of complement. J Immunol 100:691–698

    PubMed  CAS  Google Scholar 

  975. De Bruijn MHL, Fey GH (1985) Human complement component C3:cDNA coding sequence and derived primary structure. Proc Natl Acad Sci USA 82:708–712

    PubMed  Google Scholar 

  976. Ross GD, Lambris JD, Cain JA, Newman SL (1982) Generation of three different fragments of bound C3 with purified factor I or serum: I. Requirements for factor H vs CR1 cofactor activity. J Immunol 129:2051–2060

    PubMed  CAS  Google Scholar 

  977. Medicus RG, Melamed J, Arnaout MA (1983) Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules. Eur J Immunol 13:465–470

    PubMed  CAS  Google Scholar 

  978. Lachmann PJ, Pangburn MK, Oldroyd RG (1982) Breakdown of C3 after complement activation. Identification of a new fragment, C3g, using monoclonal antibodies. J Exp Med 156:205–216

    PubMed  CAS  Google Scholar 

  979. Davis AE, Harrison RA, Lachmann PJ (1984) Physiological inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3dg (α2D), and C3g. I Immunol 132:1960–1966

    CAS  Google Scholar 

  980. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1977) Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein β1H for cleavage of C3b and C4b in solution. J Exp Med 146:257–270

    PubMed  CAS  Google Scholar 

  981. Gigli I, Fujita T, Nussenzweig V (1979) Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein, and C3b inactivator. Proc Natl Acad Sci USA 76:6596–6600

    PubMed  CAS  Google Scholar 

  982. Minta JO, Lepow IH (1974) Studies on the subunit structure of human properdin. Immunochemistry 11:361–368

    PubMed  CAS  Google Scholar 

  983. Götze O, Müller-Eberhard HJ (1974) The role of properdin in the alternative pathway of complement activation. J Exp Med 139:44–57

    PubMed  Google Scholar 

  984. Schreiber RD, Medicus RG, Götze O, Müller-Eberhard HJ (1975) Properdin and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med 142:760–772

    PubMed  CAS  Google Scholar 

  985. Fearon DT, Austen KF (1975) Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med 142:856–863

    PubMed  CAS  Google Scholar 

  986. Götze O, Medicus RG, Müller-Eberhard HJ (1977) Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin. J Immunol 118:525–528

    PubMed  Google Scholar 

  987. Discipio RG (1982) Properdin is a trimer. Mol Immunol 19:631–635

    PubMed  CAS  Google Scholar 

  988. Smith CA, Pangburn MK, Vogel C-W, Müller-Eberhard HJ (1984) Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. J Biol Chem 259:4582–4588

    PubMed  CAS  Google Scholar 

  989. Spitzer RE, Vallota EH, Forristal J, Sudora E, Stitzel A, Davis NC, West CD (1969) Serum C3 lytic system in patients with glomerulonephritis. Science 164:436–437

    PubMed  CAS  Google Scholar 

  990. Vallota EH, Forristal J, Spitzer RE, Davis NC, West CD (1970) Characteristics of a noncomplement dependent C3-reactive complex formed from factors in nephritic and normal serum. J Exp Med 131:1306–1324

    PubMed  CAS  Google Scholar 

  991. Sissons JGP, West RJ, Fallows J, Williams DG, Boucher BJ, Amos N, Peters DK (1976) The complement abnormalities of lipodystrophy. N Engl J Med 294:461

    PubMed  CAS  Google Scholar 

  992. Bennett WM, Bardana EJ, Wuepper K, Houghton D, Border WA, Götze O, Schreiber R (1977) Partial lipodystrophy, C3 nephritic factor and clincally inapparent mesangiocapillary glomerulonephritis. Am J Med 62:757–760

    PubMed  CAS  Google Scholar 

  993. Scott DM, Amos N, Sissons JGP, Lachmann PJ, Peters DK (1978) The immunoglobulin nature of nephritic factor (NeF). Clin Exp Immunol 32:12–24

    PubMed  CAS  Google Scholar 

  994. Davis AE III, Arnaout MA, Alper CA, Rosen FS (1977) Transfer of C3 nephritic factor from mother to fetus. Is C3 nephritic factor IgG? N Engl J Med 297:144–145

    PubMed  Google Scholar 

  995. Platts-Mills TAE, Ishizaka K (1974) Activation of the alternate pathway of human complement by rabbit cells. J Immunol 113:348–358

    PubMed  CAS  Google Scholar 

  996. Schreiber RD, Morrison DC, Podack ER, Müller-Eberhard HJ (1979) Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med 149:870–882

    PubMed  CAS  Google Scholar 

  997. Müller-Eberhard HJ, Schreiber RD (1980) Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol 29:1–53

    PubMed  Google Scholar 

  998. Brown EJ, Joiner KA, Frank MM (1983) The role of complement in host resistance to bacteria. Springer Semin Immunopathol 6:349–360

    PubMed  CAS  Google Scholar 

  999. Bitter-Suermann D, Hadding U, Schorlemmer H-U, Limbert M, Dierich M, Dukor P (1975) Activation by some T-independent antigens and B cell mitogens of the alternative pathway of the complement system. J Immunol 115:425–430

    PubMed  CAS  Google Scholar 

  1000. Sandberg AL, Oliveira B, Osier AG (1971) Two complement interaction sites in guinea pig immunoglobulins. J Immunol 106:282–285

    PubMed  CAS  Google Scholar 

  1001. Sandberg AL, Götze O, Müller-Eberhard HJ, Osier AG (1971) Complement utilization by guinea pig gamma-1 and gamma-2 immunoglobulins through the C3 activator system. J Immunol 197:920–923

    Google Scholar 

  1002. Reid KBM (1971) Complement fixation by the F(ab’)2-fragment of pepsin-treated rabbit antibody. Immunology 20:649–658

    PubMed  CAS  Google Scholar 

  1003. Fearon DT (1978) Regulation by membrane sialic acid of β1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci USA 75:1971–1975

    PubMed  CAS  Google Scholar 

  1004. Kazatchkine MD, Fearon DT, Austen KF (1979) Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and β1H-bound C3b. J Immunol 122:75–81

    PubMed  CAS  Google Scholar 

  1005. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1983) Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 80:5430–5434

    PubMed  CAS  Google Scholar 

  1006. Pangburn MK, Müller-Eberhard HJ (1984) The alternative pathway of complement. Springer Semin Immunopathol 7:163–192

    PubMed  CAS  Google Scholar 

  1007. Pangburn MK, Morrison DC, Schreiber RD, Müller-Eberhard HJ (1980) Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol 124:977–982

    PubMed  CAS  Google Scholar 

  1008. Ratnoff WD, Fearon DT, Austen KF (1983) The role of antibody in the activation of the alternative complement pathway. Springer Semin Immunopathol 6:361–371

    PubMed  CAS  Google Scholar 

  1009. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF (1982) Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 129:184–189

    PubMed  CAS  Google Scholar 

  1010. Pangburn MK, Schreiber RD, Trombold JS, Müller-Eberhard HJ (1983) Paroxysmal nocturnal hamoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med 157:1971–1980

    PubMed  CAS  Google Scholar 

  1011. Götze O, Müller-Eberhard HJ (1970) Lysis of erythrocytes by complement in the absence of antibody. J Exp Med 132:898–915

    PubMed  Google Scholar 

  1012. Wintrobe MM, Lee GR, Boggs DR, Bithell TC, Foerster J, Athens JW, Lukens JN (1981) Clinical hematology. Lea and Febiger, Philadelphia, pp 978–990

    Google Scholar 

  1013. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF (1983) Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 80:5066–5070

    PubMed  CAS  Google Scholar 

  1014. Rothman IK, Gelfand JA, Fauci AS, Frank MM (1975) The immune adherence receptor: dissociation between the expression of erythrocyte and mononuclear cell C3b receptors. J Immunol 115:1312–1315

    PubMed  CAS  Google Scholar 

  1015. Aster RH, Enright SE (1969) A platelet and granulocyte membrane defect in paroxysmal nocturnal hemoglobinuria: usefulness for the detection of platelet antibodies. J Clin Invest 48:1199–1210

    PubMed  CAS  Google Scholar 

  1016. Gardner FH, Murphy S (1972) Granulocyte and platelet functions in PNH. Ser Haematol 5:78–87

    PubMed  CAS  Google Scholar 

  1017. Praz F, Ruuth E (1986) Growth-supporting activity of fragment Ba of the human alternative complement pathway for activated murine B lymphocytes. J Exp Med 163:1349–1354

    PubMed  CAS  Google Scholar 

  1018. Sundsmo JS, Götze O (1981) Human monocyte spreading induced by factor Bb of the alternative pathway of complement activation. J Exp Med 154:763–777

    PubMed  CAS  Google Scholar 

  1019. Sundsmo JS, Götze O (1983) Human monocyte spreading induced by activated factor B of the complement alternative pathway: differential effects of Fab’ and F(ab’)2-antibody fragments directed to C5, C6 and C7. Cell Immunol 77:176–186

    PubMed  CAS  Google Scholar 

  1020. Hänseh GM, Schönermark S, Roelke D (1987) Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9. J Clin Invest 80:7–12

    Google Scholar 

  1021. Brower MS, Harpel PC (1982) Proteolytic cleavage and inactivation of α2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 257:9849–9854

    PubMed  CAS  Google Scholar 

  1022. Chesne S, Villiers CL, Arlaud GJ, Lacroix MB, Colomb MG (1982) Fluid-phase interaction of C1 inhibitor (C1 INH) and the subcomponents C1r and C1s of the first component of complement, C1. Biochem J 201:61–70

    PubMed  CAS  Google Scholar 

  1023. De Bracco MME, Stroud RM, Christian CL (1972) Studies on the first component of complement (C1) and the inhibitor of C1 esterase in rheumatoid synovial fluids. Clin Exp Immunol 11:209–218

    PubMed  Google Scholar 

  1024. Demus PS, Mico M, Rosenberg RD (1973) Anticoagulant action of heparin. Nature 246:355–357

    Google Scholar 

  1025. Donaldson VH, Harrison RA (1982) Complexes between #-inhibitor, kallikrein, high molecular weight kinonogen, plasma thromboplastin antecedent, and plasmin in normal human plasma and hereditary angioneurotic edema plasmas containing dysmorphic #-inhibitors: role of cold activation. Blood 60:121–129

    PubMed  CAS  Google Scholar 

  1026. Forbes DC, Pensky J, Ratnoff OD (1970) Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J Lab Clin Med 76:809–815

    PubMed  CAS  Google Scholar 

  1027. Gallimore MJ (1980) Discrepancies between antigen concentrations and functional activity of plasma protease inhibitors. In: Peters H (ed) Proteins and related subjects, vol 28. Pergamon, Oxford, pp 345–348

    Google Scholar 

  1028. Gigli I, Ruddy S, Austen KF (1968) The stoichiometric measurement of the serum inhibitor of the first component of complement by the inhibition of immune hemolysis. J Immunol 100:1154–1164

    PubMed  CAS  Google Scholar 

  1029. Gigli I, Mason JW, Colman RW, Austen KF (1970) Interaction of plasma kallikrein with the # inhibitor. J Immunol 104:574–581

    PubMed  CAS  Google Scholar 

  1030. Haines HL, Lepow IH (1964) Studies on human C1-esterase. II. Function of purified C1-esterase in the human complement system. J Immunol 92:468–478

    PubMed  CAS  Google Scholar 

  1031. Harpel PC (1970) A sensitive, colorimetric method for the measurement of serum C1 inactivator using the substrate N-alpha-acetyl-l-lysine methyl ester. J Immunol 104:1024–1030

    PubMed  CAS  Google Scholar 

  1032. Harpel PC, Cooper NR (1975) Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with Cls, plasmin and trypsin. J Clin Invest 55:593–604

    PubMed  CAS  Google Scholar 

  1033. Harpel PC, Hugli TE, Cooper NR (1975) Studies on human plasma C1 inactivator interactions. II. Structural features of an abnormal C1 inactivator from a kindred with hereditary angioneurotic edema. J Clin Invest 55:605–611

    PubMed  CAS  Google Scholar 

  1034. Haupt H, Heimburger N, Kranz T, Schwick HG (1970) Ein Beitrag zur Isolierung und Charakterisierung des #-Inaktivators aus Humanplasma. Eur J Biochem 17:254–261

    PubMed  CAS  Google Scholar 

  1035. Heck LW, Kaplan AP (1974) Substrates of Hageman factor. I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by α1-antitrypsin. J Exp Med 140:1615–1630

    PubMed  CAS  Google Scholar 

  1036. Inai S, Hiramatsu S, Nagaki K (1967) Separation of C’4 inactivator and purification of both substances. Biken J 10:155–174

    PubMed  CAS  Google Scholar 

  1037. Klein PG (1960) Studies on immune hemolysis: preparation of a stable and highly reactive complex of sensitized erythrocytes and the first component of complement (EAC’1); inactivation of cell-fixed C’1 by some complement reagents. J Exp Med 111:77–92

    PubMed  CAS  Google Scholar 

  1038. Laurell AB, Martensson U, Sjöholm AG (1976) C1 subcomponent complexes in normal and pathological sera studied by crossed Immunoelectrophoresis. Acta Pathol Microbiol Immunol Scand [C] 84:455–464

    Google Scholar 

  1039. Laurell AB, Johnson U, Martensson U, Sjöholm AG (1978) Formation of complexes composed of C1r, C1s and C1 inactivator in human serum on activation of C1. Acta Pathol Microbiol Scand [C] 86:299–306

    Google Scholar 

  1040. Leon MA, Plescia OJ, Heidelberger M (1956) Fractions of pig complement. III. An inhibitor of active complement. J Immunol 76:28–32

    PubMed  CAS  Google Scholar 

  1041. Levy L, Lepow IH (1959) Assay and properties of serum inhibitor of C1-esterase. Proc Soc Exp Biol Med 101:608–611

    PubMed  CAS  Google Scholar 

  1042. Loos M, Wagner H, Opferkuch W (1969) Guinea pig C1s -inactivation: purification and characterization. Prot Biol Fluids 17:311–314

    CAS  Google Scholar 

  1043. Loos M, Opferkuch W, Ringelmann R (1971) Studien über den #-Inaktivator des Meerschweinchenkomplements: Testmethode, Reinigung und Charakterisierung des Proteins. Med Mikrobiol Immunol 156:194–207

    CAS  Google Scholar 

  1044. Loos M, Wolf HU, Opferkuch W (1972) The C1 inactivtor from guinea pig serum. III. Characterization and kinetic data of the reaction between the inactivator and EAC1 and EAC14. Immunochemistry 9:451–459

    PubMed  CAS  Google Scholar 

  1045. Mandle RJ, Colman RW, Kaplan AP (1976) Identification of prekallikrein and high molecular weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 73:4179–4183

    PubMed  CAS  Google Scholar 

  1046. Meier HL, Pierce JV, Colman RW, Kaplan AP (1977) Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. J Clin Invest 60:18–31

    PubMed  CAS  Google Scholar 

  1047. Minta JO (1981) The role of sialic acid in the functional activity and the hepatic clearance of C1-INH. J Immunol 126:245–249

    PubMed  CAS  Google Scholar 

  1048. Minta JO, Aziz E (1981) Analysis of the reactive site peptide bond in C1-inhibitor by chemical modification of tyrosyl, lysyl, and arginine residues: the essential role of lysyl residues in the functional activity of #-INH. J Immunol 126:250–255

    PubMed  CAS  Google Scholar 

  1049. Nagaki K, Iida K, Inai S (1974) The inactivator of the first component of human complement (C1 INA). The complex formation with the activated first component of human complement (C1) or with its subcomponents. Int Arch Allergy Appl Immunol 46:935–348

    PubMed  CAS  Google Scholar 

  1050. Nelson RA, Jensen J, Gigli I, Tamura N (1966) Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea pig serum. Immunochemistry 3:111–135

    PubMed  CAS  Google Scholar 

  1051. Nilsson T, Wiman B (1982) Purification and characterization of human C1-esterase inhibitor. Biochem Biophys Acta 705:271–276

    PubMed  CAS  Google Scholar 

  1052. Pensky J, Schwick HG (1969) Human serum inhibitor of C1-esterase: identity with α2-neur- aminoglycoprotein. Science 163:698–699

    PubMed  CAS  Google Scholar 

  1053. Pensky J, Levy LR, Lepow IH (1961) Partial purification of a serum inhibitor of C1-esterase. J Biol Chem 236:1674–1679

    PubMed  CAS  Google Scholar 

  1054. Ratnoff OD, Pensky J, Ogston D, Naff GB (1969) The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C’1r subcomponent of the first component of complement by serum C1 esterase inhibitor. J Exp Med 129:315–331

    PubMed  CAS  Google Scholar 

  1055. Reboul A, Arlaud GJ, Sim RB, Colomb MG (1977) A simplified procedure for the purification of #-inactivator from human plasma. FEBS Lett 79:45–50

    PubMed  CAS  Google Scholar 

  1056. Schapira M, Scott DF, Colman RW (1981) Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry 20:2738–2743

    PubMed  CAS  Google Scholar 

  1057. Schapira M, Scott CF, Colman RW (1982) Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 69:462–468

    PubMed  CAS  Google Scholar 

  1058. Schreiber AD, Kaplan AP, Austen KF (1973 a) Plasma inhibitors of the components of the fibrinolytic pathway in man. J Clin Invest 52:1394–1401

    PubMed  CAS  Google Scholar 

  1059. Schreiber AD, Kaplan AP, Austen KF (1973b) Inhibition by #-INH of Hageman factor, fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 52:1402–1409

    PubMed  CAS  Google Scholar 

  1060. Seito H, Goldsmith GM, Moroi M, Aski N (1979) Inhibitory spectrum of α2-plasmin inhibitor. Proc Natl Acad Sci USA 76:2013–2017

    Google Scholar 

  1061. Sim RB, Arlaud GJ, Colomb MG (1980) Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and Cls. Biochem Biophys Acta 612:433–449

    PubMed  CAS  Google Scholar 

  1062. Vogt W, Dugal B (1976) Generation of an esterolytic and kinin-forming kallikrein α2-mac- roglobulin complex in human serum by treatment with acetone. Naunyn-Schmiedeberg’s Arch Pharmacol 294:75–84

    CAS  Google Scholar 

  1063. Vroon DH, Schultz DR, Zarco RM (1970) The separation of nine components and two inactivators of components of complement in human serum. Immunochemistry 7:43–61

    PubMed  CAS  Google Scholar 

  1064. Ziccardi RJ, Cooper NR (1978) Modulation of the antigenicity of # and # by #-inactivator. J Immunol 121:2148–2152

    PubMed  CAS  Google Scholar 

  1065. Ziccardi RJ, Cooper NR (1979) Active disassembly of the first complement component, #, by # inactivator. J Immunol 123:788–792

    PubMed  CAS  Google Scholar 

  1066. Adinolfi M, Dobson NC, Bradwell AR (1981) Synthesis of two components of human complement, β1H and C3bINA during fetal life. Acta Paediatr Scand 70:705–710

    PubMed  CAS  Google Scholar 

  1067. Bitter-Suermann D, Burger R, Hadding U (1981) Activation of the alternative pathway of complement: efficient fluid phase amplification by blockade of the regulatory complement protein β1H through sulfated polyanions. Eur J Immunol 11:281–295

    Google Scholar 

  1068. Boackle RJ, Caughman GB, Vesely J, Medgyesi G, Fudenberg HH (1983) Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway. Mol Immunol 20:1157

    PubMed  CAS  Google Scholar 

  1069. Burge J, Nicholson-Weller A, Austen KF (1981) Isolation of C4-binding protein from g.p. plasma and demonstration of its function as a control protein of the classical pathway of complement C3 convertase. J Immunol 126:232–235

    PubMed  CAS  Google Scholar 

  1070. Carlo JR, Ruddy S, Studer EJ, Conrad DH (1979) Complement receptor binding of C3b-coated cells treated with C3b inactivator. J Immunol 123:523–528

    PubMed  CAS  Google Scholar 

  1071. Charlesworth JA, Scott DM, Pussell BA, Peters DK (1979) Metabolism of human β1H. in man and experimental animals. Clin Exp Immunol 38:397–404

    PubMed  CAS  Google Scholar 

  1072. Conrad DH, Carlo JR, Ruddy S (1978) Interaction of β1H globulin with cell-bound C3b: quantitative analysis of binding and influence of alternative pathway components on binding. J Exp Med 147:1792–1805

    PubMed  CAS  Google Scholar 

  1073. Cooper NR (1969) Immune adherence by the fourth component of complement. Science 165:396–398

    PubMed  CAS  Google Scholar 

  1074. Cooper NR (1975) Isolation and analysis of the mechanism of action of an inactivator of C4b in normal human serum. J Exp Med 141:890–903

    PubMed  CAS  Google Scholar 

  1075. Crossley LG, Porter RR (1980) Purification of the human complement control protein C3b inactivator. Biochem J 191:173–182

    PubMed  CAS  Google Scholar 

  1076. Daha MR, Es LA van (1982) Isolation, characterization, and mechanism of action of rat β1H. J Immunol 128:1839–1843

    PubMed  CAS  Google Scholar 

  1077. Dahlbäck B, Stenflo J (1981) High molecular weight complex in human plasma between vitamin K — dependent protein S and complement C4b-binding protein. Proc Natl Acad Sci USA 78:2512–2516

    PubMed  Google Scholar 

  1078. Davis AE (1981) The C3b inactivator of the human complement system: homology with serine proteases. FEBS Lett 132:147–150

    Google Scholar 

  1079. DiScipio RG (1981) The binding of human complement proteins C5, factor B, β1H and properdin to complement fragment C3b on zymosan. Biochem J 199:485–496

    PubMed  CAS  Google Scholar 

  1080. DiScipio RG, Hugli TE (1982) Circular dichroism of factor H — a regulatory component of the complement system. Biochem Biophys Acta 709:58–64

    PubMed  CAS  Google Scholar 

  1081. Dobson NJ, Lambris JD, Ross GD (1981) Characteristics of isolated erythrocyte complement-receptor type one (CR1, C4b-C3b-receptor) and CR1-specific antibodies. J Immunol 126:693–698

    PubMed  CAS  Google Scholar 

  1082. Dykman TR, Cole JL, Iida K, Atkinson JP (1983) Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci USA 80:1698–1702

    PubMed  CAS  Google Scholar 

  1083. Dykman TR, Hatch JA, Atkinson JP (1984) Polymorphism of the human C3b/C4b receptor: identification of a third allele and analysis of receptor phenotypes in families and patients with systemic lupus erythematosus. J Exp Med 159:691–703

    PubMed  CAS  Google Scholar 

  1084. Fearon DT (1977) Purification of C3b inactivator and demonstration of its two polypeptide chain structures. J Immunol 119:1248–1252

    PubMed  CAS  Google Scholar 

  1085. Fearon DT (1978) Regulation by membrane sialic acid of β1H dependent decay dissociation of the amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci USA 75:1971–1975

    PubMed  CAS  Google Scholar 

  1086. Fearon DT (1979) Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 76:5867–5871

    PubMed  CAS  Google Scholar 

  1087. Fearon DT (1980) Identification of the membrane glycoprotein that is the C3b-receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte and monocyte. J Exp Med 152:20–30

    PubMed  CAS  Google Scholar 

  1088. Fearon DT, Austen KF (1977) Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogeneous control proteins. J Exp Med 146:22–33

    PubMed  CAS  Google Scholar 

  1089. Ferreira A, Takahoshi M, Nussenzweig V (1977) Purification and characterization of mouse serum protein with specific binding affinity for C4 (Ss protein). J Exp Med 146:1001–1018

    PubMed  CAS  Google Scholar 

  1090. Fischer E, Kazatchkine MD (1983) Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement. J Immunol 130:2821–2824

    PubMed  CAS  Google Scholar 

  1091. Fujita T, Nussenzweig V (1979) The role of C4 binding protein and β1H in proteolysis of C4b and C3b. J Exp Med 150:267–276

    PubMed  CAS  Google Scholar 

  1092. Fujita T, Tamura N (1983) Interaction of C4 binding protein with cell-bound C4b. A quantitative analysis of binding and the role of C4 binding protein in proteolysis of cell bound C4b. J Exp Med 157:1239–1251

    PubMed  CAS  Google Scholar 

  1093. Fujita T, Gigli I, Nussenzweig V (1978) Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med 148:1044–1051

    PubMed  CAS  Google Scholar 

  1094. Fujita T, Takata Y, Tamura N (1981) Solubilization of immune precipitates by six isolated alternative pathway proteins. J Exp Med 154:1743–1751

    PubMed  CAS  Google Scholar 

  1095. Gaither TA, Hammer CH, Frank MM (1979) Studies of the molecular mechanisms of C3b inactivation and a simplified assay of β1H and the C3b inactivator (C3bINA). J Immunol 123:1195–1205

    PubMed  CAS  Google Scholar 

  1096. Gigli I, Nelson RA (1968) Complement dependent immune phagocytosis. I. Requirements for C1, C4, C2, C3. Exp Cell Res 51:45–67

    PubMed  CAS  Google Scholar 

  1097. Gigli I, Fujita T, Nussenzweig V (1979) Modulation of the classical pathway C3 convertase by the plasma proteins, C4 binding protein, and C3b inactivator. Proc Natl Acad Sci USA 76:6596–6600

    PubMed  CAS  Google Scholar 

  1098. Gitlin JD, Rosen FS, Lachmann PJ (1975) The mechanism of action of the C3b-inactivator (conglutinogen-activating factor) on its natural occurring substrate, the mayor fragment of the third component of complement (C3b). J Exp Med 141:1221–1226

    PubMed  CAS  Google Scholar 

  1099. Harrison RA, Lachmann PJ (1979) An improved purification procedure for the third component of complement and β1H globulin from human serum. Mol Immunol 16:767–776

    PubMed  CAS  Google Scholar 

  1100. Harrison RA, Lachmann PJ (1980) The physiological breakdown of the third component of human complement. Mol Immunol 17:9–20

    PubMed  CAS  Google Scholar 

  1101. Hoffmann EM (1969 a) Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata. Immunochemistry 6:391–403

    CAS  Google Scholar 

  1102. Hoffmann EM (1969 b) Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action. Immunochemistry 6:405–419

    PubMed  CAS  Google Scholar 

  1103. Hoffmann EM, Etlinger HM (1973) Extraction of complement inhibitory factors from the erythrocyte of non-human species. J Immunol 111:946–951

    PubMed  CAS  Google Scholar 

  1104. Hsiung LM, Barelay AN, Brandon MR, Sim E, Porter RR (1982) Purification of human C3b-INA by monoclonal antibody affinity chromatography. Biochem J 203:293–298

    PubMed  CAS  Google Scholar 

  1105. Iida K, Nussenzweig V (1981) Complement receptor is an inhibitor of the complement cascade. J Exp Med 153:1138–1150

    PubMed  CAS  Google Scholar 

  1106. Isenman DE, Podack ER, Cooper NR (1980) The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase. J Immunol 124:326–331

    PubMed  CAS  Google Scholar 

  1107. Kai S, Fujita T, Gigli I, Nussenzweig V (1980) Mouse C3b/C4b-inactivator: purification and properties. J Immunol 125:2409–2415

    PubMed  CAS  Google Scholar 

  1108. Kaidoh T, Natsuume-Sakai S, Takahashi M (1981) Murine C4-binding protein: a rapid purification method by affinity chromatography. J Immunol 126:463–467

    PubMed  CAS  Google Scholar 

  1109. Kazatchkine MD, Fearon DT, Austen KF (1979 a) Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and β1H for cell- bound C3b. J Immunol 122:75–89

    PubMed  CAS  Google Scholar 

  1110. Kazatchkine MD, Fearon DT, Silbert JE, Austen KF (1979 b) Surface-associated heparin inhibits zymosan-induced activation of the alternative pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med 150:1202–1215

    PubMed  CAS  Google Scholar 

  1111. Kinoshita T, Nussenzweig V (1984) Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. I. Isolation and characterization of factor H: the serum cofactor for the C3b/C4b inactivator (factor I). J Immunol Methods 71:247–257

    PubMed  CAS  Google Scholar 

  1112. Lachmann PJ, Müller-Eberhard HJ (1968) The demonstration in human serum of conglutinogen-activating factor and its effect on the third component of complement. J Immunol 100:691–698

    PubMed  CAS  Google Scholar 

  1113. Lachmann PJ, Nicol P, Aston WP (1973) Further studies on the C3b inactivator or conglutinogen activating factor (KAF). Immunochemistry 10:695–700

    PubMed  CAS  Google Scholar 

  1114. Lambré CR, Kazatchkine MD, Maillet F, Thibou M (1982) Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desiliation of the cells. J Immunol 128:629–634

    PubMed  Google Scholar 

  1115. Law SK, Fearon DT, Levine RP (1975) Action of the C3b-inactivator on cell-bound C3b. J Immunol 122:759–765

    Google Scholar 

  1116. Leonard EJ, Borsos T (1972) Effect of C3 inactivator on bound C3 antigen. J Immunol 108:776–781

    PubMed  CAS  Google Scholar 

  1117. Mayer MM, Levine L, Rapp HJ, Marucci AA (1954) Kinetic studies on immune hemolysis. VII. Decay of EAC1, 4, 2 fixation of C3 and other factors influencing the hemolytic action of complement. J Immunol 73:443–454

    PubMed  CAS  Google Scholar 

  1118. Medof ME, Nussenzweig V (1984) Control of the function of substrate-bound C4b-C3b by the complement receptor CRI. J Exp Med 159:1669–1685

    PubMed  CAS  Google Scholar 

  1119. Medof ME, Iida K, Mold C, Nussenzweig V (1982) Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med 156:1739–1754

    PubMed  CAS  Google Scholar 

  1120. Medof ME, Lam T, Prince GM, Mold C (1983) Requirement for human red blood cells in inactivation of C3b in immune complexes and enhancement of binding to spleen cells. J Immunol 130:1336–1340

    PubMed  CAS  Google Scholar 

  1121. Medicus RG, Melamed J, Arnaout MA (1983) Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules. Eur J Immunol 13:465–470

    PubMed  CAS  Google Scholar 

  1122. Müller-Eberhard HJ, Götze O (1972) C3 proactivator convertase and its mode of action. J Exp Med 135:1003–1008

    PubMed  Google Scholar 

  1123. Nagaki K, Iida K, Okubo M, Inai S (1978) Reaction mechanisms of β1H globulin. Int Arch Allergy Appl Immunol 57:221–232

    PubMed  CAS  Google Scholar 

  1124. Nagasawa S, Stroud RM (1977) Mechanism of action of the C3b inactivator: requirement for a high molecular weight cofactor (C3b-C4b INA cofactor) and production of a non-C3b derivative (C3b’). Immunochemistry 14:749–756

    PubMed  CAS  Google Scholar 

  1125. Nagasawa S, Stroud RM (1980) Purification and characterization of a macromolecular weight cofactor for C3b inactivator, C4bC3bINA-cofactor, of human plasma. Mol Immunol 17:1365–1372

    PubMed  CAS  Google Scholar 

  1126. Nagasawa S, Ichihara C, Stroud RM (1980) Cleavage of C4b by C3b inactivator: production of a nicked form of C4b, C4b’, as an intermediate cleavage product of C4b by C3b inactivator. J Immunol 125:578–582

    PubMed  CAS  Google Scholar 

  1127. Nakano Y, Tobe T, Matsuda T, Sakamoto T, Tomita M (1984) Isolation and characterization of rabbit H of the alternative complement pathway. J Biochem Tokyo 95:1469–1475

    PubMed  CAS  Google Scholar 

  1128. Nelson RA, Jensen J, Gigli I, Tamura N (1966) Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea pig serum. Immunochemistry 3:111–135

    PubMed  CAS  Google Scholar 

  1129. Nicholson-Weller A, Burge J, Austen KF (1981) Purification from guinea pig erythrocyte stroma of a decay-accelerating factor for the classical C3 convertase, C4b,2a. J Immunol 127:2035–2039

    PubMed  CAS  Google Scholar 

  1130. Nicholson-Weller A, Burge J, Fearon DT (1982) Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 129:184–189

    PubMed  CAS  Google Scholar 

  1131. Nilsson UR, Müller-Eberhard HJ (1965) Isolation of β1F-globulin from human serum and its characterization as the fifth component of complement. J Exp Med 122:277–298

    PubMed  CAS  Google Scholar 

  1132. Nishioka K, Linscott WD (1963) Components of guinea pig complement. I. Separation of a serum fraction essential for immune hemolysis and immune adherence. J Exp Med 118:767–793

    PubMed  CAS  Google Scholar 

  1133. Nydegger UE, Fearon DT, Austen KF (1978) Autosomal locus regulates inverse relationship between sialic acid content and capacity of mouse erythrocytes to activate human alternative complement pathway. Proc Natl Acad Sci USA 75:6078–6082

    PubMed  CAS  Google Scholar 

  1134. Okada H, Kawadu S, Nishioka K (1969) A new complement inhibitor in guinea pig serum. Jpn J Exp Med 39:527–531

    PubMed  CAS  Google Scholar 

  1135. Opferkuch W, Loos M, Borsos T (1971 a) Decay of SAC4,2: evidence for three accelerating factors in serum. Fed Proc 31:740

    Google Scholar 

  1136. Opferkuch W, Loos M, Borsos T (1971 b) Isolation and characterization of a factor from human and guinea pig serum that accelerates the decay of SAC1,4,2. J Immunol 107:313

    Google Scholar 

  1137. Pangburn MK, Müller-Eberhard HJ (1978) Complement C3 convertase: cell surface restriction of β1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci USA 75:2416–2420

    PubMed  CAS  Google Scholar 

  1138. Pangburn MK, Müller-Eberhard HJ (1983) Kinetic and thermodynamic analysis of the control of C3b by the complement regulatory proteins factor H and facotr I. Biochemistry 22:178–185

    PubMed  CAS  Google Scholar 

  1139. Pangburn MK, Schreiber RD, Müller-Eberhard HJ (1977) Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein β1H for cleavage of C3b and C4b in solution. J Exp Med 146:257–270

    PubMed  CAS  Google Scholar 

  1140. Pangburn MK, Morrison DC, Schreiber RD, Müller-Eberhard HJ (1980) Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol 124:977–982

    PubMed  CAS  Google Scholar 

  1141. Reid KB, Gagnon J (1982) Human C4-binding protein: N-terminal amino-acid sequence analysis and limited proteolysis by trypsin. FEBS Lett 137:75–79

    PubMed  CAS  Google Scholar 

  1142. Ripoche J, Al Salihi A, Rousseaux J, Fontaine M (1984) Isolation of two molecular populations of human complement factor H by hydrophobic affinity chromatography. Biochem J 221:89–96

    PubMed  CAS  Google Scholar 

  1143. Ross GD, Polley MJ (1975) Specificity of human lymphocyte complement receptors. J Exp Med 141:1163–1180

    PubMed  CAS  Google Scholar 

  1144. Ross GD, Lambris JD, Cain JA, Newman SL (1982) Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs. CR1 cofactor activity. J Immunol 192:2051–2060

    Google Scholar 

  1145. Ruddy S, Austen KF (1969) C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol 102:533–543

    PubMed  CAS  Google Scholar 

  1146. Ruddy S, Austen KF (1971) C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol 107:742–750

    PubMed  CAS  Google Scholar 

  1147. Scharfstein J, Ferreira A, Gigli I, Nussenzweig V (1978) Human C4-binding protein. I. Isolation and characterization. J Exp Med 148:207–222

    PubMed  CAS  Google Scholar 

  1148. Shiraishi S, Stroud RM (1975) Cleavage products of C4b produced by enzymes in human serum. Immunochemistry 12:935–939

    PubMed  CAS  Google Scholar 

  1149. Sim RB, DiScipio RG (1982) Purification and structural studies on the complement system control protein β1H (factor H). Biochem J 205:285–293

    PubMed  CAS  Google Scholar 

  1150. Sim E, Wood AB, Hsiung LM, Sim RB (1981) Pattern of degradation of human complement fragment, C3b. FEBS Lett 132:55–60

    PubMed  CAS  Google Scholar 

  1151. Sim E, Palmer MS, Puklavec M, Sim RB (1983) Monoclonal antibodies against the complement control protein factor H (β1H). Biosci Rep 3:1119–1131

    PubMed  CAS  Google Scholar 

  1152. Tamura N, Nelson RA (1967) Three naturally occurring inhibitors of components of complement in guinea pig and rabbit serum. J Immunol 99:582–589

    PubMed  CAS  Google Scholar 

  1153. Torisu M, Sonozaki H, Shiraishi S, Nishioka K (1968) Purification of C’3 inactivator from human serum. Nature 218:1163–1164

    PubMed  CAS  Google Scholar 

  1154. Amerongen A van, Dijk H van, Wilier JMN (1982) Role of C4-binding protein in the defective lysis of sensitized sheep erythrocytes by mouse complement. Int Arch Allergy Appl Immunol 68:209–213

    PubMed  Google Scholar 

  1155. Vroon DH, Schultz DR, Zarco RM (1970) The separation of nine components and two inactivators of components of complement in human serum. Immunochemistry 7:43–61

    PubMed  CAS  Google Scholar 

  1156. Weiler JM, Daha MR, Austen KF, Fearon DT (1976) Control of the amplification convertase of complement by the plasma protein β1H. Proc Natl Acad Sci USA 73:3268–3272

    PubMed  CAS  Google Scholar 

  1157. Whaley K, Ruddy S (1976 a) Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. Science 193:1011–1013

    PubMed  CAS  Google Scholar 

  1158. Whaley K, Ruddy S (1976 b) Modulation of the alternative pathway by β1H globulin. J Exp Med 144:1147–1163

    PubMed  CAS  Google Scholar 

  1159. Whaley K, Thompson RA (1978) Requirements for β1H globulin and C3b inactivator in the control of the alternative complement pathway in human serum. Immunology 35:1045–1069

    PubMed  CAS  Google Scholar 

  1160. Wong WW, Wilson JG, Fearon DT (1983) Genetic regulation of a structural polymorphism of human C3b receptor. J Clin Invest 72:685–693

    PubMed  CAS  Google Scholar 

  1161. Bhakdi S, Tranum-Jensen J (1982 a) Terminal membrane C5b-9 complex of human complement: transition from an amphiphilic to a hydrophilic state through binding of the S protein from serum. J Cell Biol 94:755–759

    PubMed  CAS  Google Scholar 

  1162. Bhakdi S, Tranum-Jensen J (1982 b) Hydrophilic — amphiphilic transition of the terminal SC5b-8 complement complex through tryptic modification: biochemical and ultrastructural studies. Mol Immunol 19:1167–1177

    PubMed  CAS  Google Scholar 

  1163. Bhakdi S, Ey P, Bhakdi-Lehnen B (1976) Isolation of the terminal complement complex from target sheep erythrocyte membranes. Biochim Biophys Acta 419:445–452

    PubMed  CAS  Google Scholar 

  1164. Bhakdi S, Bhakdi-Lehnen B, Tranum-Jensen J (1979 a) Proteolytic transformation of SC5b- 9 into amphiphilic macromolecule resembling the C5b-9 membrane attack complex of complement. Immunology 37:901–912

    PubMed  CAS  Google Scholar 

  1165. Bhakdi S, Bhakdi-Lehnen B, Bjerrum OJ, Tranum-Jensen J (1979 b) Difference in antigenic reactivity and ultrastructure between fluid-phase SC5b-9 and C5b-9 membrane attack complex of human complement. FEBS Lett 99:15–19

    PubMed  CAS  Google Scholar 

  1166. Biesecker G, Podack ER, Halverson CA, Müller-Eberhard HJ (1979) C5b-9 dimer: isolation from complement lysed cells and ultrastructural identification with complement-dependent membrane lesions. J Exp Med 149:448–458

    PubMed  CAS  Google Scholar 

  1167. Kinoshita T, Hong K, Inoue K (1979) C9 hemolytic activity of the soluble C5b-9 complex of guinea pig complement analogous to human SC5b-9. J Immunol 123:1989–1995

    PubMed  CAS  Google Scholar 

  1168. Kolb WP, Müller-Eberhard HJ (1973) The membrane attack mechanism of complement. Verification of a stable C5–9 complex in free solution. J Exp Med 138:438–451

    PubMed  CAS  Google Scholar 

  1169. Kolb WP, Müller-Eberhard HJ (1975) The membrane attack mechanism of complement: isolation and subunit composition of the C5b-9 complex. J Exp Med 141:724–735

    PubMed  CAS  Google Scholar 

  1170. Lint TF, Behrends CL, Gewurz H (1977) Serum lipoproteins and C567-inhibitor activity. J Immunol 119:883–888

    PubMed  CAS  Google Scholar 

  1171. McLeod BC, Baker P, Gewurz H (1974 a) Studies on the inhibition of C56 initiated lysis (reactive lysis). I. Description of the phenomenon and methods of assay. Immunology 26:1145–1157

    PubMed  CAS  Google Scholar 

  1172. McLeod BC, Baker P, Gewurz H (1974 b) Studies on the inhibition of # initiated lysis (reactive lysis). II. #-INH — An inhibitor of the C567 trimolecular complex of complement. Int Arch Allergy Appl Immunol 47:623–632

    PubMed  CAS  Google Scholar 

  1173. McLeod BC, Baker P, Gewurz H (1975) Studies on the inhibition of # initiated lysis (reactive lysis). III. Characterization of the inhibitory activity #-INH and its mode of action. Immunology 28:133–149

    PubMed  CAS  Google Scholar 

  1174. Nemerov GR, Yamamoto K, Lint TF (1979) Restriction of complement-mediated membrane damage by the eighth component of complement: a dual role for C8 in the complement attack sequence. J Immunol 123:1245–1252

    Google Scholar 

  1175. Podack ER, Müller-Eberhard HJ (1979) Isolation of human S-protein, an inhibitor of the membrane attack complex of complement. J Biol Chem 254:9908–9914

    Google Scholar 

  1176. Podack ER, Müller-Eberhard HJ (1980) SC5b-9 complex of complement: formation of the dimeric membrane attack complex by removal of S-protein. J Immunol 124:1779–1783

    PubMed  CAS  Google Scholar 

  1177. Podack ER, Kolb WP, Müller-Eberhard HJ (1976) The C5b-9 complex: subunit composition of the classical and alternative pathway-generated complex. J Immunol 116:1431–1434

    PubMed  CAS  Google Scholar 

  1178. Podack ER, Kolb WP, Müller-Eberhard HJ (1977) The C5b-7 complex: formation, isolation, properties, and subunit composition. J Immunol 119:2024–2029

    PubMed  CAS  Google Scholar 

  1179. Podack ER, Kolb WP, Müller-Eberhard HJ (1978) The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum. J Immunol 120:1841–1848

    PubMed  CAS  Google Scholar 

  1180. Podack ER, Preissner KT, Müller-Eberhard HJ (1984) Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol Microbiol Immunol Scand [C] [Suppl] 284:89–92

    CAS  Google Scholar 

  1181. Welleck B, Opferkuch W (1975) A case of deficiency of the seventh component of complement in man. Clin Exp Immunol 19:223–235

    Google Scholar 

  1182. Zeitz HJ, Zeff RA, Gewurz H, Lint TF (1983) Decreased C5b67-inhibitor activity in two families with hereditary functional deficiency of the eighth component of complement. J Immunol 130:2809–2813

    PubMed  CAS  Google Scholar 

  1183. Conradie JD, Volanakis JE, Stroud RM (1975) Evidence for a serum inhibitor of C1q. Immunochemistry 12:967–971

    PubMed  CAS  Google Scholar 

  1184. Ghebrehiwet B (1981) C1q inhibitor (Clq INH): functional properties and possible relationship to a lymphocyte membrane-associated C1q precipitin. J Immunol 126:1837–1842

    PubMed  CAS  Google Scholar 

  1185. Ghebrehiwet B, Hamburger M (1982) Purification and partial characterization of a C1q inhibitor from the membranes of human peripheral blood lymphocytes. J Immunol 129:157–162

    PubMed  CAS  Google Scholar 

  1186. Kolb PK, Kolb LM, Podack ER (1979) C1q: isolation from human serum in high yield by affinity chromatography and development of a highly sensitive hemolytic assay. J Immunol 122:2103–2111

    PubMed  CAS  Google Scholar 

  1187. Silvestri L, Baker JR, Rodén L, Stroud RM (1981) The C1q inhibitor in serum is a chondroitin 4-sulfate proteoglycan. J Biol Chem 256:7383–7387

    PubMed  CAS  Google Scholar 

  1188. Baker PJ, Osofsky SG (1981) Isolation and characterization of a low molecular weight complement inhibitor present in normal human serum. Clin Exp Immunol 43:549–556

    PubMed  CAS  Google Scholar 

  1189. Baker PJ, Parker CJ, Osofsky SG (1984) Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor. Clin Exp Immunol 55:166–176

    PubMed  CAS  Google Scholar 

  1190. Bokisch VA, Müller-Eberhard HJ (1970) Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest 49:2427–2438

    PubMed  CAS  Google Scholar 

  1191. Bokisch VA, Müller-Eberhard HJ, Cochrane CG (1969) Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med 129:1109–1130

    PubMed  CAS  Google Scholar 

  1192. Nagaki N, Matsumoto M, Kitamura H (1980) A low molecular weight inhibitor of the alternative complement pathway. I. Its isolation from human urine and the reaction mechanism. Immunology 41:789–798

    PubMed  CAS  Google Scholar 

  1193. Spitzer R, Stitzel A, Florio L, Urmson J (1976) Inhibition of the alternative pathway of complement activation by a serum factor generated during transplant rejection. Immunochemistry 13:395–400

    PubMed  CAS  Google Scholar 

  1194. Tamura N, Nelson RA (1967) Three naturally occurring inhibitors of components of complement in guinea pig and rabbit serum. J Immunol 99:582–589

    PubMed  CAS  Google Scholar 

  1195. Gigli I, Austen KF (1971) Phylogeny and function of the complement system. Ann Rev Microbiol 25:309–332

    CAS  Google Scholar 

  1196. Ballow M (1977) Phylogenetics and ontogenetics of the complement systems. In: Day NK, Good RA (eds) Biological amplification systems in immunology. Plenum, New York London, pp 183–204 (Comprehensive immunology, vol 2)

    Google Scholar 

  1197. Alexander RJ, Steiner LA (1980) The first component of complement from the bullfrog, Rana catesbeiana: functional properties of C1 and isolation of subcomponent C1q. J Immunol 124:1418–1425

    PubMed  CAS  Google Scholar 

  1198. Jensen JA, Smith DS, Cayer M (1981) The complement system of the nurse shark: hemolytic and comparative characteristics. Science 214:566–569

    PubMed  CAS  Google Scholar 

  1199. Nonaka M, Iwaki M, Nakai C, Nozaki M, Kaidoh T, Nonaka M, Natsuume-Sakai S, Takahashi M (1984) Purification of a major serum protein from rainbow trout (Salmo gairdneri) homologous to the third component of mammalian complement. J Immunol 259:6327–6333

    CAS  Google Scholar 

  1200. Zabern I von, Nolte R, Vogt W (1979) Incompatibility between complement components C3 and C5 of guinea-pig and man, an indication of their interaction in C5 activation by classical and alternative C5 convertases. Scand J Immunol 9:69–74

    Google Scholar 

  1201. Nicholson A, Fearon DT, Austen KF (1978) Complement. In: Vane JR, Ferreira SH (eds) Inflammation. Springer, Berlin Heidelberg New York, pp 425–463 (Handbook of Experimental Pharmacology, vol 50/1)

    Google Scholar 

  1202. Boyle MDP, Ohanian SH (1980) Evidence for the influence of the initial complement components on the assembly and activity of the membrane attack complex. J Immunol 124:2824–2827

    PubMed  CAS  Google Scholar 

  1203. Miyakawa Y, Sekine T, Shibata S, Nishioka K (1971) Studies on rat complement: a method for titration of rat C1, C2, C3, C4 as well as C5, and the effect of rabbit nephrotoxic serum on the first five components of complement in rat serum. J Immunol 106:545–551

    PubMed  CAS  Google Scholar 

  1204. Caldwell JR, Ruddy S, Austen KF (1972) Assay of complement components C1, C4, C2, C3 and C9 in whole rat serum. Int Arch Allergy Appl Immunol 43:887–897

    PubMed  CAS  Google Scholar 

  1205. Atkinson JP, McGinnis K, Shreffler D (1980) Development and characterization of a hemolytic assay for mouse C4. J Immunol Methods 33:351–368

    PubMed  CAS  Google Scholar 

  1206. Fukuoka Y, Seino J, Okuda T, Tachibana T (1984) Purification of the fourth, second and fifth components of mouse complement. Immunology 51:493–501

    PubMed  CAS  Google Scholar 

  1207. Pepys MB, Dash AC, Fielder AHL, Mirjah DD (1977) Isolation and study of murine C3. Immunology 33:491–499

    PubMed  CAS  Google Scholar 

  1208. Kinoshita T, Nussenzweig V (1984) Regulatory proteins of the activated third and fourth components of complement (C3b and C4b) in mice. I. Isolation and characterization of factor H, the serum cofactor for the C3b/C4b inactivator (factor I). J Immunol Methods 71:247–257

    PubMed  CAS  Google Scholar 

  1209. Barta O, Nelson RA, Kuo CY (1976) Separation of six bovine complement components and one inactivator. Immunol Commun 5:75–86

    PubMed  CAS  Google Scholar 

  1210. Booth NA, Campbell RD, Fothergill JE (1979) The purification and characterization of bovine C4, the fourth component of complement. Biochem J 177:959–965

    PubMed  CAS  Google Scholar 

  1211. Vogel CW, Müller-Eberhard HJ (1985) The cobra complement system: the alternative pathway of activation. Dev Comp Immunol 9:311–325

    PubMed  CAS  Google Scholar 

  1212. Brade V, Dieminger L, Schmidt G, Vogt W (1976) Incompatibility between C3b and B of guinea pig and man and its influence on the titration of the alternative pathway factors D and B in these two species. Immunology 30:171–179

    PubMed  CAS  Google Scholar 

  1213. Daha MR, Es LA van (1980) Isolation and characterization of rat complement factor B and its interaction with cell-bound human C3. Immunology 41:849–855

    PubMed  CAS  Google Scholar 

  1214. Nicholson A, Austen KF (1977) Isolation and characterization of guinea-pig properdin. J Immunol 118:103–108

    PubMed  CAS  Google Scholar 

  1215. Bitter-Suermann D, Burger R, Brade V, Hadding U (1976) Mouse factor B of the alternative pathway of complement activation. I. Purification, characterization, and functional behaviour. J Immunol 117:1799–1804

    PubMed  CAS  Google Scholar 

  1216. Horstmann RD, Müller-Eberhard HJ (1985) Isolation of rabbit C3, factor B, and factor H and comparison of their properties with those of the human analog. J Immunol 134:1094–1100

    PubMed  CAS  Google Scholar 

  1217. Burge J, Nicholson A, Austen KF (1981) Isolation of C4-binding protein from guinea-pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase. J Immunol 126:232–235

    PubMed  CAS  Google Scholar 

  1218. Kai S, Fujita T, Gigli I, Nussenzweig V (1980) Mouse C3b/C4b inactivator: purification and properties. J Immunol 125:2409–2415

    PubMed  CAS  Google Scholar 

  1219. Daha M, Es L van (1982) Isolation, characterization and mechanism of action of rat β1H. Immunology 128:1839–1843

    CAS  Google Scholar 

  1220. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF (1983) Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 80:5066–5070

    PubMed  CAS  Google Scholar 

  1221. Brown EJ, Ramsen J, Hammer CH, Frank MM (1983) Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig and human erythrocytes. J Immunol 131:403–408

    PubMed  CAS  Google Scholar 

  1222. Schönermark S, Rauterberg EW, Shin ML, Löke S, Roelcke D, Hänsch GM (1986) Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 136:1772–1776

    PubMed  Google Scholar 

  1223. Yamamoto K-I (1977) Lytic activity of # complexes for erythrocytes from the species other than sheep: C9 rather than C8 dependent variation in lytic activity. J Immunol 119:1482–1485

    PubMed  CAS  Google Scholar 

  1224. Adler S, Baker P, Johnson RJ, Ochi R, Pritzl P, Couser WG (1986) Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. J Clin Invest 77:762–767

    PubMed  CAS  Google Scholar 

  1225. Alving CR (1977) Immune reactions of lipid and lipid model membranes. In: Sela M (ed) The antigens. Academic, New York, pp 1–72

    Google Scholar 

  1226. Alving CR, Fowble JW, Joseph KC (1974) Comparative properties of four galactosyl lipids as antigens in liposomes. Immunochemistry 11:475–481

    PubMed  CAS  Google Scholar 

  1227. Arroyave CM, Müller-Eberhard HJ (1973) Interaction between human C5, C6 and C7 and their functional significance in complement dependent cytolysis. J Immunol 111:536–545

    PubMed  CAS  Google Scholar 

  1228. Baker PJ, Lint TF, McLeod BC, Behrends CL, Gewurz H (1975) Studies on the inhibition of #-induced lysis (reactive lysis). VI. Modulation of #-induced lysis by polyanions and polycations. J Immunol 114:554–558

    PubMed  CAS  Google Scholar 

  1229. Baker PJ, Lint TF, Siegel J, Kies MW, Gewurz H (1976) Potentiation of C5,6 initiated lysis by leukocyte cationic proteins, myelin basic protein and lysine-rich histones. Immunology 30:467–473

    PubMed  CAS  Google Scholar 

  1230. Balkarova-Ständer J, Rother U, Rauterberg EW (1981) The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. J Immunol 129:1089–1093

    Google Scholar 

  1231. Barfort P, Arquilla ER, Vogelhut PO (1968) Resistance changes in lipid bilayers: immunological applications. Science 160:1119–1121

    PubMed  CAS  Google Scholar 

  1232. Bartholomew RM, Esser AF (1978) Differences in activation of human and guinea pig complement by retroviruses. J Immunol 121:1748–1751

    PubMed  CAS  Google Scholar 

  1233. Bauer J, Valet G (1983) Cell volume and osmotic properties of erythrocytes after complement lysis measured by flow cytometry. J Immunol 130:839–844

    PubMed  CAS  Google Scholar 

  1234. Bauer J, Podack ER, Valet G (1979) Determination of the number of lytic sites in biconcave and spheroid erythrocyte ghosts after complement lysis. J Immunol 122:2032–2036

    PubMed  CAS  Google Scholar 

  1235. Betz M, Hänsch GM (1984) Release of arachidonic acid: a new function of the late complement components. Immunobiology 166:473–479

    PubMed  CAS  Google Scholar 

  1236. Betz M, Hänsch GM (1987) Thromboxane B2 synthesis in human platelets induced by the late complement components C5b-9. Int Arch Allergy Appl Immunol 82:313–316

    PubMed  CAS  Google Scholar 

  1237. Bhakdi S (1983) Membrane damage by complement. Biochim Biophys Acta 737:343–372

    PubMed  CAS  Google Scholar 

  1238. Bhakdi S, Tranum-Jensen J (1978) Molecular nature of the complement lesion. Proc Natl Acad Sci USA 75:5655–5659

    PubMed  CAS  Google Scholar 

  1239. Bhakdi S, Tranum-Jensen J (1979) Evidence for a two-domain structure of the terminal membrane C5b-9 complex of human complement. Proc Natl Acad Sci USA 76:5872–5876

    PubMed  CAS  Google Scholar 

  1240. Bhakdi S, Tranum-Jensen J (1983) Molecular composition of the terminal membrane and fluid phase C5b-9 complexes of rabbit complement. Absence of disulphide bound C9 dimers in the membrane. Biochem J 209:753–761

    PubMed  CAS  Google Scholar 

  1241. Bhakdi S, Tranum-Jensen J (1984) On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum. J Immunol 133:1453–1463

    PubMed  CAS  Google Scholar 

  1242. Bhakdi S, Bjerrum OJ, Rother U, Knüfermann H, Wallach DFH (1975) Immunochemical analyses of membrane-bound complement: detection of the terminal complement complex and its similarity to intrinsic erythrocyte membrane proteins. Biochem Biophys Acta 406:21–33

    PubMed  CAS  Google Scholar 

  1243. Bhakdi S, Ey P, Bhakdi-Lehnen B (1976) Isolation of the terminal complement complex from target sheep erythrocyte membranes. Biochim Biophys Acta 419:445–447

    PubMed  CAS  Google Scholar 

  1244. Bhakdi S, Bjerrum OJ, Bhakdi-Lehnen B, Tranum-Jensen J (1978) Complement lysis: evidence for an amphiphilic nature of the terminal membrane C5–9 complex of human complement. J Immunol 121:2526–2532

    PubMed  CAS  Google Scholar 

  1245. Bhakdi S, Bhakdi-Lehnen B, Bjerrum OJ, Tranum-Jensen J (1979) Difference in antigenetic reactivity and ultrastructure between fluid phase C5b-9 and the membrane attack complex of human complement. FEBS Lett 99:15–19

    PubMed  CAS  Google Scholar 

  1246. Biesecker G, Podack ER, Halverson CA, Müller-Eberhard HJ (1979) C5–9 dimer: isolation from complement lysed cells and ultrastructural identification with complement-dependent membrane lesions. J Exp Med 149:448–458

    PubMed  CAS  Google Scholar 

  1247. Biesecker G, Katz S, Koffler D (1981) Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis. J Exp Med 154:1779–1784

    PubMed  CAS  Google Scholar 

  1248. Bordet J (1900) Les serums hemolytique, les antitoxins et les théories de serums cytolique. Ann de l’institut Pasteur 7:257

    Google Scholar 

  1249. Borsos T, Rapp HJ, Mayer MM (1961) Studies on the second component of complement. I. The reaction between EAC’1,4 and C’2: evidence on the single site mechanism of immune hemolysis and determination of C’2 on a molecular basis. J Immunol 87:310–325

    CAS  Google Scholar 

  1250. Boyle MDP, Ohanian SH, Borsos T (1975) Lysis of tumor cells by antibody and complement. III. Lack of correlation between antigen movement and cell lysis. J Immunol 115:473–475

    PubMed  CAS  Google Scholar 

  1251. Boyle MDP, Ohanian SH, Borsos T (1976 a) Studies on the terminal stages of antibody — complement mediated killing of a tumor cell. I. Evidence for the existence of a intermediate, T*. J Immunol 116:1272–1275

    PubMed  CAS  Google Scholar 

  1252. Boyle MDP, Ohanian S, Borsos T (1976 b) Studies on the terminal stages of antibody — complement-mediated killing of a tumor cell. II. Inhibition of transformation of T* to dead cells by 3′5′ cAMP. J Immunol 116:1276–1279

    PubMed  CAS  Google Scholar 

  1253. Boyle MDP, Ohanian S, Borsos T (1976 c) Studies on the terminal stages of antibody — complement mediated killing of a tumor cell. III. Effect of membrane active agents. J Immunol 117:106–109

    PubMed  CAS  Google Scholar 

  1254. Boyle MDP, Ohanian S, Borsos T (1976 d) Lysis of tumor cells by antibody and complement. VI. Enhanced killing of enzyme pretreated tumor cells. J Immunol 116:661–668

    PubMed  CAS  Google Scholar 

  1255. Boyle MDP, Ohanian S, Borsos T (1976 e) Lysis of tumor cells by antibody and complement. VII. Complement-dependent 86Rb release — a nonlethal event. J Immunol 117:1346–1350

    PubMed  CAS  Google Scholar 

  1256. Boyle MDP, Ohanian S, Borsos T (1978 a) Effect of protease treatment on the sensitivity of tumor cells to antibody-GPC killing. Clin Immunol Immunopathol 10:84–94

    PubMed  CAS  Google Scholar 

  1257. Boyle MDP, Langone JJ, Borsos T (1978 b) Study on the terminal stages of immune hemolysis. III. Distinction between the insertion of C9 and the formation of a transmembrane channel. J Immunol 120:1721–1725

    PubMed  CAS  Google Scholar 

  1258. Boyle MDP, Langone JJ, Borsos T (1979 a) Studies on the terminal stages of immune hemolysis. IV. Effect of metal salts. J Immunol 122:1209–1213

    PubMed  CAS  Google Scholar 

  1259. Boyle MDP, Gee AP, Borsos T (1979 b) Studies on the terminal stages of immune hemolysis. VI. Osmotic blockers of differing stokes’ radii detect complement-induced transmembrane channels of differing size. J Immunol 123:77–82

    PubMed  CAS  Google Scholar 

  1260. Boyle MDP, Gee AP, Borsos T (1981) Heterogeneity in the size and stability of transmembrane channels produced by whole complement. Clin Immunol Immunopathol 20:287–295

    PubMed  CAS  Google Scholar 

  1261. Brauch H, Roelcke D, Rother U (1983) Glycophorin A inhibits lysis by the complement attack phase. Immunobiology 165:115–120

    PubMed  CAS  Google Scholar 

  1262. Brickner A, Sodetz JM (1985) Functional domains of the a subunit of the eight component of human complement. Identification and characterization of a distinct binding site for the γ-chain. Biochemistry 24:4603–4607

    PubMed  CAS  Google Scholar 

  1263. Brown E, Ramsey J, Hammer C, Frank M (1983) Surface modulation of classical pathway activation. Immunobiology 164:27 (Abstract)

    Google Scholar 

  1264. Buchner H (1889) Über die nähere Natur der bakterientötenden Substanz in Blutserum. Zentralbl Bakteriol 6:561–572

    Google Scholar 

  1265. Buchner H (1889) Über die bakterientötende Wirkung des zellfreien Blutserums. Zentralbl Bakteriol 6:1–11

    Google Scholar 

  1266. Burakoff SJ, Martz E, Benacerraf B (1975) Is the primary complement lesion insufficient for lysis? Failure of cells, damaged under osmotic protection to lyse in EDTA or at low temperature after removal of osmotic protection. Clin Immunol Immunopathol 4:108–126

    PubMed  CAS  Google Scholar 

  1267. Campbell AK, Daw RA, Luzio JP (1979) Rapid increase in intracellular free Ca2+ induced by antibody plus complement. FEBS Lett 107:55–62

    PubMed  CAS  Google Scholar 

  1268. Carney D, Koski CL, Shin ML (1985) Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J Immunol 134:1804–1809

    PubMed  CAS  Google Scholar 

  1269. Carney D, Hammer C, Shin ML (1986) Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2 + . J Immunol 137:263–270

    PubMed  CAS  Google Scholar 

  1270. Chow YM, Giavedoni EB, Dalmasso AP (1977) Properties of the lesion induced by complement on erythrocyte membranes. Fed Proc 36:1282 (Abstract)

    Google Scholar 

  1271. Cooper NR, Welsch RM (1979) Antibody and complement-dependent viral neutralization. Springer Semin Immunopathol 2:285–310

    CAS  Google Scholar 

  1272. Cooper NR, Polley MJ, Oldstone MBA (1974) Failure of terminal complement components to induce lysis of moloney virus transformed lymphocytes. J Immunol 112:866–868

    PubMed  CAS  Google Scholar 

  1273. Dahl CE, Levine RP (1978) Electron spin resonance studies on the interaction of the complement proteins and cell membranes. Proc Natl Acad Sci USA 75:4930–4934

    PubMed  CAS  Google Scholar 

  1274. Dahl JS, Dahl CE, Levine RP (1979) Role of lipid fatty acid composition and membrane fluidity in the resistance of Acholeplasma laidlawii to complement-mediated killing. J Immunol 123:104–108

    PubMed  CAS  Google Scholar 

  1275. Dalmasso AP, Benson BA (1981) Lesions of different functional size produced by human and guinea pig complement in sheep red cell membranes. J Immunol 127:2214–2218

    PubMed  CAS  Google Scholar 

  1276. Dalmasso AP, Benson BA (1983) Direct participation of C9 in the structure of functional transmembrane complement channels. Immunobiology 164:45 (Abstract)

    Google Scholar 

  1277. Dalmasso AP, Lelchuk R, Giavedoni EB, de Isola ED (1975) The modifications of the final stages of the complement reaction by alkali metal cations. J Immunol 115:63–68

    PubMed  CAS  Google Scholar 

  1278. Dalmasso AP, Falk RJ, Michael AF (1983) Immunological and functional properties of a monoclonal antibody to a neoantigen of C9. Immunobiology 164:44 (Abstract)

    Google Scholar 

  1279. Dankert J, Esser AF (1985) Proteolytic modification of human complement protein C9: loss of poly (C9) and circular lesion formation without impairment of function. Proc Natl Acad Sci USA 82:2128–2132

    PubMed  CAS  Google Scholar 

  1280. Dessauer A, Rother U, Rother K (1984) Freeze thaw activation of the complement attack phase: I. separation of two steps in the formation of the active # complex. II. comparison of convertase generated # with # generated by freezing and thawing. Acta Pathol Microbiol Immunol Scand [C] [Suppl 284] 92:75–88

    Google Scholar 

  1281. Dourmashkin RR (1978) The structural events associated with the attachment of complement components to cell membranes in reactive lysis. Immunology 35:205–212

    PubMed  CAS  Google Scholar 

  1282. Ebbesen P, Arnung KM (1973) Enhancement of dye-exclusion cytotoxicity test by insulin and inhibition by cyclic adenosine 3,5-monophosphate and theophylline. Transplantation 16:476–478

    PubMed  CAS  Google Scholar 

  1283. Esser AF (1982) Interaction between complement proteins and biological and model membranes. In: Chapman D (ed) Biological membranes. Academic, New York, pp 277–316

    Google Scholar 

  1284. Esser AF (1986) C9-mediated cytotoxicity and the function of poly (C9). In: Membrane mediated cytotoxicity. UCLA Symposia 56 (in press)

    Google Scholar 

  1285. Esser AF, Kolb WP, Podack ER, Müller-Eberhard HJ (1979) Molecular reorganization of lipid bilayers by complement: a possible mechanism for membranolysis. Proc Natl Acad Sci USA 76:1410–1414

    PubMed  CAS  Google Scholar 

  1286. Esser AF, Bartholomew RM, Jensen FC, Müller-Eberhard HJ (1979) Disassembly of viral membranes by complement independent of channel formation. Proc Natl Acad Sci USA 76:5843–5847

    PubMed  CAS  Google Scholar 

  1287. Fearon DT (1978) Regulation of membrane sialic acid of β1H dependent decay-dissociation of the amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci USA 75:1971–1975

    PubMed  CAS  Google Scholar 

  1288. Fell HB, Weiss L (1965) The effect of antiserum, alone or with hydrocortisone, on foetal mouse bones in cultures. J Exp Med 121:551–560

    PubMed  CAS  Google Scholar 

  1289. Fischer H (1964) Lysolecithin and the action of complement. Ann NY Acad Sci 116:1063–1069

    PubMed  CAS  Google Scholar 

  1290. Fischer H, Haupt I (1960) Das cytolysierende Prinzip von Serumkomplement. Nature 47:137

    CAS  Google Scholar 

  1291. Fischer H, Haupt I (1961) Das cytolysierende Prinzip von Serumkomplement. Z Naturforsch 166:321–323

    Google Scholar 

  1292. Frank MM, Rapp HJ, Borsos T (1964) Studies on the terminal steps of immune hemolysis. I. Inhibition by trisodium ethylene diamine tetraacetate (EDTA). J Immunol 93:409–413

    PubMed  CAS  Google Scholar 

  1293. Frank MM, Rapp HJ, Borsos T (1965) Studies on the terminal steps of immune hemolysis. II. Resolution of the E* transformation reaction into multiple steps. J Immunol 94:295–300

    PubMed  CAS  Google Scholar 

  1294. Gewurz H, Wernick PR, Quie PE, Good RA (1965) Effect of hydrocortisone succinate on the complement system. Nature 208:755–757

    PubMed  CAS  Google Scholar 

  1295. Giavedoni EB, Dalmasso AP (1976) The induction by complement of a change in KSCN-dissociable red cell membrane lipids. J Immunol 116: 1163–1169

    PubMed  CAS  Google Scholar 

  1296. Giavedoni EB, Chow YM, Dalmasso AP (1979 a) The functional size of the primary complement lesion in resealed erythrocyte membrane ghosts. J Immunol 122:240–245

    PubMed  CAS  Google Scholar 

  1297. Giavedoni EB, Chow YM, Dalmasso AP (1979 b) Complement lysis of resealed red cell membrane ghosts pretreated with glutaraldehyde. J Immunol 122:1643–1648

    PubMed  CAS  Google Scholar 

  1298. Goldlust MB, Shin HS, Hammer CH, Mayer MM (1974) Studies of complement complex C5b.6 eluted from EAC1–6: reaction of C5b.6 with EAC4b3b and evidence on the role of C2a and C3b in the activation of C5. J Immunol 113:988–1007

    Google Scholar 

  1299. Goldman JN, Ruddy S, Austen KF (1972) Reaction mechanisms of nascent # (reactive lysis). I. Reaction characteristics for production of # and lysis by C8 and C9. J Immunol 109:353–359

    PubMed  CAS  Google Scholar 

  1300. Green H, Goldberg BC (1960) The action of antibody and complement on mammalian cells. Ann NY Acad Sci 87:352–362

    PubMed  CAS  Google Scholar 

  1301. Green H, Barrow CP, Goldberg B (1959) Effect of antibody and complement on permeability control in ascites tumor cells and erythrocytes. J Exp Med 110:699–713

    PubMed  CAS  Google Scholar 

  1302. Groggel CG, Adler S, Rennke HG, Couser WG, Salant DJ (1983) Role of the terminal complement pathway in experimental membraneous nephropathy in the rabbit. J Clin Invest 72:1948–1957

    PubMed  CAS  Google Scholar 

  1303. Güttler F (1972) Phospholipid synthesis in Hela cells exposed to immunoglobulin G and complement. Biochem J 128:953–960

    PubMed  Google Scholar 

  1304. Güttler F, Clausen J (1969) Changes in lipid pattern of Hela cells exposed to immunoglobulin G and complement. Biochem J 115:959–968

    PubMed  Google Scholar 

  1305. Ham TH (1937) Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: study of the mechanism of hemolysis in relation to acid-base equilibrium. N Engl J Med 217:915–917

    CAS  Google Scholar 

  1306. Hammer CH, Nicholson A, Mayer MM (1975) On the mechanism of cytolysis by complement. Evidence for insertion of C5b and C1 subunits of C5b.6, C1 complexes into the phospholipid bilayers on erythrocyte membranes. Proc Natl Acad Sci USA 72:5076–5080

    PubMed  CAS  Google Scholar 

  1307. Hammer CH, Abramovitz AS, Mayer MM (1976) A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b6 and terminal components. J Immunol 117:830–834

    PubMed  CAS  Google Scholar 

  1308. Hammer CH, Shin ML, Abramovitz AS, Mayer MM (1977) On the mechanism of cell membrane damage by complement. Evidence on insertion of polypeptide chains from C8 and C9 into lipid bilayer of erythrocytes. J Immunol 119:1–8

    PubMed  CAS  Google Scholar 

  1309. Hammer CH, Hänsch GM, Gresham H, Shin ML (1983) Activation of the fifth and sixth component of the human complement system. C6 dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C56a. J Immunol 131:892–898

    PubMed  CAS  Google Scholar 

  1310. Hänsch GM, Betz M (1987) Effect of the late complement components C5b-9 on human monocytes: release of prostanoids, oxygen radicals and of a factor inducing cell proliferation. Int Arch Allergy Appl Immunol 82:317–321

    PubMed  Google Scholar 

  1311. Hänsch GM, Rother U, Rother K (1977) Deviated lysis: transfer of complement lytic activity to unsensitized cells. IV. Partial isolation of the activity. Z Immunforsch 153:48–59

    Google Scholar 

  1312. Hänsch GM, Hammer C, Mayer MM, Shin ML (1981) Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell bound C3b or A2C, and species preferences of target cell. J Immunol 127:999–1002

    PubMed  Google Scholar 

  1313. Hänsch GM, Hammer CH, Vanguri P, Shin ML (1981) Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci USA 78:5118–5121

    PubMed  Google Scholar 

  1314. Hänsch GM, Hammer CH, Jiji R, Rother U, Shin M (1983) Lysis of paroxysmal nocturnal hemoglobulinuria erythrocytes by acid-activated serum. Immunobiology 164:118–126

    PubMed  Google Scholar 

  1315. Hänsch GM, Rummel G, Gänzler F (1984) Purification and characterization of the ninth component of rabbit complement. Complement 1:116–122

    PubMed  Google Scholar 

  1316. Hänsch GM, Betz M, Shin ML (1984) Cytolysis of nucleated cells by complement: inhibition of transmethylation enhances killing by C5b-9. J Immunol 132:1440–1444

    PubMed  Google Scholar 

  1317. Hänsch GM, Seitz M, Martinotti G, Betz M, Rauterberg EW, Gemsa D (1984) Macrophages release arachidonic acid, prostaglandin E2 and thromboxane in response to late complement components. J Immunol 133:2145–2150

    PubMed  Google Scholar 

  1318. Hänsch GM, Gemsa D, Resch K (1985) Induction of prostanoid synthesis in human platelets by the late complement components C5b-9 and the channel forming antibiotic nystatin: inhibition of the reacylation of liberated arachidonic acid. J Immunol 135:1320–1324

    PubMed  Google Scholar 

  1319. Hänsch GM, Schönermark S, Roelcke D (1986) The role of C8 binding protein in homologous species restriction of complement-mediated lysis: The C8bp interacts with the C8α-γ subunit and inhibits C9 polymerization. Fed Proc 45(3):538 (Abstract)

    Google Scholar 

  1320. Hänsch GM, Rother K, Günther J, Filsinger S, Sterzel RB (1986) Terminal complement components stimulate prostanoid production of cultured glomerular epithelial cells. Kidney Int 29(1):277 (Abstract)

    Google Scholar 

  1321. Haxby J, Kinsky CB, Kinsky SC (1968) Immune response of liposomal model membranes. Biochemistry 61:300–307

    CAS  Google Scholar 

  1322. Hesketh TR, Dourmashkin RR, Payne SN, Humphrey JH, Lachman PJ (1971) Lesions due to complement in lipid membranes. Nature 233:620–633

    PubMed  CAS  Google Scholar 

  1323. Hoffman EM (1969) Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata. Immunochemistry 6:391–403

    PubMed  CAS  Google Scholar 

  1324. Hoffman EM (1969) Inhibition of complement by a substance isolated from human erythrocytes. II. Studies in the mechanism of action. Immunochemistry 6:405–412

    Google Scholar 

  1325. Hoffman LG (1969) Statistical evaluation of the reaction mechanism in immune hemolysis. II. The kinetics of release of 86rubidium and hemoglobin from erythrocytes damaged by antibody and complement. Immunochemistry 6:309–325

    Google Scholar 

  1326. Houle J, Hoffmann EM (1984) Evidence for restriction of the ability of complement to lyse homologous erythrocytes. J Immunol 133:1444–1452

    PubMed  CAS  Google Scholar 

  1327. Hu VW (1983) Photolabeling provides evidence that C9 forms the major part of a transmembrane complement channel. Immunobiology 164:94 (Abstract)

    Google Scholar 

  1328. Hu VW, Nicholson-Weller A (1985) Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization. Proc Natl Acad Sci USA 82:5520–5524

    PubMed  CAS  Google Scholar 

  1329. Hu VW, Shin ML (1984) Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9. J Immunol 133:2133–2137

    PubMed  CAS  Google Scholar 

  1330. Hu VW, Esser A, Podack E, Wisnieski BJ (1981) The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane. J Immunol 127:380–386

    PubMed  CAS  Google Scholar 

  1331. Hug F, Hänsch GM, Rauterberg EW, Greulich KO, Wolfrum I (1986) Fluorescence studies on the C9 monomer and poly C9 of human complement. Immunobiol 173:461

    Google Scholar 

  1332. Humphrey HJ, Dourmashkin RR (1969) The lesions in cell membranes caused by complement. Adv Immunol 11:75–115

    PubMed  CAS  Google Scholar 

  1333. Humphries GK, McConnell HM (1975) Antigen mobility in membranes and complement- mediated immune attack. Proc Natl Acad Sci USA 72:2483–2487

    CAS  Google Scholar 

  1334. Iles GH, Seeman P, Naylor D, Cinader B (1973) Membrane lesions in immune hemolysis. Surface rings, globule aggregates and transient openings. J Cell Biol 56:528–539

    PubMed  CAS  Google Scholar 

  1335. Imagawa DK, Osifchin NE, Paznekas WA, Shin ML, Mayer MM (1983) Consequence of cell membrane attack by complement: release of arachidonate and formation of inflammatory derivatives. Proc Natl Acad Sci 80:6647–6651

    PubMed  CAS  Google Scholar 

  1336. Inoue K, Kinsky SC (1970) Fate of phospholipids in liposomal model membranes damaged by antibody and complement. Biochemistry 9:4767–4776

    PubMed  CAS  Google Scholar 

  1337. Inoue K, Kinoshita T, Okado M, Akiyama Y (1977) Release of phospholipids from complement-mediated lesions on the surface structure of E. coli. J Immunol 119:65–72

    PubMed  CAS  Google Scholar 

  1338. Jennings JF (1966) The effect of hydrocortisone on immune lysis of cells induced by cytotoxic antibody and complement in vitro. J Immunol 96:409–414

    PubMed  CAS  Google Scholar 

  1339. Kaliner M, Austen KF (1974) Adenosine 3′5-monophosphate: inhibition of complement mediated cell lysis. Science 183:659–661

    PubMed  CAS  Google Scholar 

  1340. Kinoshita T, Inoue K, Okada M, Akiyama Y (1977) Release of phospholipids from lysosomal model membrane damaged by antibody and complement. J Immunol 119:73–78

    PubMed  CAS  Google Scholar 

  1341. Kinski S (1972) Antibody-complement interaction with lipid model membranes. Biochim Biophys Acta 265:1–23

    Google Scholar 

  1342. Kinski SC, Haxby JA, Zopf PA, Alving CR, Kinski CB (1969) Complement dependent damage to liposomes prepared from pure lipid and Forssman hapten. Biochemistry 8:4149–4158

    Google Scholar 

  1343. Kitamura H, Inai S (1974) Molecular analysis of the reaction of C9 with EAC1–8. J Immunol 113:1992–2003

    PubMed  CAS  Google Scholar 

  1344. Kolb WP, Müller-Eberhard HJ (1973) The membrane attack mechanism of complement. Verification of the stable C5–9 complex in free solution. J Exp Med 138:438–451

    PubMed  CAS  Google Scholar 

  1345. Kolb WP, Müller-Eberhard HJ (1974) Mode of action of human C9: adsorption of multiple C9 molecules to cell-bound C8. J Immunol 113:479–488

    PubMed  CAS  Google Scholar 

  1346. Kolb WP, Müller-Eberhard HJ (1975) Neoantigens of the membrane attack complex of human complement. Proc Natl Acad Sci USA 72:1687–1689

    PubMed  CAS  Google Scholar 

  1347. Kolb WP, Müller-Eberhard HJ (1975) The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex. J Exp Med 141:724–735

    PubMed  CAS  Google Scholar 

  1348. Kolb WP, Haxby JA, Arroyave CM, Müller-Eberhard HJ (1973) The membrane attack mechanism of complement: reversible interactions among the five native complement components. J Exp Med 139:428–437

    Google Scholar 

  1349. Kolb WP, Kolb LM, Savary IR (1982) Biochemical characterization of the sixth component (C6) of human complement. Biochemistry 21:294–301

    PubMed  CAS  Google Scholar 

  1350. Körner CF, Hausman G, Gemsa D, Resch K (1984) Rate of prostaglandin synthesis is not controlled by phospholipase activity but by reincorporation of released fatty acids into phospholipids. Agent Actions 15:25–29

    Google Scholar 

  1351. Koski CL, Ramm LE, Hammer CH, Mayer MM, Shin ML (1983) Cytolysis of nucleated cells by complement: cell death displays multi hit characteristics. Proc Natl Acad Sci USA 80:3816–3820

    PubMed  CAS  Google Scholar 

  1352. Kosower EM, Kosower NS, Faltin Z, Diver A, Saltoun G, Frensdorff A (1974) Membrane mobility agents. A new class of biologically active molecules. Biochim Biophys Acta 363:261–266

    PubMed  CAS  Google Scholar 

  1353. Lachmann PJ, Thompson RA (1970) Reactive lysis: The complement-mediated lysis of unsensitized cells. II. the characterization of activated reactor as # and the participation of C8 and C9. J Exp Med 131:643–657

    PubMed  CAS  Google Scholar 

  1354. Lachmann PJ, Bowyer DE, Nicol P, Dawson RMC, Munn EA (1973) Studies on the terminal stages of complement lysis. Immunology 24:135–145

    PubMed  CAS  Google Scholar 

  1355. Latta H, Kutsakis A (1957) Cytotoxic effects of specific antiserum and 17-hydroxycorticos- terone on cells in tissue culture. Lab Invest 6:12–27

    PubMed  Google Scholar 

  1356. Lauf PK (1975) Immunological and physiological characteristics of the rapid immune hemolysis of neuraminidase-treated sheep red cells by fresh guinea pig serum. J Exp Med 142:974–988

    PubMed  CAS  Google Scholar 

  1357. Lerner RA, Oldstone MBA, Cooper NR (1971) Cell cycle dependent immune lysis of Moloney virus-transformed lymphocytes; presence of viral antigens, accessibility to antibody, and complement activation. Proc Natl Acad Sci USA 68:2584–2589

    PubMed  CAS  Google Scholar 

  1358. Lint TF, Behrends CL, Gewurz H (1977) Serum lipoproteins and #-INH activity. J Immunol 119:883–888

    PubMed  CAS  Google Scholar 

  1359. Lovett D, Hänsch GM, Resch K, Gemsa D (1987) Activation of glomerular mesangial cells by the terminal membrane attack complex of complement. J Immunol 138:2473–2477

    PubMed  CAS  Google Scholar 

  1360. Mason RP, Giavedoni EB, Dalmasso AP (1977) Complement induced decrease in membrane mobility: introducing a more sensitive index of spin label motion. Biochemistry 16:1196–1201

    PubMed  CAS  Google Scholar 

  1361. Mayer MM (1961) Development of the one-hit theory of immune lysis. In: Heidelberger M, Plescia O (eds) Immunological approaches to problems in microbiology. Rutgers University Press, New Brunswick, NY, pp 268–279

    Google Scholar 

  1362. Mayer MM (1972) Mechanism of cytolysis by complement. Proc Natl Acad Sci USA 69:2954–2958

    PubMed  CAS  Google Scholar 

  1363. Mayer MM (1984) Complement. Historical perspectives and some current issues. Complement 1:2–26

    PubMed  CAS  Google Scholar 

  1364. Mayer MM, Michaels DW, Ramm LE, Whitlow MB, Willoughby JB, Shin ML (1981) Membrane damage by complement. Crit Rev Immunol 2:133–165

    CAS  Google Scholar 

  1365. Medof ME, Kinoshita T, Nussenzweig V (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 160:1558–1564

    PubMed  CAS  Google Scholar 

  1366. Michaels DW, Abramovitz AS, Hammer CH, Mayer MM (1976) Increased ion permeability of planar lipid bilayer membrane after treatment with the C5b-9 cytolytic attack mechanism of complement. Proc Natl Acad Sci USA 73:2852–2856

    PubMed  CAS  Google Scholar 

  1367. Michaels DW, Abramovitz AS, Mayer MM (1978) Characterization of the complement lesion: the formation of transmembrane channels and their mechanism of assembly. J Immunol 120:1785 (Abstract)

    Google Scholar 

  1368. Monahan JB, Sodetz JM (1980) Binding of the eighth component of human complement to the soluble cytolytic complex is mediated by its β subunit. J Biol Chem 255:10579–10582

    PubMed  CAS  Google Scholar 

  1369. Monahan JB, Sodetz JM (1981) Role of the β-subunit in interaction of the eighth component of human complement with the membrane-bound cytolytic complex. J Biol Chem 256:3258–3262

    PubMed  CAS  Google Scholar 

  1370. Mueller P, Rudin DO (1970) Translocators in bimolecular lipid membranes. Their role in dissipative and bioenergy transductions. Curr Top Bioenergetics 3:157–169

    Google Scholar 

  1371. Nakamura M, Ohnishi S, Kitamura H, Inai S (1974) Membrane fluidity change in erythrocyte induced by complement system. Biochemistry 15:4838–4843

    Google Scholar 

  1372. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF (1983) Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 80:5066–5070

    PubMed  CAS  Google Scholar 

  1373. Ohanian SH (1983) Cell growth-dependent variation in the sensitivity of human and mouse tumor cells to complement-mediated killing. Cancer Res 43:491–495

    PubMed  CAS  Google Scholar 

  1374. Ohanian SH, Schlager SI (1981) Humoral killing of nucleated cells: mechanisms of complement-mediated attack and target cell defense. CRC Critical Rev Immunol 1:165–209

    CAS  Google Scholar 

  1375. Ohanian SH, Schlager SI, Borsos T (1978) Molecular interaction of cells with antibody and complement: influence of metabolic and physical properties of the target on the outcome of the immune attack. In: Reisfeld RA, Imman F (eds) Contemporary topics in molecular immunology. Plenum, New York, pp 153–180

    Google Scholar 

  1376. Packman CH, Rosenfeld SI, Jenkins DE, Thiem PA, Leddy JP (1979) Complement lysis of human erythrocytes: differing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9. J Clin Invest 64:428–433

    PubMed  CAS  Google Scholar 

  1377. Pangburn MK, Schreiber RD, Trombold JS, Müller-Eberhard HJ (1983) Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med 157:1971–1980

    PubMed  CAS  Google Scholar 

  1378. Parker CJ, Baker PJ, Rosse WF (1982) Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 69:337–346

    PubMed  CAS  Google Scholar 

  1379. Podack ER, Müller-Eberhard HJ (1978) Binding of deoxycholate, phosphatidyl choline vesicles, lipoprotein or S-protein to complexes of terminal complement components. J Immunol 121:1025–1030

    PubMed  CAS  Google Scholar 

  1380. Podack ER, Tschopp J (1982) Polymerization of the ninth component of complement C9: formation of poly C9 with a tubular ultrastructure resembling the membrane attack complex of complement. Proc Natl Acad Sci 79:574–578

    PubMed  CAS  Google Scholar 

  1381. Podack ER, Tschopp J (1982) Circular polymerization of the ninth component of complement. Ring closure of the tubular complex confers resistance to detergent dissociation and to proteolytic degradation. J Biol Chem 257:15204–15212

    PubMed  CAS  Google Scholar 

  1382. Podack ER, Kolb WP, Müller-Eberhard HJ (1977) The SC5b-7 complex: formation, isolation, properties, and subunit composition. J Immunol 119:2024–2029

    PubMed  CAS  Google Scholar 

  1383. Podack ER, Kolb WP, Müller-Eberhard HJ (1978) The C5b6 complex: formation, isolation and inhibition of its activity by lipoprotein and the S-protein of human serum. J Immunol 120:1841–1848

    PubMed  CAS  Google Scholar 

  1384. Podack ER, Biesecker G, Müller-Eberhard HJ (1979) Membrane attack complex of complement: generation of high affinity phospholipid binding sites by fusion of five hydrophilic plasma proteins. Proc Natl Acad Sci USA 76:897–901

    PubMed  CAS  Google Scholar 

  1385. Podack ER, Esser AF, Biesecker G, Müller-Eberhard HJ (1980) Membrane attack complex of complement: a structural analysis of its assembly. J Exp Med 151:301–313

    PubMed  CAS  Google Scholar 

  1386. Podack ER, Tschopp J, Müller-Eberhard HJ (1982) Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med 156:268–282

    PubMed  CAS  Google Scholar 

  1387. Podack ER, Müller-Eberhard HJ, Horst H, Hoppe W (1982) Membrane attack complex of complement (MAC): three dimensional analysis of MAC-phospholipid vesicles recombinants. J Immunol 128:2353–2357

    PubMed  CAS  Google Scholar 

  1388. Podack ER, Preissner K, Müller-Eberhard HJ (1983) Inhibition of C9 polymerization by S-protein. Immunobiology 164:149 (Abstract)

    Google Scholar 

  1389. Polley MJ, Nachman RL, Weksler BB (1981) Human complement in the arachidonic acid transformation pathway of platelets. J Exp Med 153:257–268

    PubMed  CAS  Google Scholar 

  1390. Ramm LE, Mayer MM (1980) Life-span and size of the transmembrane channels formed by large doses of complement. J Immunol 124:2281–2287

    PubMed  CAS  Google Scholar 

  1391. Ramm LE, Whitlow MB, Mayer MM (1982) Transmembrane channel formation by complement: functional analysis of the number of C5b6, C7, C8 and C9 molecules required for a single channel. Proc Natl Acad Sci USA 79:4751–4755

    PubMed  CAS  Google Scholar 

  1392. Ramm LE, Whitlow MB, Mayer MM (1982) Size of the transmembrane channels produced by complement proteins C5b-8. J Immunol 129:1143–1146

    PubMed  CAS  Google Scholar 

  1393. Ramm LE, Whitlow MB, Mayer MM (1983) Size distribution and stability of the transmembrane channels formed by complement complex C5b-9. Mol Immunol 20:155–160

    PubMed  CAS  Google Scholar 

  1394. Ramm LE, Whitlow MB, Koski CL, Shin ML, Mayer MM (1983) Elimination of complement channels from the plasma membranes of U937, a nucleated mammalian cell line: temperature dependence of the elimination rate. J Immunol 131:1411–1415

    PubMed  CAS  Google Scholar 

  1395. Ramm LE, Whitlow MB, Mayer MM (1984) Complement lysis of nucleated cells: effect of temperature and puromycin on the number of channels required for cytolysis. Mol Immunol 21:1015–1019

    PubMed  CAS  Google Scholar 

  1396. Raisz LG, Sandberg AL, Goodson JM, Simmons HA, Mergenhagen SE (1974) Complement dependent stimulation of prostaglandin-synthesis and bone resorption. Science 185:789–791

    PubMed  CAS  Google Scholar 

  1397. Rauterberg EW (1978 a) On the perturbation of phospholipid bilayers by complement: the use of inside-out vesicles from complement-lysed erythrocytes for the demonstration of perturbing peptide chains. J Immunol 120:1793 (Abstract)

    Google Scholar 

  1398. Rauterberg EW (1978 b) On the perturbation of phospholipid bilayers by complement: resealing of EAC membranes is limited by the number of lytic sites. 4th European complement workshop, Cambridge, December 11

    Google Scholar 

  1399. Rauterberg EW, Gebest HJ (1975) Darstellung von C9 an Komplement-induzierten Membranveränderungen durch eine indirekte Immuno-Ferritin-Methode. Z Immunforsch 150:228 (Abstract)

    Google Scholar 

  1400. Rauterberg EW, Gebest HJ, Weissbach S (1977) Association of late complement components with membrane lesions. Monogr Allergy 12:62–63

    PubMed  CAS  Google Scholar 

  1401. Rauterberg EW, Ungemach B, Gebest HJ (1979) Quantitative measurement of C9 sites and their association to the ring-like “lesions” on complement-lysed membranes: a morphometric immunoferritin study. J Immunol 122:355–365

    PubMed  CAS  Google Scholar 

  1402. Rauterberg EW, Gehrig T, Kohl PL (1981) The attack complex of complement in epimembranous and anti-basement membrane antibody glomerulonephritis. Kidney Int 20:160

    Google Scholar 

  1403. Richards RL, Gewurz H, Siegel J, Alving C (1979) Interaction of C-reactive protein and complement with liposomes. II. Influence of membrane composition. J Immunol 122:1185–1189

    PubMed  CAS  Google Scholar 

  1404. Rommel FA, Mayer MM (1973) Studies of guinea pig complement component C9. Reaction kinetics and evidence that lysis of EAC1–8 results from a single membrane lesion caused by one molecule of C9. J Immunol 110:637–647

    PubMed  CAS  Google Scholar 

  1405. Rosenfeld SI, Packman CH, Jenkins DE, Countryman JK, Leddy JP (1980) Complement lysis of human erythrocytes. III. Differing effectiveness of human and guinea pig C9 on normal and paroxysmal nocturnal hemoglobinuria cells. J Immunol 125:2063–2068

    PubMed  CAS  Google Scholar 

  1406. Rosenfeld SI, Jenkins DE, Leddy JP (1985) Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding of cell- bound C3b. J Immunol 134:506

    PubMed  CAS  Google Scholar 

  1407. Rosse WF, Dacie JV (1966 a) Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. II. The role of complement components in the increased sensitivity of PNH red blood cells to immune lysis. J Clin Invest 45:749–761

    PubMed  CAS  Google Scholar 

  1408. Rosse WF, Dacie JV (1966 b) Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody. J Clin Invest 45:736–748

    PubMed  CAS  Google Scholar 

  1409. Rother U, Hänsch G, Menzel J, Rother K (1974) Deviated lysis: transfer of complement lytic activity to unsensitized cells. I. Generation of the transferable activity on the surface of complement resistant bacteria. Z Immunforsch 148:172–186

    CAS  Google Scholar 

  1410. Rother U, Hänsch GM, Rauterberg EW, Jungfer H, Rother K (1978) Deviated lysis: lysis of unsensitized cells by complement. V. Generation of the activity by low pH or low ionic strength. Z Immunforsch 155:118–129

    CAS  Google Scholar 

  1411. Sandberg AL, Raisz LG, Goodson MJ, Simmons HA, Mergenhagen SE (1977) Initiation of bone resorption by the classical and alternative pathways and its mediation by prostaglandins. J Immunol 119:1378–1381

    PubMed  CAS  Google Scholar 

  1412. Sandberg AL, Raisz LG, Wahl LM, Simmons HA (1982) Enhancement of complement- mediated prostaglandin synthesis and bone resorption by arachidonic acid and inhibition by cortisol. Prostaglandins, Leukotrienes Med 8:419–427

    CAS  Google Scholar 

  1413. Schlager SI, Ohanian SH (1976) Inhibition of antibody-complement mediated killing of tumor cells by hormones. Cancer Res 36:3672–3676

    PubMed  CAS  Google Scholar 

  1414. Schlager SI, Ohanian SH (1977) Correlation between lipid synthesis in tumor cells and their sensitivity to hormonal immune attack. Science 197:773–776

    PubMed  CAS  Google Scholar 

  1415. Schlager SI, Boyle MDP, Ohanian SH, Borsos T (1977) Effect of inhibiting DNA, RNA and protein synthesis of tumor cells on their susceptibility to killing by antibody and complement. Cancer Res 37:1432–1437

    PubMed  CAS  Google Scholar 

  1416. Schlager MDP, Ohanian SH, Borsos T (1977) Kinetics of hormone-induced tumor cell resistance to killing by antibody and complement. Cancer Res 37:765–771

    PubMed  CAS  Google Scholar 

  1417. Schlager SI, Ohanian SH, Borsos T (1978) Identification of lipid synthesized and released by tumor cells under complement attack by antibody and complement. J Immunol 120:1644–1650

    PubMed  CAS  Google Scholar 

  1418. Schlager SI, Ohanian SH, Borsos T (1978) Correlation between the ability of a tumor cell to resist humoral attack and their ability to synthesize lipid. J Immunol 120:463–471

    PubMed  CAS  Google Scholar 

  1419. Schlager SI, Ohanian SH, Borsos T (1978) Correlation between the ability of tumor cells to incorporate specific fatty acids and their sensitivity to killing by a specific antibody plus GPC. JNCI 61:931–934

    PubMed  CAS  Google Scholar 

  1420. Schlager SI, Ohanian SH, Borsos T (1979) Synthesis of specific lipids associated with the hormone-induced resistance of tumor cells to humoral immune killing. J Immunol 122:108–114

    PubMed  CAS  Google Scholar 

  1421. Schönermark S, Rauterberg EW, Shin ML, Löke S, Roelcke D, Hänsch GM (1986) Homologous species restriction in lysis of human erythrocytes: a membrane derived protein with C8-binding capacity functions as an inhibitor. J Immunol 136:1772–1776

    PubMed  Google Scholar 

  1422. Schreiber AD (1983) Paroxysmal nocturnal hemoglobinuria revisited. N Engl J Med 309:723–725

    PubMed  CAS  Google Scholar 

  1423. Schreiber RD, Pangburn MK, Medicus RG, Müller-Eberhard HJ (1980) Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. Clin Immunol Immunopathol 15:384–396

    PubMed  CAS  Google Scholar 

  1424. Sears DA, Weed RI, Swisher SN (1964) Differences in the mechanism of in vitro immune hemolysis related to antibody specificity. J Clin Invest 43:975–985

    PubMed  CAS  Google Scholar 

  1425. Seeman P (1974) Ultrastructure of membrane lesions in immune lysis, osmotic lysis and drug-induced lysis. Fed Proc 33:2116–2124

    PubMed  CAS  Google Scholar 

  1426. Segerling MS, Ohanian SH, Borsos T (1974) Effect of metabolic inhibitors on killing of tumor cells by antibody and complement. JNCI 53:1411–1413

    PubMed  CAS  Google Scholar 

  1427. Segerling MS, Ohanian SH, Borsos T (1975) Enhancing effect by metabolic inhibitors on the killing of tumor cells by antibody and complement. Cancer Res 35:3195–3203

    PubMed  CAS  Google Scholar 

  1428. Shearer WT, Crouch JA (1977) Humoral immunostimulation. VIII. Increased incorporation of phosphate and turnover of phosphatidylinositol in cells treated with antibody. J Immunol 119:911–917

    PubMed  CAS  Google Scholar 

  1429. Shin HS, Snyderman R, Friedman E, Mellors A, Mayer MM (1968) Chemotactic and anaphylatoxic fragments cleaved from the fifth component of guinea pig complement. Science 162:361–362

    PubMed  CAS  Google Scholar 

  1430. Shin HS, Pickering RJ, Mayer MM (1971) The fifth component of the guinea pig complement system. III. Dissociation and transfer of C5b, and the probable site of C5b fixation. J Immunol 106:480–493

    PubMed  CAS  Google Scholar 

  1431. Shin ML, Paznekas WA, Abramovitz AS, Mayer MM (1977) On the mechanism of membrane damage by C: exposure of hydrophobic sites on activated C-proteins. J Immunol 119:1358–1364

    PubMed  CAS  Google Scholar 

  1432. Shin ML, Paznekas WA, Mayer MM (1978) On the mechanism of membrane damage by complement: the effect of length and unsaturation of the acyl chains in liposomal bilayers and the effect of cholesterol concentration in sheep erythrocytes and liposomal membranes. J Immunol 120:1996–2002

    PubMed  CAS  Google Scholar 

  1433. Shin ML, Paznekas WA, Mayer MM (1979) Effect of membrane fluidity on efficiency of sheep erythrocyte lysis by terminal complement proteins. Fed Proc 38:1468

    Google Scholar 

  1434. Shin ML, Hänsch G, Mayer MM (1981) Effect of agents that produce membrane disorder on lysis of erythrocytes by complement. Proc Natl Acad Sci USA 78:2522–2525

    PubMed  CAS  Google Scholar 

  1435. Shin ML, Hänsch GM, Hu VW, Nicholson-Weller A (1986) Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J Immunol 136:1777–1782

    PubMed  CAS  Google Scholar 

  1436. Shipley WU (1971) Immune cytolysis in relation to growth cycle of Chinese hamster cells. Cancer Res 31:925–931

    PubMed  CAS  Google Scholar 

  1437. Shipley WU (1972) Immunosuppressive agents and immune cytolysis in vitro. The effect of azathioprine, hydrocortisone, and radiation on antiserum and complement-mediated lysis of cultured mammalian cells. Transplantation 14:392–404

    PubMed  CAS  Google Scholar 

  1438. Silverman B, Weller P, Shin ML (1984) Effect of membrane modulation of lysolecithin on cell lysis by C5b-9. J Immunol 132:386–391

    PubMed  CAS  Google Scholar 

  1439. Simone CB, Henkart P (1982) Inhibition of marker influx into complement-treated resealed erythrocyte ghosts by anti-C5. J Immunol 128:1168–1175

    PubMed  CAS  Google Scholar 

  1440. Sims PJ (1981) Permeability characteristics of complement damaged membranes: evaluation of the membrane leak generated by the complement proteins C5b-9. Proc Natl Acad Sci USA 78:1838–1842

    PubMed  CAS  Google Scholar 

  1441. Sims PJ (1983) Complement pores in erythrocyte membranes. Analysis of C8/C9 binding required for functional membrane damage. Biochim Biophys Acta 732:541–552

    PubMed  CAS  Google Scholar 

  1442. Sims PJ, Lauf PK (1978) Steady-state analysis of tracer exchange across C5b-9 complement lesion in a biological membrane. Proc Natl Acad Sci USA 75:5669–5673

    PubMed  CAS  Google Scholar 

  1443. Sims PJ, Lauf PK (1980) Analysis of solute diffusion across the C5b-9 membrane lesion of complement: evidence that individual C5b-9 complexes do not function as discrete, uniform pores. J Immunol 125:2617–2625

    PubMed  CAS  Google Scholar 

  1444. Smith JK, Becker EL (1968) Serum complement and the enzymatic degradation of erythrocyte phospholipids. J Immunol 100:459–474

    PubMed  CAS  Google Scholar 

  1445. Snyderman R, Shin HS, Phillips JK, Gewurz H, Mergenhagen SE (1969) A neutrophil chemotactic factor derived from C’5 upon interaction of guinea pig serum with endotoxin. J Immunol 103:413–422

    PubMed  CAS  Google Scholar 

  1446. Stanley K, Kocher HP, Luzio JP, Jackson P, Tschopp J (1985) The sequence and topology of human complement component C9. EMBO J 4:375–382

    PubMed  CAS  Google Scholar 

  1447. Steckel EW, York RG, Monahan JB, Sodetz JM (1980) The eighth component of human complement. J Biol Chem 255:11997–12005

    PubMed  CAS  Google Scholar 

  1448. Stephens CL, Henkart PA (1979) Electrical measurements of complement-mediated membrane damage in cultured nerve and muscle cells. J Immunol 122:455–458

    PubMed  CAS  Google Scholar 

  1449. Steward J, Sodetz JM (1985) Analysis of the specific association of the eight and ninth component of human complement: identification of a direct role for the subunit of C8. Biochemistry 24:4598–4602

    Google Scholar 

  1450. Stolfi RL (1968) Immune lytic transformation. A state of irreversible damage generated as a result of the reaction of the eighth component in the guinea pig complement system. J Immunol 100:46–54

    PubMed  CAS  Google Scholar 

  1451. Tamura N, Shimada A, Chang S (1972) Further evidence for immune hemolysis by antibody and the first eighth complement components in the absence of C9. Immunology 22:131–136

    PubMed  CAS  Google Scholar 

  1452. Thompson RA, Lachmann PJ (1970) Reactive lysis: the complement mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med 131:629–642

    PubMed  CAS  Google Scholar 

  1453. Thompson RA, Rowe DS (1968) Reactive hemolysis: a distinct form of red cell lysis. Immunology 14:745–762

    PubMed  CAS  Google Scholar 

  1454. Tolone G, Bonasera L, Bellona A, Ferina F (1974) Effects of cortisol on immune cytolysis. Pathol Microbiol 40:30–34

    CAS  Google Scholar 

  1455. Tranum-Jensen J, Bhakdi S (1983) Freeze-fracture analysis of the membrane lesion of human complement. J Cell Biol 97:528–538

    Google Scholar 

  1456. Tranum-Jensen J, Bhakdi S, Bhakdi-Lehnen B, Bjerrum OJ, Speth V (1978) Complement lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte membranes. Scand J Immunol 7:45–56

    PubMed  CAS  Google Scholar 

  1457. Tschopp J, Podack ER (1981) Membranolysis by the ninth component of human complement. Biochem Biophys Res Commun 100:1409–1414

    PubMed  CAS  Google Scholar 

  1458. Tschopp J, Podack ER, Müller-Eberhard HJ (1982) Ultrastructure of the membrane attack complex of complement: detection of the tetramolecular C9-polymerizing complex C5b-8. Proc Natl Acad Sci USA 79:7474–7478

    PubMed  CAS  Google Scholar 

  1459. Tschopp J, Müller-Eberhard HJ, Podack ER (1982) Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature 298:534–538

    PubMed  CAS  Google Scholar 

  1460. Tschopp J, Podack ER, Müller-Eberhard HJ (1985) The membrane attack complex of complement: C5b-8 complex as accelerator of C9 polymerization. J Immunol 134:495–499

    PubMed  CAS  Google Scholar 

  1461. Upreti GC, Jain MK (1978) Effect of the state of phosphatidyl-choline on the rate of its hydrolysis by phospholipase A2 (beevenom). Arch Biochem Biophys 188:364–375

    PubMed  CAS  Google Scholar 

  1462. Upreti GC, Jain MK (1980) Action of phospholipase A2 on unmodified phosphatidylcholine bilayers: organizational defects are preferred sites of action. J Membrane Biol 55:113–121

    CAS  Google Scholar 

  1463. Upreti GC, Shirley R, Jain MK (1980) Intrinsic differences in the perturbing ability of alkanols in bilayer: action of phospholipase A2 on the alkanol-modified phospholipid bilayer. J Membrane Biol 55:97–112

    CAS  Google Scholar 

  1464. Valet G, Opferkuch W (1975) Mechanism of complement-induced cell lysis: demonstration of a three-step mechanism of EAC1–8 cell lysis by C9 and of a non-osmotic swelling of erythrocytes. J Immunol 115:1028–1033

    PubMed  CAS  Google Scholar 

  1465. Valet G, Hoffmann H, Ruhenstroth-Bauer G (1976) The computer analysis of volume distribution curves: demonstration of two erythrocyte populations of different size in young guinea pig and analysis of the mechanism of immune lysis of cells by antibody and complement. J Histochem Cytochem 24:231–246

    PubMed  CAS  Google Scholar 

  1466. Vogel CW, Plückthun A, Podack ER, Dennis EA, Müller-Eberhard HJ (1983) The membrane attack complex of complement and its precursor molecules lack phospholipase activity. Mol Immunol 377–382

    Google Scholar 

  1467. Ware C, Kolb WP (1981) Assembly of the functional membrane attack complex of human complement, formation of disulfïde-linked C9 dimers. Proc Natl Acad Sci USA 78:6426–6430

    PubMed  CAS  Google Scholar 

  1468. Ware CF, Wetsel RA, Kolb WP (1981) Physicochemical characterization of fluid phase C5 (S-C5b-9) and membrane derived (MC5b-9) attack complexes of human complement purified by immunoadsorbent affinity chromatography of selective detergent extraction. Mol Immunol 18:521–531

    PubMed  CAS  Google Scholar 

  1469. Welsh RM, Jensen FC, Cooper NR, Oldstone MBA (1976) Inactivation and lysis of oncornaviruses by human serum. Virology 74:432–440

    PubMed  Google Scholar 

  1470. Whitlow MB, Ramm LE, Mayer MM (1985) Peneration of the C5b-9 complex across the erythrocyte membrane into the cytoplasmic space. J Biol Chem 260:998–1005

    PubMed  CAS  Google Scholar 

  1471. Wiedmer T, Sims PJ (1985) Effect of complement proteins C5b-9 on blood platelets. Evidence for reversible depolarisation of membrane potential. J Biol Chem 260:8014–8019

    PubMed  CAS  Google Scholar 

  1472. Wilson LA, Spitznagel JK (1971) Characteristics of complement dependent release of phospholipid from E. coli. Infect Immun 7:23–28

    Google Scholar 

  1473. Wobschall D, McKean C (1975) Step conductance increases in bilayer membranes induced by antibody-antigen-complement action. Biochim Biophys Acta 413:317–321

    PubMed  Google Scholar 

  1474. Yamamoto K (1977) Lytic activity of C5–9 complexes for erythrocytes from species other than sheep: C9 rather than the C8-dependent lytic activity. J Immunol 119:1482–1485

    PubMed  CAS  Google Scholar 

  1475. Yamamoto K, Gewurz H (1978) The complex of C5b and C6: isolation, characterization and identification of a modified form of C5b consisting in three polypeptide chains. J Immunol 120:2008–2015

    PubMed  CAS  Google Scholar 

  1476. Yamamoto K, Migita S (1982) Evidence for polymeric assembly of C9 within the membrane attack complex of complement. J Immunol 129:2335–2336

    PubMed  CAS  Google Scholar 

  1477. Yamamoto K, Lint T, Gewurz H (1977) Enhancement of #-initiated lysis by cell-bound C3 fragments: evidence for a mechanism independent of the prior binding of # to C3b. J Immunol 119:1346–1350

    PubMed  CAS  Google Scholar 

  1478. Yamamoto K, Kawashina T, Migita S (1982) Glutathione catalized disulfide linking of C9 in the membrane attack complex of complement. J Biol Chem 257:8573–8576

    PubMed  CAS  Google Scholar 

  1479. Zachariou Z, Reichel M, Seitz M, Hänsch GM, Rauterberg EW (1986) Spontaneous and complement membrane attack (MAC) induced release of prostanoids from Kupffer- and liver endothelial cells. In: Knook DI, Wisse E (eds) Proceedings of the 3rd International Kupffer cell Symposium. Elsevier, Amsterdam

    Google Scholar 

  1480. Zalman LS, Wood LM, Müller-Eberhard HJ (1986) Purification of a homologous restriction protein from human erythrocyte membranes. Fed Proc 45 (4):4136 (Abstract)

    Google Scholar 

  1481. Arroyave CM, Müller-Eberhard HJ (1973) Interactions between human C5, C6, and C1 and their functional significance in complement-dependent cytolysis. J Immunol 111:536

    PubMed  CAS  Google Scholar 

  1482. Baker PJ, Rubin LG, Lint TF, McLeod BC, Gewurz H (1975) Binding of the complement intermediate # to zymosan in acute phase human sera. Clin Exp Immunol 20:113

    PubMed  CAS  Google Scholar 

  1483. Balkarowa-Ständer J, Rother U, Rauterberg EW (1981) The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. A morphometric study. J Immunol 127:1089

    PubMed  Google Scholar 

  1484. Brauch H, Roelcke D, Rother U (1983) Glycophorin A inhibits lysis by the complement attack phase. Immunobiol 165:115

    CAS  Google Scholar 

  1485. Dessauer A, Rother U, Rother K (1984) Freeze-thaw activation of the complement attack phase. I. Separation of two steps in the formation of the active # complex. II. Comparison of convertase generated # with # generated by freezing and thawing. Acta Pathol Microbiol Immunol Scand [C] Suppl. 284, 92:75

    Google Scholar 

  1486. Götze O, Müller-Eberhard HJ (1970) Lysis of erythrocytes by complement in the absence of antibody. J Exp Med 132:898

    PubMed  Google Scholar 

  1487. Ham TH, Dingle IH (1939) Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria. Certain immunological aspects of the hemolytic mechanism with special reference to complement. J Clin Invest 18:657

    PubMed  CAS  Google Scholar 

  1488. Hammer CH, Hänsch GM, Gresham HD, Shin ML (1983) Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a. J Immunol 131:892

    PubMed  CAS  Google Scholar 

  1489. Hänsch MG, Rother U, Rother K (1977) Deviated lysis: transfer of complement lytic activity to unsensitized cells. IV. Partial isolation of the activity. Z Immun-Forsch 153:48

    Google Scholar 

  1490. Hänsch GM, Hammer C, Rother U, Shin ML (1980) Studies on activation of C5 and C6 by C5 convertase or low pH. Fed Proc 39:700

    Google Scholar 

  1491. Hänsch GM, Hammer CH, Vanguri P, Shin ML (1981) Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci US-Biol Sci 78:5118

    Google Scholar 

  1492. Hänsch GM, Hammer CH, Jiji R, Rother U, Shin ML (1983) Lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by acid-activated serum. Immunobiology 164:118

    PubMed  Google Scholar 

  1493. Kolb WP, Haxby JA, Arroyave CM, Müller-Eberhard HJ (1972) Molecular analysis of the membrane attack mechanism of complement. J Exp Med 135:549

    PubMed  CAS  Google Scholar 

  1494. Kolb WP, Haxby JA, Arroyave CM, Müller-Eberhard HJ (1973) The membrane attack mechanism of complement. Reversible interactions among the five native components in free solution. J Exp Med 138:428

    PubMed  CAS  Google Scholar 

  1495. Kolb WB, Kolb LM, Savary JR (1982) Biochemical characterization of the sixth component (C6) of human complement. Biochemistry 21:294

    PubMed  CAS  Google Scholar 

  1496. Lachmann PJ, Thompson RA (1970) Reactive lysis: the complement mediated lysis of unsensitized cells. II. The characterization of activated reactor as # and the participation of C8 and C9. J Exp Med 131:643

    PubMed  CAS  Google Scholar 

  1497. Moongkarndi P, Dessauer A, Brauch H, Hänsch GM, Rauterberg EW (1983) Immunological and functional properties of two monoclonal antibodies against human C5. Immunobiology 165:323 (Abstract)

    Google Scholar 

  1498. Okada H, Tanaka H, Okada N (1983) Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes. Eur J Immunol 13:340

    PubMed  CAS  Google Scholar 

  1499. Podack ER, Müller-Eberhard HJ (1978) Binding of DOC phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components. J Immunol 121:1025

    PubMed  CAS  Google Scholar 

  1500. Rother U, Hänsch GM, Menzel J, Rother K (1974) Deviated lysis: transfer of complement lytic activity to unsensitized cells. I. Generation of the transferable activity on the surface of complement resistant bacteria. Z Immun-Forsch 148:172

    CAS  Google Scholar 

  1501. Rother U. Hänsch GM, Rother K (1976) Deviated lysis: transfer of complement lytic activity to unsensitized cells. II. Generation of the activity by inulin and by antigen antibody complexes. Z Immun-Forsch 151:442

    CAS  Google Scholar 

  1502. Rother U, Hänsch GM, Rauterberg EW, Jungfer H, Rother K (1978) Deviated lysis: lysis of unsensitized cells by complement. V. Generation of the activity by low pH or low ionic strength. Z Immun-Forsch 155:118

    CAS  Google Scholar 

  1503. Schönermark S, Rauterberg EW, Shin ML, Löke S, Roelcke D, Hänsch GM (1986) Homologous species restriction in lysis of human erythrocytes: a membrane derived protein with C8-binding capacity functions as an inhibitor. J Immunol 136:1772

    PubMed  Google Scholar 

  1504. Thompson RA, Lachmann PJ (1970) Reactive lysis: the complement mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med 131:629

    PubMed  CAS  Google Scholar 

  1505. Thompson RA, Rowe DS (1968) Reactive haemolysis — a distinctive form of red cell lysis. Immunology 14:745

    PubMed  CAS  Google Scholar 

  1506. Wetsel RA, Kolb WP (1982) Complement-independent activation of the fifth component (C5) of human complement: limited trypsin digestion resulting in the expression of biologic activity. J Immunol 128:2209

    PubMed  CAS  Google Scholar 

  1507. Wetsel RA, Kolb WP (1983) Expression of Ca5-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments. J Exp Med 157:2029

    PubMed  CAS  Google Scholar 

  1508. Yachnin S, Ruthenberg JM (1965) The initiation and enhancement of human red cell lysis by activation of the first component of C and by first component esterase. Studies using normal red cells and red cells from patients with PNH. J Clin Invest 44:518

    PubMed  CAS  Google Scholar 

  1509. Yamamoto KJ, Gewurz H (1978) The complex of C5b and C6: isolation, characterization and identification of a modified form of C5b consisting of three polypeptide chains. J Immunol 120:2008

    PubMed  CAS  Google Scholar 

  1510. Acha-Orbea H, Groscurth P, Lang R, Stitz L, Hengartner H (1983) Characterization of cloned cytotoxic lymphocytes with NK-like activity. J Immunol 130:2952–2959

    PubMed  CAS  Google Scholar 

  1511. Adams DO, Kao KJ, Farb R, Pizzo SV (1980) Effector mechanisms of cytolytically activated macrophages. II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neutral proteases. J Immunol 124:293–300

    PubMed  CAS  Google Scholar 

  1512. van Agthoven A, Terhorst C, Reinherz E, Schlossman S (1981) Characterization of T cell surface glycoproteins T1 and T3 present on all human peripheral T lymphocytes and functionally mature thymocytes. Eur J Immunol 11:18–21

    PubMed  Google Scholar 

  1513. Allavena P, Ortaldo JR (1984) Characteristics of human NK clones: target specificity and phenotype. J Immunol 132:2363–2369

    PubMed  CAS  Google Scholar 

  1514. Andersson B, Skoglund AC, Rönnholm M, Lindsten T, Lamon EW, Collisson EW, Walia AS (1981) Functional aspects of IgM and IgG Fc receptors on murine T lymphocytes. Immunol Rev 56:5–50

    PubMed  CAS  Google Scholar 

  1515. Baines MG, Lafleur FL, Holbein BE (1983) Involvement of transferrin and transferrin receptors in human natural killer effector: target interaction. Immunol Lett 7:51–55

    PubMed  CAS  Google Scholar 

  1516. Ball EJ, Stastny P (1982) Cell-mediated cytotoxicity against HLA-D-region products expressed in monocytes and B lymphocytes. IV. Characterization of effector cells using monoclonal antibodies against human T-cell subsets. Immunogenetics 16:157–169

    PubMed  CAS  Google Scholar 

  1517. Beller DI, Springer TA, Schreiber RD (1982) Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med 156:1000–1009

    PubMed  CAS  Google Scholar 

  1518. Berke G, Clark WR (1982) T-lymphocyte-mediated cytolysis: a comprehensive theory. I. The mechanism of CTL-mediated cytolysis. Adv Exp Med Biol 146:57–68

    PubMed  CAS  Google Scholar 

  1519. Bevan MJ, Cohn M (1975) Cytotoxic effects of antigen- and mitogen-induced T cells on various targets. J Immunol 114:559–565

    PubMed  CAS  Google Scholar 

  1520. Biberfeld P, Perlmann P (1970) Morphological observations on the cytotoxicity of human blood lymphocytes for antibody-coated chicken erythrocytes. Exp Cell Res 62:433–440

    PubMed  CAS  Google Scholar 

  1521. Biddison WE, Rao PE, Talle MA, Goldstein G, Shaw S (1982) Possible involvement of the OKT4 molecule in T cell recognition of class II HLA antigens: evidence from studies of cytotoxic T lymphocytes specific for SB antigens. J Exp Med 156:1065–1076

    PubMed  CAS  Google Scholar 

  1522. Biddison WE, Rao PE, Talle MA, Goldstein G, Shaw S (1984) Possible involvement of the T4 molecule in T cell recognition of class II HLA antigens: evidence from studies of CTL-target cell binding. J Exp Med 159:783–797

    PubMed  CAS  Google Scholar 

  1523. Binz H, Fenner M, Frei D, Wigzell H (1983) Two independent receptors allow selective target lysis by T cell clones. J Exp Med 157:1252–1260

    PubMed  CAS  Google Scholar 

  1524. Blair PB, Lane MA, Mar P (1976) Antibody in the sera of tumor-bearing mice that mediates spleen cell cytotoxicity toward the autologous tumor. J Immunol 116:606–609

    PubMed  CAS  Google Scholar 

  1525. Blanca I, Herberman RB, Ortaldo JR (1985) Human natural killer cytotoxic factor. Studies on its production, specificity, and mechanism of interaction with target cells. Nat Immun Cell Growth Regul 4:48–59

    PubMed  CAS  Google Scholar 

  1526. Bloom ET, Babbitt JT (1983) Rapid kinetics of lysis in human natural cell-mediated cytotoxicity: some implications. Cell Immunol 79:197–206

    PubMed  CAS  Google Scholar 

  1527. Blumenthal R, Millard PJ, Henkart MP, Reynolds CW, Henkart PA (1984) Liposomes as targets for granule cytolysin from cytotoxic large granular lymphocyte tumors. Proc Natl Acad Sci USA 81:5551–5555

    PubMed  CAS  Google Scholar 

  1528. Bonavida B, Bradley T, Fan J, Hiserodt J, Effros R, Wexler H (1983) Molecular interactions in T-cell-mediated cytotoxicity. Immunol Rev 72:119–141

    PubMed  CAS  Google Scholar 

  1529. Bongrand P, Pierres M, Golstein P (1983) T cell-mediated cytolysis: on the strength of effector-target cell interaction. Eur J Immunol 13:424–429

    PubMed  CAS  Google Scholar 

  1530. Borst J, Alexander S, Elder J, Terhorst C (1983) The T3 complex on human T lymphocytes involves four structurally distinct glycoproteins. J Biol Chem 258:5135–5141

    PubMed  CAS  Google Scholar 

  1531. van Boxel JA, Paul WE, Green I, Frank MM (1974) Antibody-dependent lymphoid cell- mediated cytotoxicity: role of complement. J Immunol 112:398–403

    PubMed  Google Scholar 

  1532. Bradley TP, Bonavida B (1981) Mechanism of cell-mediated cytotoxicity at the single cell level. III. Evidence that cytotoxic T lymphocytes lyse both antigen-specific and -nonspecific targets pretreated with lectins or periodate. J Immunol 126:208–213

    PubMed  CAS  Google Scholar 

  1533. Bradley TP, Bonavida B (1982) Mechanism of cell-mediated cytotoxicity at the single cell level. IV. Natural killing and antibody-dependent cellular cytotoxicity can be mediated by the same human effector cell as determined by the two-target conjugate assay. J Immunol 129:2260–2265

    PubMed  CAS  Google Scholar 

  1534. Brooks CG, Urdal DL, Henney CS (1983) Lymphokine-driven “differentiation” of cytotoxic T-cell clones into cells with NK-like specificity: correlations with display of membrane macromolecules. Immunol Rev 72:43–72

    PubMed  CAS  Google Scholar 

  1535. Brunda MJ, Wiltrout RH, Holden HT, Varesio L (1983) Selective inhibition by monosaccharides of tumor cell cytotoxicity mediated by mouse macrophages, macrophage-like cell lines and natural killer cells. Int J Cancer 31:373–379

    PubMed  CAS  Google Scholar 

  1536. Bykovskaja SN, Rytenko AN, Rauschenbach MO, Bykovsky AF (1978 a) Ultrastructural alteration of cytolytic T lymphocytes following their interaction with target cells. I. Hypertrophy and change of orientation of the Golgi apparatus. Cell Immunol 40:164–174

    PubMed  CAS  Google Scholar 

  1537. Bykovskaja SN, Rytenko AN, Rauschenbach MO, Bykovsky AF (1978 b) Ultrastructural alteration of cytolytic T lymphocytes following their interaction with target cells. II. Morphogenesis of secretory granules and intracellular vacuoles. Cell Immunol 40:175–185

    PubMed  CAS  Google Scholar 

  1538. Callewaert DM, Johnson DF, Kearney J (1978) Spontaneous cytotoxicity of cultured human cell lines mediated by normal peripheral blood lymphocytes. III. Kinetic parameters. J Immunol 121:710–717

    PubMed  CAS  Google Scholar 

  1539. Callewaert DM, Kaplan J, Johnson DF, Peterson WD Jr (1979) Spontaneous cytotoxicity of cultured human cell lines mediated by normal peripheral blood lymphocytes. II. Specificity for target antigens. Cell Immunol 42:103–112

    PubMed  CAS  Google Scholar 

  1540. Carls C, Rauterberg EW, Hambeck R, Filsinger S, Reichel M (1982) Inhibition of antibody-dependent cellular cytotoxicity (ADCC) by a rat antiserum against cell membranes lysed by ADCC. Immunobiology 162:337–338

    Google Scholar 

  1541. Carls C, Piennisch G, Rauterberg EW (1987) A molecular transfer from the effector cell to the target cell membrane in the ADCC. Immunobiology (to be published)

    Google Scholar 

  1542. Carpen O, Virtanen I, Saksela E (1981) The cytotoxic activity of human natural killer cells requires an intact secretory apparatus. Cell Immunol 58:97–106

    PubMed  CAS  Google Scholar 

  1543. Carpen O, Virtanen I, Saksela E (1982) Ultrastructure of human natural killer cells: nature of the cytolytic contacts in relation to cellular secretion. J Immunol 128:2691–2697

    PubMed  CAS  Google Scholar 

  1544. Carpen O, Virtanen I, Lehto VP, Saksela E (1983) Polarization of NK cell cytoskeleton upon conjugation with sensitive target cells. J Immunol 131:2695–2698

    PubMed  CAS  Google Scholar 

  1545. Cerottini JC, Brunner KT (1974) Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol 18:67–132

    PubMed  CAS  Google Scholar 

  1546. Chang TW, Kung PC, Gingras SP, Goldstein G (1981) Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells? Proc Natl Acad Sci USA 78:1805–1808

    PubMed  CAS  Google Scholar 

  1547. Christiaansen JE, Sears DW (1985) Lack of lymphocyte-induced DNA fragmentation in human targets during lysis represents a species-specific difference between human and murine cells. Proc Natl Acad Sci USA 82:4482–4485

    PubMed  CAS  Google Scholar 

  1548. Clark WR, Berke G (1982) T lymphocyte-mediated cytolysis: a comprehensive theory. II. Lytic vs. nonlytic interactions of T lymphocytes. Adv Exp Med Biol 146:69–74

    PubMed  CAS  Google Scholar 

  1549. Criado M, Lindstrom JM, Anderson CG, Dennert G (1985) Cytotoxic granules from killer cells: specificity of granules and insertion of channels of defined size into target membranes. J Immunol 135:4245–4251

    PubMed  CAS  Google Scholar 

  1550. Dennert G, Lennox ES (1973) Phagocytic cells as effectors in a cell-mediated immunity system. J Immunol 111:1844–1854

    PubMed  CAS  Google Scholar 

  1551. Dennert G, Podack ER (1983) Cytolysis by H-2-specifle T killer cells: assembly of tubular complexes on target membranes. J Exp Med 157:1483–1495

    PubMed  CAS  Google Scholar 

  1552. Dialynas DP, Wilde DB, Marrack P, Pierres A, Wall KA, Havran W, Otten G, Loken MR, Pierres M, Kappler J, Fitch FW (1983) Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev 74:29–56

    PubMed  CAS  Google Scholar 

  1553. DiScipio RG, Gehring MR, Podack ER, Kan CC, Hugli TE, Fey GH (1984) Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9. Proc Natl Acad Sci USA 81:7298–7302

    PubMed  CAS  Google Scholar 

  1554. Dokhélar MC, Garson D, Testa U, Tursz T (1984) Target structure for natural killer cells: evidence against a unique role for transferrin receptor. Eur J Immunol 14:340–344

    PubMed  Google Scholar 

  1555. Dourmashkin RR, Deteix P, Simone CB, Henkart P (1980) Electron microscopic demonstration of lesions in target cell membranes associated with antibody-dependent cellular cytotoxicity. Clin Exp Immunol 42:554–560

    PubMed  CAS  Google Scholar 

  1556. Duke RC, Chervenak R, Cohen JJ (1983) Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis. Proc Natl Acad Sci USA 80:6361–6365

    PubMed  CAS  Google Scholar 

  1557. Duwe AK, Werkmeister J, Roder JC, Lauzon R, Payne U (1985) Natural killer cell-mediated lysis involves an hydroxyl radical-dependent step. J Immunol 134:2637–2644

    PubMed  CAS  Google Scholar 

  1558. Erdei A, Benczur M, Fábry Z, Dierich MP, Gergely J (1984) C3 cleaved by membrane proteases binds to C3b acceptors expressed on concanavalin A-stimulated human lymphocytes and enhances antibody-dependent cellular cytotoxicity. Scand J Immunol 20:125–131

    PubMed  CAS  Google Scholar 

  1559. Evans RL, Wall DW, Platsoucas CD, Siegal FP, Fikrig SM, Testa CM, Good RA (1981) Thymus-dependent membrane antigens in man: inhibition of cell-mediated lympholysis by monoclonal antibodies to TH2 antigen. Proc Natl Acad Sci USA 78:544–548

    PubMed  CAS  Google Scholar 

  1560. Fishelson Z, Berke G (1978) T-lymphocyte mediated cytolysis: dissociation of the binding and lytic mechanisms of the effector cell. J Immunol 120:1121–1126

    PubMed  CAS  Google Scholar 

  1561. Fuson EW, Lamon EW (1977) IgM-induced cell-mediated cytotoxicity with antibody and effector cells of human origin. J Immunol 118:1907–1909

    PubMed  CAS  Google Scholar 

  1562. Fuson EW, Walia AS, Cox BA, Lamon EW (1979) Antibody-dependent cell-mediated cytotoxicity in the moloney sarcoma virus system: no requirement for exogenous C5. Clin Immunol Immunopathol 14:35–46

    PubMed  CAS  Google Scholar 

  1563. Geiger B, Rosen D, Berke G (1982) Spatial relationships of microtubule-organizing centers and the contact area of cytotoxic T lymphocytes and target cells. J Cell Biol 95:137–143

    PubMed  CAS  Google Scholar 

  1564. Ghebrehiwet B, Müller-Eberhard HJ (1978) Lysis of C1q-coated chicken erythrocytes by human lymphoblastoid cell lines. J Immunol 120:27–32

    PubMed  CAS  Google Scholar 

  1565. Ghebrehiwet B, Medicus RG, Müller-Eberhard HJ (1979) Potentiation of antibody-dependent cell-mediated cytotoxicity by target cell-bound C3b. J Immunol 123:1285–1288

    PubMed  CAS  Google Scholar 

  1566. Götze O, Bianco C, Cohn ZA (1979) The induction of macrophage spreading by factor B of the properdin system. J Exp Med 149:372–386

    PubMed  Google Scholar 

  1567. Golstein P (1982) Sequential analysis of T cell-mediated cytolysis: a brief reminder of some possibly informative markers at the recognition and lethal hit stages. Adv Exp Med Biol 146:111–119

    PubMed  CAS  Google Scholar 

  1568. Golstein P, Smith ET (1976) The lethal hit stage of mouse T and non-T cell-mediated cytolysis: differences in cation requirements and characterization of an analytical “cation pulse” method. Eur J Immunol 6:31–37

    PubMed  CAS  Google Scholar 

  1569. Golstein P, Goridis C, Schmitt-Verhulst AM, Hayot B, Pierres A, van Agthoven A, Kaufmann Y, Eshhar Z, Pierres M (1982) Lymphoid cell surface interaction structures detected using cytolysis-inhibiting monoclonal antibodies. Immunol Rev 68:5–42

    PubMed  CAS  Google Scholar 

  1570. Green WR (1982) Studies on the mechanism of lectin-dependent T cell-mediated cytolysis: use of lens culinaris hemagglutinin A to define the role of lectin. Adv Exp Med Biol 146:81–100

    PubMed  CAS  Google Scholar 

  1571. Greenberg AH, Shen L (1973) A class of specific cytotoxic cells demonstrated in vitro by arming with antigen-antibody complexes. Nat New Biol 245:282–285

    PubMed  CAS  Google Scholar 

  1572. van de Griend RJ, Ten Berge I, Tanke HJ, Roos D, Schellekens PTA, Melief CJM, Zeijlemaker WP, Astaldi A (1982) Characterization of two subsets of human Tγ cells. J Immunol 128:1979–1985

    PubMed  Google Scholar 

  1573. Grimm E, Bonavida B (1979) Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. J Immunol 123:2861–2869

    PubMed  CAS  Google Scholar 

  1574. Gromkowski SH, Heagy W, Martz E (1985) Blocking of CTL-mediated killing by monoclonal antibodies to LFA-1 and Lyt-2,3. II. Evidence that trypsin pretreatment of target cells removes a non-H-2 molecule important in killing. J Immunol 134:70–77

    PubMed  CAS  Google Scholar 

  1575. Gromkowski SH, Brown TC, Cerutti PA, Cerottini JC (1986) DNA of human Raji target cells is damaged upon lymphocyte-mediated lysis. J Immunol 136:752–756

    PubMed  CAS  Google Scholar 

  1576. Hall RE, Blaese RM, Davis III AE, Decker JM, Tack BF, Colten HR, Muchmore AV (1982) Cooperative interaction of factor B and other complement components with mononuclear cells in the antibody-independent lysis of xenogeneic erythrocytes. J Exp Med 156:834–843

    PubMed  CAS  Google Scholar 

  1577. Hall RE, Schall RP, Black LA (1985) A monoclonal antibody (RH1–38) which inhibits multiple systems of cell-mediated cytotoxicity. II. Evidence that the epitope recognized is involved in a late step in the cytolytic mechanism. Mol Immunol 22:765–773

    PubMed  CAS  Google Scholar 

  1578. Hall TJ, Brostoff J (1985) Lack of effect of LTB4 on human natural killer cell activity and T lymphocyte transformation. Immunol Lett 9:255–258

    PubMed  CAS  Google Scholar 

  1579. Hattori T, Hirata F, Hoffman T, Hizuta A, Herberman RB (1983) Inhibition of human natural killer (NK) activity and antibody-dependent cellular cytotoxicity (ADCC) by lipomodulin, a phospholipase inhibitory protein. J Immunol 131:662–665

    PubMed  CAS  Google Scholar 

  1580. Henkart MP, Henkart PA (1982) Lymphocyte-mediated cytolysis as a secretory phenomen. Adv Exp Med Biol 146:227–242

    PubMed  CAS  Google Scholar 

  1581. Henkart MP, Timonen T, Millard PJ, Henkart PA (1982) Role of lymphocyte cytoplasmic granules in ADCC and NK killing. Fed Proc 41:475 (Abstract)

    Google Scholar 

  1582. Henkart PA (1985) Mechanism of lymphocyte-mediated cytotoxicity. Ann Rev Immunol 3:31–58

    CAS  Google Scholar 

  1583. Henkart PA, Blumenthal R (1975) Interaction of lymphocytes with lipid bilayer membranes: a model for lymphocyte-mediated lysis of target cells. Proc Natl Acad Sci USA 72:2789–2793

    PubMed  CAS  Google Scholar 

  1584. Henkart PA, Millard PJ, Reynolds CW, Henkart MP (1984) Cytolytic activity of purified cytoplasmic granules from cytotoxic rat large granular lymphocyte tumors. J Exp Med 160:75–93

    PubMed  CAS  Google Scholar 

  1585. Henney CS (1973) On the mechanism of T-cell mediated cytolysis. Transplant Rev 17:37–70

    PubMed  CAS  Google Scholar 

  1586. Henney CS, Bubbers JE (1973) Studies on the mechanism of lymphocyte-mediated cytolysis. I. The role of divalent cations in cytolysis by T lymphocytes. J Immunol 110:63–72

    PubMed  CAS  Google Scholar 

  1587. Henney CS, Mayer MM (1971) Specific cytolytic activity of lymphocytes: effect of antibodies against complement components C2, C3 and C5. Cell Immunol 2:702–705

    PubMed  CAS  Google Scholar 

  1588. Herberman RB, Reynolds CW, Ortaldo JR (1986) Mechanism of cytotoxicity by natural killer (NK) cells. Ann Rev Immunol 4:651–680

    CAS  Google Scholar 

  1589. Hercend T, Reinherz EL, Meuer S, Schlossman SF, Ritz J (1983) Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature 301:158–160

    PubMed  CAS  Google Scholar 

  1590. Hiserodt JC (1985) Studies on the cytolytic attack mechanism of the cytotoxic T lymphocyte (CTL): preparation of antisera against cellfree cytosolic extracts of a CTL clone capable of blocking the lethal hit stage of CTL cytolysis and analysis of the cytolytic structure. J Immunol 135:53–62

    PubMed  CAS  Google Scholar 

  1591. Hiserodt JC, Bonavida B (1981) Studies on the induction and expression of T cell-mediated immunity. XI. Inhibition of the “lethal hit” in T cell-mediated cytotoxicity by heterologous rat antiserum made against alloimmune cytotoxic T lymphocytes. J Immunol 126:256–262

    PubMed  CAS  Google Scholar 

  1592. Hiserodt JC, Britvan LJ, Targan SR (1982) Inhibition of human natural killing by heterologous and monoclonal antibodies. J Immunol 129:2248–2254

    PubMed  CAS  Google Scholar 

  1593. Hoffmann T, Hirata F, Bougnoux P, Fraser BA, Goldfarb RH, Herberman RB, Axelrod J (1981) Phospholipid méthylation and phospholipase A2 activation in cytotoxcity by human natural killer cells. Proc Natl Acad Sci USA 78:3839–3843

    Google Scholar 

  1594. Hong K, Kinoshita T, Miyazaki W, Izawa T, Inoue K (1979) An anticomplementary agent, K-76 monocarboxylic acid: its site and mechanism of inhibition of the complement activation cascade. J Immunol 122:2418–2423

    PubMed  CAS  Google Scholar 

  1595. Hong K, Kinoshita T, Kitajima H, Inoue K (1981) Inhibitory effect of K-76 monocarboxylic acid, an anticomplementary agent, on the C3b inactivator system. J Immunol 127:104–108

    PubMed  CAS  Google Scholar 

  1596. Hudig D, Redelman D, Minning L, Carine K (1984 a) Inhibition of human lymphocyte natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity by K-76 COONa, a reagent that blocks complement activity. J Immunol 133:408–414

    PubMed  CAS  Google Scholar 

  1597. Hudig D, Redelman D, Minning LL (1984b) The requirement for proteinase activity for human lymphocyte-mediated natural cytotoxicity (NK): evidence that the proteinase is serine dependent and has aromatic amino acid specificity of cleavage. J Immunol 133:2647–2654

    PubMed  CAS  Google Scholar 

  1598. Humphrey JH, Dourmashkin RR (1963) Discussion on mechanisms of blood cell damage produced by immunological reactions. In: Grabar P, Miescher P (eds) Proceedings of the third international symposium on immunopathology. Schwabe & Co, Basel, Switzerland, p 369

    Google Scholar 

  1599. Imir T, Saksela E, Mäkelä O (1976) Two types of antibody dependent cell-mediated cytotoxicity, arming and sensitization. J Immunol 117:1938–1942

    PubMed  CAS  Google Scholar 

  1600. Kahle R, Hiserodt J, Bonavida B (1983) Characterization of antibody-mediated inhibition of natural killer (NK) cytotoxicity: evidence for blocking of both recognition and lethal hit stages of cytolysis. Cell Immunol 80:97–104

    PubMed  CAS  Google Scholar 

  1601. Kanellopoulos JM, Wigglesworth NM, Owen MJ, Crumpton MJ (1983) Biosynthesis and molecular nature of the T3 antigen of human T lymphocytes. EMBO J 2:1807–1814

    PubMed  CAS  Google Scholar 

  1602. Karpovsky B, Titus JA, Stephany DA, Segal DM (1984) Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fcγ-receptor antibodies. J Exp Med 160:1686–1701

    PubMed  CAS  Google Scholar 

  1603. Katz P, Simone CB, Henkart PA, Fauci AS (1980) Mechanisms of antibody-dependent cellular cytotoxicity. The use of effector cells from chronic granulomatous disease patients as investigative probes. J Clin Invest 65:55–63

    PubMed  CAS  Google Scholar 

  1604. Katz P, Roder JC, Zaytoun AM, Herberman RB, Fauci AS (1982 a) Mechanisms of human cell-mediated cytotoxicity. II. Correction of the selective defect in natural killing in the Chédiak-Higashi syndrome with inducers of intracellular cyclic GMP. J Immunol 129:297–302

    PubMed  CAS  Google Scholar 

  1605. Katz P, Zaytoun AM, Lee Jr JH (1982 b) Mechanisms of human cell-mediated cytotoxicity. III. Dependence of natural killing on microtubule and microfilament integrity. J Immunol 129:2816–2825

    PubMed  CAS  Google Scholar 

  1606. Kay HD, Horwitz DA (1980) Evidence by reactivity with hybridoma antibodies for a probable myeloid origin of peripheral blood cells active in natural cytotoxicity and antibody- dependent cell-mediated cytotoxicity. J Clin Invest 66:847–851

    PubMed  CAS  Google Scholar 

  1607. Kay HD, Smith DL, Sullivan G, Mandell GL, Donowitz GR (1983) Evidence for a nonoxidative mechanism of human natural killer (NK) cell cytotoxicity by using mononuclear effector cells from healthy donors and from patients with chronic granulomatous disease. J Immunol 131:1784–1788

    PubMed  CAS  Google Scholar 

  1608. Kedar E, Ikejiri BL, Sredni B, Bonavida B, Herberman RB (1982) Propagation of mouse cytotoxic clones with characteristics of natural killer (NK) cells. Cell Immunol 69:305–329

    PubMed  CAS  Google Scholar 

  1609. Klein M, Roder J, Haliotis T, Korec S, Jett JR, Herberman RB, Katz P, Fauci AS (1980) Chédiak-Higashi gene in humans. II. The selectivity of the defect in natural-killer and antibody-dependent cell-mediated cytotoxicity function. J Exp Med 151:1049–1058

    PubMed  CAS  Google Scholar 

  1610. Krensky AM, Reiss CS, Mier JW, Strominger JL, Burakoff SJ (1982 a) Long-term human cytolytic T-cell lines allospeciflc for HLA-DR6 antigen are OKT4 + . Proc Natl Acad Sci USA 79:2365–2369

    PubMed  CAS  Google Scholar 

  1611. Krensky AM, Clayberger C, Reiss CS, Strominger JL, Burakoff SJ (1982 b) Specificity of OKT4+ cytotoxic T lymphocyte clones. J Immunol 129:2001–2003

    PubMed  CAS  Google Scholar 

  1612. Krensky AM, Sanchez-Madrid F, Robbins E, Nagy JA, Springer TA, Burakoff SJ (1983) The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J Immunol 131:611–616

    PubMed  CAS  Google Scholar 

  1613. Krensky AM, Robbins E, Springer TA, Burakoff SJ (1984) LFA-1, LFA-2 and LFA-3 antigens are involved in CTL-target conjugation. J Immunol 132:2180–2182

    PubMed  CAS  Google Scholar 

  1614. Kronenberg M, Siu G, Hood LE, Shastri N (1986) The molecular genetics of the T-cell antigen receptor and T-cell antigen recognition. Ann Rev Immunol 4:529–591

    CAS  Google Scholar 

  1615. Kürzinger K, Ho MK, Springer TA (1982) Structural homology of a macrophage differentiation antigen and an antigen involved in T-cell-mediated killing. Nature 296:668–670

    PubMed  Google Scholar 

  1616. Kung PC, Goldstein G, Reinherz EL, Schlossman SF (1979) Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206:347–349

    PubMed  CAS  Google Scholar 

  1617. Kupfer A, Dennert G (1984) Reorientation of the microtubule-organizing center and the Golgi apparatus in cloned cytotoxic lymphocytes triggered by binding to lysable target cells. J Immunol 133:2762–2766

    PubMed  CAS  Google Scholar 

  1618. Kupfer A, Singer SJ, Dennert G (1986) On the mechanism of unidirectional killing in mixtures of two cytotoxic T lymphocytes: unidirectional polarization of cytoplasmic organelles and the membrane-associated cytoskeleton in the effector cell. J Exp Med 163:489–498

    PubMed  CAS  Google Scholar 

  1619. Küppers RC, Henney CS (1976) Evidence for direct linkage between antigen recognition and lytic expression in effector T cells. J Exp Med 143:684–689

    PubMed  Google Scholar 

  1620. Küppers RC, Henney CS (1977) Studies on the mechanism of lymphocyte-mediated cytolysis. IX. Relationship between antigen recognition and lytic expression in killer T cells. J Immunol 118:71–76

    PubMed  Google Scholar 

  1621. Lachmann PJ (1979) An evolutionary view of the complement system. Behring Inst Mitt 63:25–37

    CAS  Google Scholar 

  1622. Lachmann PJ, Hobart MJ, Woo P (1978) Combined genetic deficiency of C6 and C1 in man. Clin Exp Immunol 33:193–203

    PubMed  CAS  Google Scholar 

  1623. Lamon EW, Skurzak HM, Andersson B, Whitten HD, Klein E (1975) Antibody-dependent lymphocyte cytotoxicity in the murine sarcoma virus system: activity of IgM and IgG with specificity for MLV determined antigen(s). J Immunol 114:1171–1176

    PubMed  CAS  Google Scholar 

  1624. Lamon EW, Williams BR, Fuson EW, Whitten HD, Walia AS (1978) Murine T cells that lyse antibody-sensitized target cells. I. Kinetics and dose-response studies of control and cortisone-resistant thymocytes. J Immunol 120:244–248

    PubMed  CAS  Google Scholar 

  1625. Landegren U, Ramstedt U, Axberg I, Ullberg M, Jondal M, Wigzell H (1982) Selective inhibition of human T cell cytotoxicity at levels of target recognition or initiation of lysis by monoclonal OKT3 and Leu-2a antibodies. J Exp Med 155:1579–1584

    PubMed  CAS  Google Scholar 

  1626. Leeuwenberg JFM, Spits H, Tax WJM, Capel PJA (1985) Induction of nonspecific cytotoxicity by monoclonal anti-T3 antibodies. J Immunol 134:3770–3775

    PubMed  CAS  Google Scholar 

  1627. Lustig HJ, Bianco C (1976) Antibody-mediated cell cytotoxicity in a defined system: regulation by antigen, antibody, and complement. J Immunol 116:253–258

    PubMed  CAS  Google Scholar 

  1628. MacDermott P, Kienker LJ, Bertovich MJ, Muchmore AV (1981) Inhibition of spontaneous but not antibody-dependent cell-mediated cytotoxicity by simple sugars: evidence that endogenous lectins may mediate spontaneous cell-mediated cytotoxicity. Immunology 44:143–152

    PubMed  CAS  Google Scholar 

  1629. Marone G, Hammarström S, Lichtenstein LM (1980) An inhibitor of lipoxygenase inhibits histamine release from human basophils. Clin Immunol Immunopathol 17:117–122

    PubMed  CAS  Google Scholar 

  1630. Martz E (1976) Multiple target cell killing by the cytolytic T lymphocyte and the mechanism of cytotoxicity. Transplantation 21:5–11

    PubMed  CAS  Google Scholar 

  1631. Martz E (1977) Mechanism of specific tumor-cell lysis by alloimmune T lymphocytes: resolution and characterization of discrete steps in the cellular interaction. Contemp Top Immunobiol 7:301–361

    PubMed  CAS  Google Scholar 

  1632. Martz E, Parker WL, Gately MK, Tsoukas CD (1982) The role of calcium in the lethal hit of T lymphocyte-mediated cytolysis. Adv Exp Med Biol 146:121–147

    PubMed  CAS  Google Scholar 

  1633. Martz E, Heagy W, Gromkowski SH (1983) The mechanism of CTL-mediated killing: monoclonal antibody analysis of the roles of killer and target-cell membrane proteins. Immunol Rev 72:73–96

    PubMed  CAS  Google Scholar 

  1634. Masson D, Tschopp J (1985) Isolation of a lytic, pore-forming protein (Perforin) from cytolytic T-lymphocytes. J Biol Chem 260:9069–9072

    PubMed  CAS  Google Scholar 

  1635. Mayer MM (1977) Mechanism of cytolysis by lymphocytes: a comparison with complement. J Immunol 119:1195–1203

    PubMed  CAS  Google Scholar 

  1636. Mayer MM, Hammer CH, Michaels DW, Shin ML (1979) Immunologically mediated membrane damage: the mechanism of complement action and the similarity of lymphocyte- mediated cytotoxicity. Immunochem 15:813–831

    Google Scholar 

  1637. Mayer MM, Michaels DW, Ramm LE, Shin ML, Whitlow MB, Willoughby JB (1981) Membrane damage by complement. CRC Crit Rev Immunol 2:133–165

    CAS  Google Scholar 

  1638. Meuer SC, Hussey RE, Hodgdon JC, Hercend T, Schlossman SF, Reinherz EL (1982) Surface structures involved in target recognition by human cytotoxic T lymphocytes. Science 218:471–473

    PubMed  CAS  Google Scholar 

  1639. Meuer SC, Cooper DA, Hodgdon JC, Hussey RE, Fitzgerald KA, Schlossman SF, Reinherz EL (1983) Identification of the receptor for antigen and major histocompatibility complex on human inducer T lymphocytes. Science 222:1239–1242

    PubMed  CAS  Google Scholar 

  1640. Meuer SC, Acuto O, Hercend T, Schlossman SF, Reinherz EL (1984) The human T-cell receptor. Ann Rev Immunol 2:23–50

    CAS  Google Scholar 

  1641. Millard PJ, Henkart MP, Reynolds CW, Henkart PA (1984) Purification and properties of cytoplasmic granules from cytotoxic rat LGL tumors. J Immunol 132:3197–3204

    PubMed  CAS  Google Scholar 

  1642. Möller E (1965) Contact-induced cytotoxicity by lymphoid cells containing foreign isoantigens. Science 147:873–879

    Google Scholar 

  1643. Möller G, Svehag SE (1972) Specificity of lymphocyte-mediated cytotoxicity induced by in vitro antibody-coated target cells. Cell Immunol 4:1–19

    PubMed  Google Scholar 

  1644. Moretta A, Pantaleo G, Mingari MC, Moretta L, Cerottini JC (1984) Clonal heterogeneity in the requirement for T3, T4 and T8 molecules in human cytolytic T lymphocyte function. J Exp Med 159:921–934

    PubMed  CAS  Google Scholar 

  1645. Muchmore AV, Decker JM, Blaese RM (1979 a) Synergistic cytotoxicity. I. Characterization of a heat labile plasma fraction that induces nonspecific cytotoxicity by human mononuclear cells. J Immunol 122:1146–1151

    PubMed  CAS  Google Scholar 

  1646. Muchmore AV, Decker JM, Blaese RM (1979 b) Synergistic cytotoxicity. II. In vitro arming of monocytes and T cells by a heat labile fraction of human plasma. J Immunol 122:1152–1155

    PubMed  CAS  Google Scholar 

  1647. Nathan CF, Silverstein SC, Brukner LH, Cohn ZA (1979) Extracellular cytolysis by activated macrophages and granulocytes. II. Hydrogen peroxide as a mediator of cytotoxicity. J Exp Med 149:100–113

    PubMed  CAS  Google Scholar 

  1648. Nathan CF, Mercer-Smith JA, Desantis NM, Palladino MA (1982) Role of oxygen in T cell-mediated cytolysis. J Immunol 129:2164–2171

    PubMed  CAS  Google Scholar 

  1649. Neighbour PA, Huberman HS (1982) Sr2+-induced inhibition of human natural killer (NK) cell-mediated cytotoxicity. J Immunol 128:1236–1240

    PubMed  CAS  Google Scholar 

  1650. Neighbour PA, Huberman HS, Kress Y (1982) Human large granular lymphocytes and natural killing: ultrastructural studies of strontium-induced degranulation. Eur J Immunol 12:588–595

    PubMed  CAS  Google Scholar 

  1651. Neville ME, Hiserodt JC (1982) Inhibition of human antibody-dependent cellular cytotoxicity, cell-mediated cytotoxicity, and natural killing by a xenogeneic antiserum prepared against “activated” alloimmune human lymphocytes. J Immunol 128:1246–1251

    PubMed  CAS  Google Scholar 

  1652. Nicolas G, Zagury D (1980) Etude par cryofracture de la zone de contact entre cellule cytolytique et cellule cible. Biol Cellulaire 37:231–234

    Google Scholar 

  1653. Old LJ (1985) Tumor necrosis factor (TNF). Science 230:630–632

    PubMed  CAS  Google Scholar 

  1654. Oldham RK, Herberman RB (1973) Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigens with 125I-Iododeoxyuridine labeled target cells. J Immunol 111:1862–1871

    CAS  Google Scholar 

  1655. Oldham RK, Siwarski D, McCoy JL, Plata EJ, Herberman RB (1973) Evaluation of a cell- mediated cytotoxicity assay utilizing 125I-Iododeoxyuridine-labeled tissue-culture target cells. Natl Cancer Inst Monogr 37:49–58

    PubMed  CAS  Google Scholar 

  1656. Ortaldo JR, Herberman RB (1984) Heterogeneity of natural killer cells. Ann Rev Immunol 2:359–394

    CAS  Google Scholar 

  1657. Ortaldo JR, Oldham RK, Cannon GC, Herberman RB (1977) Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukaemia cell line. J Natl Cancer Inst 59:77–82

    PubMed  CAS  Google Scholar 

  1658. Ortaldo JR, Timonen TT, Herberman RB (1984) Inhibition of activity of human NK and K cells by simple sugars: discrimination between binding and postbinding events. Clin Immunol Immunopathol 31:439–443

    PubMed  CAS  Google Scholar 

  1659. Pedersen B, Norrild B, Krebs HJ (1982) The effect of monensin on the antibody-dependent cell-mediated killing. Cell Immunol 72:208–214

    PubMed  CAS  Google Scholar 

  1660. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV (1984) Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312:724–729

    PubMed  CAS  Google Scholar 

  1661. Perelson AS, Bell GI (1982) Delivery of lethal hits by cytotoxic T lymphocytes in multicellular conjugates occurs sequentially but at random times. J Immunol 129:2796–2801

    PubMed  CAS  Google Scholar 

  1662. Perelson AS, Macken CA, Grimm EA, Roos LS, Bonavida B (1984) Mechanism of cell- mediated cytotoxicity at the single cell level. VIII. Kinetics of lysis of target cells bound by more than one cytotoxic T lymphocyte. J Immunol 132:2190–2198

    PubMed  CAS  Google Scholar 

  1663. Perlmann H, Perlmann P, Schreiber RD, Müller-Eberhard HJ (1981 a) Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors: enhancement of antibody-mediated cellular cytotoxicity. J Exp Med 153:1592–1603

    PubMed  CAS  Google Scholar 

  1664. Perlmann H, Perlmann P, Moretta L, Rönnholm M (1981 b) Regulation of IgG antibody- dependent cellular cytotoxicity in vitro by IgM antibodies: mechanism and characterization of effector lymphocytes. Scand J Immunol 14:47–60

    PubMed  CAS  Google Scholar 

  1665. Perlmann P, Perlmann H (1970) Contactual lysis of antibody-coated chicken erythrocytes by purified lymphocytes. Cell Immunol 1:300–315

    PubMed  CAS  Google Scholar 

  1666. Perlmann P, Perlmann H, Wigzell H (1972) Lymphocyte mediated cytotoxicity in vitro: induction and inhibition by humoral antibody and nature of effector cells. Transplant Rev 13:91–114

    PubMed  CAS  Google Scholar 

  1667. Perlmann P, Perlmann H, Müller-Eberhard HJ (1975 a) Cytolytic lymphocytic cells with complement receptor in human blood: induction of cytolysis by IgG antibody but not by target cell-bound C3. J Exp Med 141:287–296

    PubMed  CAS  Google Scholar 

  1668. Perlmann P, Perlmann H, Larsson Å, Wâhlin B (1975 b) Antibody dependent cytolytic effector lymphocytes (K cells) in human blood. J Reticuloendothel Soc 17:241–250

    PubMed  CAS  Google Scholar 

  1669. Peters SP, Siegel MI, Kagey-Sobotka A, Lichtenstein LM (1981) Lipoxygenase products modulate histamine release in human basophils. Nature 292:455–457

    PubMed  CAS  Google Scholar 

  1670. Platsoucas CD, Good RA (1981) Inhibition of specific cell-mediated cytotoxicity by monoclonal antibodies to human T cell antigens. Proc Natl Acad Sci USA 78:4500–4504

    PubMed  CAS  Google Scholar 

  1671. Podack ER, Dennert G (1983) Assembly of two types of tubules with putative cytolytic function by cloned natural killer cells. Nature 302:442–445

    PubMed  CAS  Google Scholar 

  1672. Podack ER, Königsberg PJ (1984) Cytolytic T cell granules: isolation, structural, biochemical, and functional characterization. J Exp Med 160:695–710

    PubMed  CAS  Google Scholar 

  1673. Podack ER, Tschopp J, Müller-Eberhard HJ (1982) Molecular organization of C9 within the membrane attack complex of complement: induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med 156:268–282

    PubMed  CAS  Google Scholar 

  1674. Podack ER, Young JDE, Weeks-Levy C, Lowrey D, Cohn ZA (1985) Isolation and characterization of perforin 1, a cytolytic T cell granule protein with homology to C9. Complement 2:63–64

    Google Scholar 

  1675. Pollack S, Nelson K (1973) Effects of carrageenan and high serum dilution on synergistic cytotoxicity to tumor cells. J Immunol 110:1440–1443

    PubMed  CAS  Google Scholar 

  1676. Ramstedt U, Serhan CN, Lundberg U, Wigzell H, Samuelsson B (1984) Inhibition of human natural killer cell activity by (14R,15S)-14,15-dihydroxy-5Z,8Z,10E,12E-icosatetraenoic acid. Proc Natl Acad Sci USA 81:6914–6918

    PubMed  CAS  Google Scholar 

  1677. Rauterberg EW, Gebest HJ (1975) Darstellung von C9 an Komplement-induzierten Membranveränderungen durch eine indirekte Immuno-Ferritin-Methode. Z Immunforsch 150:228 (Abstract)

    Google Scholar 

  1678. Rauterberg EW, Ungemach B, Gebest HJ (1979) Quantitative measurement of C9 sites and their association to the ring-like “lesions” on complement-lysed membranes: a morphometric immunoferritin study. J Immunol 122:355–365

    PubMed  CAS  Google Scholar 

  1679. Redelman D, Hudig D (1983) The mechanism of cell-mediated cytotoxicity. III. Protease- specific inhibitors preferentially block later events in cytotoxic T lymphocyte-mediated lysis than do inhibitors of methylation or thiol-reactive agents. Cell Immunol 81:9–21

    PubMed  CAS  Google Scholar 

  1680. Redelman D, Hudig D (1984) The mechanism of cell-mediated cytotoxicity. IV. K-76 COONa, which inhibits the activity of factor I and of C5, inhibits early events in cytotoxic T-lymphocyte-mediated cytolysis and in T-lymphocyte activation. Cell Immunol 88:16–28

    PubMed  CAS  Google Scholar 

  1681. Reinherz EL, Hussey RE, Schlossman SF (1980) A monoclonal antibody blocking human T cell function. Eur J Immunol 10:758–762

    PubMed  CAS  Google Scholar 

  1682. Reinherz EL, Hussey RE, Fitzgerald K, Snow P, Terhorst C, Schlossman SF (1981) Antibody directed at a surface structure inhibits cytolytic but not suppressor function of human T lymphocytes. Nature 294:168–170

    PubMed  CAS  Google Scholar 

  1683. Roberts K, Moore M (1985) A clonal analysis of human peripheral blood lymphocytes displaying natural killer-like activity. Eur J Immunol 15:448–456

    PubMed  CAS  Google Scholar 

  1684. Roder JC (1979) The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol 123:2168–2173

    PubMed  CAS  Google Scholar 

  1685. Roder JC, Lohmann-Matthes ML, Domzig W, Wigzell H (1979) The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect. J Immunol 123:2174–2181

    PubMed  CAS  Google Scholar 

  1686. Rola-Pleszczynski M, Gagnon L, Sirois P (1983) Leukotriene B4 augments human natural cytotoxic cell activity. Biochem Biophys Res Commun 113:531–537

    PubMed  CAS  Google Scholar 

  1687. Rosenau W (1968) Target cell destruction. Fed Proc 27:34–38

    PubMed  CAS  Google Scholar 

  1688. Russell JH (1983) Internal disintegration model of cytotoxic lymphocyte-induced target damage. Immunol Rev 72:97–118

    PubMed  CAS  Google Scholar 

  1689. Russell JH, Masakowski VR, Dobos CB (1980) Mechanisms of immune lysis. I. Physiological distinction between target cell death mediated by cytotoxic T lymphocytes and antibody plus complement. J Immunol 124:1100–1105

    PubMed  CAS  Google Scholar 

  1690. Ryser JE, Rungger-Brändle E, Chaponnier C, Gabbiani G, Vassalli P (1982) The area of attachment of cytotoxic T lymphocytes to their target cells shows high motility and polarization of actin, but not myosin. J Immunol 128:1159–1162

    PubMed  CAS  Google Scholar 

  1691. Saksela E, Imir T, Mäkelä O (1975) Specifically cytotoxic human and mouse lymphood [sic] cells induced with antibody or antigen-antibody complexes. J Immunol 115:1488–1492

    PubMed  CAS  Google Scholar 

  1692. Sanchez-Madrid F, Krensky AM, Ware CF, Robbins E, Strominger JL, Burakoff SJ, Springer TA (1982) Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc Natl Acad Sci USA 79:7489–7493

    PubMed  CAS  Google Scholar 

  1693. Sanderson CJ (1981) The mechanism of lymphocyte-mediated cytotoxicity. Biol Rev 56:153–197

    PubMed  CAS  Google Scholar 

  1694. Sanderson CJ (1982) Morphological aspects of lymphocyte mediated cytotoxicity. Adv Exp Med Biol 146:3–21

    PubMed  CAS  Google Scholar 

  1695. Sarmiento M, Dialynas DP, Lancki DW, Wall KA, Lorber MI, Loken MR, Fitch FW (1982) Cloned T lymphocytes and monoclonal antibodies as probes for cell surface molecules active in T cell-mediated cytolysis. Immunol Rev 68:135–169

    PubMed  CAS  Google Scholar 

  1696. Schönermark S, Rauterberg EW, Shin ML, Löke S, Roelcke D, Hänsch GM (1986) Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 136:1772–1776

    PubMed  Google Scholar 

  1697. Seaman WE (1983) Human natural killer cell activity is reversibly inhibited by antagonists of lipoxygenation. J Immunol 131:2953–2957

    PubMed  CAS  Google Scholar 

  1698. Shau H, Dawson JR (1984) The role of the lysosome in natural killing: inhibition by lysosomotropic vital dyes. Immunology 53:745–751

    PubMed  CAS  Google Scholar 

  1699. Shau H, Dawson JR (1985 a) Regulation of human natural killing by lysosomotropic and thiol-reactive agents. Immunology 55:647–659

    PubMed  CAS  Google Scholar 

  1700. Shau H, Dawson JR (1985 b) Identification and purification of NK cells with lysosomotropic vital stains: correlation of lysosome content with NK activity. J Immunol 135:137–140

    PubMed  CAS  Google Scholar 

  1701. Shau H, Golub SH (1985) Depletion of NK cells with the lysosomotropic agent L-leucine methyl ester and the in vitro generation of NK activity from NK precursor cells. J Immunol 134:1136–1141

    PubMed  CAS  Google Scholar 

  1702. Shipley WU, Baker AR, Colten HR (1971) DNA degradation in mammalian cells following complement-mediated cytolysis. J Immunol 106:576–579

    PubMed  CAS  Google Scholar 

  1703. Simon MM, Weltzien HU, Bühring HJ, Eichmann K (1984) Aged murine killer T-cell clones acquire specific cytotoxicity for P815 mastocytoma cells. Nature 308:367–370

    PubMed  CAS  Google Scholar 

  1704. Simone CB, Henkart P (1980) Permeability changes induced in erythrocyte ghost targets by antibody-dependent cytotoxic effector cells: evidence for membrane pores. J Immunol 124:954–963

    PubMed  CAS  Google Scholar 

  1705. Springer TA, Davignon D, Ho MK, Kürzinger K, Martz E, Sanchez-Madrid F (1982) LFA-1 and Lyt-2,3, molecules associated with T lymphocyte-mediated killing; and Mac-1, and LFA-1 homologue associated with complement receptor function. Immunol Rev 68:171–196

    PubMed  CAS  Google Scholar 

  1706. Stanley KK, Kocher HP, Luzio JP, Jackson P, Tschopp J (1985) The sequence and topology of human complement component C9. EMBO J 4:375–382

    PubMed  CAS  Google Scholar 

  1707. Stutman O, Dien P, Wisun RE, Lattime EC (1980) Natural cytotoxic cells against solid tumors in mice: blocking of cytotoxicity by D-mannose. Proc Natl Acad Sci USA 77:2895–2898

    PubMed  CAS  Google Scholar 

  1708. Sundsmo JS, Götze O (1980) Human monocyte spreading induced by factor B of the alternative pathway of complement activation. Cell Immunol 52:1–17

    PubMed  CAS  Google Scholar 

  1709. Sundsmo JS, Müller-Eberhard HJ (1979) Neoantigen of the complement membrane attack complex on cytotoxic human peripheral blood lymphocytes. J Immunol 122:2371–2378

    PubMed  CAS  Google Scholar 

  1710. Sundsmo JS, Curd JG, Kolb WP, Müller-Eberhard HJ (1978) Leukocyte complement: assembly of the membrane attack complex of complement by human peripheral blood leukocytes in the presence and absence of serum. J Immunol 120:855–860

    PubMed  CAS  Google Scholar 

  1711. Takasugi M, Mickey MR, Terasaki PI (1973) Reactivity of normal lymphocytes from normal persons on cultured tumor cells. Cancer Res 33:2898–2902

    PubMed  CAS  Google Scholar 

  1712. Thiernesse N, David A, Bernard J, Jeannesson P, Zagury D (1977) Activité phosphatosique acide de la cellule T cytolytique au cours du processus de cytolyse. C R Acad Sci Cer D 285:713–724

    CAS  Google Scholar 

  1713. Thom RM, Henney CS (1976) Kinetic analysis of target cell destruction by effector T cells. I. Delineation of parameters related to the frequency and lytic efficiency of killer cells. J Immunol 117:2213–2219

    Google Scholar 

  1714. Timonen T, Ortaldo JR, Herberman RB (1981) Characteristics of human large granular lymphoctes and relationship to natural killer and K cells. J Exp Med 153:569–582

    PubMed  CAS  Google Scholar 

  1715. Tsoukas CD, Fox RI, Carson DA, Fong S, Vaughan JH (1982 a) Molecular interactions in human T-cell-mediated cytotoxicity to Epstein-Barr virus. I. Blocking of effector cell function by monoclonal antibody OKT3. Cell Immunol 69:113–121

    PubMed  CAS  Google Scholar 

  1716. Tsoukas CD, Carson DA, Fong S, Vaughan JH (1982 b) Molecular interactions in human T cell-mediated cytotoxicity to EBV. II. Monoclonal antibody OKT3 inhibits a post-killer- target recognition/adhesion step. J Immunol 129:1421–1425

    PubMed  CAS  Google Scholar 

  1717. Ullberg M, Jondal M (1981) Recycling and target binding capacity of human natural killer cells. J Exp Med 153:615–628

    PubMed  CAS  Google Scholar 

  1718. Verhoef J, Sharma SD (1983) Inhibition of human natural killer activity by lysosomotropic agents. J Immunol 131:125–131

    PubMed  CAS  Google Scholar 

  1719. Vodinelich L, Sutherland R, Schneider C, Newman R, Greaves M (1983) Receptor for transferrin may be a “target” structure for natural killer cells. Proc Natl Acad Sci USA 80:835–839

    PubMed  CAS  Google Scholar 

  1720. Vose BM, Harding M, Withe W, Moore M, Gallagher J (1983) Effect of simple sugars on natural killing: evidence against the involvement of a lectin like mechanism in target recognition. Clin Exp Immunol 51:517–524

    PubMed  CAS  Google Scholar 

  1721. Wâhlin B, Perlmann H, Perlmann P, Schreiber RD, Müller-Eberhard HJ (1983) C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments. J Immunol 130:2831–2836

    PubMed  Google Scholar 

  1722. Walenga R, Vanderhook JY, Feinstein MB (1980) Serine esterase inhibitors block stimulus-induced mobilization of arachidonic acid and phosphatidylinositide-speciflc phospholipase C activity in platelets. J Biol Chem 255:6024–6027

    PubMed  CAS  Google Scholar 

  1723. Ward RHR, Lachmann PJ (1985) Monoclonal antibodies which react with lymphocytelysed target cells and which cross-react with complement-lysed ghosts. Immunology 56:179–188

    PubMed  CAS  Google Scholar 

  1724. Wei WZ, Lindquist RR (1981) Alloimmune cytolytic T lymphocyte activity: triggering and expression of killing mechanisms in cytolytic T lymphocytes. J Immunol 126:513–516

    PubMed  CAS  Google Scholar 

  1725. Weiss A, Imboden J, Shoback D, Stobo J (1984) Role of T3 surface molecules in human T cell activation: T3 dependent activation results in an increase in cytoplasmic free calcium. Proc Natl Acad Sci USA 81:4169–4173

    PubMed  CAS  Google Scholar 

  1726. Werkmeister JA, Pross HF, Roder JC (1983 a) Modulation of K562 cells with sodium butyrate: association of impaired NK susceptibility with sialic acid and analysis of other parameters. Int J Cancer 32:71–78

    PubMed  CAS  Google Scholar 

  1727. Werkmeister JA, Roder JC, Curry C, Pross HF (1983 b) The effect of unphosphorylated and phosphorylated sugar moieties on human and mouse natural killer cell activity: is there selective inhibition at the level of target recognition and lytic acceptor site? Cell Immunol 80:172–186

    PubMed  CAS  Google Scholar 

  1728. West WH, Boozer RB, Herberman RB (1978) Low affinity E-rosette formation by the human K cell. J Immunol 120:90–95

    PubMed  CAS  Google Scholar 

  1729. Wexler H, Fan J, Hiserodt JC, Bonavida B (1983) Studies on the induction and expression of T-cell-mediated immunity. XIII. Membrane-associated antigens of cytotoxic T lymphocytes involved in cytotoxicity. Cell Immunol 75:214–225

    PubMed  CAS  Google Scholar 

  1730. Yannelli JR, Sullivan JA, Mandell GL, Engelhard VH (1986) Reorientation and fusion of cytotoxic T lymphocyte granules after interaction with target cells as determined by high resolution cinemicrography. J Immunol 136:377–382

    PubMed  CAS  Google Scholar 

  1731. Yefenof E, Klein E, Yron I (1984) Contribution of activated C3 to lymphocyte-mediated target lysis: complement-dependent cellular cytotoxicity. Mol Immunol 21:1211–1214

    PubMed  CAS  Google Scholar 

  1732. Yogeeswaran G, Gronberg A, Hansson M, Dalianis T, Kiessling R, Welsh RM (1981) Correlation of glycosphingolipids and sialic acid in YAC-1 lymphoma variants with their sensitivity to natural killer-cell-mediated lysis. Int J Cancer 28:517–526

    PubMed  CAS  Google Scholar 

  1733. Young JDE, Nathan CF, Podack ER, Palladino MA, Cohn ZA (1986) Functional channel formation associated with cytotoxic T-cell granules. Proc Natl Acad Sci USA 83:150–154

    PubMed  CAS  Google Scholar 

  1734. Young WW, Durdik JM, Urdal D, Hakomori SI, Henney CS (1981) Glycolipid expression in lymphoma cell variants: chemical quantity, immunologic reactivity, and correlations with susceptibility to NK cells. J Immunol 126:1–6

    PubMed  CAS  Google Scholar 

  1735. Zagury D (1982) Direct analysis of individual killer T cells: susceptibility of target cells to lysis and secretion of hydrolytic enzymes by CTL. Adv Exp Med Biol 146:149–169

    PubMed  CAS  Google Scholar 

  1736. Zalman LS, Brothers MA, Chiu FJ, Müller-Eberhard HJ (1985) Anti-C9 reactive protein in the granules of large granular human lymphocytes. Complement 2:90 (Abstract)

    Google Scholar 

  1737. Zalman LS, Brothers MA, Chiu FJ, Müller-Eberhard HJ (1986) Mechanism of cytotoxicity of human large granular lymphocytes: relationship of the cytotoxic lymphocyte protein to C9 of human complement. Proc Natl Acad Sci USA 83:5262–5266

    PubMed  CAS  Google Scholar 

  1738. Zeijlemaker WP, van Oers RHJ, de Goede REY, Schellekens PTA (1977) Cytotoxic activity of human lymphocytes: quantitative analysis of T cell and K cell cytotoxicity, revealing enzyme-like kinetics. J Immunol 119:1507–1514

    PubMed  CAS  Google Scholar 

  1739. Zöller M, Heyman B, Andrighetto G, Wigzell H (1982) IgG- and IgM-induced cellular cytotoxicity. Scand J Immunol 16:379–388

    PubMed  Google Scholar 

  1740. Zucker-Franklin D, Grusky G, Yang JS (1983) Arylsulfatase in natural killer cells: its possible role in cytotoxicity. Proc Natl Acad Sci USA 80:6977–6981

    PubMed  CAS  Google Scholar 

  1741. Arnaout MA, Pitt J, Cohen HJ, Melamed J, Rosen FS, Colten HR (1982) Deficiency of a granulocyte-membrane glycoprotein (gp 150) in a boy with recurrent bacterial infections. N Engl J Med 306:694

    Google Scholar 

  1742. Cuatrecasas P (1974) Membrane receptors. Annu Rev Biochem 43:169–214

    PubMed  CAS  Google Scholar 

  1743. Dierich MP, Mussel HH, Scheiner O, Ehlen T, Burger R, Peters H, Schmitt M, Trepke S, Zimmer G (1982) Differentiation of C3b receptors on human lymphocytes, phagocytes, erythrocytes and renal glomerulum cells by monoclonal antibodies. Immunology 45:85–96

    PubMed  CAS  Google Scholar 

  1744. Dierich MP, Scheiner O, Mussel HH, Hammann KP, Schopf RE, Schulz T (1982) Characterization of complement receptors. Mol Immunol 19:1255–1265

    PubMed  CAS  Google Scholar 

  1745. Dierich MP, Schulz T (1983) The nature and function of complement receptors. In: Yamamura Y, Tada T (eds) Progress in immunology V. Academic, Tokyo, pp 407–418

    Google Scholar 

  1746. Dierich MP, Schulz ThF (1984) Multifactorial basis of C3b-receptor reactivity. Mol Immunol 21 [12]:1201–1204

    PubMed  CAS  Google Scholar 

  1747. Dykmann TR, Cole JL, Jida K, Atkinson JP (1983) Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci USA 80:1698–1702

    Google Scholar 

  1748. Erdei A, Späth E, Alsenz J, Rüde E, Schulz T, Dierich MP (1984) Role of C3b receptors in the enhancement of IL-2 dependent T-cell proliferation. Mol Immunol 21:1215–1221

    PubMed  CAS  Google Scholar 

  1749. Erdei A, Melchers F, Schulz T, Dierich MP (1985) The action of human C3 in soluble or crosslinked form with resting and activated murine B lymphocytes. Eur J Immunol 15:184–188

    PubMed  CAS  Google Scholar 

  1750. Fearon DT (1983) The human C3b receptor. Springer Semin Immunopathol 6:159–172

    PubMed  CAS  Google Scholar 

  1751. Fearon DT (1984) Structure and function of the human C3b receptor. Fed Proc 43:2553–2557

    PubMed  CAS  Google Scholar 

  1752. Frade R, Barel M, Eulin-Henriksson B, Klein G (1985) gp 140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci USA 82:1490–1493

    PubMed  CAS  Google Scholar 

  1753. Friedman HM, Cohen G, Eisenberg R, Seidel C, Cines D (1984) Glycoprotein C of HSV1 functions as a receptor for the complement component C3b. Nature 309:633–635

    PubMed  CAS  Google Scholar 

  1754. Ghebrehiwet B, Müller-Eberhard HJ (1978) Lysis of C1q-coated chicken erythrocytes by human lymphoblastoid cell lines. J Immunol 120:27

    PubMed  CAS  Google Scholar 

  1755. Ghebrehiwet B, Müller-Eberhard HJ (1979) C3e: an acidic fragment of human C3 with leukocytosis-inducing activity. J Immunol 123:616

    PubMed  CAS  Google Scholar 

  1756. Griffin JA, Griffin FM (1979) Augmentation of macrophage complement receptor function in vitro. I. Characterization of the cellular interactions required for the generation of a T-lymphocyte product that enhances macrophage complement receptor function. J Exp Med 150:653–675

    PubMed  CAS  Google Scholar 

  1757. Heidenreich F, Dierich MP (1985) Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b. Infect Immun 50[2]:598–600

    PubMed  CAS  Google Scholar 

  1758. Hoeprich PD Jr, Dahinden CA, Hugly TE (1984) Synthetic nonapeptide from C3d-K capable of inducing leukocytosis in rabbits and mice. Fed Proc 43:1491

    Google Scholar 

  1759. Jida K, Nadler L, Nussenzweig V (1983) Identification of the membrane receptors for the complement fragment C3d by means of a monoclonal antibody. J Exp Med 158:1021

    Google Scholar 

  1760. Inada S, Brown EJ, Gaither TA, Hammer CH, Takahashi T, Frank MM (1983) C3d receptors are expressed on human monocytes after in vitro cultivation. Proc Natl Acad Sci USA 80:2351

    PubMed  CAS  Google Scholar 

  1761. Lachmann PJ (1983) Biology of the complement system: a summary. In: Yamamura Y, Tada T (eds) Progress in immunology V. Academic, Tokyo, pp 445–452

    Google Scholar 

  1762. Lambris JD, Cohen PL, Dobson NJ, Wheeler PW, Papamichail M, Ross GD (1982) Effect of antibodies to CR2 (C3d receptors) on lymphocyte activation. Clin Res 30:514A

    Google Scholar 

  1763. Lambris JD, Ross GD (1982) Characterization of the lymphocyte membrane receptor for factor H (β1H-globulin) with an antibody to anti-factor H idiotype. J Exp Med 155:1400–1411

    PubMed  CAS  Google Scholar 

  1764. Medof EM, Jida K, Mold C, Nussenzweig V (1982) Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med 156:1739–1754

    PubMed  CAS  Google Scholar 

  1765. Melamed J, Arnaout MA, Colten HR (1982) Complement (C3b) interaction with the human granulocyte receptor: correlation of binding of fluid-phase radiolabeled ligand with histaminase release. J Immunol 128:2313–2318

    PubMed  CAS  Google Scholar 

  1766. Melchers F, Erdei A, Schulz Th, Dierich MP (1985) Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature 317:264–267

    PubMed  CAS  Google Scholar 

  1767. Michl J, Pieczonka MP, Unkeless JC, Silverstein SC (1979) Effects of immobilized immune complexus on Fc- and complement-receptor function in resident and thioglycollate-elicited mouse peritoneal macrophages. J Exp Med 150:607–621

    PubMed  CAS  Google Scholar 

  1768. Morgan EL, Weigle WO, Hugli TE (1984) Anaphylatoxin-mediated regulation of human and murine immune responses. Fed Proc 43:2543–2547

    PubMed  CAS  Google Scholar 

  1769. Mussel H-H, Ehlen T, Schmitt M, Kazatchkine MD, Neyses L, Dierich MP (1982) Isolation and characterization of the C3b-binding entity of C3b-receptor from human erythrocytes. Immunol Lett 4:1–6

    PubMed  CAS  Google Scholar 

  1770. Perlmann H, Perlmann P, Schreiber RD, Müller-Eberhard HJ (1981) Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors — enhancement of antibody-mediated cellular cytotoxicity. J Exp Med 153:1592–1603

    PubMed  CAS  Google Scholar 

  1771. Ross GD (1982) Structure and function of membrane complement receptors. Fed Proc 41:3089–3093

    PubMed  CAS  Google Scholar 

  1772. Ross GD, Lambris JD, Chain JA, Newman SL (1982) Generation of three different fragments of bound C3 with purified factor I or serum I. Requirements for factor H or CR1 cofactor activity. J Immunol 129:2051–2060

    PubMed  CAS  Google Scholar 

  1773. Ross GD, Newman SL, Lambris JD, Devery-Pocins JE, Cain JA, Lachmann PJ (1983) Generation of three different fragments of bound C3 with purified factor I or serum. II. Localization of binding sites in the C3 fragments for factor B and H, complement receptors and bovine conglutinin. J Exp Med 158:334

    PubMed  CAS  Google Scholar 

  1774. Rother K (1972) Leukocyte mobilizing factor: a new biological activity from the third component of complement. Eur J Immunol 2:550–558

    PubMed  CAS  Google Scholar 

  1775. Ryan US, Schultz DR, Ryan JW (1981) Fc and C3b receptors on pulmonary endothelial cells: induction by injury. Science 214:557–559

    PubMed  CAS  Google Scholar 

  1776. Sanchez-Madrid F, Nagy JA, Robbins E, Simon P, Springer TA (1983) A human leukocyte differentiation antigen family with distinct-subunits and a common β-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule. J Exp Med 158:1785–1803

    PubMed  CAS  Google Scholar 

  1777. Schmitt M, Mussel H-H, Hammann KP, Scheiner O, Dierich MP (1981) Role of β1H for the binding of C3b-coated particles to human lymphoid and phagocytic cells. Eur J Immunol 11:739–745

    PubMed  CAS  Google Scholar 

  1778. Schopf RE, Hammann KP, Scheiner O, Lemmel EM, Dierich MP (1982) Activation of human monocytes by both human β1H and C3b. Immunology 46:307–312

    PubMed  CAS  Google Scholar 

  1779. Schreiber RD (1984) The chemistry and biology of complement receptors. Springer Semin Immunopathol 7:221–249

    PubMed  CAS  Google Scholar 

  1780. Schreiber RD, Pangburn MK, Bjomson AB, Brothers MA, Müller-Eberhard HJ (1982) The role of C3 fragments in endocytosis and extracellular cytotoxic reactions by polymorphonuclear leukocytes. Clin Immunol Immunopathol 23:335–357

    PubMed  CAS  Google Scholar 

  1781. Schulz Th, Scheiner O, Alsenz J, Lambris J, Dierich MP (1984) Use of monoclonal antibodies against factor H to investigate the role of a membrane-associated protein antigenically related to H in C3b receptor function. J Immunol 132:392–398

    PubMed  CAS  Google Scholar 

  1782. Schulz TF, Scharfenberger H, Lambris JD, Rieber P, Riethmüller G, Dierich MP (1985) Antigenic relationship between the alpha-chain of C3, a leucocyte-surface antigen involved in the activation of phagocytic cells, and a 50000 MW B-cell antigen. Immunology 54:791–800

    PubMed  CAS  Google Scholar 

  1783. Sobel AT, Bokisch VA (1975) Receptors for C4b and C1q on human peripheral lymphocytes and lymphoblastoid cells. In: Seligmann M, Preud’Homme JL, Kourilsky FM (eds) Membrane receptors of lymphocytes. North-Holland, Amsterdam, pp 151–158

    Google Scholar 

  1784. Tenner AJ, Cooper NR (1980) Analysis of receptor-mediated C1q binding to human peripheral blood mononuclear cells. J Immunol 125:1658

    PubMed  CAS  Google Scholar 

  1785. Tenner AJ, Cooper NR (1982) Stimulation of a human polymorphonuclear leukocyte oxidative response by the C1q subunit of the first complement component. J Immunol 128:2547

    PubMed  CAS  Google Scholar 

  1786. Vogel SN, English KE, Fertsch D, Fultz MJ (1983) Differential modulation of macrophage membrane markers by interferon: analysis of Fc and C3b receptors, Mac-1 and Ia antigen expression. J Interferon Res 3:153

    PubMed  CAS  Google Scholar 

  1787. Wilson JG, Wong WW, Schrr PH, Fearon DT (1982) Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med 307:981–986

    PubMed  CAS  Google Scholar 

  1788. Wright SD, Rao PE, van Voorhis WC, Craigmyle LS, Jida K, Talle MA, Westberg EF, Goldstein G, Silverstein SC (1983) Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies. Proc Natl Acad Sci USA 80:5699

    PubMed  CAS  Google Scholar 

  1789. Berglund K, Laurell A-B, Nived O, Sjöholm AG, Sturfelt G (1980) Complement activation, circulating C1q binding substances and inflammatory activity in rheumatoid arthritis. Relations and changes on suppression of inflammation. J Clin Lab Immunol 4:7–14

    PubMed  CAS  Google Scholar 

  1790. Border WA, Wilson CC, Götze O (1976) Nephritic factor: description of a new quantitative assay and findings in glomerulonephritis. Kidney Int 10:311–318

    PubMed  CAS  Google Scholar 

  1791. Brandslund I, Siersted HC, Svehag S-E, Teisner B (1981) Double-decker rocket Immunoelectrophoresis for direct quantitation of complement split products with C3d specificities in plasma. J Immunol Methods 44:63–71

    PubMed  CAS  Google Scholar 

  1792. Caldwell JR, Ruddy S, Schur PH, Austen KF (1972) Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol 1:39–52

    Google Scholar 

  1793. Cooper NR, Nemerow GR, Mayes JT (1983) Methods to detect and quantitate complement activation. Springer Semin Immunopathol 6:195–212

    PubMed  CAS  Google Scholar 

  1794. Daha RM, van Es LA (1979) Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase. J Immunol 122:801–805

    PubMed  CAS  Google Scholar 

  1795. Davis AE, Kenney DM (1979) Properdin factor D. Effects on thrombin-induced platelet aggregation. J Clin Invest 64:721–728

    PubMed  CAS  Google Scholar 

  1796. Di Scipio RG (1982) The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 45:587–595

    Google Scholar 

  1797. Fearon DT, Austen KF (1978) Immunochemistry of the classical and alternative pathways of complement. In: Glynn LE, Steward MW (eds) Immunochemistry: an advanced textbook. Whiley, New York, pp 365–397

    Google Scholar 

  1798. Gelfand JA, Boss CR, Conley CL, Reinhart R, Frank MM (1979) Acquired C1 esterase inhibitor deficiency and angioedema. A review. Medicine 58:321–328

    CAS  Google Scholar 

  1799. Gewurz AT, Lint TF, Imherr SM, Garber SS, Gewurz H (1982) Detection and analysis of inborn and acquired complement abnormalities. Clin Immunol Immunopathol 23:297–311

    PubMed  CAS  Google Scholar 

  1800. Gorski JP (1981) Quantitation of human complement fragment C4a in physiological fluids by a competitive inhibition radio-immune assay. J Immunol Methods 47:61

    PubMed  CAS  Google Scholar 

  1801. Götze O, Müller-Eberhard HJ (1970) Lysis of erythrocytes in absence of antibody. J Exp Med 132:898–915

    PubMed  Google Scholar 

  1802. Götze O, Müller-Eberhard HJ (1972) Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med 286:180–184

    PubMed  Google Scholar 

  1803. Hack CE, Hannema AJ, Eerenberg-Behmer AJ, Out AT, Aalberse RC (1981) A C1 inhibitor complex assay (INCA): a method to detect C1 activation in vitro and in vivo. J Immunol 127:1450–1453

    PubMed  CAS  Google Scholar 

  1804. Harpel PC, Cooper NJ (1982) Circulating C1 inactivator-Cls-Clr complexes. Quantification by an enzyme-linked differential antibody immunosorbent assay. Clin Res 30:566A

    Google Scholar 

  1805. Hugh TE, Chenoweth DE (1980) Biologically active peptides of complement. Techniques and significance of C3a and C5a measurements. In: Nakamura RM, Dito WR, Tucker ES (eds) Immunoassays: clinical techniques for the 1980. Liss, Inc, New York, pp 443–460

    Google Scholar 

  1806. Johnson U (1984) The influence of polyethylene glycol precipitation and of ageing of plasma and serum on the measurement of C3dg/d. Acta Pathol Microbiol Immunol Scand C 92:193–196

    PubMed  CAS  Google Scholar 

  1807. Johnson U, Holmström E (1982) C3 fragmentation in human serum: formation of a mixed disulphide between C3d and albumin. Acta Pathol Microbiol Scand C 90:321–326

    CAS  Google Scholar 

  1808. Johnson U, Kamme C, Laurell A-B, Nilsson NI (1977) C1 subcomponents in acute pneumococcal otitis media in children. Acta Pathol Microbiol Scand C 85:10–16

    PubMed  CAS  Google Scholar 

  1809. Kazatschkine MD, Nydegger UE (1982) The human alternative complement pathway. Biology and immunopathology of activation and regulation. Prog Allergy 30:193–234

    Google Scholar 

  1810. Lachmann PJ, Hobart MJ (1978) Complement technology. In: Weir DM (ed) Handbook of experimental immunology, 3rd edn. Blackwell, Oxford, pp 5A-5A23

    Google Scholar 

  1811. Laurell A-B (1984) Hereditary angioedema and acquired (nonallergic) angioedema and urticaria. Association with C1 inhibitor dysfuntion and/or complement activation. In: Dukor P et al. (eds) PAR Pseudoallergic reactions, vol 4. Karger, Basel, pp 13–46

    Google Scholar 

  1812. Laurell A-B, Siboo R (1966) Activation of C1 to C1 esterase on gel filtration on Sephadex 200. Acta Pathol Microbiol Scand 68:230–242

    PubMed  CAS  Google Scholar 

  1813. Laurell A-B, Mårtensson U (1971) C1 inhibitor protein complexed with albumin in plasma from a patient with angioneurotic edema. Eur J Immunol 1:146–149

    PubMed  CAS  Google Scholar 

  1814. Laurell A-B, Mårtensson U, Sjöholm AG (1975) Complement components in hereditary angioedema and chronic urticaria. Int Arch Allergy Appl Immunol 49:86–88

    PubMed  CAS  Google Scholar 

  1815. Laurell A-B, Mårtensson U, Sjöholm AG (1976) C1 subcomponents complexes in normal and pathological sera studied by crossed immunoeletrophoresis. Acta PatholkMicrobiol Scand C 84:455–464

    Google Scholar 

  1816. Laurell A-B, Mårtensson U, Sjöholm AG (1977) Studies of C1 subcomponents in chronic urticaria and angioedema. Int Arch Allergy Appl Immunol 54:434–442

    PubMed  CAS  Google Scholar 

  1817. Laurell A-B, Mårtensson U, Sjöholm AG (1978) The development of simple tests for C1q, Clr, C1s and C2 and the determination of properdin. In: Opferkuch W, Rother K, Schultz DR (eds) Clinical aspects of the complement system. Thieme, Stuttgart, pp 12–14

    Google Scholar 

  1818. Laurell A-B, Johnson U, Mårtensson U, Sjöholm AG (1978) Formation of complexes composed of Clr, C1s and C1 inactivator in human serum on activation of C1. Acta Pathol Microbiol Scand C 86:299–306

    Google Scholar 

  1819. Laurell A-B, Mårtensson U, Sjöholm AG (1979) Quantitation of # inactivator complexes by electroimmunoassay. Acta Pathol Microbiol Scand C 87:79–81

    Google Scholar 

  1820. Laurell A-B, Mårtensson U, Sjöholm AG (1981) Quantitation of proenzyme C1r-C1s complexes in serum by electroimmunoassay. Acta Pathol Microbiol Scand C 89:391–392

    PubMed  CAS  Google Scholar 

  1821. Levy LR, Lepow IH (1959) Assay and properties of serum inhibitor of C1 esterase. Proc Soc Exp Biol 101:608–611

    PubMed  CAS  Google Scholar 

  1822. Lindgren S, Laurell A-B, Eriksson S (1984) Complement component and activation in primary biliary cirrhosis. Hepatology 4:9–14

    PubMed  CAS  Google Scholar 

  1823. Loos M (1982) The classical complement pathway: mechanism of activation of the first component by antigen-antibody complexes. Prog Allergy 30:135–192

    PubMed  CAS  Google Scholar 

  1824. Loos M, Laurell A-B, Sjöholm AG, Mårtensson U, Berkel I (1980) Immunochemical and functional analysis of a complete C1q deficiency in man: evidence that C1r and C1s are in the native form and that they reassociate with purified C1q to form macromolecular C1. J Immunol 124:59–63

    PubMed  CAS  Google Scholar 

  1825. Mancini G, Carbonara AO, Heremans JF (1965) Immunochemical qantitation of antigens by single radial immunodiffusion. Immunochemistry 2:235–254

    PubMed  CAS  Google Scholar 

  1826. Martin A, Lachmann PJ, Halbwachs L, Hobart MJ (1976) Hemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry 13:317–324

    PubMed  CAS  Google Scholar 

  1827. Mayes JT, Schreiber RD, Cooper NJ (1983) Development and application of an enzyme linked immunosorbent assay for quantitation of alternative complement pathway activation in human serum. Clin Res 31:539A

    Google Scholar 

  1828. Milgrom H, Curd JG, Kaplan RA, Müller-Eberhard HJ, Vaughan JH (1980) Activation of the fourth component of complement (C4): assessment by rocket Immunoelectrophoresis in correlation with metabolism of C4. J Immunol 124:2780–2785

    PubMed  CAS  Google Scholar 

  1829. Mollnes TE (1985) Quantification of the C3d split products of human complement by a sensitive enzyme-linked immunosorbent assay. Scand J Immunol 21:607–613

    PubMed  CAS  Google Scholar 

  1830. Mollnes TE, Lea T, Harboe M, Tschopp J (1985) Monoclonal antibodies recognizing a neoantigen of poly (C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 22:183–195

    PubMed  CAS  Google Scholar 

  1831. Mollnes TE, Lea T, Frøland SS, Harboe M (1985) Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 22:197–202

    PubMed  CAS  Google Scholar 

  1832. Müller-Eberhard HJ (1975) The complement system. In: Putman FW (ed) The plasma proteins. Academic, New York, pp 393–432

    Google Scholar 

  1833. Perrin LH, Lambert PH, Miescher PA (1975) Complement break down products in plasma from patients with systemic lupus erythematosus and patients with membrano-proliferative or other glomerulonephritis. J Clin Invest 56:165–176

    PubMed  CAS  Google Scholar 

  1834. Peters DK, Martin A, Weinstein A, Barrott TM, Cameron JS, Ogg CS, Lachmann PJ (1972) Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol 11:311–320

    PubMed  CAS  Google Scholar 

  1835. Peters DK, Williams DG, Charlesworth JA, Boulton-Jones JM, Sissons JGP, Evans DJ, Kourilsky O, Morel-Maroger L (1973) Mesangiocapillary nephritis, partial lipodystrophia and hypocomplementemia. Lancet 2:535–538

    PubMed  CAS  Google Scholar 

  1836. Prellner K (1981) C1q binding and complement activation by capsular and cell wall components of S. pneumoniae, type XIX. Acta Pathol Microbiol Scand 89:359–364

    CAS  Google Scholar 

  1837. Prellner K, Nilsson NI (1980) Complement aberrations in serum from children with otitis due to S. pneumoniae or H. influenzae. Acta Oto-Laryng 94:275–282

    Google Scholar 

  1838. Prellner K, Braconier JH, Sjöholm AG (1985) Combined IgG2, IgG4 and IgA deficiency in an adult patient with recurrent pneumococcal infections. Acta Pathol Microbiol Immunol Scand C 93:257–263

    PubMed  CAS  Google Scholar 

  1839. Rapp HJ, Borsos T (1970) Molecular basis of complement action. Appleton-Centure-Crofts, New York

    Google Scholar 

  1840. Rosen FS, Alper CA, Pensky J, Klemperer MR, Donaldson VH (1971) Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 50:2143–2149

    PubMed  CAS  Google Scholar 

  1841. Rother U (1982) A new screening test of C3 nephritic factor based on a stable cell bound convertase on sheep erythrocytes. J Immunol Methods 51:101–107

    PubMed  CAS  Google Scholar 

  1842. Rother U, Till G, Vorländer V, Hänsch G (1982) The complement system. In: Dukor P, Kallos P, Schlumberger HD, West GD (eds) PAR. Pseudoallergic reactions, vol 2. Karger, Basel, pp 71–104

    Google Scholar 

  1843. Sjöholm AG (1975) Complement components in normal serum and plasma quantitated by electroimmunoassay. Scand J Immunol 4:25–30

    PubMed  Google Scholar 

  1844. Sjöholm AG (1979) Complement components and complement activation in acute poststreptococcal glomerulonephritis. Int Arch Allergy Appl Immunol 58:274–284

    PubMed  Google Scholar 

  1845. Sjöholm AG, Sturfelt G (1984) Cleavage of C2 in pathological sera and plasma studied by crossed Immunoelectrophoresis. Acta Pathol Microbiol Immunol Scand C 92:265–269

    PubMed  Google Scholar 

  1846. Sjöholm AG, Mårtensson U, Laurell A-B (1976) C1r levels in normal human serum determined by electroimmunoassay. Acta Pathol Microbiol Scand C 84:425–427

    Google Scholar 

  1847. Sjöholm AG, Braconier JH, Söderström C (1982) Properdin deficiency in a family with fulminant meningococcal infections. Clin Exp Immunol 50:291–297

    PubMed  Google Scholar 

  1848. Sjöholm AG, Mårtensson U, Laurell A-B (1985) C1 dissociation in serum: estimation of free C1q by electroimmunoassay. Acta Pathol Microbiol Immunol Scand C 93:161–168

    PubMed  Google Scholar 

  1849. Sjöholm AG, Berglund K, Johnson U, Laurell A-B, Sturfelt G (1986) C1 activation with C1q in access of functional C1 in synovial fluid from patients with rheumatoid arthritis. Int Arch Allergy Appl Immunol 79:113–119

    PubMed  Google Scholar 

  1850. Sobel AT, Cooper NR, Schreiber RD (1979) Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3-C5 convertase. J Immunol 122:34–38

    PubMed  CAS  Google Scholar 

  1851. Sturfelt G, Sjöholm AG (1984) Complement components, complement activation and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 75:75–83

    PubMed  CAS  Google Scholar 

  1852. Sturfelt G, Sjöholm AG, Svensson B (1983) Complement components, C1 activation and disease activity in SLE. Int Arch Allergy Appl Immunol 70:12–18

    PubMed  CAS  Google Scholar 

  1853. Sturfelt G, Truedsson L, Thysell H, Björck L (1984) Serum level of complement factor D in systemic lupus erythematosus (SLE) — an indicator of glomerular filtration rate. Acta Med Scand 216:171–177

    PubMed  CAS  Google Scholar 

  1854. Sturfelt G, Johnson U, Sjöholm AG (1985) Sequential studies of complement activation in systemic lupus erythematosus. Scand J Rheumatol 14:184–196

    PubMed  CAS  Google Scholar 

  1855. Sturfelt G, Keller C, Truedsson L, Thysell H, Björck L (1985) Complement factor D in serum: an indicator of glomerular filtration rate in chronic inflammatory arthritis. Scand J Rheumatol 14:315–317

    PubMed  CAS  Google Scholar 

  1856. Thompson RA (1972) C3 inactivating factor in the serum of a patient with chronic hypocomplementemic proliferative glomerulonephritis. Immunology 22:147–158

    PubMed  CAS  Google Scholar 

  1857. Thompson RA (1981) Assessment of clinical hypocomplementemia. In: Thompson RA (ed) Techniques in clinical immunology. Blackwell Scientific, Oxford, p 95

    Google Scholar 

  1858. Thompson RA, Haeney M, Reid KBM, Davies MB, White RHR, Cameron AH (1980) A genetic defect of the C1q subcomponent of complement associated with childhood (immune complex) nephritis. N Engl J Med 303:22–24

    PubMed  CAS  Google Scholar 

  1859. Truedsson L, Sturfelt G (1983) Human factor D of the alternative pathway: purification and the quantitation by enzyme amplified electroimmunoassay. J Immunol Methods 63:207–214

    PubMed  CAS  Google Scholar 

  1860. Truedsson L, Sturfelt G (1983) False positive Waaler-Rose test due to anti-rabbit IgM antibodies in IgA deficiency. Clin Exp Rheumatol 1:307–310

    PubMed  CAS  Google Scholar 

  1861. Truedsson L, Sjöholm AG, Laurell A-B (1981) Screening for deficiencies of the classical and alternative pathway of complement by hemolysis in gel. Acta Pathol Microbiol Scand C 89:161–166

    PubMed  CAS  Google Scholar 

  1862. Truedsson L, Axelsson U, Laurell A-B (1982) Frequent occurrence of anti-rabbit IgM in IgA deficiency. Acta Pathol Microbiol Scand C 90:315–320

    CAS  Google Scholar 

  1863. Wilson WA, Thomas EJ, Sissons JGP (1979) Complement activation in asymptomatic patients with sickle cell anemia. Clin Exp Immunol 36:130–139

    PubMed  CAS  Google Scholar 

  1864. Ziccardi RJ, Cooper NR (1978) Modulation of the antigenicity of C1r and C1s by C1 inactivator. J Immunol 121:2148–2152

    PubMed  CAS  Google Scholar 

  1865. Ziccardi RJ, Cooper NR (1979) Active disassembly of the first complement component, C1, by C1 inactivator. J Immunol 123:788–792

    PubMed  CAS  Google Scholar 

  1866. Ziccardi RJ, Cooper NR (1980) Development of an immunochemical test to assess # inactivator function in human serum and its use for the diagnosis of hereditary angioedema. Clin Immunol Immunopathol 15:465–471

    PubMed  CAS  Google Scholar 

  1867. Adler S, Salant DJ, Dittmer JE, Rennke HG, Madaio MP, Couser WG (1983) Mediation of proteinuria in membranous nephropathy due to a planted glomerular antigen. Kidney Int 23:807–815

    PubMed  CAS  Google Scholar 

  1868. Adler S, Baker PJ, Pritzl P, Couser WG (1984) Detection of terminal complement components in experimental immune glomerular injury. Kidney Int 26:830–837

    PubMed  CAS  Google Scholar 

  1869. Adler S, Striker L, Striker G, Perkinson D, Hibbert J, Couser W (1985) Mechanisms of progressive glomerular sclerosis in the rat. Kidney Int 27:204 (abstr.)

    Google Scholar 

  1870. Baart de la Faille H, Baart de la Faille-Kuyper EH (1969) Immunofluorescent studies of the skin in rosacea. Dermatologica 139:49–54

    Google Scholar 

  1871. Baart de la Faille-Kuyper EH, van der Meer JB, Baart de la Faille H (1974) An immuno-histochemical study of the skin of healthy individuals. Acta Derm Venereol (Stockh) 54:271–274

    Google Scholar 

  1872. Baker PJ, Osofsky SG (1980) Activation of human complement by heat-killed human kidney cells grown in cell culture. J Immunol 124:81–86

    PubMed  CAS  Google Scholar 

  1873. Baker PJ, Adler S, Yang Y, Couser WG (1984) Complement activation by heat-killed human kidney cells: formation, activity, and stabilization of cell-bound C3 convertases. J Immunol 133:877–881

    PubMed  CAS  Google Scholar 

  1874. Baker PJ, Ochi R, Adler S, Johnson RJ, Couser WG (1985) C6 depletion abolishes proteinuria in experimental membranous nephropathy. Clin Res 33:475A (abstr.)

    Google Scholar 

  1875. Balkarowa-Ständer J, Rother U, Rauterberg EW (1981) The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. A morphometric immunoferritin study. J Immunol 127:1089–1093

    PubMed  Google Scholar 

  1876. Bean SF, Rogers RS, Jordon RE, Furey NL, Michel B (1979) Cicatricial pemphigoid. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin. Wiley, New York, pp 257–271

    Google Scholar 

  1877. Beutner EH, Chorzelski TP, Bean SF (eds) (1979 a) Immunopathology of the skin. Wiley, New York

    Google Scholar 

  1878. Beutner EH, Chorzelski TP, Jablonska S (1979 b) The nature of pemphigus antibodies and antigens. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin. Wiley, New York, pp 196–230

    Google Scholar 

  1879. Biesecker G, Katz S, Koffler D (1981) Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis. J Exp Med 154:1779–1794

    PubMed  CAS  Google Scholar 

  1880. Biesecker G, Lavin L, Ziskind M, Koffler D (1982) Cutaneous localization of the membrane attack complex in discoid and systemic lupus erythematosus. N Engl J Med 306:264–270

    PubMed  CAS  Google Scholar 

  1881. Biesecker G, Noble B, Andres GA, Koffler D (1984) Immunopathogenesis of Heymann’s nephritis. Clin Immunol Immunopathol 33:333–338

    PubMed  CAS  Google Scholar 

  1882. Boyce NW, Holdsworth ST (1986) Evidence for direct renal injury as a consequence of glomerular complement activation. J Immunol 136:2421–2425

    PubMed  CAS  Google Scholar 

  1883. Bozsik BP (1983) Demonstration of an autoantibody binding to human membrane attack complex. Immunobiology 164:215–216

    Google Scholar 

  1884. Brandt KD, Cathcart ES, Cohen AS (1968) Studies of immune deposits in synovial membranes and corresponding synovial fluids. J Lab Clin Med 72:631–647

    PubMed  CAS  Google Scholar 

  1885. Braun-Falco O, Maciejewski W, Schmoeckel C, Scherer R (1977) Immunoelectronmicroscopical demonstration of in vivo bound complement C3 in psoriatic lesions. Arch Dermatol Res 260:57–62

    PubMed  CAS  Google Scholar 

  1886. Bullock GR, Petrusz P (eds) (1982) Techniques in immunocytochemistry, vols 1–3. Academic, London

    Google Scholar 

  1887. Burnham TK, Neblett TR, Fine G (1963) The application of the fluorescent antibody technique to the investigation of lupus erythematosus and various dermatoses. J Invest Dermatol 41:451–456

    PubMed  CAS  Google Scholar 

  1888. Bystryn JC (1981) Intercellular deposits of complement in skin of patients with pemphigus. Arch Dermatol 117:682–685

    PubMed  CAS  Google Scholar 

  1889. Campbell AK, Daw RA, Lucio JP (1979) Rapid increase in intracellular free Ca2 + induced by antibody plus complement. FEBS Lett 107:55–60

    PubMed  CAS  Google Scholar 

  1890. Carlo JR, Gammon WR, Sams WM, Ruddy S (1979) Demonstration of the complement regulating protein, β1H, in skin biopsies from patients with bullous pemphigoid. J Invest Dermatol 73:551–553

    PubMed  CAS  Google Scholar 

  1891. Chorzelski TP, Jablonska S, Beutner EH (1979) Pemphigoid. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin. Wiley, New York, pp 243–256

    Google Scholar 

  1892. Clayton R, Haffenden G (1978) An immunofluorescence study of pityriasis lichenoides. Br J Dermatol 99:491–493

    PubMed  CAS  Google Scholar 

  1893. Cochrane CG (1968) Immunologic tissue injury mediated by neutrophilic leukocytes. Adv Immunol 9:97–162

    PubMed  CAS  Google Scholar 

  1894. Cochrane CG, Weigle WO, Dixon FJ (1959) The role of polymorphonuclear leukocytes in the initiation and cessation of the arthus vasculitis. J Exp Med 110:481–494

    PubMed  CAS  Google Scholar 

  1895. Cochrane CG, Müller-Eberhard HJ, Aikin BS (1970) Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol 105:55–69

    PubMed  CAS  Google Scholar 

  1896. Coggins CH, Frommer JP, Glassock RJ (1982) Membranous nephropathy. Semin Nephrol 2:264–273

    Google Scholar 

  1897. Cohen AH, Border WA (1982) Mesangial proliferative glomerulonephritis. Semin Nephrol 2:228–239

    Google Scholar 

  1898. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, Macdonald S, Pulford KAF, Stein H, Mason DY (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219–229

    PubMed  CAS  Google Scholar 

  1899. Cormane RH, Szabo E, Hauge LS (1970) Immunofluorescence of the skin: the interpretation of the staining of blood vessels and connective tissue aided by new techniques. Br J Dermatol [Suppl 5] 82:26–43

    CAS  Google Scholar 

  1900. Coulet M, Delage J, Molina C, Bidet JM, Betail G, Brun J (1978) Complement et asthme de l’adulte. Rev Fr Mal Respir 6:55–59

    Google Scholar 

  1901. Couser WG, Baker PJ, Adler S (1985 a) Complement and the direct mediation of immune glomerular injury: a new perspective. Kidney Int 28:879–890

    PubMed  CAS  Google Scholar 

  1902. Couser WG, Darby C, Salant DJ, Adler S, Stilmant MM, Lowenstein LM (1985 b) Anti-GBM antibody-induced proteinuria in isolated perfused rat kidney. Am J Physiol 249:F241-F250

    PubMed  CAS  Google Scholar 

  1903. Cybulsky AV, Rennke HG, Feintzweig ID, Salant DJ (1986) Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy. J Clin Invest 77:1096–1107

    PubMed  CAS  Google Scholar 

  1904. Cyong JC, Witkin SS, Rieger B, Barbarese E, Good RA, Day NK (1982) Antibody-independent complement activation by myelin via the classical complement pathway. J Exp Med 155:587–598

    PubMed  CAS  Google Scholar 

  1905. Dabeisteen E (1978) Distribution of complement and immunoglobulin in oral pemphigus lesions. Acta Derm Venereol 58:540–543

    Google Scholar 

  1906. Dahl MGC, McGibbon DH (1979) Complement C3 and immunoglobulin in inflammatory acne vulgaris. Br J Dermatol 101:633–640

    PubMed  CAS  Google Scholar 

  1907. Dalakas MC, Engel WK (1980) Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol 37:637–640

    PubMed  CAS  Google Scholar 

  1908. de Heer E, Daha MR, Bhakdi S, Bazin H, van Es LA (1985) Possible involvement of terminal complement complex in active Heymann nephritis. Kidney Int 27:388–393

    PubMed  Google Scholar 

  1909. Dixon FJ, Kunkel HG (eds) (1968) Advances in immunology, vol 9. Academic, London

    Google Scholar 

  1910. Donadio JV, Slack TK, Holley KE, Ilstrup DM (1979) Idiopathic membranoproliferative (mesangiocapillary) glomerulonephritis: a clinicopathologic study. Mayo Clin Proc 54:141–150

    PubMed  Google Scholar 

  1911. Doolittle RF (1985) The genealogy of some recently evolved vertebrate proteins. TIBS 10:233–237

    CAS  Google Scholar 

  1912. Duheille J, Puchelle E, Horsky P, Amor M, Sadoul P, Hettich D (1979) Localisation tissulaire des differentes classes d’immunoglobulines et des facteurs C1q, C3, C9 et B du complement en fonction des stades évolutifs de la bronchite chronique. Nouv Presse Med 8:2109–2112

    PubMed  CAS  Google Scholar 

  1913. Eikelenboom P, Stam FC (1982) Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol 57:239–242

    PubMed  CAS  Google Scholar 

  1914. Emanuel DA, Wenzel FJ, Bowerman Cl, Lawton BR (1964) Farmer’s lung. Clinical, pathologic and immunologic study of twenty-four patients. Am J Med 37:392–401

    PubMed  CAS  Google Scholar 

  1915. Engel AG, Biesecker G (1982) Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Ann Neurol 12:289–296

    PubMed  CAS  Google Scholar 

  1916. Engel AG, Lambert EH, Howard FM (1977) Immune complexes (IgG and C3) at the motor end-plate in myastenia gravis. Ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 52:267–280

    PubMed  CAS  Google Scholar 

  1917. Epstein JH, Tuffanelli DL, Epstein WL (1973) Cutaneous changes in the porphyrias. A microscopic study. Arch Dermatol 107:689–698

    PubMed  CAS  Google Scholar 

  1918. Epstein JH, Tuffanelli DL, Epstein WL (1979) Cutaneous porphyriasis and porphyrialike cutaneous changes induced by drug photosensitization. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin. Wiley, New York, pp 445–461

    Google Scholar 

  1919. Falk RJ, Jennette JC (1986) The role of the fifth component of complement (C5) in immune complex glomerulonephritis (GN) in mice. Kidney Int 29:274 (A)

    Google Scholar 

  1920. Falk RJ, Dalmasso AP, Kim Y, Tsai CH, Scheinman JI, Gewurz H, Michael AF (1983) Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest 72:560–573

    PubMed  CAS  Google Scholar 

  1921. Falk RJ, Dalmasso AP, Kim Y, Lam S, Michael AF (1985) Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 312:1594–1599

    PubMed  CAS  Google Scholar 

  1922. Faulk WP, Jarret R, Keane M, Johnson PM, Boackle RJ (1980) Immunological studies of human placentae: complement components in immature and mature chorionic villi. Clin Exp Immunol 40:299–305

    PubMed  CAS  Google Scholar 

  1923. Francois P, Francois M, Plouvier B, Devulder B (1978) Maladie de horton et étude en immunofluorescence des arteres temporales. Bull Soc Ophtalmol Fr 78:329–330

    PubMed  CAS  Google Scholar 

  1924. Freedman P, Markowitz AS (1959) Immunological studies in nephritis. Lancet II:45–46

    Google Scholar 

  1925. Fry L (1979) Dermatitis herpetiformis: basic findings. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin. Wiley, New York, pp 283–301

    Google Scholar 

  1926. Fujiwara H, Torisu M, Koitabashi Y, Baba T, Esaki H (1981) Immune complex deposits in thyroid glands of patients with Graves’ disease. I. Complement system in serum and thyroid gland of patients with Graves’ disease. Clin Immunol Immunopathol 19:98–108

    PubMed  CAS  Google Scholar 

  1927. Furness JB, Lewis SY, Rush R, Costa M, Geffen LB (1977) Involvement of complement in degeneration of sympathetic nerves after administration of antiserum to dopamine β-hydroxylase. Brain Res 136:67–75

    PubMed  CAS  Google Scholar 

  1928. Gajl-Peczalska KJ, Fish AJ, Meuwissen HJ, Frommei D, Good RA (1969) Localization of immunological complexes fixing β 1C (C3) in germinal centers of lymph nodes. J Exp Med 150:1367–1393

    Google Scholar 

  1929. Gammon WR, Merritt CC, Henke DC, Robinson T, Henley N, Deangelo L (1983) Complement-activating immune deposits in systemic lupus erythematosus skin. J Invest Dermatol 81:14–20

    PubMed  CAS  Google Scholar 

  1930. Geertinger P, Sorensen H (1970) Complement as a factor in arteriosclerosis. Acta Pathol Microbiol Scand [A] 78:284–288

    CAS  Google Scholar 

  1931. Gerdes J, Stein H (1982) Complement (C3) receptors on dendritic reticulum cells of normal and malignant lymphoid tissue. Clin Exp Immunol 48:348–352

    PubMed  CAS  Google Scholar 

  1932. Gerdes J, Stein H, Mason DY, Ziegler A (1983) Human dendritic reticulum cells of lymphoid follicles: their antigenic profile and their identification as multinucleated giant cells. Virchows Arch (Cell Pathol) 42:161–172

    CAS  Google Scholar 

  1933. Ghose T, Landrigan P, Asif A (1974) Localization of immunoglobulin and complement in pulmonary sarcoid granulomas. Chest 66:264–267

    PubMed  CAS  Google Scholar 

  1934. Glassock RJ, Cohen AH (1981) Secondary glomerular diseases. In: Brenner BM, Rector FC (eds) The kidney. Saunders, Philadelphia, pp 1493–1570

    Google Scholar 

  1935. Glassock RJ, Adler SG, Ward HJ, Cohen AH (1986) Primary glomerular diseases. In: Brenner BM, Rector FC (eds) The kidney. Saunders, Philadelphia, pp 929–1013

    Google Scholar 

  1936. Glassock RJ, Cohen AH, Adler AS, Ward HJ (1986) Secondary glomerular diseases. In: Brenner BM, Rector FC (eds) The kidney. Saunders, Philadelphia, pp 1014–1084

    Google Scholar 

  1937. Gogate P, Valenzuela R, Deodhar SD, Bergfeld WF, Yeip M (1980) Globular deposits of immunoglobulins and complement in the papillary dermis. Clinical significance. Am J Clin Pathol 73:512–517

    PubMed  CAS  Google Scholar 

  1938. Gower RG, Sams WM, Thorne EG, Kohler PF, Claman HN (1977) Leukocytoclastic vasculitis: sequential appearance of immunoreactants and cellular changes in serial biopsies. J Invest Dermatol 69:477–484

    PubMed  CAS  Google Scholar 

  1939. Greenberg CS, Hammerschmidt DE, Craddock PR, Jacob HS (1979) Atheroma cholesterol activates complement and aggregates granulocytes: possible role in ischemic manifestations of atherosclerosis. Trans Assoc Am Physicians 92:130–135

    PubMed  CAS  Google Scholar 

  1940. Groggel GC, Adler S, Rennke HG, Couser WG (1983) Role of the terminal complement pathway in experimental membranous nephropathy in the rabbit. J Clin Invest 72:1948–1957

    PubMed  CAS  Google Scholar 

  1941. Groggel GC, Salant DJ, Darby C, Rennke HG, Couser WG (1985) Role of terminal complement pathway in the heterologous phase of antiglomerular basement membrane nephritis. Kidney Int 27:643–651

    PubMed  CAS  Google Scholar 

  1942. Guilhou JJ, Malbos S, Delalleau D, Meynadier J (1981) Immunofluorescence in psoriasis: studies of immunoglobulins, complement deposits, and three membrane markers. Arch Dermatol Res 271:295–303

    PubMed  CAS  Google Scholar 

  1943. Halberg P, Ullman S, Jorgensen F (1982) The lupus band test as a measure of disease activity in systemic lupus erythematosus. Arch Dermatol 118:572–576

    PubMed  CAS  Google Scholar 

  1944. Hannuksela M, Salo OP, Karvonen J (1975) Immunohistological development of the kveim reaction. Dermatologica 151:354–359

    PubMed  CAS  Google Scholar 

  1945. Hänsch GM, Torbohm I, Wingen A-M, Günther J, Rother KO (1987) The late complement components C5b-9 stimulate the type IV collagen synthesis in cultured rat epithelial cells (GEC). Kidney Int 31:322 (abstr)

    Google Scholar 

  1946. Hartmann J, Robinson J, Gunnar R (1975) Infarct size and chemotactic activity: comparison of decomplementation and enzyme inhibition. Circulation [Suppl] 11:22 (abstr)

    Google Scholar 

  1947. Hashimoto T, Sugiura M, Kurihara S, Nishikawa T (1982) In vitro complement activation by intercellular antibodies. J Invest Dermatol 78:316–318

    PubMed  CAS  Google Scholar 

  1948. Hatle L, Melbye OJ (1976) Immunoglobulins and complement in chronic myocardial disease. A myocardial biopsy study. Acta Med Scand 200:385–389

    PubMed  CAS  Google Scholar 

  1949. Heptinstall RH (1983) Pathology of the kidney, 3rd edn. Little Brown, Boston, pp 519

    Google Scholar 

  1950. Hill JH, Ward PA (1970) The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 133:885–900

    Google Scholar 

  1951. Hinglais N, Kazatchkine MD, Bhakdi S, Appay MD, Mandet C, Grossetete J, Bariety J (1986) Immunohistochemical study of the C5b-9 complex of complement in human kidneys. Kidney Int 30:399–410

    PubMed  CAS  Google Scholar 

  1952. Hollander W, Colombo MA, Kramsch DM, Kirkpatrick B (1974) Immunological aspects of atherosclerosis. Adv Cardiol 13:192–207

    PubMed  CAS  Google Scholar 

  1953. Hollander W, Colombo MA, Kirkpatrick B, Paddock J (1979) Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3-complement component, al-antitrypsin and a2-macroglobulin. Atherosclerosis 34:391–405

    PubMed  CAS  Google Scholar 

  1954. Holubar K, Dorait M, Eggerth G (1971) Immunofluorescence patterns in dermatitis herpetiformis. Investigations on skin and intestinal mucosa. Br J Dermatol 85:505–510

    PubMed  CAS  Google Scholar 

  1955. Huschka U, Pfarr A, Kohl P, Rauterberg EW (1981a) Immunglobulinablagerungen in der Haut bei Lupus erythematodes: Komplementaktivierung in vivo und in vitro. Verh Dtsch Ges Inn Med 87:1139–1141

    Google Scholar 

  1956. Huschka U, Pfarr A, Kohl PK, Rauterberg EW (1981 b) Complement activation in systemic and discoid lupus erythematosus in vivo and in vitro. Its possible pathogenic role. Immunobiology 160:46 (abstr)

    Google Scholar 

  1957. Jablonska S, Beutner EH, Binder WL, Jarzabek-Chorzelska M, Rzesa G, Chowaniec O (1979 a) Immunopathology of psoriasis. Arch Dermatol Res 264:65–71

    PubMed  CAS  Google Scholar 

  1958. Jablonska S, Jarzabek-Chorzelska M, Beutner EH, Rzesa G, Maciejowska E, Chorzelski TP (1979 b) Clinical relevance of stratum corneum antibodies in psoriasis. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin. Wiley, New York, pp 427–443

    Google Scholar 

  1959. Ji-Yun Y, Melvin T, Sibley R, Michael AF (1984) No evidence for a specific role of IgM in mesangial proliferation in idiopathic nephrotic syndrome. Kidney Int 25:100–106

    PubMed  CAS  Google Scholar 

  1960. Johannessen AC, Nilsen R, Skaug N (1983) Deposits of immunoglobulins and complement factor C3 in human dental periapical inflammatory lesions. Scand J Dent Res 91:191–199

    PubMed  CAS  Google Scholar 

  1961. Johnson KJ, Ward PA (1974) Acute immunologic pulmonary alveolitis. J Clin Invest 54:349–357

    PubMed  CAS  Google Scholar 

  1962. Johnson KJ, Wilson BS, Till GO, Ward PA (1984) Acute lung injury in rat caused by immunoglobulin A immune complexes. J Clin Invest 74:358–369

    PubMed  CAS  Google Scholar 

  1963. Jordon RE (1975) Complement activation in bullous skin diseases. J Invest Dermatol 65:162–169

    PubMed  CAS  Google Scholar 

  1964. Jordon RE (1979) The complement system in pemphigus and bullous pemphigoid. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin. Wiley, New York, pp 135–145

    Google Scholar 

  1965. Jordon RE (1980) Complement activation in pemphigus. J Invest Dermatol 74:357–359

    PubMed  CAS  Google Scholar 

  1966. Jordon RE, Schroeter AL, Rogers RS, Perry HO (1974) Classical and alternate pathway activation of complement in pemphigus vulgaris lesions. J Invest Dermatol 63:256–259

    PubMed  CAS  Google Scholar 

  1967. Jordon RE, Schroeter AL, Good RA, Day NK (1975) The complement system in bullous pemphigoid: II. Immunofluorescent evidence for both classical and alternate-pathway activation. Clin Immunol Immunopathol 3:307–314

    PubMed  CAS  Google Scholar 

  1968. Kaplan MH, Meyeserian M (1962) An immunological cross-reaction between group-A streptococcal cells and human heart tissue. Lancet I:706–710

    Google Scholar 

  1969. Katz SI, Lawley TJ (1979) Dermatitis herpetiformis: recent advances. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin. Wiley, New York, pp 303–313

    Google Scholar 

  1970. Kerr RO, Dalmasso AP, Kaplan ME (1971) Erythrocyte bound C5 and C6 in auto-immune hemolytic anemia. J Immunol 107:1209–1210

    PubMed  CAS  Google Scholar 

  1971. Kim Y, Vernier RL, Fish AJ, Michael AF (1979) Immunofluorescence studies of dense deposit disease. The presence of railroad track and mesangial rings. Lab Invest 30:474–480

    Google Scholar 

  1972. Klaus GGB, Humphrey JH, Kunkl A, Dongworth DW (1980) The follicular dendritic cell: its role in antigen presentation in the generation of immunological memory. Immunol Rev 53:3–28

    PubMed  CAS  Google Scholar 

  1973. Klein P, Burkholder P (1959) Ein Verfahren zur fluoreszenzoptischen Darstellung der Komplementbindung und seine Anwendung zur histo-immunologischen Untersuchung der experimentellen Nierenanaphylaxie. Dtsch Med Wochenschr 84:2001–2004

    PubMed  CAS  Google Scholar 

  1974. Koffler D, Biesecker G, Noble B, Andres GA, Martinez-Hernandez A (1983) Localization of the membrane attack complex (MAC) in experimental immune complex glomerulonephritis. J Exp Med 157:1885–1905

    PubMed  CAS  Google Scholar 

  1975. Kofler H, Kofler R, Wolf H, Wick G (1983) Immunofluorescence studies on the codistribution of immune deposits and complement in the thyroid glands of obese strain (OS) chikkens. Immunobiology 164:390–401

    PubMed  CAS  Google Scholar 

  1976. Kolb WP, Müller-Eberhard HJ (1975) Neoantigens of the membrane attack complex of human complement. Proc Natl Acad Sci USA 72:1687–1689

    PubMed  CAS  Google Scholar 

  1977. Kurihara S, Nishikawa T, Sugawara M, Hatano H (1980) Correlation between complement-fixing pemphigoid antibody titres and disease activity. J Dermatol 7:127–130

    PubMed  CAS  Google Scholar 

  1978. Labib RS, Anhalt GJ, Patel HP, Mutasim DF, Diaz LA (1986) Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 136:1231–1235

    PubMed  CAS  Google Scholar 

  1979. Laskaris G (1981) Oral pemphigus vulgaris: an immunofluorescent study of fifty-eight cases. Oral Surg 51:626–631

    PubMed  CAS  Google Scholar 

  1980. Lennon VA, Lambert EH (1981) Monoclonal antibodies to acetylcholine receptors: evidence for a dominant idiotype and requirement of complement for pathogenicity. Ann N Y Acad Sci 377:77–95

    PubMed  CAS  Google Scholar 

  1981. Lewis EJ, Schwartz MM (1982) Idiopathic crescentic glomerulonephritis. Semin Nephrol 2:193–199

    Google Scholar 

  1982. Lief PD, Barland P, Bank N (1977) Diagnosis of lupus nephritis by skin immunofluorescence, in the absence of extrarenal manifestations of systemic lupus erythematosus. Am J Med 63:441–448

    PubMed  CAS  Google Scholar 

  1983. Lim H, Gigli I (1981) The role of complement in phototoxic reactions. Springer Semin Immunopathol 4:209–219

    PubMed  CAS  Google Scholar 

  1984. Linder E, Lehto VP, Stenman S (1979) Activation of complement by cytoskeletal intermediate filaments. Nature 278:176–177

    PubMed  CAS  Google Scholar 

  1985. Ljunghall K, Tjernlund U (1983) Dermatitis herpetiformis: effect of glutein-restricted and gluten-free diet on dapsone requirement and on IgA and C3 deposits in uninvolved skin. Acta Derm Venereol 63:129–136

    PubMed  CAS  Google Scholar 

  1986. Lovett D, Hänsch GM, Resch K, Gemsa D (1986) Activation of glomerular mesangial cells by the terminal membrane attack complex of complement. J Immunol (to be published)

    Google Scholar 

  1987. Macher S (1981) Immunhistologie der chronisch bullösen Dermatosen. Nachweis und Bedeutung von gewebsgebundenen Komplementkomponenten, insbesondere C3d. Dissertationsschrift, Fakultät für Theoretische Medizin der Universität Heidelberg

    Google Scholar 

  1988. Macher S, Kohl PK, Rauterberg EW (1980) Tissue-bound complement and immunoglobulins in bullous dermatoses. Diagnostic value of C3d staining. Immunobiology 157:248 (abstr)

    Google Scholar 

  1989. Maclean D, Fishbein MC, Braunwald E, Maroko PR (1978) Long-term preservation of ischemic myocardium after experimental coronary artery occlusion. J Clin Invest 61:541–551

    PubMed  CAS  Google Scholar 

  1990. Mariot A, Bene MC, de Ligny BH, Faure G, Martin JM, Kessler M, Duheille J (1984) C9 deposits in renal tissue. Nephron 37:69–76

    PubMed  CAS  Google Scholar 

  1991. Maroko PR, Carpenter CB, Chiariello M, Fishbein MC, Radvany P, Knostman JD, Hale SL (1978) Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest 61:661–670

    PubMed  CAS  Google Scholar 

  1992. McConnell I, Hopkins J (1981) Lymphocyte traffic through antigen-stimulated lymph nodes. I. Complement activation within lymph nodes initiates cell shutdown. Immunology 42:217–223

    PubMed  CAS  Google Scholar 

  1993. McLean IW, Nakane PK (1974) Periodate-lysine-paraformaldehyde fixative a new fixative for immunoelectron microscopy. J Histochem Cytochem 22:1077–1083

    PubMed  CAS  Google Scholar 

  1994. McManus LM, Kolb WP, Crawford MH, O’Rourke RA, Grover FL, Pinckard RN (1983) Complement localization in ischemic baboon myocardium. Lab Invest 48:436–447

    PubMed  CAS  Google Scholar 

  1995. Melchers F, Erdei A, Schulz T, Dierich MP (1985) Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature 317:264–267

    PubMed  CAS  Google Scholar 

  1996. Mellors RC, Ortega LG (1956) Analytical pathology: III. New observations on the pathogenesis of glomerulonephritis, lipid nephrosis, periarteritis nodosa, and secondary amyloidosis in man. Am J Pathol 32:455–499

    PubMed  CAS  Google Scholar 

  1997. Michel B (1979) Localized chronic pemphigoid of Brunsting-Perry: its relationship to bullous pemphigoid. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin. Wiley, New York, pp 265–271

    Google Scholar 

  1998. Millns JL, Meurer M, Jordon RE (1979) The complement system in bullous pemphigoid: VI. C3 fixing activity in the absence of detectable antibody. Clin Immunol Immunopathol 13:475–483

    PubMed  CAS  Google Scholar 

  1999. Morgan BP, Sewry CA, Siddle K, Luzio JP, Campbell AK (1984) Immunolocalization of complement component C9 on necrotic and non-necrotic muscle fibres in myositis using monoclonal antibodies: a primary role of complement in autoimmune cell damage. Immunology 52:181–188

    PubMed  CAS  Google Scholar 

  2000. Morioka S, Naito K, Ogawa H (1981) The pathogenic role of pemphigus antibodies and proteinase in epidermal acantholysis. J Invest Dermatol 76:337–341

    PubMed  CAS  Google Scholar 

  2001. Naff GB, Byers PH (1973) Complement as a mediator of inflammation in acute gouty arthritis. I. Studies on the reaction between human serum complement and sodium urate crystals. J Lab Clin Med 81:747–760

    PubMed  CAS  Google Scholar 

  2002. Nieboer C, Boorsma DM, Woerdeman MJ, Kalsbeek GL (1980) Epidemolysis bullosa ac- quisita. Immunofluorescence, electron microscopic and immunoelectron microscopic studies in four patients. Br J Dermatol 102:383–392

    PubMed  CAS  Google Scholar 

  2003. Nishikawa T, Sigiura M, Hashimoto T, Kurihara S, Tamura N (1983) Demonstration of β1H globulin in pemphigus. Acta Derm Venereol 63:39–41

    PubMed  CAS  Google Scholar 

  2004. Noel LH, Droz D, Rothfleld NF (1978) Clinical and serologic significance of cutaneous deposits of immunoglobulins, C3, and C1q in SLE patients with nephritis. Clin Immunol Immunopathol 10:381–388

    PubMed  CAS  Google Scholar 

  2005. Okuda K, Takazoe I (1980) Activation of complement by dental plaque. J Periodont Res 15:232–239

    PubMed  CAS  Google Scholar 

  2006. Pang ASD, Minta JO (1980) Inhibition of vitamin D2-induced arteriosclerosis in rats by depletion of complement with cobra venom factor. Artery 7:109–122

    PubMed  CAS  Google Scholar 

  2007. Papamichail M, Gutierrez C, Embling P, Johnson P, Holborow EJ, Pepys MB (1975) Complement dependence of localisation of aggregated IgG in germinal centres. Scand J Immunol 4:343–347

    PubMed  CAS  Google Scholar 

  2008. Parra G, Platt JL, Falk RF, Rodriguez-Iturbe B, Michael AF (1984) Cell populations and membrane attack complex in glomeruli of patients with post-streptococcal glomerulonephritis: identification using monoclonal antibodies by indirect immunofluorescence. Clin Immunol Immunopathol 33:324–332

    PubMed  CAS  Google Scholar 

  2009. Parra G, Takekoshi Y, Vernier RL (1985) Association of localization of poly C9 with proteinuria and local loss of anionic sites in the glomerular basement membrane (GBM) in acute serum sickness nephritis. Kidney Int 27:219 (abstr)

    Google Scholar 

  2010. Patthy L (1985) Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 41:657–663

    PubMed  CAS  Google Scholar 

  2011. Pehamberger H, Konrad K, Stingl G, Holubar K (1977) Immunoelectron microscopy of linear dermatitis herpetiformsi: report of a case. Acta Derm Venereol 57:462–465

    PubMed  CAS  Google Scholar 

  2012. Perkinson DT, Baker PJ, Couser WG, Johnson RJ, Adler S (1985) Membrane attack complex deposition in experimental glomerular injury. Am J Pathol 120:121–128

    PubMed  CAS  Google Scholar 

  2013. Pernis B, Governa M, Scelsi R, Maura E, Ferrarini M (1969) Absence of complement binding by immunoglobulin aggregates in germinal centers. In: Fiore-Donati L, Hanna MG (eds) Lymphatic tissue and germinal centers in immune response. Plenum, New York, pp 431–439

    Google Scholar 

  2014. Persellin ST, Ramirez G, Moatamed F (1982) Immunopathology of rheumatic pericarditis. Arthritis Rheum 25:1054–1058

    PubMed  CAS  Google Scholar 

  2015. Peterson LL, Wuepper KD (1984) Isolation and purification of a pemphigus vulgaris antigen from human epidermis. J Clin Invest 73:1113–1120

    PubMed  CAS  Google Scholar 

  2016. Pinckard RN, Olson MS, Giclas PC, Terry R, Boyer JT, O’Rourke RA (1975) Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest 56:740–750

    PubMed  CAS  Google Scholar 

  2017. Pinckard RN, O’Rourke RA, Crawford MH, Gorver FS, McManus LM, Ghidoni JJ, Storrs SB, Olson MS (1980) Complement localization and mediation of ischemic injury in baboon myocardium. J Clin Invest 66:1050–1056

    PubMed  CAS  Google Scholar 

  2018. Provost TT (1979) Lupus band test. In: Beutner HE, Chorzelski TP, Bean SF (eds) Immunopathology of the skin. Wiley, New York, pp 399–410

    Google Scholar 

  2019. Provost TT, Tomasi TB (1974) Immunopathology of bullous pemphigoid. Basement membrane deposition of IgE, alternative pathway components and fibrin. Clin Exp Immunol 18:193–200

    PubMed  CAS  Google Scholar 

  2020. Provost TT, Tomasi TB (1974) Evidence for the activation of complement via the alternate pathway in skin diseases. II. Dermatitis Herpetiformis. Clin Immunol Immunopathol 3:178–186

    PubMed  CAS  Google Scholar 

  2021. Provost TT, Yaoita H, Katz SI (1979) Herpes gestationis. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin. Wiley, New York, pp 273–282

    Google Scholar 

  2022. Pryjma J, Humphrey JH, Klaus GGB (1974) C3 activation and T-independent B cell stimulation. Nature 252:505–508

    PubMed  CAS  Google Scholar 

  2023. Prystowsky S, Gilliam JN (1976) Benign chronic bullous dermatosis of childhood. Arch Dermatol 112:837–838

    PubMed  CAS  Google Scholar 

  2024. Rauterberg EW (1987) Pathogenetische Differentialdiagnose. In: Sarre H (ed) Nierenkrankheiten. Thieme, Stuttgart (to be published)

    Google Scholar 

  2025. Rauterberg EW, Gebest JH (1975) Darstellung von C9 an Komplement-induzierten Mem- branveränderungen durch eine indirekte Immuno-Feritin-Methode. Immunobiology 150:228 (abstr)

    Google Scholar 

  2026. Rauterberg EW, Hegemann P (1980) Binding of antibodies against C5, C6, C8 and the C59- neo-antigens to the ringlike structures on complement lysed membranes “in situ”. An immunoferritin study. Immunobiology 157:264 (abstr)

    Google Scholar 

  2027. Rauterberg EW, Rother KO (1986) Bullous dermatoses. Immunostaining for C3b and C3d to assess disease activity. In: Proceedings of the XHIth European Academy of Allergology and Clinical Immunology. Csaba B. Leövey A., Szemere P. (eds) Alföldi Nyomda Debrecen Ungarn p. 677–698

    Google Scholar 

  2028. Rauterberg EW, Ungemach B, Gebest HJ (1979) Quantitative measurement of C9 sites and their association to the ring-like “lesions” on complement-lysed membranes: a morphometric immunoferritin study. J Immunol 122:355–365

    PubMed  CAS  Google Scholar 

  2029. Rauterberg EW, Schieck C, Gehrig T (1980) Nachweis lytischer Komplementkomplexe (C59) bei der epimembranösen Glomerulonephritis. Verh Dtsch Ges Inn Med 86:1445–1448

    Google Scholar 

  2030. Rauterberg EW, Gehrig T, Lieberknecht M (1982) C5–9 neoantigen detection indicates a complete complement activation in various types of glomerulonephritis. Mol Immunol 19:1398 (abstr)

    Google Scholar 

  2031. Rauterberg EW, Wingen AM, Lieberknecht HM, Ritz E (1985) Demonstration of C3d and C3b in mesangial IgA-glomerulonephritis and Henoch-Schönlein purpura nephritis. Proc EDTA-ERA 22:763–766

    Google Scholar 

  2032. Rauterberg EW, Wingen AM, Gehrig T, Lieberknecht M, Macher S (1985) Immuno-histological detection of C3d- a “scar” of local complement activation in various kidney and skin diseases. Immunobiol 170:74 (abstr)

    Google Scholar 

  2033. Rauterberg EW, Lieberknecht M, Schoel J, Wingen AM (1987 a) Complement-related mediators of inflammation: immunohistological demonstration in the vessel walls of skin and kidney. In: Messmer K, Hammersen F (eds) Progress in applied microcirculation, vol 12. Karger, Basel, pp 170–184

    Google Scholar 

  2034. Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E (1987 b) Complement membrane attack complex (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int 31:820–829

    PubMed  CAS  Google Scholar 

  2035. Rehan A, Wiggins DC, Kunkel RG, Till GO, Johnson KJ (1986) Glomerular injury and proteinuria in rats after intrarenal injection of cobra venom factor. Am J Pathol 123:57–66

    PubMed  CAS  Google Scholar 

  2036. Reynes M, Aubert JP, Cohen JHM, Audouin J, Tricottet V, Diebold J, Kazatchkine MK (1985) Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 135:2687–2694

    PubMed  CAS  Google Scholar 

  2037. Riggs JL, Seiwald RJ, Burckhalter JH, Downs CM, Metcalf TG (1958) Isothiocyanate compounds as fluorescent labeling agents for immune serum. Am J Pathol 34:1081–1092

    PubMed  CAS  Google Scholar 

  2038. Roska AKB, Garancis JC, Moore VL, Abramoff P (1977) Immune-complex disease in guinea pig lungs. I. Elicitation by aerosol challenge, suppression with cobra venom factor, and passive transfer with serum. Clin Immunol Immunopathol 8:213–224

    PubMed  CAS  Google Scholar 

  2039. Roth E, Hunstein W, Seelig HP, Waldherr R, Roth E (1982) Immunhistologische und histologische Befunde der Arteria temporalis bei Polymyalgia Rheumatica. Z Rheumatol 41:256–262

    PubMed  CAS  Google Scholar 

  2040. Rother K, Rauterberg EW (1983) Niere. In: Vorlaender KO (ed) Immunologie. Grundlagen-Klinik-Praxis, 2nd edn. Thieme, Stuttgart, pp 362–402

    Google Scholar 

  2041. Rother K, Rother U, Vassalli P, McCluskey RT (1967) Nephrotoxic serum nephritis in C6-deficient rabbits. I. Study of the second phase of the disease. J Immunol 98:965–971

    PubMed  CAS  Google Scholar 

  2042. Rowlands DT (ed section 0) (1986) Immunopathology and immunohistology. In: Rose NR, Friedman H, Fahey JL (eds) Manual of clinical laboratory immunology. American Society for Microbiology, Washington

    Google Scholar 

  2043. Sahashi K, Engel AG, Lindstrom JM, Lambert EH, Lennon VA (1978) Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol 37:212–223

    PubMed  CAS  Google Scholar 

  2044. Sahashi K, Engel AG, Lambert EH, Howard FM (1980) Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor endplate in myasthenia gravis. J Neuropathol Exp Neurol 39:160–172

    PubMed  CAS  Google Scholar 

  2045. Salant DJ, Belok S, Madaio MP, Couser WG (1980) A new role for complement in experimental membranous nephropathy in rats. J Clin Invest 66:1339–1350

    PubMed  CAS  Google Scholar 

  2046. Sams WM (1979) Leukocytoclastic vasculitis. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin. Wiley, New York, pp 463–471

    Google Scholar 

  2047. Scherer R, Braun-Falco O (1976) Alternative pathway activation: a possible mechanism inducing skin lesions in benign gonococcal sepsis. Br J Dermatol 95:303–309

    PubMed  CAS  Google Scholar 

  2048. Schiltz JR, Michel B (1976) Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 67:254–260

    PubMed  CAS  Google Scholar 

  2049. Schnait FG, Wolff K, Konrad K (1975) Erythropoietic protoporphyria-submicroscopic events during the acute photosensitivity flare. Br J Dermatol 92:545–557

    PubMed  CAS  Google Scholar 

  2050. Schoel J, Bersch A, Rauterberg EW (1986) Infiltrating cells in cutaneous leukocytoclastic vasculitis and hemorrhagic drug eruption: a comparative study using monoclonal antibodies. Immunobiology 173:421 (abstr)

    Google Scholar 

  2051. Schrager MA, Rothfield NF (1976) Clinical significance of serum properdin levels and properdin deposition in the dermal-epidermal junction in systemic lupus erythematosus. J Clin Invest 57:212–221

    PubMed  CAS  Google Scholar 

  2052. Schroeter AL, Copeman PWM, Jordon RE, Sams WM, Winkelmann RK (1971) Immunofluorescence of cutaneous vasculitis associated with systemic disease. Arch Dermatol 104:254–259

    PubMed  CAS  Google Scholar 

  2053. Scott BB, Scott DG, Losowsky MS (1977) Jejunal mucosal immunoglobulins and complement in untreated coeliac disease. J Pathol 121:219–223

    PubMed  CAS  Google Scholar 

  2054. Seah PP, Fry L, Mazaheri MR, Mowbray JF, Hoffbrand AV, Holborow EJ (1973) Alternate-pathway complement fixation by IgA in the skin in dermatitis herpetiformis. Lancet II:175–177

    Google Scholar 

  2055. Silva FG (1983) The nephropathies of systemic lupus erythematosus. In: Rosen S (ed) Pathology of glomerular disease. Churchill Livingstone, New York, p 79

    Google Scholar 

  2056. Singer KH, Sawka NJ, Samowitz HR, Lazarus GS (1980) Proteinase activation: a mechanism for cellular dyshesion in pemphigus. J Invest Dermatol 74:363–367

    PubMed  CAS  Google Scholar 

  2057. Singer KH, Hashimoto K, Lazarus GS (1981) Antibody-induced proteinase activation: a proposed mechanism for pemphigus. Springer Semin Immunopathol 4:17–32

    PubMed  CAS  Google Scholar 

  2058. Smith WR, Glauser FL, Dearden LC, Wells ID, Novey HS, McRae DM, Reid JS, Newcomb KA (1978) Deposits of immunoglobulin and complement in the pulmonary tissue of patients with “heroin lung”. Chest 73:471–476

    PubMed  CAS  Google Scholar 

  2059. Sorger K, Gessler U, Hubner FK, Kohler H, Schulz W, Stuhlinger W, Thoenes GH, Thoenes W (1982) Subtypes of post-infectious glomerulonephritis. Synopsis of clinical and pathological features. Clin Nephrol 17:114–128

    PubMed  CAS  Google Scholar 

  2060. Sorger K, Balun J, Hubner FK, Kohler H, Olbing H, Schulz W, Seybold D, Thoenes GH, Thoenes W (1983) The garland type of acute post-infectious glomerulonephritis: morphological characteristics and follow-up studies. Clin Nephrol 20:17–26

    PubMed  CAS  Google Scholar 

  2061. Stanley JR, Yaar M, Hawley-Nelson P, Katz SI (1982) Pemphigus antibodies identify a cell surface glycoprotein synthesized by human and mouse keratinocytes. J Clin Invest 70:281–288

    PubMed  CAS  Google Scholar 

  2062. Stanley JR, Koulu L, Thivolet C (1984) Distinction between epidermal antigens binding pemphigus vulgaris and pemphigus foliaceus autoantibodies. J Clin Invest 74:313–320

    PubMed  CAS  Google Scholar 

  2063. Stanley JR, Koulu L, Klaus-Kovtun V, Steinberg MS (1986) A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in pemphigus foliaceus. J Immunol 136:1227–1230

    PubMed  CAS  Google Scholar 

  2064. Stastny P (1970) Bound immunoglobulin and complement in heart allografts undergoing rejection. Transplantation 10:248–257

    PubMed  CAS  Google Scholar 

  2065. Stringa SG, Bianchi C, Casala AM, Bianchi O (1967) Allergic vasculitis Gougerot-Ruiter syndrome. Arch Dermatol 95:23–27

    PubMed  CAS  Google Scholar 

  2066. Thaiss F, Batsford S, Mihatsch MJ, Heintz PU, Bitter-Suermann D, Vogt A (1986) Mediator systems in a passive model of in situ immune complex glomerulonephritis. Role for complement, polymorphonuclear granulocytes and monocytes. Lab Invest 54:624–635

    PubMed  CAS  Google Scholar 

  2067. Tomimo Y, Endoh M, Nomoto Y, Sakai H (1982) Double immunofluorescence studies of immunoglobulins, complement components and their control proteins a patients with IgA nephropathy. Acta Pathol Jpn 32:251–256

    Google Scholar 

  2068. Tsoi MS, Storb R, Jones E, Weiden PL, Shulman H, Witherspoon R, Atkinson K, Thomas ED (1978) Deposition of IgM and complement at the dermo-epidermal junction in acute and chronic cutaneous graft-vs-host disease in man. J Immunol 120:1485–1492

    PubMed  CAS  Google Scholar 

  2069. Tursi A, Trizio D, Bonomo L (1970) An immunofluorescence mixed staining technique for the detection of IgG-rheumatoid factor and IgG-β 1C complexes in tissues. Clin Exp Immunol 6:767–772

    PubMed  CAS  Google Scholar 

  2070. Ullman S, Spielvogel RL, Kersey JH, Goltz RW (1976) Immunoglobulins and complement in skin in graft-versus-host disease. Ann Intern Med 85:205–209

    PubMed  CAS  Google Scholar 

  2071. Valenzuela R, Deodhar SD (1980) Interpretation of immunofluorescent patterns in renal diseases. Pathol Annu 10:183–221

    CAS  Google Scholar 

  2072. van der Meer JB (1969) Granular deposits of immunoglobulins in the skin of patients with dermatitis herpetiformis. An immunofluorescent study. Br J Dermatol 81:493–503

    PubMed  Google Scholar 

  2073. Varelzidis A, Tosca A, Perissios A, Capetanakis J (1979) Immunohistochemistry in lichen planus. Dermatologica 159:137–144

    PubMed  CAS  Google Scholar 

  2074. Velvart M, Felder M, Fehr K, Sommermeyer G, Cancer M, Wagenhäuser FJ, Böni A (1983) Temporal arteritis in polymyalgia rheumatica: immune complex deposits and the role of leukocyte elastase in the pathogenesis. Z Rheumatol 42:320–327

    PubMed  CAS  Google Scholar 

  2075. Vlaicu R, Niculecu F, Rus HG, Cristea A (1983) Immune deposits in human aortic atherosclerotic wall. Med Interne 21:3–8

    PubMed  CAS  Google Scholar 

  2076. Vogt W, Damerau B, Lühmann B, Hesse D, Haller Y (1986) Complement activation in human lymph: modulation by the contact activation system and by leukocytes. Int Arch Allergy Appl Immunol 79:423–433

    PubMed  CAS  Google Scholar 

  2077. Wanstrup J, Elling P (1968) Immunochemistry of sarcoidosis. Acta Pathol Microbiol Scand 73:37–48

    PubMed  CAS  Google Scholar 

  2078. Weidner F (1975) Immunofluorescent investigations in cutaneous vasculitis. I. Histotopical demonstration of complement/component factors. Arch Dermatol Res 253:249–259

    PubMed  CAS  Google Scholar 

  2079. Weir DM (ed) (1986) Handbook of experimental immunology, vol 4: Applications of immunological methods in biomedical sciences. Blackwell Scientific, Oxford

    Google Scholar 

  2080. Werner SC, Wegelius O, Hsu KC (1971) Immune responses in stroma and basement membranes of the Graves’ disease thyroid (IgM, IgE, IgG, and complement). Trans Assoc Am Physicians 84:139–143

    PubMed  CAS  Google Scholar 

  2081. Werner SC, Wegelius O, Fierer JA, Hsu KC (1972) Immunoglobulins (E, M, G) and complement in the connective tissues of the thyroid in Gravs’s disease. N Engl J Med 287:421–425

    PubMed  CAS  Google Scholar 

  2082. Wertheimer D, Barland P (1976) Clinical significance of immune deposits in the skin in SLE. Arthritis Rheum 19:1249–1255

    PubMed  CAS  Google Scholar 

  2083. Whitaker JN, Engel WK (1971) Vascular deposits of immunoglobulin and complement in inflammatory myopathy. Trans Am Neurol Assoc 96:24–28

    PubMed  CAS  Google Scholar 

  2084. Wilson CB, Dixon FJ (1981) The renal response to immunological injury. In: Brenner BM, Rector FC (eds) The kidney, vol 1. Saunders, Philadelphia, pp 1237–1350

    Google Scholar 

  2085. Wilson CB, Dixon FJ (1986) The renal response to immunological injury. In: Brenner BM, Rector FC (eds) The kidney, vol 1. Saunders, Philadelphia, pp 800–899

    Google Scholar 

  2086. Winiarski J, Holm G (1983) Platelet associated immunoglobulins and complement in idiopathic thrombocytopenic purpura. Clin Exp Immunol 53:201–207

    PubMed  CAS  Google Scholar 

  2087. Woodley DT, Briggaman RA, O’Keefe EJ, Inman AO, Queen LL, Gammon WR (1984) Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquitta. N Engl J Med 310:1007–1013

    PubMed  CAS  Google Scholar 

  2088. Woodroffe AJ, Gormly AA, McKenzie PE, Wootton AM, Thompson AJ, Seymour AE, Clarkson AR (1980) Immunologic studies in IgA nephropathy. Kidney Int 18:366–374

    PubMed  CAS  Google Scholar 

  2089. Woodroffe AJ, Clarkson AR, Seymour AE, Lomax-Smith JD (1982) Mesangial IgA nephritis. Springer Semin Immunopathol 5:321–332

    PubMed  CAS  Google Scholar 

  2090. Yaoita H, Katz SI (1976) Immunoelectronmicroscopic localization of IgA in skin of patients with dermatitis herpetiformis. J Invest Dermatol 67:502–506

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. H. Hammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. S. Cole
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. R. Colten
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Burger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Rittner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. M. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Loos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W. Vogt
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. O. Götze
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. K.-H. Büscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. W. Opferkuch
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. I. von Zabern
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. G. M. Hänsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. U. Rother
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. E. W. Rauterberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M. P. Dierich
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. A.-B. Laurell
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Immunologie, Im Neuenheimer Feld 305, D-6900, Heidelberg, Germany

    Klaus Rother

  2. Department of Pathology, University of Michigan Medical School, 1150 W. Medical Center Drive, Ann Arbor, MI, 48109, USA

    Gerd O. Till M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Berger, M. et al. (1988). Complement and Complement Reactions. In: Rother, K., Till, G.O. (eds) The Complement System. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-97038-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-97038-2_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-97040-5

  • Online ISBN: 978-3-642-97038-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation